However,	O
there	O
are	O
some	O
major	O
shortcomings	O
in	O
the	O
currently	O
available	O
data.	O
	
Determination	O
of	O
the	O
infecting	B-KP
species	I-KP
was	O
based	O
on	O
cultured	O
isolates	O
in	O
many	O
of	O
these	O
studies,	O
but	O
culture	O
of	O
Borrelia	B-KP
spp.	I-KP
	
is	O
not	O
very	O
sensitive,	O
particularly	O
in	O
CSF	B-KP
samples	I-KP
[104,110,111,397],	O
and	O
even	O
less	O
so	O
in	O
synovial	B-KP
fluid	I-KP
or	O
tissue	B-KP
samples	I-KP
[112,113].	O
	
PCR-based	B-KP
amplification	I-KP
of	I-KP
DNA	I-KP
isolated	O
directly	O
from	O
tissue	B-KP
specimens	I-KP
generally	O
shows	O
greater	O
sensitivity	O
[114],	O
but	O
largely	O
depends	O
on	O
the	O
specific	O
PCR	B-KP
target	I-KP
[23,104],	O
still	O
lacks	O
sensitivity,	O
particularly	O
in	O
CSF	B-KP
[104,115,116],	O
and	O
does	O
not	O
necessarily	O
detect	O
Borrelia	B-KP
spp.	I-KP
	
in	O
all	O
samples	O
that	O
are	O
culture	O
positive	O
[104,108].	O
	
Furthermore,	O
since	O
patients	O
with	O
EM	B-KP
are	O
now	O
routinely	O
treated	O
with	O
antibiotics,	B-KP
determination	O
of	O
the	O
infecting	O
species	O
of	O
Borrelia	B-KP
in	O
samples	O
from	O
extracutaneous	B-KP
lesions	I-KP
is	O
likely	O
to	O
yield	O
results	O
that	O
are	O
skewed	O
towards	O
those	O
strains	O
that	O
do	O
not	O
also	O
cause	O
easily	O
recognizable	O
EM	B-KP
lesions.	I-KP
	
Fewof	O
these	O
studies	O
examined	O
what	O
is	O
likely	O
to	O
be	O
a	O
major	O
determinant	O
of	O
the	O
probability	O
of	O
acquiring	O
an	O
infection	O
with	O
a	O
particular	O
species	O
of	O
Borrelia,	B-KP
namely	O
its	O
prevalence	O
in	O
regional	O
ticks	O
[20,24,111,386,391,398].	O
	
The	O
results	O
are	O
somewhat	O
conflicting,	O
most	O
likely	O
because	O
of	O
the	O
small	O
number	O
of	O
ticks	O
and/or	O
human	O
samples	O
examined	O
in	O
some	O
of	O
these	O
investigations.	O
	
In	O
addition,	O
tick	O
and	O
human	O
samples	O
were	O
collected	O
during	O
different	O
time	O
periods	O
and	O
in	O
different	O
locations,	O
thereby	O
not	O
taking	O
into	O
consideration	O
that	O
there	O
may	O
be	O
considerable	O
temporal	O
and	O
regional	O
variation	O
in	O
the	O
number	O
of	O
infected	O
ticks	O
and	O
the	O
distribution	O
of	O
Borrelia	B-KP
spp.	I-KP
	
in	O
ticks	O
[20,71,399,400].	O
	
Overall,	O
the	O
results	O
suggest	O
that	O
B.	B-KP
	
garinii	I-KP
may	O
be	O
underrepresented	O
in	O
skin	O
rather	O
than	O
overrepresented	O
in	O
CSF	B-KP
[20,24,386,391].	O
	
Note,	O
however,	O
that	O
B.	B-KP
	
afzelii	I-KP
infection	I-KP
of	O
the	O
nervous	B-KP
system	I-KP
may	O
simply	O
be	O
underrecognized	O
because	O
it	O
does	O
not	O
cause	O
the	O
typical	O
clinical	O
picture	O
of	O
European	O
LNB	B-KP
associated	O
with	O
B.	B-KP
	
garinii	I-KP
infection,	I-KP
namely	O
radiculoneuritis	B-KP
and/or	O
peripheral	B-KP
facial	I-KP
palsy	I-KP
[110].	O
	
Instead,	O
detection	O
of	O
B.	B-KP
	
afzelii	I-KP
in	O
CSF	B-KP
was	O
associated	O
with	O
mostly	O
nonspecific	O
symptoms,	O
and	O
most	O
of	O
the	O
patients	O
from	O
whose	O
CSF	B-KP
B.	I-KP
	
afzelii	I-KP
could	O
be	O
cultured	O
did	O
not	O
fulfill	O
the	O
European	O
diagnostic	O
criteria	O
for	O
LNB.	B-KP
	
However,	O
there	O
are	O
some	O
major	O
shortcomings	O
in	O
the	O
currently	O
available	O
data.	O
	
Determination	O
of	O
the	O
infecting	B-KP
species	I-KP
was	O
based	O
on	O
cultured	O
isolates	O
in	O
many	O
of	O
these	O
studies,	O
but	O
culture	O
of	O
Borrelia	B-KP
spp.	I-KP
	
is	O
not	O
very	O
sensitive,	O
particularly	O
in	O
CSF	B-KP
samples	I-KP
[104,110,111,397],	O
and	O
even	O
less	O
so	O
in	O
synovial	B-KP
fluid	I-KP
or	O
tissue	B-KP
samples	I-KP
[112,113].	O
	
PCR-based	B-KP
amplification	I-KP
of	I-KP
DNA	I-KP
isolated	O
directly	O
from	O
tissue	B-KP
specimens	I-KP
generally	O
shows	O
greater	O
sensitivity	O
[114],	O
but	O
largely	O
depends	O
on	O
the	O
specific	O
PCR	B-KP
target	I-KP
[23,104],	O
still	O
lacks	O
sensitivity,	O
particularly	O
in	O
CSF	B-KP
[104,115,116],	O
and	O
does	O
not	O
necessarily	O
detect	O
Borrelia	B-KP
spp.	I-KP
	
in	O
all	O
samples	O
that	O
are	O
culture	O
positive	O
[104,108].	O
	
Furthermore,	O
since	O
patients	O
with	O
EM	B-KP
are	O
now	O
routinely	O
treated	O
with	O
antibiotics,	B-KP
determination	O
of	O
the	O
infecting	O
species	O
of	O
Borrelia	B-KP
in	O
samples	O
from	O
extracutaneous	B-KP
lesions	I-KP
is	O
likely	O
to	O
yield	O
results	O
that	O
are	O
skewed	O
towards	O
those	O
strains	O
that	O
do	O
not	O
also	O
cause	O
easily	O
recognizable	O
EM	B-KP
lesions.	I-KP
	
Fewof	O
these	O
studies	O
examined	O
what	O
is	O
likely	O
to	O
be	O
a	O
major	O
determinant	O
of	O
the	O
probability	O
of	O
acquiring	O
an	O
infection	O
with	O
a	O
particular	O
species	O
of	O
Borrelia,	B-KP
namely	O
its	O
prevalence	O
in	O
regional	O
ticks	O
[20,24,111,386,391,398].	O
	
The	O
results	O
are	O
somewhat	O
conflicting,	O
most	O
likely	O
because	O
of	O
the	O
small	O
number	O
of	O
ticks	O
and/or	O
human	O
samples	O
examined	O
in	O
some	O
of	O
these	O
investigations.	O
	
In	O
addition,	O
tick	O
and	O
human	O
samples	O
were	O
collected	O
during	O
different	O
time	O
periods	O
and	O
in	O
different	O
locations,	O
thereby	O
not	O
taking	O
into	O
consideration	O
that	O
there	O
may	O
be	O
considerable	O
temporal	O
and	O
regional	O
variation	O
in	O
the	O
number	O
of	O
infected	O
ticks	O
and	O
the	O
distribution	O
of	O
Borrelia	B-KP
spp.	I-KP
	
in	O
ticks	O
[20,71,399,400].	O
	
Overall,	O
the	O
results	O
suggest	O
that	O
B.	B-KP
	
garinii	I-KP
may	O
be	O
underrepresented	O
in	O
skin	O
rather	O
than	O
overrepresented	O
in	O
CSF	B-KP
[20,24,386,391].	O
	
Note,	O
however,	O
that	O
B.	B-KP
	
afzelii	I-KP
infection	I-KP
of	O
the	O
nervous	B-KP
system	I-KP
may	O
simply	O
be	O
underrecognized	O
because	O
it	O
does	O
not	O
cause	O
the	O
typical	O
clinical	O
picture	O
of	O
European	O
LNB	B-KP
associated	O
with	O
B.	B-KP
	
garinii	I-KP
infection,	I-KP
namely	O
radiculoneuritis	B-KP
and/or	O
peripheral	B-KP
facial	I-KP
palsy	I-KP
[110].	O
	
Instead,	O
detection	O
of	O
B.	B-KP
	
afzelii	I-KP
in	O
CSF	B-KP
was	O
associated	O
with	O
mostly	O
nonspecific	O
symptoms,	O
and	O
most	O
of	O
the	O
patients	O
from	O
whose	O
CSF	B-KP
B.	I-KP
	
afzelii	I-KP
could	O
be	O
cultured	O
did	O
not	O
fulfill	O
the	O
European	O
diagnostic	O
criteria	O
for	O
LNB.	B-KP
	
Histopathology	B-KP
of	O
peripheral	B-KP
nerve	I-KP
biopsy	I-KP
specimens	I-KP
from	O
patients	O
with	O
neurological	O
manifestations	O
of	O
Lyme	B-KP
disease	I-KP
shows	O
a	O
perivascular	O
infiltrate	O
of	O
lymphocytes,	B-KP
plasma	B-KP
cells	I-KP
and	O
histiocytes	B-KP
in	O
association	O
with	O
patchy	B-KP
multifocal	I-KP
axonal	I-KP
degeneration	I-KP
[179,484_486].	O
	
A	O
lymphocytic	B-KP
infiltrate	I-KP
has	O
also	O
been	O
observed	O
in	O
the	O
meninges	B-KP
[365],	O
extending	O
into	O
the	O
white	B-KP
and	I-KP
gray	I-KP
matter	I-KP
in	O
an	O
advanced	O
case,	O
along	O
with	O
infiltration	O
of	O
dorsal	B-KP
root	I-KP
ganglia	I-KP
and	O
nerve	B-KP
roots	I-KP
[484,487].	O
	
It	O
is	O
likely	O
that	O
these	O
infiltrating	O
immune	B-KP
cells	I-KP
also	O
contribute	O
to	O
the	O
production	O
of	O
inflammatory	B-KP
and	I-KP
neurotoxic	I-KP
substances.	I-KP
	
T-cell	B-KP
lines	I-KP
and	O
clones	O
isolated	O
from	O
the	O
CSF	B-KP
of	O
patients	O
with	O
LNB	B-KP
show	O
a	O
strong	O
polarization	O
towards	O
a	O
type	B-KP
1	I-KP
cytokine	I-KP
pattern	I-KP
(high	O
production	O
of	O
IFNg	B-KP
and	O
mostly	O
undetectable	O
levels	O
of	O
IL-4)	B-KP
[488,489].	O
	
When	O
CSF	B-KP
mononuclear	I-KP
cells	I-KP
(MNC)	B-KP
from	O
adult	O
patients	O
with	O
LNB	I-KP
are	O
stimulated	O
with	O
borrelial	I-KP
antigens	I-KP
in	O
vitro,	O
there	O
is	O
a	O
marked	O
upregulation	O
of	O
the	O
number	O
of	O
IFNgsecreting	I-KP
cells	I-KP
[490-494],	O
and	O
this	O
upregulation	O
is	O
significantly	O
greater	O
compared	O
to	O
peripheral	I-KP
blood,	O
suggesting	O
a	O
strong	O
compartmentalization	O
of	O
the	O
Borrelia-specific	O
IFNg	O
response	O
[490,494].	O
	
However,	O
the	O
number	O
of	O
responder	I-KP
cells	I-KP
shows	O
pronounced	O
variation	O
between	O
patients	O
[490e494],	O
as	O
do	O
the	O
concentrations	O
of	O
IFNg	I-KP
and	O
essentially	O
all	O
other	O
cytokines	I-KP
and	O
chemokines	I-KP
that	O
have	O
been	O
measured	O
in	O
CSF	I-KP
of	O
patients	O
with	O
LNB	I-KP
[495e497].	O
	
The	O
actual	O
concentrations	O
of	O
IFNg	I-KP
in	O
CSF	I-KP
are	O
remarkably	O
low	O
[495,497].	O
	
Not	O
only	O
have	O
CD8þ	I-KP
T	I-KP
cells	I-KP
been	O
detected	O
in	O
nerve	I-KP
biopsy	I-KP
samples	I-KP
from	O
patients	O
with	O
ACA-associated	I-KP
polyneuropathy	I-KP
[216],	O
but	O
clonal	O
expansion	O
of	O
CD8	I-KP
T	I-KP
cells	I-KP
has	O
been	O
demonstrated	O
in	O
the	O
CSF	I-KP
of	O
patients	O
with	O
acute	I-KP
LNB	I-KP
[498].	O
	
The	O
expanded	O
clones	O
produced	O
TNFa	I-KP
and	O
some	O
IFNg	I-KP
in	O
response	O
to	O
stimulation	O
with	O
Borrelia	I-KP
antigens.	O
	
While	O
the	O
role	O
of	O
these	O
Borrelia-specific	I-KP
CD8þ	I-KP
T	I-KP
cells	I-KP
in	O
LNB	I-KP
remains	O
to	O
be	O
established,	O
their	O
detection	O
in	O
tissues	O
that	O
are	O
targeted	O
soon	O
after	O
Borrelia	I-KP
infection	I-KP
suggests	O
a	O
role	O
in	O
early	O
host	O
defense.	O
	
On	O
the	O
other	O
hand,	O
peripheral	I-KP
CD8þ	I-KP
and	O
gd	I-KP
T	I-KP
cells	I-KP
were	O
identified	O
as	O
the	O
predominant	O
sources	O
of	O
Borrelia-specific	I-KP
IFNg	I-KP
production	O
in	O
patients	O
with	O
chronic	I-KP
Lyme	I-KP
borreliosis	I-KP
(mostly	O
LNB)	O
[499].	O
	
In	O
view	O
of	O
the	O
strong	O
CSF	I-KP
compartmentalization	O
of	O
the	O
immune	I-KP
response,	O
the	O
relevance	O
of	O
these	O
findings	O
is	O
unclear	O
and	O
the	O
precise	O
role	O
of	O
this	O
T	I-KP
cell	I-KP
subset	O
remains	O
to	O
be	O
elucidated.	O
	
Histopathology	B-KP
of	O
peripheral	B-KP
nerve	I-KP
biopsy	I-KP
specimens	I-KP
from	O
patients	O
with	O
neurological	O
manifestations	O
of	O
Lyme	B-KP
disease	I-KP
shows	O
a	O
perivascular	O
infiltrate	O
of	O
lymphocytes,	B-KP
plasma	B-KP
cells	I-KP
and	O
histiocytes	B-KP
in	O
association	O
with	O
patchy	B-KP
multifocal	I-KP
axonal	I-KP
degeneration	I-KP
[179,484_486].	O
	
A	O
lymphocytic	B-KP
infiltrate	I-KP
has	O
also	O
been	O
observed	O
in	O
the	O
meninges	B-KP
[365],	O
extending	O
into	O
the	O
white	B-KP
and	I-KP
gray	I-KP
matter	I-KP
in	O
an	O
advanced	O
case,	O
along	O
with	O
infiltration	O
of	O
dorsal	B-KP
root	I-KP
ganglia	I-KP
and	O
nerve	B-KP
roots	I-KP
[484,487].	O
	
It	O
is	O
likely	O
that	O
these	O
infiltrating	O
immune	B-KP
cells	I-KP
also	O
contribute	O
to	O
the	O
production	O
of	O
inflammatory	B-KP
and	I-KP
neurotoxic	I-KP
substances.	I-KP
	
T-cell	B-KP
lines	I-KP
and	O
clones	O
isolated	O
from	O
the	O
CSF	B-KP
of	O
patients	O
with	O
LNB	B-KP
show	O
a	O
strong	O
polarization	O
towards	O
a	O
type	B-KP
1	I-KP
cytokine	I-KP
pattern	I-KP
(high	O
production	O
of	O
IFNg	B-KP
and	O
mostly	O
undetectable	O
levels	O
of	O
IL-4)	B-KP
[488,489].	O
	
When	O
CSF	B-KP
mononuclear	I-KP
cells	I-KP
(MNC)	B-KP
from	O
adult	O
patients	O
with	O
LNB	I-KP
are	O
stimulated	O
with	O
borrelial	I-KP
antigens	I-KP
in	O
vitro,	O
there	O
is	O
a	O
marked	O
upregulation	O
of	O
the	O
number	O
of	O
IFNgsecreting	I-KP
cells	I-KP
[490-494],	O
and	O
this	O
upregulation	O
is	O
significantly	O
greater	O
compared	O
to	O
peripheral	I-KP
blood,	O
suggesting	O
a	O
strong	O
compartmentalization	O
of	O
the	O
Borrelia-specific	O
IFNg	O
response	O
[490,494].	O
	
However,	O
the	O
number	O
of	O
responder	I-KP
cells	I-KP
shows	O
pronounced	O
variation	O
between	O
patients	O
[490e494],	O
as	O
do	O
the	O
concentrations	O
of	O
IFNg	I-KP
and	O
essentially	O
all	O
other	O
cytokines	I-KP
and	O
chemokines	I-KP
that	O
have	O
been	O
measured	O
in	O
CSF	I-KP
of	O
patients	O
with	O
LNB	I-KP
[495e497].	O
	
The	O
actual	O
concentrations	O
of	O
IFNg	I-KP
in	O
CSF	I-KP
are	O
remarkably	O
low	O
[495,497].	O
	
Not	O
only	O
have	O
CD8þ	I-KP
T	I-KP
cells	I-KP
been	O
detected	O
in	O
nerve	I-KP
biopsy	I-KP
samples	I-KP
from	O
patients	O
with	O
ACA-associated	I-KP
polyneuropathy	I-KP
[216],	O
but	O
clonal	O
expansion	O
of	O
CD8	I-KP
T	I-KP
cells	I-KP
has	O
been	O
demonstrated	O
in	O
the	O
CSF	I-KP
of	O
patients	O
with	O
acute	I-KP
LNB	I-KP
[498].	O
	
The	O
expanded	O
clones	O
produced	O
TNFa	I-KP
and	O
some	O
IFNg	I-KP
in	O
response	O
to	O
stimulation	O
with	O
Borrelia	I-KP
antigens.	O
	
While	O
the	O
role	O
of	O
these	O
Borrelia-specific	I-KP
CD8þ	I-KP
T	I-KP
cells	I-KP
in	O
LNB	I-KP
remains	O
to	O
be	O
established,	O
their	O
detection	O
in	O
tissues	O
that	O
are	O
targeted	O
soon	O
after	O
Borrelia	I-KP
infection	I-KP
suggests	O
a	O
role	O
in	O
early	O
host	O
defense.	O
	
On	O
the	O
other	O
hand,	O
peripheral	I-KP
CD8þ	I-KP
and	O
gd	I-KP
T	I-KP
cells	I-KP
were	O
identified	O
as	O
the	O
predominant	O
sources	O
of	O
Borrelia-specific	I-KP
IFNg	I-KP
production	O
in	O
patients	O
with	O
chronic	I-KP
Lyme	I-KP
borreliosis	I-KP
(mostly	O
LNB)	O
[499].	O
	
In	O
view	O
of	O
the	O
strong	O
CSF	I-KP
compartmentalization	O
of	O
the	O
immune	I-KP
response,	O
the	O
relevance	O
of	O
these	O
findings	O
is	O
unclear	O
and	O
the	O
precise	O
role	O
of	O
this	O
T	I-KP
cell	I-KP
subset	O
remains	O
to	O
be	O
elucidated.	O
	
Early	O
disseminated	O
infection	B-KP
typically	O
occurs	O
within	O
a	O
few	O
days	O
to	O
weeks	O
after	O
contact	O
with	O
the	O
infected	O
tick.	O
	
Signs	O
include	O
multiple	O
(secondary)	O
erythema	B-KP
migrans	I-KP
lesions.	I-KP
	
Additionally,	O
musculoskeletal,	B-KP
neurologic,	B-KP
or	O
cardiovascular	B-KP
symptoms	I-KP
can	O
occur.	O
	
Musculoskeletal	B-KP
symptoms	I-KP
(present	O
in	O
60%	O
of	O
those	O
infected)	O
include	O
migratory	B-KP
joint	I-KP
or	O
muscle	B-KP
pain,	I-KP
with	O
or	O
without	O
joint	B-KP
swelling.	I-KP
	
Neurologic	B-KP
manifestations	I-KP
(present	O
in	O
15%	O
of	O
cases)	O
may	O
include	O
meningitis,	B-KP
paralysis	O
of	O
the	O
facial	B-KP
cranial	I-KP
nerve,	I-KP
and	O
radicular	B-KP
neuropathies.	I-KP
	
Cardiovascular	B-KP
symptoms	I-KP
are	O
less	O
common	O
(present	O
in	O
8%	O
of	O
those	O
infected)	O
but	O
may	O
include	O
temporary	B-KP
atrioventricular	I-KP
blocks	I-KP
of	O
varying	O
degree.	O
	
Although	O
temporary	O
pacing	O
may	O
be	O
necessary	O
in	O
more	O
than	O
30%	O
of	O
patients	O
with	O
cardiac	B-KP
involvement,	I-KP
complete	O
heart	B-KP
block	I-KP
rarely	O
develops.15	O
Untreated	O
or	O
inadequately	O
treated	O
Lyme	B-KP
disease	I-KP
may	O
progress	O
to	O
late	O
disseminated	O
disease	O
within	O
weeks	O
to	O
months	O
after	O
initial	O
infection.	O
	
Early	O
disseminated	O
infection	B-KP
typically	O
occurs	O
within	O
a	O
few	O
days	O
to	O
weeks	O
after	O
contact	O
with	O
the	O
infected	O
tick.	O
	
Signs	O
include	O
multiple	O
(secondary)	O
erythema	B-KP
migrans	I-KP
lesions.	I-KP
	
Additionally,	O
musculoskeletal,	B-KP
neurologic,	B-KP
or	O
cardiovascular	B-KP
symptoms	I-KP
can	O
occur.	O
	
Musculoskeletal	B-KP
symptoms	I-KP
(present	O
in	O
60%	O
of	O
those	O
infected)	O
include	O
migratory	B-KP
joint	I-KP
or	O
muscle	B-KP
pain,	I-KP
with	O
or	O
without	O
joint	B-KP
swelling.	I-KP
	
Neurologic	B-KP
manifestations	I-KP
(present	O
in	O
15%	O
of	O
cases)	O
may	O
include	O
meningitis,	B-KP
paralysis	O
of	O
the	O
facial	B-KP
cranial	I-KP
nerve,	I-KP
and	O
radicular	B-KP
neuropathies.	I-KP
	
Cardiovascular	B-KP
symptoms	I-KP
are	O
less	O
common	O
(present	O
in	O
8%	O
of	O
those	O
infected)	O
but	O
may	O
include	O
temporary	B-KP
atrioventricular	I-KP
blocks	I-KP
of	O
varying	O
degree.	O
	
Although	O
temporary	O
pacing	O
may	O
be	O
necessary	O
in	O
more	O
than	O
30%	O
of	O
patients	O
with	O
cardiac	B-KP
involvement,	I-KP
complete	O
heart	B-KP
block	I-KP
rarely	O
develops.15	O
Untreated	O
or	O
inadequately	O
treated	O
Lyme	B-KP
disease	I-KP
may	O
progress	O
to	O
late	O
disseminated	O
disease	O
within	O
weeks	O
to	O
months	O
after	O
initial	O
infection.	O
	
In	O
many	O
areas	O
of	O
the	O
United	O
States,	O
tick	O
bites	O
are	O
extremely	O
common.	O
	
B	B-KP
burgdorferi	I-KP
is	O
endemic	B-KP
in	O
New	O
England,	O
the	O
mid-Atlantic	O
states,	O
Minnesota,	O
and	O
Wisconsin.	O
	
In	O
these	O
areas,	O
the	O
risk	O
of	O
infection	O
after	O
a	O
prolonged	O
bite	O
can	O
be	O
high	O
(10%-25%).	O
	
[23,24]	O
Risk	O
of	O
infection	O
is	O
much	O
lower	O
in	O
the	O
southern	O
and	O
western	O
United	O
States.	O
	
Furthermore,	O
there	O
is	O
no	O
risk	O
of	O
transmission	O
of	O
B	B-KP
burgdorferi	I-KP
from	O
an	O
unengorged	O
tick	O
because	O
the	O
spirochetes	B-KP
require	O
up	O
to	O
36	O
hours	O
after	O
a	O
bite	O
to	O
migrate	O
from	O
the	O
tick	O
gut	O
to	O
the	O
salivary	B-KP
glands.	I-KP
	
[25-27]	O
Because	O
of	O
these	O
factors,	O
routine	O
antibiotic	B-KP
prophylaxis	I-KP
is	O
not	O
recommended.	O
	
However,	O
if	O
an	O
engorged	O
Ixodes	B-KP
tick	I-KP
has	O
been	O
removed	O
from	O
a	O
patient	O
in	O
an	O
endemic	B-KP
area	I-KP
(local	O
rate	O
of	O
infection	O
of	O
ticks	O
with	O
B	B-KP
burgdorferi	I-KP
≥20%),	O
or	O
if	O
the	O
tick	O
has	O
been	O
attached	O
for	O
at	O
least	O
36	O
hours,	O
a	O
single	O
200-mg	O
oral	O
dose	O
of	O
doxycycline	B-KP
can	O
be	O
administered	O
within	O
72	O
hours	O
after	O
removal	O
of	O
the	O
tick	O
for	O
prophylaxis	B-KP
against	O
Lyme	B-KP
disease.	I-KP
	
[2,24]	O
Prophylaxis	B-KP
is	O
generally	O
unnecessary	O
after	O
an	O
I	B-KP
pacificus	I-KP
bite	O
unless	O
the	O
local	O
rate	O
of	O
infection	O
with	O
B	B-KP
burgdorferi	I-KP
is	O
20%	O
or	O
greater.	O
	
[2]	O
In	O
many	O
areas	O
of	O
the	O
United	O
States,	O
tick	O
bites	O
are	O
extremely	O
common.	O
	
B	B-KP
burgdorferi	I-KP
is	O
endemic	B-KP
in	O
New	O
England,	O
the	O
mid-Atlantic	O
states,	O
Minnesota,	O
and	O
Wisconsin.	O
	
In	O
these	O
areas,	O
the	O
risk	O
of	O
infection	O
after	O
a	O
prolonged	O
bite	O
can	O
be	O
high	O
(10%-25%).	O
	
[23,24]	O
Risk	O
of	O
infection	O
is	O
much	O
lower	O
in	O
the	O
southern	O
and	O
western	O
United	O
States.	O
	
Furthermore,	O
there	O
is	O
no	O
risk	O
of	O
transmission	O
of	O
B	B-KP
burgdorferi	I-KP
from	O
an	O
unengorged	O
tick	O
because	O
the	O
spirochetes	B-KP
require	O
up	O
to	O
36	O
hours	O
after	O
a	O
bite	O
to	O
migrate	O
from	O
the	O
tick	O
gut	O
to	O
the	O
salivary	B-KP
glands.	I-KP
	
[25-27]	O
Because	O
of	O
these	O
factors,	O
routine	O
antibiotic	B-KP
prophylaxis	I-KP
is	O
not	O
recommended.	O
	
However,	O
if	O
an	O
engorged	O
Ixodes	B-KP
tick	I-KP
has	O
been	O
removed	O
from	O
a	O
patient	O
in	O
an	O
endemic	B-KP
area	I-KP
(local	O
rate	O
of	O
infection	O
of	O
ticks	O
with	O
B	B-KP
burgdorferi	I-KP
≥20%),	O
or	O
if	O
the	O
tick	O
has	O
been	O
attached	O
for	O
at	O
least	O
36	O
hours,	O
a	O
single	O
200-mg	O
oral	O
dose	O
of	O
doxycycline	B-KP
can	O
be	O
administered	O
within	O
72	O
hours	O
after	O
removal	O
of	O
the	O
tick	O
for	O
prophylaxis	B-KP
against	O
Lyme	B-KP
disease.	I-KP
	
[2,24]	O
Prophylaxis	B-KP
is	O
generally	O
unnecessary	O
after	O
an	O
I	B-KP
pacificus	I-KP
bite	O
unless	O
the	O
local	O
rate	O
of	O
infection	O
with	O
B	B-KP
burgdorferi	I-KP
is	O
20%	O
or	O
greater.	O
	
[2]	O
Avoidance	O
of	O
tick	O
bites	O
is	O
the	O
most	O
obvious	O
means	O
to	O
prevent	O
B	B-KP
burgdorferi	I-KP
infection.	I-KP
	
If	O
people	O
must	O
be	O
outside	O
in	O
areas	O
where	O
Ixodes	B-KP
ticks	I-KP
are	O
found,	O
they	O
are	O
advised	O
to	O
wear	O
protective	O
clothing	O
and	O
tick	O
repellent	O
containing	O
N,N-di-ethyl-m-toluamide	B-KP
(DEET).	B-KP
	
Frequent	O
skin	I-KP
inspection	O
and	O
prompt	O
removal	O
of	O
ticks	O
should	O
also	O
decrease	O
the	O
risk	O
of	O
infection.	O
	
However,	O
data	O
regarding	O
the	O
efficacy	O
of	O
these	O
measures	O
are	O
limited.	O
	
Other	O
measures,	O
including	O
burning	O
or	O
removal	O
of	O
vegetation	O
in	O
tick-harboring	O
areas,	O
use	O
of	O
acaricides,	O
and	O
control	O
of	O
the	O
deer	O
population,	O
result	O
in	O
up	O
to	O
a	O
94%	O
decrease	O
in	O
the	O
population	O
of	O
I	I-KP
scapularis	I-KP
ticks.	O
	
Studies	O
show	O
that,	O
despite	O
warnings,	O
only	O
40%	O
to	O
50%	O
of	O
adults	O
take	O
precautions	O
against	O
tick	O
bites	O
even	O
when	O
they	O
are	O
aware	O
of	O
Lyme	I-KP
disease.10	O
Immediate	O
removal	O
of	O
attached	O
ticks	O
can	O
help	O
prevent	O
Lyme	I-KP
disease	I-KP
infection.	O
	
Therefore,	O
complete	O
inspection	O
of	O
the	O
skin	I-KP
and	O
scalp,	O
particularly	O
for	O
children,	O
is	O
recommended	O
after	O
spending	O
time	O
outside	O
in	O
endemic	I-KP
areas.	O
	
Avoidance	O
of	O
tick	O
bites	O
is	O
the	O
most	O
obvious	O
means	O
to	O
prevent	O
B	B-KP
burgdorferi	I-KP
infection.	I-KP
	
If	O
people	O
must	O
be	O
outside	O
in	O
areas	O
where	O
Ixodes	B-KP
ticks	I-KP
are	O
found,	O
they	O
are	O
advised	O
to	O
wear	O
protective	O
clothing	O
and	O
tick	O
repellent	O
containing	O
N,N-di-ethyl-m-toluamide	B-KP
(DEET).	B-KP
	
Frequent	O
skin	I-KP
inspection	O
and	O
prompt	O
removal	O
of	O
ticks	O
should	O
also	O
decrease	O
the	O
risk	O
of	O
infection.	O
	
However,	O
data	O
regarding	O
the	O
efficacy	O
of	O
these	O
measures	O
are	O
limited.	O
	
Other	O
measures,	O
including	O
burning	O
or	O
removal	O
of	O
vegetation	O
in	O
tick-harboring	O
areas,	O
use	O
of	O
acaricides,	O
and	O
control	O
of	O
the	O
deer	O
population,	O
result	O
in	O
up	O
to	O
a	O
94%	O
decrease	O
in	O
the	O
population	O
of	O
I	I-KP
scapularis	I-KP
ticks.	O
	
Studies	O
show	O
that,	O
despite	O
warnings,	O
only	O
40%	O
to	O
50%	O
of	O
adults	O
take	O
precautions	O
against	O
tick	O
bites	O
even	O
when	O
they	O
are	O
aware	O
of	O
Lyme	I-KP
disease.10	O
Immediate	O
removal	O
of	O
attached	O
ticks	O
can	O
help	O
prevent	O
Lyme	I-KP
disease	I-KP
infection.	O
	
Therefore,	O
complete	O
inspection	O
of	O
the	O
skin	I-KP
and	O
scalp,	O
particularly	O
for	O
children,	O
is	O
recommended	O
after	O
spending	O
time	O
outside	O
in	O
endemic	I-KP
areas.	O
	
Lyme	B-KP
disease,	I-KP
also	O
referred	O
to	O
as	O
Lyme	B-KP
borreliosis,	I-KP
was	O
first	O
clinically	O
described	O
in	O
1977	O
by	O
Dr.	O
	
Allen	O
Steere,	O
a	O
rheumatologist	B-KP
who	O
led	O
an	O
investigation	O
of	O
an	O
outbreak	O
of	O
arthritis,	B-KP
initially	O
believed	O
to	O
be	O
juvenile	B-KP
rheumatoid	I-KP
arthritis,	I-KP
in	O
39	O
children	O
and	O
12	O
adults	O
clustered	O
in	O
the	O
small	O
town	O
of	O
Lyme,	O
Connecticut.	O
	
[1]	O
First	O
called	O
“Lyme	B-KP
Arthritis”,	O
he	O
suspected	O
this	O
condition	O
was	O
caused	O
by	O
an	O
arthropod-born	O
infection,	O
as	O
most	O
patients	O
suffered	O
from	O
asymmetric	O
swelling	O
of	O
large	O
joints,	O
many	O
of	O
whom	O
also	O
presented	O
with	O
an	O
erythematous	I-KP
annular	I-KP
rash	I-KP
similar	O
to	O
that	O
described	O
decades	O
earlier	O
in	O
Europe	O
associated	O
with	O
the	O
bite	O
of	O
the	O
Ixodes	O
ricinus	O
tick.	O
	
[2]	O
Although	O
the	O
causative	O
agent	O
was	O
unknown,	O
the	O
etiology	I-KP
was	O
believed	O
to	O
be	O
a	B-KP
bacterial	I-KP
pathogen	O
in	O
that	O
the	B-KP
rash	O
seemed	O
to	O
respond	O
to	O
treatment	O
with	B-KP
penicillin.	O
	
During	O
this	O
time,	O
the	O
entity	O
was	O
given	O
several	O
names	O
including	O
erythema	I-KP
chronicum	I-KP
migrans,	O
Bannwarth’s	I-KP
syndrome,	O
and	I-KP
acrodermatitis	I-KP
chronica	I-KP
atrophicans.	O
	
[3]	O
It	O
was	O
not	O
until	O
1982	O
that	O
Dr.	O
	
Willy	O
Burgdorfer,	O
a	O
microbiologist	O
studying	O
the	O
microbiology	O
of	O
the	O
hindgut	O
of	O
ticks,	O
successfully	O
isolated	O
the	I-KP
pathogen,	O
named	O
in	O
his	O
honor	B-KP
Borrelia	I-KP
burgdorferfi,	O
from	I-KP
I.	I-KP
	
damimini	O
(I.	I-KP
	
scapularis)	O
ticks	O
found	O
on	O
Shelter	O
Island,	O
New	O
York.4,5	O
Subsequently,	O
this	O
causative	O
spirochete	I-KP
bacterium	O
has	O
been	O
isolated	O
from	O
the	O
typical	B-KP
skin	I-KP
lesions,	O
as	O
well	O
as	O
blood	B-KP
and	I-KP
cerebrospinal	O
fluid	O
of	O
infected	O
individuals.	O
	
Since	O
its	O
early	O
discovery,	B-KP
Lyme	O
disease	O
has	O
geographically	O
spread	O
to	O
an	O
extent	O
that	I-KP
this	I-KP
zoonotic	I-KP
infection	O
is	O
currently	O
the	O
most	O
prevalent	O
vector-borne	O
disease	O
in	O
both	O
North	O
America	O
and	O
Europe.	O
	
Lyme	B-KP
disease,	I-KP
also	O
referred	O
to	O
as	O
Lyme	B-KP
borreliosis,	I-KP
was	O
first	O
clinically	O
described	O
in	O
1977	O
by	O
Dr.	O
	
Allen	O
Steere,	O
a	O
rheumatologist	B-KP
who	O
led	O
an	O
investigation	O
of	O
an	O
outbreak	O
of	O
arthritis,	B-KP
initially	O
believed	O
to	O
be	O
juvenile	B-KP
rheumatoid	I-KP
arthritis,	I-KP
in	O
39	O
children	O
and	O
12	O
adults	O
clustered	O
in	O
the	O
small	O
town	O
of	O
Lyme,	O
Connecticut.	O
	
[1]	O
First	O
called	O
“Lyme	B-KP
Arthritis”,	O
he	O
suspected	O
this	O
condition	O
was	O
caused	O
by	O
an	O
arthropod-born	O
infection,	O
as	O
most	O
patients	O
suffered	O
from	O
asymmetric	O
swelling	O
of	O
large	O
joints,	O
many	O
of	O
whom	O
also	O
presented	O
with	O
an	O
erythematous	I-KP
annular	I-KP
rash	I-KP
similar	O
to	O
that	O
described	O
decades	O
earlier	O
in	O
Europe	O
associated	O
with	O
the	O
bite	O
of	O
the	O
Ixodes	O
ricinus	O
tick.	O
	
[2]	O
Although	O
the	O
causative	O
agent	O
was	O
unknown,	O
the	O
etiology	I-KP
was	O
believed	O
to	O
be	O
a	B-KP
bacterial	I-KP
pathogen	O
in	O
that	O
the	B-KP
rash	O
seemed	O
to	O
respond	O
to	O
treatment	O
with	B-KP
penicillin.	O
	
During	O
this	O
time,	O
the	O
entity	O
was	O
given	O
several	O
names	O
including	O
erythema	I-KP
chronicum	I-KP
migrans,	O
Bannwarth’s	I-KP
syndrome,	O
and	I-KP
acrodermatitis	I-KP
chronica	I-KP
atrophicans.	O
	
[3]	O
It	O
was	O
not	O
until	O
1982	O
that	O
Dr.	O
	
Willy	O
Burgdorfer,	O
a	O
microbiologist	O
studying	O
the	O
microbiology	O
of	O
the	O
hindgut	O
of	O
ticks,	O
successfully	O
isolated	O
the	I-KP
pathogen,	O
named	O
in	O
his	O
honor	B-KP
Borrelia	I-KP
burgdorferfi,	O
from	I-KP
I.	I-KP
	
damimini	O
(I.	I-KP
	
scapularis)	O
ticks	O
found	O
on	O
Shelter	O
Island,	O
New	O
York.4,5	O
Subsequently,	O
this	O
causative	O
spirochete	I-KP
bacterium	O
has	O
been	O
isolated	O
from	O
the	O
typical	B-KP
skin	I-KP
lesions,	O
as	O
well	O
as	O
blood	B-KP
and	I-KP
cerebrospinal	O
fluid	O
of	O
infected	O
individuals.	O
	
Since	O
its	O
early	O
discovery,	B-KP
Lyme	O
disease	O
has	O
geographically	O
spread	O
to	O
an	O
extent	O
that	I-KP
this	I-KP
zoonotic	I-KP
infection	O
is	O
currently	O
the	O
most	O
prevalent	O
vector-borne	O
disease	O
in	O
both	O
North	O
America	O
and	O
Europe.	O
	
B.	B-KP
	
burgdorferi	I-KP
sensu	O
lato	O
are	O
obligate	B-KP
parasites	I-KP
heavily	O
dependent	O
upon	O
their	O
hosts	O
for	O
nutritional	O
support.	O
	
Proliferation	O
of	O
each	O
B.	B-KP
	
burgdorferi	I-KP
species	I-KP
is	O
contingent	O
upon	O
its	O
transmission	O
to	O
other	O
reservoir	B-KP
animals.	I-KP
	
This	O
is	O
accomplished	O
via	O
each	O
species’	O
preferred	O
Ixodes	O
tick,	O
which	O
acquires	O
the	O
spirochetes	B-KP
during	O
its	O
larval	O
stage	O
blood	O
feed	O
and	O
passes	O
them	O
on	O
to	O
other	O
reservoir	B-KP
hosts	I-KP
after	O
molting	O
into	O
its	O
nymphal	B-KP
stage.	I-KP
	
Essential	O
to	O
the	O
propagation	O
and	O
survival	O
of	O
these	O
Borrelia	B-KP
species	I-KP
is	O
their	O
plasmid-encoded	O
production	O
of	O
lipoproteins.	B-KP
	
The	O
most	O
important	O
and	O
well	O
researched	O
are	O
outer-surface	B-KP
proteins	I-KP
(Osp)	B-KP
A-F	I-KP
and	O
VIsE.16	O
These	O
components	O
along	O
with	O
other	O
surface	I-KP
lipoproteins	I-KP
allow	O
the	O
spirochete	O
to	O
attach	O
to	O
and	O
survive	O
in	O
a	O
variety	O
of	O
small	O
mammals,	O
birds,	O
and	O
tick	O
arthropods.	O
	
Throughout	O
most	O
the	O
year	O
life	O
cycle,	O
the	O
spirochetes	I-KP
remain	O
dormant	O
within	O
the	O
gut	O
of	O
the	O
nymphal	O
tick.	O
	
During	O
this	O
period,	O
the	O
dominant	O
protein	O
expressed	O
on	O
the	O
outer-surface	O
of	O
the	O
bacteria	O
is	O
protein	I-KP
OspA.	O
	
In	O
late	O
spring	O
and	O
summer,	O
when	O
the	O
nymphal	O
tick	O
engages	O
in	O
another	O
feed,	O
constituents	O
present	O
in	O
the	O
ingested	O
mammalian	O
blood	O
stimulates	O
the	O
spirochete’s	I-KP
production	O
of	O
OspC,	O
which	O
enables	O
the	O
organism	O
to	O
spread	O
in	O
the	O
tick	O
eventually	O
reaching	O
the	O
tick’s	O
salivary	O
gland,	O
where	O
it	O
becomes	O
coated	O
by	O
a	O
protective	O
tick	O
protein,	O
known	O
as	O
VIsE.17	O
Once	O
the	O
tick	O
bites	O
the	O
reservoir	O
host,	O
OspC	I-KP
affords	O
the	O
bacteria	O
protection	O
from	O
the	O
animal’s	O
innate	O
immune	I-KP
system.	O
	
The	O
VIsE	I-KP
protein	I-KP
is	O
involved	O
in	O
resistance	O
to	O
acquired	O
immunity.18,19	O
The	O
reservoir	O
hosts,	O
chiefly	O
rodents	O
and	O
birds,	O
provide	O
a	O
favorable	O
environment	O
supporting	O
bacterial	O
growth,	O
but	O
they	O
do	O
not	O
themselves	O
develop	O
disease.	O
	
Because	O
B.	I-KP
	
burgdorferi	I-KP
do	O
not	O
possess	O
other	O
virulence	O
factors	O
or	O
have	O
the	O
ability	O
to	O
produce	O
toxins,	O
disease	O
in	O
humans	O
is	O
the	O
consequence	O
of	O
the	O
immunopathologic	I-KP
response	I-KP
to	O
the	O
invading	O
organism	O
and	O
to	O
the	O
bacterial	O
products	O
it	O
produces.	O
	
In-vitro	O
laboratory	O
growth	O
of	O
B.	I-KP
	
burgdorferi	I-KP
requires	O
incubation	O
in	O
a	O
special	O
medium	O
named	O
Barbour–Stoenner–Kelly	O
medium,	O
preferably	O
at	O
33°C.	O
	
B.	B-KP
	
burgdorferi	I-KP
sensu	O
lato	O
are	O
obligate	B-KP
parasites	I-KP
heavily	O
dependent	O
upon	O
their	O
hosts	O
for	O
nutritional	O
support.	O
	
Proliferation	O
of	O
each	O
B.	B-KP
	
burgdorferi	I-KP
species	I-KP
is	O
contingent	O
upon	O
its	O
transmission	O
to	O
other	O
reservoir	B-KP
animals.	I-KP
	
This	O
is	O
accomplished	O
via	O
each	O
species’	O
preferred	O
Ixodes	O
tick,	O
which	O
acquires	O
the	O
spirochetes	B-KP
during	O
its	O
larval	O
stage	O
blood	O
feed	O
and	O
passes	O
them	O
on	O
to	O
other	O
reservoir	B-KP
hosts	I-KP
after	O
molting	O
into	O
its	O
nymphal	B-KP
stage.	I-KP
	
Essential	O
to	O
the	O
propagation	O
and	O
survival	O
of	O
these	O
Borrelia	B-KP
species	I-KP
is	O
their	O
plasmid-encoded	O
production	O
of	O
lipoproteins.	B-KP
	
The	O
most	O
important	O
and	O
well	O
researched	O
are	O
outer-surface	B-KP
proteins	I-KP
(Osp)	B-KP
A-F	I-KP
and	O
VIsE.16	O
These	O
components	O
along	O
with	O
other	O
surface	I-KP
lipoproteins	I-KP
allow	O
the	O
spirochete	O
to	O
attach	O
to	O
and	O
survive	O
in	O
a	O
variety	O
of	O
small	O
mammals,	O
birds,	O
and	O
tick	O
arthropods.	O
	
Throughout	O
most	O
the	O
year	O
life	O
cycle,	O
the	O
spirochetes	I-KP
remain	O
dormant	O
within	O
the	O
gut	O
of	O
the	O
nymphal	O
tick.	O
	
During	O
this	O
period,	O
the	O
dominant	O
protein	O
expressed	O
on	O
the	O
outer-surface	O
of	O
the	O
bacteria	O
is	O
protein	I-KP
OspA.	O
	
In	O
late	O
spring	O
and	O
summer,	O
when	O
the	O
nymphal	O
tick	O
engages	O
in	O
another	O
feed,	O
constituents	O
present	O
in	O
the	O
ingested	O
mammalian	O
blood	O
stimulates	O
the	O
spirochete’s	I-KP
production	O
of	O
OspC,	O
which	O
enables	O
the	O
organism	O
to	O
spread	O
in	O
the	O
tick	O
eventually	O
reaching	O
the	O
tick’s	O
salivary	O
gland,	O
where	O
it	O
becomes	O
coated	O
by	O
a	O
protective	O
tick	O
protein,	O
known	O
as	O
VIsE.17	O
Once	O
the	O
tick	O
bites	O
the	O
reservoir	O
host,	O
OspC	I-KP
affords	O
the	O
bacteria	O
protection	O
from	O
the	O
animal’s	O
innate	O
immune	I-KP
system.	O
	
The	O
VIsE	I-KP
protein	I-KP
is	O
involved	O
in	O
resistance	O
to	O
acquired	O
immunity.18,19	O
The	O
reservoir	O
hosts,	O
chiefly	O
rodents	O
and	O
birds,	O
provide	O
a	O
favorable	O
environment	O
supporting	O
bacterial	O
growth,	O
but	O
they	O
do	O
not	O
themselves	O
develop	O
disease.	O
	
Because	O
B.	I-KP
	
burgdorferi	I-KP
do	O
not	O
possess	O
other	O
virulence	O
factors	O
or	O
have	O
the	O
ability	O
to	O
produce	O
toxins,	O
disease	O
in	O
humans	O
is	O
the	O
consequence	O
of	O
the	O
immunopathologic	I-KP
response	I-KP
to	O
the	O
invading	O
organism	O
and	O
to	O
the	O
bacterial	O
products	O
it	O
produces.	O
	
In-vitro	O
laboratory	O
growth	O
of	O
B.	I-KP
	
burgdorferi	I-KP
requires	O
incubation	O
in	O
a	O
special	O
medium	O
named	O
Barbour–Stoenner–Kelly	O
medium,	O
preferably	O
at	O
33°C.	O
	
Microbiologic	O
isolation	O
of	O
a	O
pathogen	O
remains	O
the	O
‘gold	O
standard’	O
in	O
infectious	O
diseases	O
diagnosis.	O
	
However,	O
some	O
etiologic	B-KP
agents,	I-KP
for	O
example	O
Treponema	B-KP
pallidum	I-KP
(the	O
causative	O
agent	O
of	O
syphilis),	B-KP
cannot	O
be	O
cultivated	O
on	O
artificial	O
medium	O
leaving	O
diagnosis	O
to	O
rely	O
on	O
the	O
direct	O
detection	O
of	O
the	O
pathogen	O
in	O
patient	O
specimens	O
and/or	O
reactivity	O
in	O
serologic	B-KP
tests.	I-KP
	
Advances	O
in	O
molecular	O
medicine,	O
particularly	O
PCR	B-KP
assays	I-KP
designed	O
to	O
detect	O
even	O
minute	O
quantities	O
of	O
organism-specific	B-KP
nucleic	I-KP
acid,	I-KP
have	O
greatly	O
enhanced	O
the	O
laboratory’s	O
ability	O
to	O
make	O
a	O
specific	O
diagnosis	O
of	O
an	O
infectious	O
disease.	O
	
B.	B-KP
	
burgdorferi	I-KP
can	O
be	O
isolated	O
in-vitro	O
from	O
EM	B-KP
skin	I-KP
tissue,	I-KP
blood	B-KP
samples,	I-KP
and	O
on	O
occasions	O
from	O
cerebrospinal	B-KP
(meningitis	B-KP
cases)	O
and	O
joint	I-KP
fluids.	O
	
However,	O
this	O
requires	O
incubation	O
on	O
specialized	O
Barbour–Stoenner–Kelly	O
(BSK)	O
medium,	O
has	O
a	O
low	O
yield,	O
and	O
generally	O
is	O
not	O
performed	O
in	O
most	O
clinical	O
microbiology	O
laboratories.65	O
Moreover,	O
routine	O
hematologic,	O
metabolic,	O
and	O
liver	I-KP
profile	I-KP
tests	I-KP
are	O
usually	O
unremarkable	O
and	O
offer	O
limited	O
diagnostic	O
utility	O
in	O
confirming	O
Lyme	I-KP
disease.	O
	
Microbiologic	O
isolation	O
of	O
a	O
pathogen	O
remains	O
the	O
‘gold	O
standard’	O
in	O
infectious	O
diseases	O
diagnosis.	O
	
However,	O
some	O
etiologic	B-KP
agents,	I-KP
for	O
example	O
Treponema	B-KP
pallidum	I-KP
(the	O
causative	O
agent	O
of	O
syphilis),	B-KP
cannot	O
be	O
cultivated	O
on	O
artificial	O
medium	O
leaving	O
diagnosis	O
to	O
rely	O
on	O
the	O
direct	O
detection	O
of	O
the	O
pathogen	O
in	O
patient	O
specimens	O
and/or	O
reactivity	O
in	O
serologic	B-KP
tests.	I-KP
	
Advances	O
in	O
molecular	O
medicine,	O
particularly	O
PCR	B-KP
assays	I-KP
designed	O
to	O
detect	O
even	O
minute	O
quantities	O
of	O
organism-specific	B-KP
nucleic	I-KP
acid,	I-KP
have	O
greatly	O
enhanced	O
the	O
laboratory’s	O
ability	O
to	O
make	O
a	O
specific	O
diagnosis	O
of	O
an	O
infectious	O
disease.	O
	
B.	B-KP
	
burgdorferi	I-KP
can	O
be	O
isolated	O
in-vitro	O
from	O
EM	B-KP
skin	I-KP
tissue,	I-KP
blood	B-KP
samples,	I-KP
and	O
on	O
occasions	O
from	O
cerebrospinal	B-KP
(meningitis	B-KP
cases)	O
and	O
joint	I-KP
fluids.	O
	
However,	O
this	O
requires	O
incubation	O
on	O
specialized	O
Barbour–Stoenner–Kelly	O
(BSK)	O
medium,	O
has	O
a	O
low	O
yield,	O
and	O
generally	O
is	O
not	O
performed	O
in	O
most	O
clinical	O
microbiology	O
laboratories.65	O
Moreover,	O
routine	O
hematologic,	O
metabolic,	O
and	O
liver	I-KP
profile	I-KP
tests	I-KP
are	O
usually	O
unremarkable	O
and	O
offer	O
limited	O
diagnostic	O
utility	O
in	O
confirming	O
Lyme	I-KP
disease.	O
	
Lyme	B-KP
borreliosis’	I-KP
natural	O
propensity	O
to	O
evolve	O
from	O
one	O
stage	O
into	O
another,	O
which	O
at	O
times	O
overlap	O
but	O
typically	O
present	O
with	O
their	O
own	O
set	O
of	O
signs,	O
symptoms,	O
and	O
objective	O
measures,	O
is	O
a	O
unique	O
feature	O
of	O
this	O
disease	O
and	O
important	O
factor	O
when	O
creating	O
a	O
differential	O
diagnosis	O
inclusive	O
of	O
both	O
infectious	B-KP
and	I-KP
non-infectious	I-KP
entities	I-KP
potentially	O
accounting	O
for	O
a	O
patient’s	O
condition.	O
	
Furthermore,	O
for	O
some	O
stages	O
of	O
Lyme	B-KP
disease,	I-KP
the	O
time	O
of	O
year	O
of	O
onset	O
coupled	O
with	O
the	O
geographic	O
area	O
where	O
the	O
patient	O
lives	O
or	O
may	O
have	O
traveled	O
to	O
are	O
important	O
epidemiologic	O
pieces	O
of	O
information	O
when	O
considering	O
infection	O
with	O
B.	B-KP
	
burgdorferi.	I-KP
	
Local	B-KP
red	I-KP
skin	I-KP
lesions	I-KP
are	O
not	O
uncommon	O
following	O
the	O
bite	O
of	O
other	O
non-infectious	O
disease	O
transmissible	O
arthropods.	O
	
Features	O
that	O
help	O
to	O
distinguish	O
this	O
hypersensitivity	O
event	O
from	O
a	O
tick	O
bite	O
from	O
those	O
of	O
B.	B-KP
	
burgdorferi	I-KP
EM	I-KP
lesions	I-KP
are	O
that	O
the	O
former	O
appears	O
almost	O
immediately,	O
rapidly	O
expands	O
in	O
size,	O
is	O
associated	O
with	O
local	O
pruritus,	O
is	O
relative	O
small	O
in	O
size,	O
and	O
tends	O
to	O
resolve	O
promptly.80	O
Localized	B-KP
soft	I-KP
tissue	I-KP
infections	I-KP
with	O
Staphylococcal	B-KP
aureus	I-KP
(especially	O
methicillin-resistant	B-KP
strains)	I-KP
frequently	O
and	O
incorrectly	O
attributed	O
to	O
unwitnessed	O
spider	O
bites,	O
along	O
with	O
other	O
pyogenic	B-KP
infections,	I-KP
generally	O
evolve	O
into	O
a	O
cellulitic	O
process	O
fairly	O
distinct	O
from	O
EM.	B-KP
	
The	O
rare	O
vesicular	B-KP
EM	I-KP
may	O
at	O
times	O
be	O
confused	O
with	O
Herpes	B-KP
simplex	I-KP
and	O
Varicella	B-KP
zoster	I-KP
infections,	I-KP
the	O
later	O
of	O
which	O
can	O
be	O
easily	O
excluded	O
by	O
its	O
dermatomal	O
distribution.	O
	
In	O
the	O
absence	O
of	O
EM,	B-KP
the	O
nonspecific	O
manifestations	O
of	O
early	O
Lyme	B-KP
disease	I-KP
such	O
as	O
fever,	B-KP
malaise,	B-KP
headache,	B-KP
myalgias,	B-KP
pain	B-KP
on	I-KP
neck	I-KP
flexion,	I-KP
regional	B-KP
and	I-KP
localized	I-KP
lymphadenopathy,	I-KP
invariably	O
are	O
attributed	O
to	O
an	O
unconfirmed	O
‘viral	O
illness’.	O
	
Altered	O
cranial	B-KP
nerve	I-KP
function	I-KP
associated	O
with	O
Lyme	B-KP
disease,	I-KP
either	O
single,	O
most	O
commonly	O
the	O
7th	O
nerve,	O
or	O
multiple,	O
may	O
also	O
be	O
a	O
manifestation	O
of	O
reactivated	O
H.	B-KP
	
simplex	I-KP
and	O
V.	B-KP
	
zoster	I-KP
(Ramsey–Hunt)	O
infection,	O
respectively.	O
	
Lyme	B-KP
arthritis	I-KP
differs	O
from	O
other	O
‘septic	B-KP
joint’	O
infections	O
by	O
its	O
insidious	O
onset	O
and	O
lack	O
of	O
pathogen	I-KP
isolation	O
from	O
synovial	I-KP
fluid	I-KP
that	O
would	O
be	O
expected	O
with	O
pyogenic	I-KP
infections	I-KP
such	O
as	O
S.	I-KP
	
aureus,	O
etc.	O
	
However,	O
in	O
adults,	O
reactive	I-KP
arthritis	I-KP
following	O
some	O
gastrointestinal	I-KP
and	I-KP
sexually	I-KP
transmitted	I-KP
infections	I-KP
as	O
well	O
as	O
non-infection	I-KP
inflammatory	I-KP
arthritic	I-KP
processes	I-KP
may	O
take	O
on	O
similar	O
presentations.	O
	
Children	O
with	O
Lyme	I-KP
arthritis	I-KP
often	O
are	O
first	O
thought	O
to	O
possibly	O
have	O
juvenile	I-KP
rheumatoid	I-KP
arthritis,	O
as	O
was	O
the	O
circumstance	O
surrounding	O
the	O
early	O
recognition	O
of	O
Lyme	I-KP
disease	I-KP
in	O
Connecticut	O
in	O
the	O
1970s.	O
	
Lyme	B-KP
borreliosis’	I-KP
natural	O
propensity	O
to	O
evolve	O
from	O
one	O
stage	O
into	O
another,	O
which	O
at	O
times	O
overlap	O
but	O
typically	O
present	O
with	O
their	O
own	O
set	O
of	O
signs,	O
symptoms,	O
and	O
objective	O
measures,	O
is	O
a	O
unique	O
feature	O
of	O
this	O
disease	O
and	O
important	O
factor	O
when	O
creating	O
a	O
differential	O
diagnosis	O
inclusive	O
of	O
both	O
infectious	B-KP
and	I-KP
non-infectious	I-KP
entities	I-KP
potentially	O
accounting	O
for	O
a	O
patient’s	O
condition.	O
	
Furthermore,	O
for	O
some	O
stages	O
of	O
Lyme	B-KP
disease,	I-KP
the	O
time	O
of	O
year	O
of	O
onset	O
coupled	O
with	O
the	O
geographic	O
area	O
where	O
the	O
patient	O
lives	O
or	O
may	O
have	O
traveled	O
to	O
are	O
important	O
epidemiologic	O
pieces	O
of	O
information	O
when	O
considering	O
infection	O
with	O
B.	B-KP
	
burgdorferi.	I-KP
	
Local	B-KP
red	I-KP
skin	I-KP
lesions	I-KP
are	O
not	O
uncommon	O
following	O
the	O
bite	O
of	O
other	O
non-infectious	O
disease	O
transmissible	O
arthropods.	O
	
Features	O
that	O
help	O
to	O
distinguish	O
this	O
hypersensitivity	O
event	O
from	O
a	O
tick	O
bite	O
from	O
those	O
of	O
B.	B-KP
	
burgdorferi	I-KP
EM	I-KP
lesions	I-KP
are	O
that	O
the	O
former	O
appears	O
almost	O
immediately,	O
rapidly	O
expands	O
in	O
size,	O
is	O
associated	O
with	O
local	O
pruritus,	O
is	O
relative	O
small	O
in	O
size,	O
and	O
tends	O
to	O
resolve	O
promptly.80	O
Localized	B-KP
soft	I-KP
tissue	I-KP
infections	I-KP
with	O
Staphylococcal	B-KP
aureus	I-KP
(especially	O
methicillin-resistant	B-KP
strains)	I-KP
frequently	O
and	O
incorrectly	O
attributed	O
to	O
unwitnessed	O
spider	O
bites,	O
along	O
with	O
other	O
pyogenic	B-KP
infections,	I-KP
generally	O
evolve	O
into	O
a	O
cellulitic	O
process	O
fairly	O
distinct	O
from	O
EM.	B-KP
	
The	O
rare	O
vesicular	B-KP
EM	I-KP
may	O
at	O
times	O
be	O
confused	O
with	O
Herpes	B-KP
simplex	I-KP
and	O
Varicella	B-KP
zoster	I-KP
infections,	I-KP
the	O
later	O
of	O
which	O
can	O
be	O
easily	O
excluded	O
by	O
its	O
dermatomal	O
distribution.	O
	
In	O
the	O
absence	O
of	O
EM,	B-KP
the	O
nonspecific	O
manifestations	O
of	O
early	O
Lyme	B-KP
disease	I-KP
such	O
as	O
fever,	B-KP
malaise,	B-KP
headache,	B-KP
myalgias,	B-KP
pain	B-KP
on	I-KP
neck	I-KP
flexion,	I-KP
regional	B-KP
and	I-KP
localized	I-KP
lymphadenopathy,	I-KP
invariably	O
are	O
attributed	O
to	O
an	O
unconfirmed	O
‘viral	O
illness’.	O
	
Altered	O
cranial	B-KP
nerve	I-KP
function	I-KP
associated	O
with	O
Lyme	B-KP
disease,	I-KP
either	O
single,	O
most	O
commonly	O
the	O
7th	O
nerve,	O
or	O
multiple,	O
may	O
also	O
be	O
a	O
manifestation	O
of	O
reactivated	O
H.	B-KP
	
simplex	I-KP
and	O
V.	B-KP
	
zoster	I-KP
(Ramsey–Hunt)	O
infection,	O
respectively.	O
	
Lyme	B-KP
arthritis	I-KP
differs	O
from	O
other	O
‘septic	B-KP
joint’	O
infections	O
by	O
its	O
insidious	O
onset	O
and	O
lack	O
of	O
pathogen	I-KP
isolation	O
from	O
synovial	I-KP
fluid	I-KP
that	O
would	O
be	O
expected	O
with	O
pyogenic	I-KP
infections	I-KP
such	O
as	O
S.	I-KP
	
aureus,	O
etc.	O
	
However,	O
in	O
adults,	O
reactive	I-KP
arthritis	I-KP
following	O
some	O
gastrointestinal	I-KP
and	I-KP
sexually	I-KP
transmitted	I-KP
infections	I-KP
as	O
well	O
as	O
non-infection	I-KP
inflammatory	I-KP
arthritic	I-KP
processes	I-KP
may	O
take	O
on	O
similar	O
presentations.	O
	
Children	O
with	O
Lyme	I-KP
arthritis	I-KP
often	O
are	O
first	O
thought	O
to	O
possibly	O
have	O
juvenile	I-KP
rheumatoid	I-KP
arthritis,	O
as	O
was	O
the	O
circumstance	O
surrounding	O
the	O
early	O
recognition	O
of	O
Lyme	I-KP
disease	I-KP
in	O
Connecticut	O
in	O
the	O
1970s.	O
	
The	O
I.	B-KP
	
scapularis	I-KP
tick	I-KP
is	O
capable	O
of	O
transmitting	O
seven	O
known	O
human	B-KP
pathogens.	I-KP
	
In	O
order	O
of	O
decreasing	O
frequency	O
of	O
reported	O
cases,	O
three	O
of	O
them,	O
B.	B-KP
	
burgdorferi,	I-KP
Anaplasma	B-KP
phagocytophilium,	I-KP
and	O
Babesia	B-KP
microti	I-KP
have	O
accounted	O
for	O
the	O
majority	O
of	O
related	O
infections	O
in	O
recent	O
years.	O
	
[68]	O
An	O
accurate	O
determination	O
of	O
the	O
rate	O
of	O
Lyme	B-KP
disease	I-KP
coinfection	O
with	O
either	O
of	O
these	O
has	O
proven	O
inconclusive	O
but	O
appears	O
to	O
be	O
an	O
uncommon	O
event.	O
	
Human	B-KP
granulocytic	I-KP
anaplasmosis	I-KP
(formerly	O
ehrlichosis)	B-KP
caused	O
by	O
A.	B-KP
	
phagocytophilium	I-KP
typically	O
produces	O
leukopenia,	B-KP
thrombocytopenia,	B-KP
and	O
mild	O
elevation	O
of	O
hepatic	B-KP
amino-transaminases,	I-KP
which	O
when	O
encountered	O
in	O
Lyme	B-KP
disease	I-KP
should	O
prompt	O
the	O
consideration	O
of	O
coinfection	O
with	O
this	O
rickettsial	B-KP
organism.	I-KP
	
[85]	O
The	O
parasitic	O
protozoa	B-KP
B.	I-KP
	
microti	I-KP
is	O
also	O
carried	O
by	O
I.	B-KP
	
scapularis	I-KP
in	O
the	O
Northeast	O
and	O
upper	O
Midwest	O
sections	O
of	O
the	O
United	O
States.	O
	
Infection	O
may	O
also	O
be	O
transmitted	O
by	O
transfusion	O
of	O
infected	B-KP
blood	I-KP
or	O
from	O
an	O
infected	O
mother	O
to	O
her	O
fetus	O
in	O
a	O
vertical	O
fashion.	O
	
[86]	O
Important	O
clues	O
that	O
should	O
raise	O
the	O
possibility	O
of	O
coinfection	O
with	O
this	O
red	B-KP
blood	I-KP
cell	I-KP
pathogen	I-KP
are	O
a	O
more	O
severe	O
presentation	O
of	O
disease,	O
hemolytic	B-KP
anemia	I-KP
and	O
low	O
platelet	O
counts,	O
and	O
the	O
observance	O
of	O
the	O
classic	O
\"maltese	B-KP
cross\"	O
arrangement	O
of	O
organisms	O
within	O
infected	O
erythrocytes.	O
	
Patients	O
with	O
functional	I-KP
or	I-KP
anatomic	I-KP
asplenia	O
are	O
known	O
to	O
suffer	O
the	O
harshest	O
infections.	O
	
[87]	O
The	O
I.	B-KP
	
scapularis	I-KP
tick	I-KP
is	O
capable	O
of	O
transmitting	O
seven	O
known	O
human	B-KP
pathogens.	I-KP
	
In	O
order	O
of	O
decreasing	O
frequency	O
of	O
reported	O
cases,	O
three	O
of	O
them,	O
B.	B-KP
	
burgdorferi,	I-KP
Anaplasma	B-KP
phagocytophilium,	I-KP
and	O
Babesia	B-KP
microti	I-KP
have	O
accounted	O
for	O
the	O
majority	O
of	O
related	O
infections	O
in	O
recent	O
years.	O
	
[68]	O
An	O
accurate	O
determination	O
of	O
the	O
rate	O
of	O
Lyme	B-KP
disease	I-KP
coinfection	O
with	O
either	O
of	O
these	O
has	O
proven	O
inconclusive	O
but	O
appears	O
to	O
be	O
an	O
uncommon	O
event.	O
	
Human	B-KP
granulocytic	I-KP
anaplasmosis	I-KP
(formerly	O
ehrlichosis)	B-KP
caused	O
by	O
A.	B-KP
	
phagocytophilium	I-KP
typically	O
produces	O
leukopenia,	B-KP
thrombocytopenia,	B-KP
and	O
mild	O
elevation	O
of	O
hepatic	B-KP
amino-transaminases,	I-KP
which	O
when	O
encountered	O
in	O
Lyme	B-KP
disease	I-KP
should	O
prompt	O
the	O
consideration	O
of	O
coinfection	O
with	O
this	O
rickettsial	B-KP
organism.	I-KP
	
[85]	O
The	O
parasitic	O
protozoa	B-KP
B.	I-KP
	
microti	I-KP
is	O
also	O
carried	O
by	O
I.	B-KP
	
scapularis	I-KP
in	O
the	O
Northeast	O
and	O
upper	O
Midwest	O
sections	O
of	O
the	O
United	O
States.	O
	
Infection	O
may	O
also	O
be	O
transmitted	O
by	O
transfusion	O
of	O
infected	B-KP
blood	I-KP
or	O
from	O
an	O
infected	O
mother	O
to	O
her	O
fetus	O
in	O
a	O
vertical	O
fashion.	O
	
[86]	O
Important	O
clues	O
that	O
should	O
raise	O
the	O
possibility	O
of	O
coinfection	O
with	O
this	O
red	B-KP
blood	I-KP
cell	I-KP
pathogen	I-KP
are	O
a	O
more	O
severe	O
presentation	O
of	O
disease,	O
hemolytic	B-KP
anemia	I-KP
and	O
low	O
platelet	O
counts,	O
and	O
the	O
observance	O
of	O
the	O
classic	O
\"maltese	B-KP
cross\"	O
arrangement	O
of	O
organisms	O
within	O
infected	O
erythrocytes.	O
	
Patients	O
with	O
functional	I-KP
or	I-KP
anatomic	I-KP
asplenia	O
are	O
known	O
to	O
suffer	O
the	O
harshest	O
infections.	O
	
[87]	O
Assuming	O
the	O
diagnosis	O
of	O
Lyme	B-KP
disease	I-KP
is	O
accurate,	O
90%	O
or	O
more	O
of	O
individuals	O
treated	O
with	O
proven	O
and	O
recommended	O
antimicrobial	B-KP
therapy	I-KP
(Table	O
2)	O
have	O
successful	O
outcomes.	O
	
[22]	O
Conversely,long-term	O
outcome	O
studies	O
of	O
untreated	O
patients	O
followed	O
prospectively	O
have	O
found	O
many	O
of	O
these	O
individuals	O
to	O
have	O
developed	O
any	O
one	O
of	O
a	O
variety	O
of	O
clinical	O
manifestations	O
contributed	O
to	O
Lyme	B-KP
borreliosis	I-KP
at	O
some	O
point	O
in	O
time	O
after	O
the	O
spontaneous	O
resolution	O
of	O
their	O
EM	B-KP
lesion.	I-KP
	
[49]	O
First	O
line	O
agents	O
consist	O
of	O
orally	O
given	O
doxycycline,	B-KP
amoxicillin,	B-KP
and	O
cefuroxime	B-KP
axetil.	I-KP
	
Doxycycline	B-KP
has	O
an	O
added	O
advantage	O
of	O
possessing	O
antimicrobial	O
activity	O
against	O
A.	B-KP
	
phagocytophilium	I-KP
in	O
the	O
event	O
that	O
coinfection	O
has	O
occurred.	O
	
Macrolide	B-KP
antibiotics	I-KP
are	O
considered	O
to	O
be	O
second-line	O
choices	O
in	O
those	O
with	O
intolerance	O
or	O
contraindications	O
to	O
beta-lactam	B-KP
medications	I-KP
and	O
doxycycline,	B-KP
but	O
require	O
cautious	O
clinical	O
follow-up	O
since	O
they	O
have	O
been	O
found	O
to	O
be	O
less	O
effective.	O
	
[95,96]	O
Historically,	O
the	O
length	O
of	O
treatment	O
has	O
been	O
[14–21]	O
days,	O
however,	O
recently	O
available	O
evidence	O
supports	O
shortening	O
the	O
duration	O
of	O
treatment	O
with	O
doxycycline	B-KP
to	O
10	O
days.	O
	
[97]	O
Retreatment	O
is	O
rarely	O
if	O
at	O
all	O
ever	O
necessary,	O
as	O
individuals	O
with	O
persistent	O
subjective	O
symptoms,	O
but	O
no	O
objective	O
findings	O
of	O
ongoing	O
active	O
infection	O
have	O
not	O
been	O
found	O
to	O
benefit	O
from	O
additional	O
courses	O
of	O
antibiotics.	B-KP
	
[98,99]	O
The	O
third-generation	O
intravenous	O
(IV)	B-KP
cephalosporin	I-KP
antibiotic,	O
ceftriaxone,	O
has	O
excellent	O
in-vitro	O
antibacterial	O
activity	O
against	O
B.	I-KP
	
burgdorferi,	O
but	O
in	O
almost	O
all	O
clinical	O
circumstances	O
provides	O
little	O
if	O
any	O
clear	O
benefit	O
over	O
the	O
use	O
of	O
oral	I-KP
doxycycline.	O
	
[100–102]	O
Nonetheless,	O
2–4-week	O
courses	O
of	O
intravenous	I-KP
ceftriaxone	I-KP
is	O
still	O
commonly	O
recommended	O
and	O
given	O
for	O
in	O
patients	O
with	O
Lyme	I-KP
disease	I-KP
and	O
unquestionable	O
objective	O
neurologic	I-KP
abnormalities.103	O
Likewise,	O
hospitalized	O
patients	O
with	O
high-degree	O
atrioventricular	I-KP
block	I-KP
are	O
initially	O
treated	O
with	O
intravenous	I-KP
ceftriaxone	I-KP
and	O
with	O
completion	O
of	O
the	O
14–21-day	O
treatment	O
course	O
using	O
an	O
oral	I-KP
agent.	O
	
[22]	O
Placement	O
of	O
a	O
permanent	O
cardiac	I-KP
pacemaker	I-KP
is	O
rarely,	O
if	O
ever	O
required,	O
although	O
at	O
times,	O
a	O
temporary	O
transvenous	O
or	O
external	O
pacemaker	O
is	O
indicated.104	O
Lesser	O
degrees	O
of	O
heart	O
block	O
(first-degree	O
AV	I-KP
block,	O
PR	O
interval	O
<	O
300	O
msec)	O
can	O
be	O
managed	O
with	O
oral	I-KP
agents	I-KP
alone.	O
	
Assuming	O
the	O
diagnosis	O
of	O
Lyme	B-KP
disease	I-KP
is	O
accurate,	O
90%	O
or	O
more	O
of	O
individuals	O
treated	O
with	O
proven	O
and	O
recommended	O
antimicrobial	B-KP
therapy	I-KP
(Table	O
2)	O
have	O
successful	O
outcomes.	O
	
[22]	O
Conversely,long-term	O
outcome	O
studies	O
of	O
untreated	O
patients	O
followed	O
prospectively	O
have	O
found	O
many	O
of	O
these	O
individuals	O
to	O
have	O
developed	O
any	O
one	O
of	O
a	O
variety	O
of	O
clinical	O
manifestations	O
contributed	O
to	O
Lyme	B-KP
borreliosis	I-KP
at	O
some	O
point	O
in	O
time	O
after	O
the	O
spontaneous	O
resolution	O
of	O
their	O
EM	B-KP
lesion.	I-KP
	
[49]	O
First	O
line	O
agents	O
consist	O
of	O
orally	O
given	O
doxycycline,	B-KP
amoxicillin,	B-KP
and	O
cefuroxime	B-KP
axetil.	I-KP
	
Doxycycline	B-KP
has	O
an	O
added	O
advantage	O
of	O
possessing	O
antimicrobial	O
activity	O
against	O
A.	B-KP
	
phagocytophilium	I-KP
in	O
the	O
event	O
that	O
coinfection	O
has	O
occurred.	O
	
Macrolide	B-KP
antibiotics	I-KP
are	O
considered	O
to	O
be	O
second-line	O
choices	O
in	O
those	O
with	O
intolerance	O
or	O
contraindications	O
to	O
beta-lactam	B-KP
medications	I-KP
and	O
doxycycline,	B-KP
but	O
require	O
cautious	O
clinical	O
follow-up	O
since	O
they	O
have	O
been	O
found	O
to	O
be	O
less	O
effective.	O
	
[95,96]	O
Historically,	O
the	O
length	O
of	O
treatment	O
has	O
been	O
[14–21]	O
days,	O
however,	O
recently	O
available	O
evidence	O
supports	O
shortening	O
the	O
duration	O
of	O
treatment	O
with	O
doxycycline	B-KP
to	O
10	O
days.	O
	
[97]	O
Retreatment	O
is	O
rarely	O
if	O
at	O
all	O
ever	O
necessary,	O
as	O
individuals	O
with	O
persistent	O
subjective	O
symptoms,	O
but	O
no	O
objective	O
findings	O
of	O
ongoing	O
active	O
infection	O
have	O
not	O
been	O
found	O
to	O
benefit	O
from	O
additional	O
courses	O
of	O
antibiotics.	B-KP
	
[98,99]	O
The	O
third-generation	O
intravenous	O
(IV)	B-KP
cephalosporin	I-KP
antibiotic,	O
ceftriaxone,	O
has	O
excellent	O
in-vitro	O
antibacterial	O
activity	O
against	O
B.	I-KP
	
burgdorferi,	O
but	O
in	O
almost	O
all	O
clinical	O
circumstances	O
provides	O
little	O
if	O
any	O
clear	O
benefit	O
over	O
the	O
use	O
of	O
oral	I-KP
doxycycline.	O
	
[100–102]	O
Nonetheless,	O
2–4-week	O
courses	O
of	O
intravenous	I-KP
ceftriaxone	I-KP
is	O
still	O
commonly	O
recommended	O
and	O
given	O
for	O
in	O
patients	O
with	O
Lyme	I-KP
disease	I-KP
and	O
unquestionable	O
objective	O
neurologic	I-KP
abnormalities.103	O
Likewise,	O
hospitalized	O
patients	O
with	O
high-degree	O
atrioventricular	I-KP
block	I-KP
are	O
initially	O
treated	O
with	O
intravenous	I-KP
ceftriaxone	I-KP
and	O
with	O
completion	O
of	O
the	O
14–21-day	O
treatment	O
course	O
using	O
an	O
oral	I-KP
agent.	O
	
[22]	O
Placement	O
of	O
a	O
permanent	O
cardiac	I-KP
pacemaker	I-KP
is	O
rarely,	O
if	O
ever	O
required,	O
although	O
at	O
times,	O
a	O
temporary	O
transvenous	O
or	O
external	O
pacemaker	O
is	O
indicated.104	O
Lesser	O
degrees	O
of	O
heart	O
block	O
(first-degree	O
AV	I-KP
block,	O
PR	O
interval	O
<	O
300	O
msec)	O
can	O
be	O
managed	O
with	O
oral	I-KP
agents	I-KP
alone.	O
	
Tick-borne	B-KP
diseases	I-KP
(TBD)	B-KP
present	O
a	O
major	O
public	O
health	O
problem	O
in	O
the	O
United	O
States,	O
where	O
74.7%of	O
clinicians	O
in	O
high-incidence	O
states	O
report	O
having	O
treated	O
a	O
patient	O
for	O
TBD	I-KP
in	O
the	O
previous	O
year	O
(Brett	O
et	O
al.,	O
2014).	O
	
In	O
the	O
United	O
States,	O
more	O
than	O
a	O
dozen	O
pathogens	I-KP
can	O
be	O
transmitted	O
by	O
five	O
different	O
genera	O
ofticks	O
(Shah	O
and	O
Sood,	O
2013).	O
	
When	O
a	O
primary	O
care	O
provider	O
sees	O
a	O
patient	O
who	O
has	O
removed	O
and	O
saved	O
an	O
attached	O
tick,	O
it	O
is	O
important	O
to	O
identify	O
the	O
tick	O
genus	O
or	O
common	O
name	O
to	O
determine	O
which	O
pathogens	I-KP
were	O
potentially	O
transmitted	O
and	O
whether	O
antibiotic	I-KP
prophylaxis	I-KP
for	O
Lyme	I-KP
disease	I-KP
is	O
appropriate.	O
	
Some	O
41.1%	O
of	O
providers	O
in	O
states	O
with	O
high	O
Lyme	I-KP
disease	I-KP
incidence	O
recently	O
reported	O
providing	O
tick-bite	I-KP
prophylaxis	I-KP
in	O
the	O
previous	O
year	O
(Brett	O
et	O
al.,	O
2014).	O
	
Notably,	O
misidentification	O
of	O
a	O
tick	O
may	O
lead	O
to	O
unnecessary	O
prophylactic	I-KP
antibiotic	I-KP
treatment,	O
unwarranted	O
testing,	O
or	O
potentially	O
a	O
missed	O
diagnosis	O
of	O
TBD.	O
	
To	O
date,	O
only	O
one	O
study	O
has	O
been	O
published	O
on	O
tick	O
identification	O
by	O
providers	O
in	O
a	B-KP
Lyme	I-KP
disease	O
endemic	I-KP
area	O
(Falco	O
et	O
al.,	O
1998).\nThis	O
study	O
examined	O
specimens	O
submitted	O
by	O
physicians	O
or	O
medical	O
groups	O
to	O
the	O
Fordham	O
University	O
Vector	O
Ecology	O
Laboratory	O
in	O
Westchester	O
County,	O
NY	O
between	O
1988	O
and	O
1990	O
for	O
tick	O
identification.	O
	
Among	O
802	O
submitted	O
specimens,	O
74.7%	O
were	O
blacklegged	O
ticks	O
(Ixodes	O
scapularis).	O
	
It	O
is	O
unclear,	O
however,	O
whether	O
all	O
of	O
these	O
specimens	O
were	O
initially	O
suspected	O
to	O
have	O
been	O
blacklegged	O
ticks	O
and	O
thus	O
whether	O
the	O
remaining	O
25.3%	O
were	O
incorrectly	O
identified.	O
	
Notably,	O
5.9%	O
of	O
specimens	O
submitted	O
for	O
tick	O
identification	O
were	O
non-tick	O
arthropods	O
including	O
beetles,	O
crab	O
lice,	O
and	O
head	O
lice.	O
	
It	O
is	O
also	O
unknown	O
how	O
well	O
this	O
sample	O
represents	O
tick	O
identification	O
by	O
providers	O
during	O
regular	O
clinical	O
practice	O
and	O
not	O
as	O
part	O
of	O
a	O
tick	O
identification	O
service.	O
	
Tick-borne	B-KP
diseases	I-KP
(TBD)	B-KP
present	O
a	O
major	O
public	O
health	O
problem	O
in	O
the	O
United	O
States,	O
where	O
74.7%of	O
clinicians	O
in	O
high-incidence	O
states	O
report	O
having	O
treated	O
a	O
patient	O
for	O
TBD	I-KP
in	O
the	O
previous	O
year	O
(Brett	O
et	O
al.,	O
2014).	O
	
In	O
the	O
United	O
States,	O
more	O
than	O
a	O
dozen	O
pathogens	I-KP
can	O
be	O
transmitted	O
by	O
five	O
different	O
genera	O
ofticks	O
(Shah	O
and	O
Sood,	O
2013).	O
	
When	O
a	O
primary	O
care	O
provider	O
sees	O
a	O
patient	O
who	O
has	O
removed	O
and	O
saved	O
an	O
attached	O
tick,	O
it	O
is	O
important	O
to	O
identify	O
the	O
tick	O
genus	O
or	O
common	O
name	O
to	O
determine	O
which	O
pathogens	I-KP
were	O
potentially	O
transmitted	O
and	O
whether	O
antibiotic	I-KP
prophylaxis	I-KP
for	O
Lyme	I-KP
disease	I-KP
is	O
appropriate.	O
	
Some	O
41.1%	O
of	O
providers	O
in	O
states	O
with	O
high	O
Lyme	I-KP
disease	I-KP
incidence	O
recently	O
reported	O
providing	O
tick-bite	I-KP
prophylaxis	I-KP
in	O
the	O
previous	O
year	O
(Brett	O
et	O
al.,	O
2014).	O
	
Notably,	O
misidentification	O
of	O
a	O
tick	O
may	O
lead	O
to	O
unnecessary	O
prophylactic	I-KP
antibiotic	I-KP
treatment,	O
unwarranted	O
testing,	O
or	O
potentially	O
a	O
missed	O
diagnosis	O
of	O
TBD.	O
	
To	O
date,	O
only	O
one	O
study	O
has	O
been	O
published	O
on	O
tick	O
identification	O
by	O
providers	O
in	O
a	B-KP
Lyme	I-KP
disease	O
endemic	I-KP
area	O
(Falco	O
et	O
al.,	O
1998).\nThis	O
study	O
examined	O
specimens	O
submitted	O
by	O
physicians	O
or	O
medical	O
groups	O
to	O
the	O
Fordham	O
University	O
Vector	O
Ecology	O
Laboratory	O
in	O
Westchester	O
County,	O
NY	O
between	O
1988	O
and	O
1990	O
for	O
tick	O
identification.	O
	
Among	O
802	O
submitted	O
specimens,	O
74.7%	O
were	O
blacklegged	O
ticks	O
(Ixodes	O
scapularis).	O
	
It	O
is	O
unclear,	O
however,	O
whether	O
all	O
of	O
these	O
specimens	O
were	O
initially	O
suspected	O
to	O
have	O
been	O
blacklegged	O
ticks	O
and	O
thus	O
whether	O
the	O
remaining	O
25.3%	O
were	O
incorrectly	O
identified.	O
	
Notably,	O
5.9%	O
of	O
specimens	O
submitted	O
for	O
tick	O
identification	O
were	O
non-tick	O
arthropods	O
including	O
beetles,	O
crab	O
lice,	O
and	O
head	O
lice.	O
	
It	O
is	O
also	O
unknown	O
how	O
well	O
this	O
sample	O
represents	O
tick	O
identification	O
by	O
providers	O
during	O
regular	O
clinical	O
practice	O
and	O
not	O
as	O
part	O
of	O
a	O
tick	O
identification	O
service.	O
	
The	O
following	O
day,	O
the	O
patient	O
was	O
evaluated	O
by	O
a	O
neurosurgeon,	O
who	O
noted	O
that	O
the	O
right	O
bicep	O
and	O
brachioradial	O
reflexes	O
were	O
absent	O
which	O
was	O
a	O
variation	O
from	O
the	O
initial	O
presentation	O
in	O
the	O
ED.	O
	
The	O
neurosurgeon	O
recommended	O
further	O
testing	O
including	O
a	O
myelogram	B-KP
and	O
lumbar	B-KP
puncture	I-KP
to	O
assess	O
the	O
cerebrospinal	B-KP
fluid	I-KP
(CSF)	B-KP
due	O
to	O
the	O
patient’s	O
symptomatology.	O
	
The	O
patient	O
was	O
placed	O
on	O
dexamethasone	I-KP
(Decadron)	B-KP
4	O
mg	O
every	O
6	O
hr	O
intravenously	O
and	O
the	O
outpatient	O
medications	O
were	O
also	O
continued.	O
	
A	B-KP
lumbar	I-KP
puncture	O
(LP)	O
was	O
performed	O
and	B-KP
CSF	I-KP
samples	O
were	O
sent	O
to	O
the	O
lab.	O
	
Results	O
were	O
positive	O
for	O
elevated	O
glucose,	O
white	I-KP
blood	I-KP
cells,	O
and	B-KP
protein	I-KP
levels.	O
	
The	B-KP
CSF	O
was	O
also	O
positive	O
for	O
Lyme	O
(Table	O
2).	O
	
An	O
infectious	O
disease	O
consult	O
was	O
ordered	O
and	O
the	O
patient	O
was	O
seen	O
that	O
day.	O
	
The	O
infectious	O
disease	O
physician	O
obtained	O
further	O
history	O
of	O
a	O
rash	O
on	O
the	O
right	O
chest	O
wall	O
that	O
developed	O
prior	O
to	O
the	O
patient’s	O
symptoms.	O
	
The	O
patient	O
did	O
not	O
recall	O
seeing	O
a	O
tick	O
at	O
the	O
site	O
of	O
the	B-KP
rash.	O
	
The	O
physician	O
noted	O
a	O
slight	O
left	O
facial	O
droop	O
and	O
an	I-KP
erythematous	I-KP
area	O
to	O
the	O
right	O
chest	O
wall	O
lateral	O
to	O
the	B-KP
breast.	O
	
According	O
to	O
the	O
physician,	O
the	B-KP
lesion	O
was	O
not	O
consistent	O
with	B-KP
erythema	I-KP
migrans	O
at	O
the	O
time	O
of	O
the	O
examination.	O
	
The	O
physician	O
ordered	O
a	O
repeat	B-KP
LP	O
to	O
further	O
evaluate	O
the	O
CSF	O
(Table	O
2).	O
	
Further	O
Lyme	O
studies	O
were	O
ordered	O
and	O
obtained	O
and	O
the	O
results	O
are	O
shown	O
in	O
Table	O
3.	O
	
The	O
following	O
day,	O
the	O
patient	O
was	O
evaluated	O
by	O
a	O
neurosurgeon,	O
who	O
noted	O
that	O
the	O
right	O
bicep	O
and	O
brachioradial	O
reflexes	O
were	O
absent	O
which	O
was	O
a	O
variation	O
from	O
the	O
initial	O
presentation	O
in	O
the	O
ED.	O
	
The	O
neurosurgeon	O
recommended	O
further	O
testing	O
including	O
a	O
myelogram	B-KP
and	O
lumbar	B-KP
puncture	I-KP
to	O
assess	O
the	O
cerebrospinal	B-KP
fluid	I-KP
(CSF)	B-KP
due	O
to	O
the	O
patient’s	O
symptomatology.	O
	
The	O
patient	O
was	O
placed	O
on	O
dexamethasone	I-KP
(Decadron)	B-KP
4	O
mg	O
every	O
6	O
hr	O
intravenously	O
and	O
the	O
outpatient	O
medications	O
were	O
also	O
continued.	O
	
A	B-KP
lumbar	I-KP
puncture	O
(LP)	O
was	O
performed	O
and	B-KP
CSF	I-KP
samples	O
were	O
sent	O
to	O
the	O
lab.	O
	
Results	O
were	O
positive	O
for	O
elevated	O
glucose,	O
white	I-KP
blood	I-KP
cells,	O
and	B-KP
protein	I-KP
levels.	O
	
The	B-KP
CSF	O
was	O
also	O
positive	O
for	O
Lyme	O
(Table	O
2).	O
	
An	O
infectious	O
disease	O
consult	O
was	O
ordered	O
and	O
the	O
patient	O
was	O
seen	O
that	O
day.	O
	
The	O
infectious	O
disease	O
physician	O
obtained	O
further	O
history	O
of	O
a	O
rash	O
on	O
the	O
right	O
chest	O
wall	O
that	O
developed	O
prior	O
to	O
the	O
patient’s	O
symptoms.	O
	
The	O
patient	O
did	O
not	O
recall	O
seeing	O
a	O
tick	O
at	O
the	O
site	O
of	O
the	B-KP
rash.	O
	
The	O
physician	O
noted	O
a	O
slight	O
left	O
facial	O
droop	O
and	O
an	I-KP
erythematous	I-KP
area	O
to	O
the	O
right	O
chest	O
wall	O
lateral	O
to	O
the	B-KP
breast.	O
	
According	O
to	O
the	O
physician,	O
the	B-KP
lesion	O
was	O
not	O
consistent	O
with	B-KP
erythema	I-KP
migrans	O
at	O
the	O
time	O
of	O
the	O
examination.	O
	
The	O
physician	O
ordered	O
a	O
repeat	B-KP
LP	O
to	O
further	O
evaluate	O
the	O
CSF	O
(Table	O
2).	O
	
Further	O
Lyme	O
studies	O
were	O
ordered	O
and	O
obtained	O
and	O
the	O
results	O
are	O
shown	O
in	O
Table	O
3.	O
	
Three	O
pathogenic	B-KP
Borrelia	I-KP
species	I-KP
are	O
primarily	O
responsible	O
for	O
Lyme	B-KP
disease,	I-KP
the	O
most	O
common	O
tick-transmitted	O
illness	O
of	O
the	O
boreal	O
hemisphere	O
(1,2).	O
	
In	O
Europe,	O
Lyme	B-KP
disease	I-KP
is	O
caused	O
by	O
Borrelia	B-KP
burgdorferi,	I-KP
Borrelia	B-KP
afzelii,	I-KP
and	O
Borrelia	B-KP
garinii,	I-KP
whereas	O
in	O
the	O
US,	O
Borrelia	B-KP
burgdorferi	I-KP
is	O
the	O
sole	O
cause	O
(3,4).	O
	
Lyme	B-KP
disease	I-KP
usually	O
begins	O
with	O
a	O
characteristic	O
expanding	O
skin	B-KP
lesion,	I-KP
erythema	B-KP
migrans	I-KP
(5).	O
	
After	O
several	O
days	O
or	O
weeks,	O
the	O
spirochete	B-KP
may	O
spread	O
to	O
different	O
sites,	O
causing	O
meningitis,	B-KP
cranial	B-KP
or	I-KP
peripheral	I-KP
neuritis,	I-KP
carditis,	B-KP
atrioventricular	B-KP
node	I-KP
block,	I-KP
or	O
migratory	B-KP
musculoskeletal	I-KP
pain.	I-KP
	
Months	O
later,	O
Lyme	B-KP
arthritis	I-KP
may	O
develop	O
in	O
untreated	O
patients	O
with	O
Borrelia	B-KP
infection,	I-KP
with	O
a	O
rapid	O
onset	O
of	O
marked	O
swelling	O
and	O
pain	O
of	O
affected	O
joints,	O
most	O
commonly	O
the	O
knee	O
(6).	O
	
In	O
these	O
patients,	O
synovial	B-KP
fluid	I-KP
contains	O
polymorphonuclear	B-KP
and	I-KP
mononuclear	I-KP
cells	I-KP
(7).	O
	
In	O
most	O
patients,	O
Lyme	B-KP
arthritis	I-KP
responds	O
to	O
appropriate	O
oral	B-KP
or	I-KP
intravenous	I-KP
antibiotic	I-KP
therapy.	I-KP
	
However,	O
in	O
rare	O
cases,	O
proliferative	B-KP
synovitis	I-KP
persists	O
after	O
2	O
months	O
of	O
treatment	O
with	O
oral	B-KP
antibiotics	I-KP
or	O
1	O
month	O
of	O
treatment	O
with	O
intravenous	B-KP
antibiotics,	I-KP
or	O
both.	O
	
This	O
condition	O
is	O
called	O
antibiotic-refractory	B-KP
Lyme	I-KP
arthritis	I-KP
(3).	O
	
Three	O
pathogenic	B-KP
Borrelia	I-KP
species	I-KP
are	O
primarily	O
responsible	O
for	O
Lyme	B-KP
disease,	I-KP
the	O
most	O
common	O
tick-transmitted	O
illness	O
of	O
the	O
boreal	O
hemisphere	O
(1,2).	O
	
In	O
Europe,	O
Lyme	B-KP
disease	I-KP
is	O
caused	O
by	O
Borrelia	B-KP
burgdorferi,	I-KP
Borrelia	B-KP
afzelii,	I-KP
and	O
Borrelia	B-KP
garinii,	I-KP
whereas	O
in	O
the	O
US,	O
Borrelia	B-KP
burgdorferi	I-KP
is	O
the	O
sole	O
cause	O
(3,4).	O
	
Lyme	B-KP
disease	I-KP
usually	O
begins	O
with	O
a	O
characteristic	O
expanding	O
skin	B-KP
lesion,	I-KP
erythema	B-KP
migrans	I-KP
(5).	O
	
After	O
several	O
days	O
or	O
weeks,	O
the	O
spirochete	B-KP
may	O
spread	O
to	O
different	O
sites,	O
causing	O
meningitis,	B-KP
cranial	B-KP
or	I-KP
peripheral	I-KP
neuritis,	I-KP
carditis,	B-KP
atrioventricular	B-KP
node	I-KP
block,	I-KP
or	O
migratory	B-KP
musculoskeletal	I-KP
pain.	I-KP
	
Months	O
later,	O
Lyme	B-KP
arthritis	I-KP
may	O
develop	O
in	O
untreated	O
patients	O
with	O
Borrelia	B-KP
infection,	I-KP
with	O
a	O
rapid	O
onset	O
of	O
marked	O
swelling	O
and	O
pain	O
of	O
affected	O
joints,	O
most	O
commonly	O
the	O
knee	O
(6).	O
	
In	O
these	O
patients,	O
synovial	B-KP
fluid	I-KP
contains	O
polymorphonuclear	B-KP
and	I-KP
mononuclear	I-KP
cells	I-KP
(7).	O
	
In	O
most	O
patients,	O
Lyme	B-KP
arthritis	I-KP
responds	O
to	O
appropriate	O
oral	B-KP
or	I-KP
intravenous	I-KP
antibiotic	I-KP
therapy.	I-KP
	
However,	O
in	O
rare	O
cases,	O
proliferative	B-KP
synovitis	I-KP
persists	O
after	O
2	O
months	O
of	O
treatment	O
with	O
oral	B-KP
antibiotics	I-KP
or	O
1	O
month	O
of	O
treatment	O
with	O
intravenous	B-KP
antibiotics,	I-KP
or	O
both.	O
	
This	O
condition	O
is	O
called	O
antibiotic-refractory	B-KP
Lyme	I-KP
arthritis	I-KP
(3).	O
	
NapA	B-KP
was	O
cloned,	O
expressed,	O
and	O
purified	O
from	O
Bacillus	B-KP
subtilis.	I-KP
	
The	O
NapA	B-KP
gene	I-KP
was	O
amplified	O
by	O
polymerase	B-KP
chain	I-KP
reaction	I-KP
(PCR)	B-KP
from	O
B	I-KP
burgdorferi	I-KP
strain	I-KP
B31,	O
using	O
standard	O
methods.	O
	
The	O
following	O
primers	O
were	O
used:	O
5-CCCGAGCTCATAAAGGAGATAG-TTATG-3'	O
and	O
5-CCCAAGCTTCTATTTTGCATCACA-CTC-3'	O
(underlining	O
indicates	O
Sac	O
I	O
and	O
Hind	O
III	O
restriction	I-KP
enzyme	I-KP
sites,	O
respectively).	O
	
The	O
amplified	O
fragment	I-KP
was	O
digested	O
and	O
inserted	O
into	O
the	O
expression	I-KP
vector	I-KP
pSM214G,	O
resulting	O
in	O
plasmid	I-KP
pSM214G-NapA.	O
	
B	I-KP
subtilis	I-KP
strain	I-KP
SMS	I-KP
118	I-KP
containing	O
the	O
plasmid	I-KP
pSM214G-NapA	I-KP
was	O
grown	O
for	O
15	O
hours	O
in	O
YT	O
medium	O
and	O
15	O
μg/ml	O
of	O
chloramphenicol.	O
	
After	O
centrifugation,	O
cells	O
were	O
resuspended	O
in	O
30	O
mM	O
Tris	O
HCl,	O
pH	O
7.8,	O
and	O
lysed	O
through	O
3	O
French	O
press	O
passages.	O
	
Debris	O
was	O
removed	O
by	O
centrifugation,	O
and	O
ammonium	O
sulfate	O
60%	O
was	O
added	O
to	O
the	O
supernatant.	O
	
NapA	B-KP
was	O
cloned,	O
expressed,	O
and	O
purified	O
from	O
Bacillus	B-KP
subtilis.	I-KP
	
The	O
NapA	B-KP
gene	I-KP
was	O
amplified	O
by	O
polymerase	B-KP
chain	I-KP
reaction	I-KP
(PCR)	B-KP
from	O
B	I-KP
burgdorferi	I-KP
strain	I-KP
B31,	O
using	O
standard	O
methods.	O
	
The	O
following	O
primers	O
were	O
used:	O
5-CCCGAGCTCATAAAGGAGATAG-TTATG-3'	O
and	O
5-CCCAAGCTTCTATTTTGCATCACA-CTC-3'	O
(underlining	O
indicates	O
Sac	O
I	O
and	O
Hind	O
III	O
restriction	I-KP
enzyme	I-KP
sites,	O
respectively).	O
	
The	O
amplified	O
fragment	I-KP
was	O
digested	O
and	O
inserted	O
into	O
the	O
expression	I-KP
vector	I-KP
pSM214G,	O
resulting	O
in	O
plasmid	I-KP
pSM214G-NapA.	O
	
B	I-KP
subtilis	I-KP
strain	I-KP
SMS	I-KP
118	I-KP
containing	O
the	O
plasmid	I-KP
pSM214G-NapA	I-KP
was	O
grown	O
for	O
15	O
hours	O
in	O
YT	O
medium	O
and	O
15	O
μg/ml	O
of	O
chloramphenicol.	O
	
After	O
centrifugation,	O
cells	O
were	O
resuspended	O
in	O
30	O
mM	O
Tris	O
HCl,	O
pH	O
7.8,	O
and	O
lysed	O
through	O
3	O
French	O
press	O
passages.	O
	
Debris	O
was	O
removed	O
by	O
centrifugation,	O
and	O
ammonium	O
sulfate	O
60%	O
was	O
added	O
to	O
the	O
supernatant.	O
	
Real-time	O
PCR	B-KP
analysis.	I-KP
	
Total	O
RNA	B-KP
was	O
isolated	O
from	O
2	O
×	O
10^6	O
monocytes	O
using	O
TRIzol	O
solution	O
(Invitrogen,	O
San	O
Diego,	O
CA)	O
according	O
to	O
the	O
manufacturer’s	O
instructions.	O
	
RNA	B-KP
was	O
reverse-transcribed	O
and	O
amplified	O
with	O
the	O
following	O
primers:	B-KP
for	O
GAPDH,	B-KP
5'-AGCAACAGGGTGGTGGAC-3'	O
and	O
5'-GTGTGGTGGGGGACTGAG-3';	O
for	O
IL-23p19,	B-KP
5'-TCC-ACCAGGGTCTGATTTTT-3'	O
and	O
5'-TTGAAGCGGAGAAGGAGACG-3';	O
for	O
IL-12p40,	B-KP
5'-ACAAAGGAGGCGAGGTTCTAA-3'	O
and	O
5'-CCCTTGGGGGTCAGAAGAG-3';	O
for	O
IL-6,	B-KP
5'-AACCTGAACCTTCCAAAGATGG-3'	O
and	O
5'-TCTGGCTTGTTCCTCACTACT-3';	O
for	O
TGFβ,	B-KP
5'-AGTGGTTGAGCCGTGGAG-3'	O
and	O
5'-CCATGAGAAGCAGGAAAGG-3';	O
and	O
for	O
IL-1,	B-KP
5-CTGTCCTGCGTGTTGAAAGA-3'	O
and	O
5'-TTGGGTAATTTTTGGGATCTACA-3'.	O
	
After	O
the	O
amplification,	O
data	O
analysis	O
was	O
performed	O
using	O
the	O
second	O
derivative	O
method	O
algorithm.	O
	
For	O
each	O
sample,	O
the	O
amount	O
of	O
messenger	B-KP
RNA	I-KP
(mRNA)	B-KP
of	O
the	O
cytokines	I-KP
(IL-23p19,	B-KP
IL-12p40,	O
IL-6,	O
TGFβ,	O
and	O
IL-1β)	O
was	O
expressed	O
as	O
the	O
n-fold	O
of	O
the	O
normalized	O
amount	O
of	O
mRNA	I-KP
in	O
untreated	O
cells	O
(1	O
arbitrary	O
unit	O
cytokine	O
mRNA	B-KP
concentration/GAPDH	O
mRNA	I-KP
concentration	O
[both	O
in	O
fmoles/μl]).	O
	
Real-time	O
PCR	B-KP
analysis.	I-KP
	
Total	O
RNA	B-KP
was	O
isolated	O
from	O
2	O
×	O
10^6	O
monocytes	O
using	O
TRIzol	O
solution	O
(Invitrogen,	O
San	O
Diego,	O
CA)	O
according	O
to	O
the	O
manufacturer’s	O
instructions.	O
	
RNA	B-KP
was	O
reverse-transcribed	O
and	O
amplified	O
with	O
the	O
following	O
primers:	B-KP
for	O
GAPDH,	B-KP
5'-AGCAACAGGGTGGTGGAC-3'	O
and	O
5'-GTGTGGTGGGGGACTGAG-3';	O
for	O
IL-23p19,	B-KP
5'-TCC-ACCAGGGTCTGATTTTT-3'	O
and	O
5'-TTGAAGCGGAGAAGGAGACG-3';	O
for	O
IL-12p40,	B-KP
5'-ACAAAGGAGGCGAGGTTCTAA-3'	O
and	O
5'-CCCTTGGGGGTCAGAAGAG-3';	O
for	O
IL-6,	B-KP
5'-AACCTGAACCTTCCAAAGATGG-3'	O
and	O
5'-TCTGGCTTGTTCCTCACTACT-3';	O
for	O
TGFβ,	B-KP
5'-AGTGGTTGAGCCGTGGAG-3'	O
and	O
5'-CCATGAGAAGCAGGAAAGG-3';	O
and	O
for	O
IL-1,	B-KP
5-CTGTCCTGCGTGTTGAAAGA-3'	O
and	O
5'-TTGGGTAATTTTTGGGATCTACA-3'.	O
	
After	O
the	O
amplification,	O
data	O
analysis	O
was	O
performed	O
using	O
the	O
second	O
derivative	O
method	O
algorithm.	O
	
For	O
each	O
sample,	O
the	O
amount	O
of	O
messenger	B-KP
RNA	I-KP
(mRNA)	B-KP
of	O
the	O
cytokines	I-KP
(IL-23p19,	B-KP
IL-12p40,	O
IL-6,	O
TGFβ,	O
and	O
IL-1β)	O
was	O
expressed	O
as	O
the	O
n-fold	O
of	O
the	O
normalized	O
amount	O
of	O
mRNA	I-KP
in	O
untreated	O
cells	O
(1	O
arbitrary	O
unit	O
cytokine	O
mRNA	B-KP
concentration/GAPDH	O
mRNA	I-KP
concentration	O
[both	O
in	O
fmoles/μl]).	O
	
Bacterial	B-KP
meningitis	I-KP
clinical	O
prediction	O
rules	O
identify	O
children	O
with	O
cerebrospinal	B-KP
fluid	I-KP
(CSF)	B-KP
pleocytosis	I-KP
who	O
are	O
at	O
very	O
low	O
risk	O
of	O
bacterial	I-KP
meningitis.	O
	
[1–6]	O
However,	O
in	O
Lyme	I-KP
disease–endemic	O
areas,	O
such	O
as	O
the	O
northeastern	O
and	O
mid-Atlantic	O
states,	O
children	O
with	O
CSF	I-KP
pleocytosis	I-KP
who	O
are	O
at	O
low	O
risk	O
of	O
bacterial	I-KP
meningitis	I-KP
may	O
still	O
have	O
Lyme	I-KP
meningitis,	O
which	O
is	O
treated	O
with	O
3	O
to	O
4	O
weeks	O
of	O
parenteral	O
antibiotics.	O
	
[7,8]	O
Because	O
it	O
takes	O
several	O
days	O
to	O
obtain	O
Borrelia	I-KP
burgdorferi	I-KP
serology	I-KP
results,	O
clinicians	O
must	O
decide	O
whether	O
to	O
hospitalize	O
and	O
to	O
start	O
empirical	O
antibiotics	I-KP
for	O
children	O
being	O
evaluated	O
for	O
Lyme	I-KP
meningitis.	O
	
Bacterial	B-KP
meningitis	I-KP
clinical	O
prediction	O
rules	O
identify	O
children	O
with	O
cerebrospinal	B-KP
fluid	I-KP
(CSF)	B-KP
pleocytosis	I-KP
who	O
are	O
at	O
very	O
low	O
risk	O
of	O
bacterial	I-KP
meningitis.	O
	
[1–6]	O
However,	O
in	O
Lyme	I-KP
disease–endemic	O
areas,	O
such	O
as	O
the	O
northeastern	O
and	O
mid-Atlantic	O
states,	O
children	O
with	O
CSF	I-KP
pleocytosis	I-KP
who	O
are	O
at	O
low	O
risk	O
of	O
bacterial	I-KP
meningitis	I-KP
may	O
still	O
have	O
Lyme	I-KP
meningitis,	O
which	O
is	O
treated	O
with	O
3	O
to	O
4	O
weeks	O
of	O
parenteral	O
antibiotics.	O
	
[7,8]	O
Because	O
it	O
takes	O
several	O
days	O
to	O
obtain	O
Borrelia	I-KP
burgdorferi	I-KP
serology	I-KP
results,	O
clinicians	O
must	O
decide	O
whether	O
to	O
hospitalize	O
and	O
to	O
start	O
empirical	O
antibiotics	I-KP
for	O
children	O
being	O
evaluated	O
for	O
Lyme	I-KP
meningitis.	O
	
Early	O
identification	O
of	O
those	O
children	O
at	O
low	O
risk	O
for	O
Lyme	B-KP
meningitis	I-KP
would	O
allow	O
for	O
outpatient	O
management	O
while	O
awaiting	O
Lyme	B-KP
serology	I-KP
results.	O
	
Previous	O
studies	O
identify	O
clinical	O
and	O
laboratory	O
differences	O
between	O
children	O
with	O
Lyme	B-KP
meningitis	I-KP
versus	O
other	O
forms	O
of	O
aseptic	B-KP
meningitis.	I-KP
	
[9–11]	O
However,	O
these	O
single-center	O
studies	O
were	O
limited	O
by	O
small	O
sample	O
size	O
and	O
lacked	O
validation.	O
	
In	O
a	O
larger	O
retrospective	O
cohort	O
of	O
175	O
children	O
evaluated	O
for	O
Lyme	B-KP
meningitis,	I-KP
Avery	O
et	O
al	O
[12]	O
derived	O
a	O
Lyme	B-KP
meningitis	I-KP
clinical	O
prediction	O
rule	O
based	O
on	O
these	O
3	O
factors:	O
duration	O
of	O
headache,	B-KP
presence	O
of	O
cranial	B-KP
neuritis,	I-KP
and	O
percentage	O
of	O
CSF	B-KP
mononuclear	I-KP
cells.	I-KP
	
In	O
a	O
prospective	O
cohort	O
of	O
50	O
children	O
evaluated	O
for	O
Lyme	B-KP
meningitis,	I-KP
the	O
Avery	O
model	O
performed	O
well.	O
	
[13]	O
These	O
investigators	O
suggested	O
a	O
simplification	O
of	O
the	O
more	O
complicated	O
Avery	O
regression	O
equation	O
termed	O
the	O
“Rule	O
of	O
79s.”	O
[13]	O
Children	O
who	O
met	O
all	O
of	O
the	O
following	O
3	O
criteria	O
were	O
classified	O
as	O
low	O
risk	O
for	O
Lyme	B-KP
meningitis:	I-KP
<7	O
days	O
of	O
headache,	O
<70%	O
CSF	B-KP
mononuclear	I-KP
cells,	I-KP
and	O
absence	O
of	O
seventh	O
(or	O
other)	O
cranial	B-KP
nerve	I-KP
palsy.	I-KP
	
Early	O
identification	O
of	O
those	O
children	O
at	O
low	O
risk	O
for	O
Lyme	B-KP
meningitis	I-KP
would	O
allow	O
for	O
outpatient	O
management	O
while	O
awaiting	O
Lyme	B-KP
serology	I-KP
results.	O
	
Previous	O
studies	O
identify	O
clinical	O
and	O
laboratory	O
differences	O
between	O
children	O
with	O
Lyme	B-KP
meningitis	I-KP
versus	O
other	O
forms	O
of	O
aseptic	B-KP
meningitis.	I-KP
	
[9–11]	O
However,	O
these	O
single-center	O
studies	O
were	O
limited	O
by	O
small	O
sample	O
size	O
and	O
lacked	O
validation.	O
	
In	O
a	O
larger	O
retrospective	O
cohort	O
of	O
175	O
children	O
evaluated	O
for	O
Lyme	B-KP
meningitis,	I-KP
Avery	O
et	O
al	O
[12]	O
derived	O
a	O
Lyme	B-KP
meningitis	I-KP
clinical	O
prediction	O
rule	O
based	O
on	O
these	O
3	O
factors:	O
duration	O
of	O
headache,	B-KP
presence	O
of	O
cranial	B-KP
neuritis,	I-KP
and	O
percentage	O
of	O
CSF	B-KP
mononuclear	I-KP
cells.	I-KP
	
In	O
a	O
prospective	O
cohort	O
of	O
50	O
children	O
evaluated	O
for	O
Lyme	B-KP
meningitis,	I-KP
the	O
Avery	O
model	O
performed	O
well.	O
	
[13]	O
These	O
investigators	O
suggested	O
a	O
simplification	O
of	O
the	O
more	O
complicated	O
Avery	O
regression	O
equation	O
termed	O
the	O
“Rule	O
of	O
79s.”	O
[13]	O
Children	O
who	O
met	O
all	O
of	O
the	O
following	O
3	O
criteria	O
were	O
classified	O
as	O
low	O
risk	O
for	O
Lyme	B-KP
meningitis:	I-KP
<7	O
days	O
of	O
headache,	O
<70%	O
CSF	B-KP
mononuclear	I-KP
cells,	I-KP
and	O
absence	O
of	O
seventh	O
(or	O
other)	O
cranial	B-KP
nerve	I-KP
palsy.	I-KP
	
The	O
constitutional	O
“flu-like”	O
symptoms	O
that	O
frequently	O
accompany	O
early	O
stage	O
LD	B-KP
may	O
also	O
act	O
as	O
a	O
guide	O
to	O
the	O
etiology	O
of	O
FNP.	B-KP
	
Fever	B-KP
and	O
headache	B-KP
are	O
the	O
most	O
frequent	O
symptoms	O
associated	O
with	O
LD.13J0	B-KP
Facial	B-KP
nerve	I-KP
palsy	I-KP
will	O
typically	O
manifest	O
itself	O
early	O
in	O
LD	B-KP
and	O
has	O
been	O
noted	O
to	O
arise	O
during	O
or	O
even	O
after	O
treatment	O
has	O
been	O
initiated.16	O
In	O
children,	O
EM	B-KP
frequently	O
occurs	O
on	O
the	O
head	B-KP
and	O
neck	B-KP
region.	O
	
This	O
is	O
in	O
contradistinction	O
to	O
adults	O
who	O
typically	O
develop	O
EM	B-KP
on	O
the	O
lower	O
extremities.	O
	
This	O
likely	O
results	O
from	O
a	O
child’s	O
shorter	O
stature.	O
	
That	O
subsequent	O
FNP	B-KP
arises	O
on	O
the	O
ipsilateral	O
side	O
suggests	O
direct	O
neural	B-KP
invasion,	I-KP
although	O
there	O
is	O
no	O
histopathologic	O
evidence	O
for	O
this.lO	O
Additionally,	O
FNP	B-KP
is	O
one	O
of	O
the	O
more	O
common	O
neurologic	O
manifestations	O
of	O
LD,	B-KP
especially	O
in	O
children.	O
	
[10,13,16,17]	O
Children	O
also	O
manifest	O
bilateral	B-KP
FNP	I-KP
more	O
frequently	O
than	O
adults.	O
	
Bilateral	B-KP
FNP	I-KP
is	O
more	O
frequently	O
caused	O
by	O
LD	B-KP
than	O
other	O
causes.	O
	
Early	O
CNS	B-KP
invasion	I-KP
can	O
occur	O
The	O
constitutional	O
“flu-like”	O
symptoms	O
that	O
frequently	O
accompany	O
early	O
stage	O
LD	B-KP
may	O
also	O
act	O
as	O
a	O
guide	O
to	O
the	O
etiology	O
of	O
FNP.	B-KP
	
Fever	B-KP
and	O
headache	B-KP
are	O
the	O
most	O
frequent	O
symptoms	O
associated	O
with	O
LD.13J0	B-KP
Facial	B-KP
nerve	I-KP
palsy	I-KP
will	O
typically	O
manifest	O
itself	O
early	O
in	O
LD	B-KP
and	O
has	O
been	O
noted	O
to	O
arise	O
during	O
or	O
even	O
after	O
treatment	O
has	O
been	O
initiated.16	O
In	O
children,	O
EM	B-KP
frequently	O
occurs	O
on	O
the	O
head	B-KP
and	O
neck	B-KP
region.	O
	
This	O
is	O
in	O
contradistinction	O
to	O
adults	O
who	O
typically	O
develop	O
EM	B-KP
on	O
the	O
lower	O
extremities.	O
	
This	O
likely	O
results	O
from	O
a	O
child’s	O
shorter	O
stature.	O
	
That	O
subsequent	O
FNP	B-KP
arises	O
on	O
the	O
ipsilateral	O
side	O
suggests	O
direct	O
neural	B-KP
invasion,	I-KP
although	O
there	O
is	O
no	O
histopathologic	O
evidence	O
for	O
this.lO	O
Additionally,	O
FNP	B-KP
is	O
one	O
of	O
the	O
more	O
common	O
neurologic	O
manifestations	O
of	O
LD,	B-KP
especially	O
in	O
children.	O
	
[10,13,16,17]	O
Children	O
also	O
manifest	O
bilateral	B-KP
FNP	I-KP
more	O
frequently	O
than	O
adults.	O
	
Bilateral	B-KP
FNP	I-KP
is	O
more	O
frequently	O
caused	O
by	O
LD	B-KP
than	O
other	O
causes.	O
	
Early	O
CNS	B-KP
invasion	I-KP
can	O
occur	O
In	O
general,	O
the	O
duration	O
of	O
FNP	B-KP
with	O
LD	B-KP
is	O
reported	O
to	O
be	O
shorter	O
than	O
with	O
other	O
causes	O
of	O
peripheral	B-KP
FNP.	I-KP
	
[11,15]	O
Resolution	O
may	O
even	O
begin	O
before	O
beginning	O
treatment,	O
and	O
overall	O
prognosis	O
is	O
typically	O
good.	O
	
[15,16]	O
We	O
did	O
note	O
several	O
patients	O
who	O
had	O
FNP	B-KP
lasting	O
many	O
months	O
even	O
after	O
intravenous	O
ceftriaxone.\nThe	O
laboratory	O
diagnosis	O
of	O
LD	B-KP
can	O
be	O
difficult.	O
	
Erythrocyte	B-KP
sedimentation	I-KP
rates,	I-KP
while	O
elevated,	O
are	O
nonspecific.	O
	
Cerebral	B-KP
spinal	I-KP
fluid	I-KP
(CSF)	B-KP
lymphocytosis	I-KP
and	O
elevated	O
CSF	O
proteins	I-KP
can	O
be	O
seen	O
in	O
viral	I-KP
meningitis	I-KP
as	O
well	O
as	O
LD.	O
	
Although	O
specific	O
antibody	I-KP
tests	I-KP
may	O
be	O
beneficial,	O
in	O
early	O
LD,	O
the	O
IgM	I-KP
may	O
not	O
be	O
positive	O
for	O
3	O
to	O
4	O
weeks	O
and	O
the	O
IgG	I-KP
may	O
not	O
be	O
positive	O
for	O
6	O
to	O
8	O
weeks.	O
	
[14]	O
In	O
general,	O
the	O
duration	O
of	O
FNP	B-KP
with	O
LD	B-KP
is	O
reported	O
to	O
be	O
shorter	O
than	O
with	O
other	O
causes	O
of	O
peripheral	B-KP
FNP.	I-KP
	
[11,15]	O
Resolution	O
may	O
even	O
begin	O
before	O
beginning	O
treatment,	O
and	O
overall	O
prognosis	O
is	O
typically	O
good.	O
	
[15,16]	O
We	O
did	O
note	O
several	O
patients	O
who	O
had	O
FNP	B-KP
lasting	O
many	O
months	O
even	O
after	O
intravenous	O
ceftriaxone.\nThe	O
laboratory	O
diagnosis	O
of	O
LD	B-KP
can	O
be	O
difficult.	O
	
Erythrocyte	B-KP
sedimentation	I-KP
rates,	I-KP
while	O
elevated,	O
are	O
nonspecific.	O
	
Cerebral	B-KP
spinal	I-KP
fluid	I-KP
(CSF)	B-KP
lymphocytosis	I-KP
and	O
elevated	O
CSF	O
proteins	I-KP
can	O
be	O
seen	O
in	O
viral	I-KP
meningitis	I-KP
as	O
well	O
as	O
LD.	O
	
Although	O
specific	O
antibody	I-KP
tests	I-KP
may	O
be	O
beneficial,	O
in	O
early	O
LD,	O
the	O
IgM	I-KP
may	O
not	O
be	O
positive	O
for	O
3	O
to	O
4	O
weeks	O
and	O
the	O
IgG	I-KP
may	O
not	O
be	O
positive	O
for	O
6	O
to	O
8	O
weeks.	O
	
[14]	O
Bilateral	B-KP
lower	I-KP
motor	I-KP
neurone	I-KP
facial	I-KP
weakness	I-KP
and	O
mononeuritis	B-KP
multiplex	I-KP
ring	I-KP
alarm	O
bells	O
for	O
Lyme	B-KP
disease	I-KP
,	O
but	O
unilateral	B-KP
lower	I-KP
motor	I-KP
neurone	I-KP
facial	I-KP
weakness	I-KP
does	O
not	O
necessarily.	O
	
It	O
is	O
important,	O
therefore,	O
to	O
consider	O
the	O
clues	O
to	O
the	O
different	O
diagnoses.	O
	
Bell’s	B-KP
palsy	I-KP
typically	O
presents	O
with	O
an	O
acute	O
onset	O
to	O
a	O
maximum	O
within	O
72	O
hours.	O
	
[11]	O
About	O
50%	O
of	O
patients	O
have	O
a	O
mild-tomoderate	O
post-auricular	B-KP
pain	I-KP
(25%	O
before	O
the	O
weakness,	O
50%	O
contemporaneous	O
with	O
the	O
weakness,	O
and	O
25%	O
after	O
the	O
weakness),	O
with	O
altered	O
taste	O
in	O
35%.11	O
In	O
30%	O
a	O
dry	B-KP
eye	I-KP
is	O
noticed,	O
and	O
in	O
20%	O
a	O
dry	O
mouth,	O
due	O
to	O
parasympathetic	O
involvement.	O
	
[11]	O
Patients	O
with	O
Lyme	B-KP
disease	I-KP
with	O
facial	B-KP
palsy	I-KP
may	O
have	O
noticed	O
a	O
tick	O
bite	O
—	O
a	O
hard-bodied	O
tick	O
attachment	O
with	O
or	O
without	O
engorgement	O
is	O
particularly	O
relevant.	O
	
[9]	O
And	O
90%	O
will	O
experience	O
a	O
transient	O
rash,	O
erythema	B-KP
migrans,	I-KP
2–40	O
days	O
after	O
exposure.	O
	
[9]	O
Approximately	O
7%	O
will	O
feel	O
generally	O
unwell,	O
and	O
arthralgia	B-KP
has	O
also	O
been	O
reported.	O
	
[3,9,12]	O
Although	O
the	O
diagnosis	O
is	O
clinical,	O
serological	B-KP
testing	I-KP
may	O
be	O
useful,	O
particularly	O
paired	O
blood	O
samples	O
taken	O
at	O
a	O
4-week	O
interval,	O
to	O
allow	O
for	O
seroconversion.	B-KP
	
[9]	O
Bilateral	B-KP
lower	I-KP
motor	I-KP
neurone	I-KP
facial	I-KP
weakness	I-KP
and	O
mononeuritis	B-KP
multiplex	I-KP
ring	I-KP
alarm	O
bells	O
for	O
Lyme	B-KP
disease	I-KP
,	O
but	O
unilateral	B-KP
lower	I-KP
motor	I-KP
neurone	I-KP
facial	I-KP
weakness	I-KP
does	O
not	O
necessarily.	O
	
It	O
is	O
important,	O
therefore,	O
to	O
consider	O
the	O
clues	O
to	O
the	O
different	O
diagnoses.	O
	
Bell’s	B-KP
palsy	I-KP
typically	O
presents	O
with	O
an	O
acute	O
onset	O
to	O
a	O
maximum	O
within	O
72	O
hours.	O
	
[11]	O
About	O
50%	O
of	O
patients	O
have	O
a	O
mild-tomoderate	O
post-auricular	B-KP
pain	I-KP
(25%	O
before	O
the	O
weakness,	O
50%	O
contemporaneous	O
with	O
the	O
weakness,	O
and	O
25%	O
after	O
the	O
weakness),	O
with	O
altered	O
taste	O
in	O
35%.11	O
In	O
30%	O
a	O
dry	B-KP
eye	I-KP
is	O
noticed,	O
and	O
in	O
20%	O
a	O
dry	O
mouth,	O
due	O
to	O
parasympathetic	O
involvement.	O
	
[11]	O
Patients	O
with	O
Lyme	B-KP
disease	I-KP
with	O
facial	B-KP
palsy	I-KP
may	O
have	O
noticed	O
a	O
tick	O
bite	O
—	O
a	O
hard-bodied	O
tick	O
attachment	O
with	O
or	O
without	O
engorgement	O
is	O
particularly	O
relevant.	O
	
[9]	O
And	O
90%	O
will	O
experience	O
a	O
transient	O
rash,	O
erythema	B-KP
migrans,	I-KP
2–40	O
days	O
after	O
exposure.	O
	
[9]	O
Approximately	O
7%	O
will	O
feel	O
generally	O
unwell,	O
and	O
arthralgia	B-KP
has	O
also	O
been	O
reported.	O
	
[3,9,12]	O
Although	O
the	O
diagnosis	O
is	O
clinical,	O
serological	B-KP
testing	I-KP
may	O
be	O
useful,	O
particularly	O
paired	O
blood	O
samples	O
taken	O
at	O
a	O
4-week	O
interval,	O
to	O
allow	O
for	O
seroconversion.	B-KP
	
[9]	O
Cases	O
of	O
Lyme	B-KP
disease	I-KP
have	O
been	O
rising	O
steadily	O
over	O
recent	O
years,	O
as	O
have	O
diagnoses	O
in	O
combination	O
with	O
Bell’s	B-KP
palsy	I-KP
(Table	O
1).	O
	
This	O
may	O
be	O
due	O
to	O
better	O
surveillance,	O
increased	O
awareness	O
of	O
the	O
disease,	O
or	O
increasing	O
infection	O
rates	O
caused	O
by	O
travel	O
to	O
endemic	B-KP
areas.	I-KP
	
[1]	O
Classically,	O
Lyme	B-KP
disease	I-KP
is	O
associated	O
with	O
areas	O
of	O
woodland,	O
pasture,	O
and	O
heath,	O
where	O
ticks	O
parasitise	O
small	O
mammals	O
such	O
as	O
field	O
mice	O
and	O
voles,	O
and	O
larger	O
animals	O
such	O
as	O
sheep,	O
deer,	O
and	O
horses.	O
	
[3]	O
The	O
majority	O
of	O
European	O
cases	O
are	O
within	O
the	O
UK,	O
including	O
forested	O
areas	O
such	O
as	O
the	O
New	O
Forest,	O
Exmoor,	O
the	O
South	O
Downs,	O
Thetford	O
Forest	O
in	O
East	O
Anglia,	O
the	O
Lake	O
District,	O
the	O
Yorkshire	O
Moors,	O
and	O
the	O
Scottish	O
Highlands,	O
although	O
there	O
are	O
also	O
cases	O
in	O
the	O
Dordogne	O
and	O
Eastern	O
Europe.	O
	
[1]	O
The	O
maps	O
provided	O
in	O
Figures	O
2–4	O
support	O
this	O
finding	O
and	O
add	O
to	O
them	O
(for	O
example,	O
one	O
of	O
the	O
highest	O
areas	O
in	O
England	O
was	O
found	O
in	O
the	O
north	O
west	O
of	O
London	O
in	O
the	O
Chiltern	O
Hills).	O
	
Cases	O
of	O
Lyme	B-KP
disease	I-KP
have	O
been	O
rising	O
steadily	O
over	O
recent	O
years,	O
as	O
have	O
diagnoses	O
in	O
combination	O
with	O
Bell’s	B-KP
palsy	I-KP
(Table	O
1).	O
	
This	O
may	O
be	O
due	O
to	O
better	O
surveillance,	O
increased	O
awareness	O
of	O
the	O
disease,	O
or	O
increasing	O
infection	O
rates	O
caused	O
by	O
travel	O
to	O
endemic	B-KP
areas.	I-KP
	
[1]	O
Classically,	O
Lyme	B-KP
disease	I-KP
is	O
associated	O
with	O
areas	O
of	O
woodland,	O
pasture,	O
and	O
heath,	O
where	O
ticks	O
parasitise	O
small	O
mammals	O
such	O
as	O
field	O
mice	O
and	O
voles,	O
and	O
larger	O
animals	O
such	O
as	O
sheep,	O
deer,	O
and	O
horses.	O
	
[3]	O
The	O
majority	O
of	O
European	O
cases	O
are	O
within	O
the	O
UK,	O
including	O
forested	O
areas	O
such	O
as	O
the	O
New	O
Forest,	O
Exmoor,	O
the	O
South	O
Downs,	O
Thetford	O
Forest	O
in	O
East	O
Anglia,	O
the	O
Lake	O
District,	O
the	O
Yorkshire	O
Moors,	O
and	O
the	O
Scottish	O
Highlands,	O
although	O
there	O
are	O
also	O
cases	O
in	O
the	O
Dordogne	O
and	O
Eastern	O
Europe.	O
	
[1]	O
The	O
maps	O
provided	O
in	O
Figures	O
2–4	O
support	O
this	O
finding	O
and	O
add	O
to	O
them	O
(for	O
example,	O
one	O
of	O
the	O
highest	O
areas	O
in	O
England	O
was	O
found	O
in	O
the	O
north	O
west	O
of	O
London	O
in	O
the	O
Chiltern	O
Hills).	O
	
The	O
primary	O
problem	O
was	O
the	O
right	O
shoulder	O
pain	O
with	O
overhead	O
activity	O
and	O
sleeping	O
on	O
his	O
right	O
side.	O
	
From	O
the	O
patient’s	O
history	O
and	O
systems	O
review,	O
the	O
potential	O
differential	O
diagnoses	O
included	O
right	B-KP
shoulder	I-KP
subacromial	I-KP
impingement	I-KP
due	O
to	O
subacromial	B-KP
bursitis,	O
rotator	I-KP
cuff	I-KP
tendinopathy,	O
or	O
a	O
partial	O
tear	O
of	O
the	O
supraspinatus	I-KP
tendon.	O
	
[1,2]	O
The	O
radiologist’s	O
interpretation	O
of	O
the	O
radiographs	O
and	O
MRI	I-KP
appeared	O
to	O
support	O
subacromial	I-KP
impingement	I-KP
due	O
to	O
supraspinatus	I-KP
tendinopathy.	O
	
The	O
evaluating	O
physical	O
therapist	O
determined	O
the	O
patient	O
needed	O
a	O
range-of-motion	O
and	O
strength	O
examination,	O
posture	O
analysis,	O
and	O
special	O
tests	O
to	O
differentiate	O
among	O
the	O
potential	O
diagnoses.	O
	
From	O
the	O
patient’s	O
history	O
and	O
following	O
examination,	O
a	B-KP
musculoskeletal	I-KP
diagnosis	O
was	O
differentiated,	O
but	O
unusual	O
and	O
atypical	O
symptoms	O
began	O
to	O
present	O
during	O
the	O
intervention.	O
	
The	O
treating	O
physical	O
therapist’s	O
ability	O
to	O
recognize	O
this	O
patient’s	O
atypical	O
symptoms	O
and	O
need	O
for	O
another	O
referral	O
contribute	O
to	O
the	O
importance	O
of	O
presenting	O
this	O
case	O
report.	O
	
The	O
primary	O
problem	O
was	O
the	O
right	O
shoulder	O
pain	O
with	O
overhead	O
activity	O
and	O
sleeping	O
on	O
his	O
right	O
side.	O
	
From	O
the	O
patient’s	O
history	O
and	O
systems	O
review,	O
the	O
potential	O
differential	O
diagnoses	O
included	O
right	B-KP
shoulder	I-KP
subacromial	I-KP
impingement	I-KP
due	O
to	O
subacromial	B-KP
bursitis,	O
rotator	I-KP
cuff	I-KP
tendinopathy,	O
or	O
a	O
partial	O
tear	O
of	O
the	O
supraspinatus	I-KP
tendon.	O
	
[1,2]	O
The	O
radiologist’s	O
interpretation	O
of	O
the	O
radiographs	O
and	O
MRI	I-KP
appeared	O
to	O
support	O
subacromial	I-KP
impingement	I-KP
due	O
to	O
supraspinatus	I-KP
tendinopathy.	O
	
The	O
evaluating	O
physical	O
therapist	O
determined	O
the	O
patient	O
needed	O
a	O
range-of-motion	O
and	O
strength	O
examination,	O
posture	O
analysis,	O
and	O
special	O
tests	O
to	O
differentiate	O
among	O
the	O
potential	O
diagnoses.	O
	
From	O
the	O
patient’s	O
history	O
and	O
following	O
examination,	O
a	B-KP
musculoskeletal	I-KP
diagnosis	O
was	O
differentiated,	O
but	O
unusual	O
and	O
atypical	O
symptoms	O
began	O
to	O
present	O
during	O
the	O
intervention.	O
	
The	O
treating	O
physical	O
therapist’s	O
ability	O
to	O
recognize	O
this	O
patient’s	O
atypical	O
symptoms	O
and	O
need	O
for	O
another	O
referral	O
contribute	O
to	O
the	O
importance	O
of	O
presenting	O
this	O
case	O
report.	O
	
A	O
physical	B-KP
examination	I-KP
was	O
conducted,	O
with	O
an	O
initial	O
clinical	B-KP
impression	I-KP
of	I-KP
supraspinatus	I-KP
tendinopathy	I-KP
and	O
impingement.	O
	
Therefore,	O
procedures	O
were	O
undertaken	O
in	O
an	O
attempt	O
to	O
confirm	O
the	O
initial	O
clinical	O
impression.	O
	
Observation	O
of	O
the	O
patient	O
revealed:	O
(1)	O
flu-like	B-KP
symptoms	I-KP
(runny	B-KP
nose,	O
sinus	I-KP
congestion,	O
and	O
itchy	I-KP
throat),	O
which	O
he	O
attributed	O
to	O
a	O
recent	O
bout	O
of	O
sinus	I-KP
congestion	I-KP
due	O
to	O
seasonal	O
allergies,	O
and	O
(2)	O
poor	O
sitting	O
posture,	O
which	O
is	O
a	O
common	O
observation	O
in	O
supraspinatus	I-KP
impingement.	O
	
[1]	O
Palpation	I-KP
examination	I-KP
of	O
the	O
right	O
upper	O
extremity	O
revealed	O
tenderness	O
at	O
the	O
distal	O
insertion	O
of	O
the	O
supraspinatus	I-KP
tendon	I-KP
and	O
in	O
the	O
supraspinatus	I-KP
muscle	I-KP
belly.	O
	
A	O
painful	O
arc	O
at	O
120	O
degrees	O
of	O
abduction,	O
minimal	I-KP
scapular	I-KP
dyskinesia	I-KP
on	I-KP
the	I-KP
right	I-KP
side,	O
and	O
pain	O
at	O
end-range	O
passive	O
shoulder	O
internal	O
rotation	O
were	O
revealed	O
in	O
right	O
shoulder	O
range-of-motion	O
testing	O
in	O
standing	O
and	O
supine	O
positions	O
as	O
described	O
by	O
Magee.25	O
After	O
range-ofmotion	O
testing,	O
manual	I-KP
muscle	I-KP
testing	I-KP
(MMT)	B-KP
on	O
a	O
0	O
to	O
5	O
scale	O
was	O
conducted	O
using	O
techniques	O
suggested	O
by	O
Hislop	O
and	O
Montgomery.	O
	
[26]	O
The	O
patient’s	O
strength	O
measurements	O
revealed	O
right	O
shoulder	O
strength	O
(force-generating	O
capacity)	O
of	O
external	O
rotation	O
and	O
abduction	O
of	O
4/5	O
and	O
provoked	O
pain	O
in	O
the	O
right	O
shoulder.	O
	
A	O
physical	B-KP
examination	I-KP
was	O
conducted,	O
with	O
an	O
initial	O
clinical	B-KP
impression	I-KP
of	I-KP
supraspinatus	I-KP
tendinopathy	I-KP
and	O
impingement.	O
	
Therefore,	O
procedures	O
were	O
undertaken	O
in	O
an	O
attempt	O
to	O
confirm	O
the	O
initial	O
clinical	O
impression.	O
	
Observation	O
of	O
the	O
patient	O
revealed:	O
(1)	O
flu-like	B-KP
symptoms	I-KP
(runny	B-KP
nose,	O
sinus	I-KP
congestion,	O
and	O
itchy	I-KP
throat),	O
which	O
he	O
attributed	O
to	O
a	O
recent	O
bout	O
of	O
sinus	I-KP
congestion	I-KP
due	O
to	O
seasonal	O
allergies,	O
and	O
(2)	O
poor	O
sitting	O
posture,	O
which	O
is	O
a	O
common	O
observation	O
in	O
supraspinatus	I-KP
impingement.	O
	
[1]	O
Palpation	I-KP
examination	I-KP
of	O
the	O
right	O
upper	O
extremity	O
revealed	O
tenderness	O
at	O
the	O
distal	O
insertion	O
of	O
the	O
supraspinatus	I-KP
tendon	I-KP
and	O
in	O
the	O
supraspinatus	I-KP
muscle	I-KP
belly.	O
	
A	O
painful	O
arc	O
at	O
120	O
degrees	O
of	O
abduction,	O
minimal	I-KP
scapular	I-KP
dyskinesia	I-KP
on	I-KP
the	I-KP
right	I-KP
side,	O
and	O
pain	O
at	O
end-range	O
passive	O
shoulder	O
internal	O
rotation	O
were	O
revealed	O
in	O
right	O
shoulder	O
range-of-motion	O
testing	O
in	O
standing	O
and	O
supine	O
positions	O
as	O
described	O
by	O
Magee.25	O
After	O
range-ofmotion	O
testing,	O
manual	I-KP
muscle	I-KP
testing	I-KP
(MMT)	B-KP
on	O
a	O
0	O
to	O
5	O
scale	O
was	O
conducted	O
using	O
techniques	O
suggested	O
by	O
Hislop	O
and	O
Montgomery.	O
	
[26]	O
The	O
patient’s	O
strength	O
measurements	O
revealed	O
right	O
shoulder	O
strength	O
(force-generating	O
capacity)	O
of	O
external	O
rotation	O
and	O
abduction	O
of	O
4/5	O
and	O
provoked	O
pain	O
in	O
the	O
right	O
shoulder.	O
	
Previous	O
authors	O
have	O
documented	O
that	O
Lyme	B-KP
disease	I-KP
affects	O
the	O
shoulder	O
joint,	O
[5,8]	O
and	O
the	O
avascular	O
articular	O
surface	O
of	O
the	O
distal	B-KP
supraspinatus	I-KP
tendon	I-KP
[28]	O
is	O
a	O
favorable	O
location	O
for	O
the	O
spirochetes	B-KP
due	O
to	O
the	O
somewhat	O
hypoxic	O
condition	O
of	O
the	O
area.	O
	
It	O
appears	O
that	O
the	O
patient’s	O
distal	B-KP
supraspinatus	I-KP
tendinopathy,	I-KP
with	O
consequent	O
pain	O
and	O
inflammation,	O
was	O
a	O
symptom	O
of	O
Lyme	B-KP
disease	I-KP
and	O
the	O
associated	O
spirochete	B-KP
load	I-KP
and	O
secondarily	O
caused	O
supraspinatus	B-KP
impingement.	I-KP
	
Several	O
symptoms	O
displayed	O
during	O
treatment	O
demonstrated	O
to	O
the	O
physical	O
therapist	O
that	O
an	O
underlying	O
condition	O
such	O
as	O
Lyme	B-KP
disease	I-KP
was	O
involved.	O
	
Previous	O
authors	O
have	O
documented	O
that	O
Lyme	B-KP
disease	I-KP
affects	O
the	O
shoulder	O
joint,	O
[5,8]	O
and	O
the	O
avascular	O
articular	O
surface	O
of	O
the	O
distal	B-KP
supraspinatus	I-KP
tendon	I-KP
[28]	O
is	O
a	O
favorable	O
location	O
for	O
the	O
spirochetes	B-KP
due	O
to	O
the	O
somewhat	O
hypoxic	O
condition	O
of	O
the	O
area.	O
	
It	O
appears	O
that	O
the	O
patient’s	O
distal	B-KP
supraspinatus	I-KP
tendinopathy,	I-KP
with	O
consequent	O
pain	O
and	O
inflammation,	O
was	O
a	O
symptom	O
of	O
Lyme	B-KP
disease	I-KP
and	O
the	O
associated	O
spirochete	B-KP
load	I-KP
and	O
secondarily	O
caused	O
supraspinatus	B-KP
impingement.	I-KP
	
Several	O
symptoms	O
displayed	O
during	O
treatment	O
demonstrated	O
to	O
the	O
physical	O
therapist	O
that	O
an	O
underlying	O
condition	O
such	O
as	O
Lyme	B-KP
disease	I-KP
was	O
involved.	O
	
In	O
conclusion,	O
many	O
overhead	O
athletes	O
lead	O
very	O
active	O
lifestyles	O
and	O
spend	O
time	O
in	O
the	O
outdoors,	O
which	O
may	O
increase	O
their	O
chances	O
of	O
contracting	O
Lyme	B-KP
disease.	I-KP
	
Lyme	B-KP
disease	I-KP
is	O
best	O
diagnosed	O
clinically,	O
as	O
no	O
currently	O
available	O
test,	O
no	O
matter	O
the	O
source	O
or	O
type,	O
is	O
definitive	O
in	O
detecting	O
an	O
infection	O
with	O
this	O
pathogen.	B-KP
	
[3,6,11,19]	O
The	O
entire	O
clinical	O
picture	O
must	O
be	O
taken	O
into	O
account,	O
[3]	O
and	O
as	O
physical	O
therapists,	O
we	O
spend	O
a	O
larger	O
portion	O
of	O
time	O
with	O
our	O
patients	O
than	O
other	O
health	O
care	O
professionals	O
and	O
may	O
be	O
best	O
positioned	O
to	O
recognize	O
the	O
signs	O
or	O
symptoms	O
of	O
atypical	B-KP
musculoskeletal	I-KP
conditions	I-KP
before	O
other	O
health	O
care	O
providers.	O
	
Because	O
there	O
has	O
been	O
an	O
upward	O
trend	O
in	O
diagnosed	O
cases	O
of	O
Lyme	B-KP
disease,9	O
it	O
is	O
important	O
for	O
physical	O
therapists	O
to	O
recognize	O
the	O
symptoms	O
of	O
Lyme	B-KP
disease	I-KP
and	O
to	O
reach	O
the	O
appropriate	O
clinical	O
diagnosis	O
with	O
all	O
patients	O
(Fig.	O
	
3).	O
	
It	O
also	O
is	O
important	O
for	O
physical	O
therapists	O
and	O
physicians	O
to	O
have	O
collaborative	O
relationships	O
through	O
which	O
the	O
patient	O
will	O
receive	O
high-quality	O
care.	O
	
In	O
conclusion,	O
many	O
overhead	O
athletes	O
lead	O
very	O
active	O
lifestyles	O
and	O
spend	O
time	O
in	O
the	O
outdoors,	O
which	O
may	O
increase	O
their	O
chances	O
of	O
contracting	O
Lyme	B-KP
disease.	I-KP
	
Lyme	B-KP
disease	I-KP
is	O
best	O
diagnosed	O
clinically,	O
as	O
no	O
currently	O
available	O
test,	O
no	O
matter	O
the	O
source	O
or	O
type,	O
is	O
definitive	O
in	O
detecting	O
an	O
infection	O
with	O
this	O
pathogen.	B-KP
	
[3,6,11,19]	O
The	O
entire	O
clinical	O
picture	O
must	O
be	O
taken	O
into	O
account,	O
[3]	O
and	O
as	O
physical	O
therapists,	O
we	O
spend	O
a	O
larger	O
portion	O
of	O
time	O
with	O
our	O
patients	O
than	O
other	O
health	O
care	O
professionals	O
and	O
may	O
be	O
best	O
positioned	O
to	O
recognize	O
the	O
signs	O
or	O
symptoms	O
of	O
atypical	B-KP
musculoskeletal	I-KP
conditions	I-KP
before	O
other	O
health	O
care	O
providers.	O
	
Because	O
there	O
has	O
been	O
an	O
upward	O
trend	O
in	O
diagnosed	O
cases	O
of	O
Lyme	B-KP
disease,9	O
it	O
is	O
important	O
for	O
physical	O
therapists	O
to	O
recognize	O
the	O
symptoms	O
of	O
Lyme	B-KP
disease	I-KP
and	O
to	O
reach	O
the	O
appropriate	O
clinical	O
diagnosis	O
with	O
all	O
patients	O
(Fig.	O
	
3).	O
	
It	O
also	O
is	O
important	O
for	O
physical	O
therapists	O
and	O
physicians	O
to	O
have	O
collaborative	O
relationships	O
through	O
which	O
the	O
patient	O
will	O
receive	O
high-quality	O
care.	O
	
Respondents	O
were	O
classified	O
as	O
having	O
had	O
personal	O
experience	O
with	O
acute	B-KP
Lyme	I-KP
disease	I-KP
or	O
PTLDS	B-KP
if	O
they	O
or	O
a	O
close	O
associate	O
had	O
the	O
disease	O
(Table	O
3).	O
	
Three	O
groups	O
were	O
formed	O
from	O
this	O
information:	O
those	O
with	O
no	O
personal	O
experience	O
with	O
Lyme	B-KP
disease	I-KP
or	O
PTLDS;	B-KP
those	O
with	O
personal	O
experience	O
with	O
Lyme	B-KP
disease,	I-KP
but	O
not	O
PTLDS;	B-KP
and	O
those	O
with	O
personal	O
experience	O
with	O
PTLDS	B-KP
with	O
or	O
without	O
personal	O
experience	O
with	O
Lyme	B-KP
disease.	I-KP
	
All	O
groups	O
agree	O
that	O
PTLDS	B-KP
can	O
be	O
severe	O
and	O
chronic	O
condition	O
that	O
can	O
last	O
for	O
many	O
years.	O
	
Less	O
than	O
5%	O
in	O
any	O
of	O
the	O
groups	O
think	O
that	O
PTLDS	B-KP
is	O
either	O
easy	O
to	O
treat	O
or	O
resolves	O
on	O
its	O
own.	O
	
The	O
uncertainty	O
ratings	O
for	O
these	O
questions	O
were	O
particularly	O
interesting	O
to	O
see.	O
	
In	O
general,	O
uncertainty	O
was	O
high	O
in	O
the	O
groups	O
with	O
no	O
experience	O
with	O
PTLDS.	B-KP
	
Uncertainty	O
regarding	O
the	O
severity	O
and	O
chronic	O
nature	O
of	O
PTLDS	B-KP
was	O
higher	O
in	O
those	O
with	O
no	O
experience	O
with	O
either	O
disease	O
(34%)	O
and	O
those	O
with	O
experience	O
with	O
Lyme	B-KP
disease,	I-KP
but	O
not	O
PTLDS	B-KP
(30%)	O
compared	O
with	O
those	O
faculty	O
members	O
with	O
experience	O
with	O
PTLDS	B-KP
(9%).	O
	
A	O
similar	O
pattern	O
was	O
seen	O
for	O
the	O
question	O
of	O
ease	O
of	O
treatment	O
and	O
resolution	O
of	O
disease	O
(Table	O
3).	O
	
Respondents	O
were	O
asked	O
to	O
give	O
their	O
opinion	O
regarding	O
the	O
aetiology	O
of	O
PTLDS.	B-KP
	
The	O
most	O
frequently	O
chosen	O
answer	O
was	O
‘an	O
ongoing	O
host	O
inflammatory	O
response	O
triggered	O
by	O
previous	O
Lyme	B-KP
disease	I-KP
but	O
not	O
due	O
to	O
persistent	O
infection,	O
regardless	O
of	O
group.	O
	
In	O
contrast,	O
a	O
large	O
minority,	O
as	O
high	O
as	O
39%	O
of	O
respondents	O
with	O
a	O
personal	O
experience	O
with	O
PTLDS,	B-KP
selected	O
‘continued	O
infection’	O
as	O
a	O
potential	O
aetiology	O
of	O
PTLDS.	B-KP
	
Respondents	O
were	O
classified	O
as	O
having	O
had	O
personal	O
experience	O
with	O
acute	B-KP
Lyme	I-KP
disease	I-KP
or	O
PTLDS	B-KP
if	O
they	O
or	O
a	O
close	O
associate	O
had	O
the	O
disease	O
(Table	O
3).	O
	
Three	O
groups	O
were	O
formed	O
from	O
this	O
information:	O
those	O
with	O
no	O
personal	O
experience	O
with	O
Lyme	B-KP
disease	I-KP
or	O
PTLDS;	B-KP
those	O
with	O
personal	O
experience	O
with	O
Lyme	B-KP
disease,	I-KP
but	O
not	O
PTLDS;	B-KP
and	O
those	O
with	O
personal	O
experience	O
with	O
PTLDS	B-KP
with	O
or	O
without	O
personal	O
experience	O
with	O
Lyme	B-KP
disease.	I-KP
	
All	O
groups	O
agree	O
that	O
PTLDS	B-KP
can	O
be	O
severe	O
and	O
chronic	O
condition	O
that	O
can	O
last	O
for	O
many	O
years.	O
	
Less	O
than	O
5%	O
in	O
any	O
of	O
the	O
groups	O
think	O
that	O
PTLDS	B-KP
is	O
either	O
easy	O
to	O
treat	O
or	O
resolves	O
on	O
its	O
own.	O
	
The	O
uncertainty	O
ratings	O
for	O
these	O
questions	O
were	O
particularly	O
interesting	O
to	O
see.	O
	
In	O
general,	O
uncertainty	O
was	O
high	O
in	O
the	O
groups	O
with	O
no	O
experience	O
with	O
PTLDS.	B-KP
	
Uncertainty	O
regarding	O
the	O
severity	O
and	O
chronic	O
nature	O
of	O
PTLDS	B-KP
was	O
higher	O
in	O
those	O
with	O
no	O
experience	O
with	O
either	O
disease	O
(34%)	O
and	O
those	O
with	O
experience	O
with	O
Lyme	B-KP
disease,	I-KP
but	O
not	O
PTLDS	B-KP
(30%)	O
compared	O
with	O
those	O
faculty	O
members	O
with	O
experience	O
with	O
PTLDS	B-KP
(9%).	O
	
A	O
similar	O
pattern	O
was	O
seen	O
for	O
the	O
question	O
of	O
ease	O
of	O
treatment	O
and	O
resolution	O
of	O
disease	O
(Table	O
3).	O
	
Respondents	O
were	O
asked	O
to	O
give	O
their	O
opinion	O
regarding	O
the	O
aetiology	O
of	O
PTLDS.	B-KP
	
The	O
most	O
frequently	O
chosen	O
answer	O
was	O
‘an	O
ongoing	O
host	O
inflammatory	O
response	O
triggered	O
by	O
previous	O
Lyme	B-KP
disease	I-KP
but	O
not	O
due	O
to	O
persistent	O
infection,	O
regardless	O
of	O
group.	O
	
In	O
contrast,	O
a	O
large	O
minority,	O
as	O
high	O
as	O
39%	O
of	O
respondents	O
with	O
a	O
personal	O
experience	O
with	O
PTLDS,	B-KP
selected	O
‘continued	O
infection’	O
as	O
a	O
potential	O
aetiology	O
of	O
PTLDS.	B-KP
	
Limitations	O
of	O
this	O
study	O
are	O
primarily	O
related	O
to	O
the	O
response	O
rate	O
of	O
the	O
survey	O
(15%).	O
	
Due	O
to	O
the	O
low	O
number	O
of	O
published	O
studies	O
of	O
public	O
health	O
faculties	O
using	O
internet	O
based	O
surveys,	O
it	O
is	O
unclear	O
if	O
this	O
is	O
an	O
acceptable	O
response	O
rate	O
or	O
how	O
it	O
compares	O
to	O
other	O
unpublished	O
studies	O
of	O
this	O
population.	O
	
It	O
is	O
hypothesized	O
that	O
respondents	O
may	O
have	O
been	O
more	O
likely	O
to	O
have	O
an	O
interest	O
or	O
personal	O
experience	O
with	O
Lyme	B-KP
disease,	I-KP
meaning	O
that	O
their	O
answers	O
may	O
not	O
be	O
representative	O
of	O
others	O
in	O
the	O
field.	O
	
Nevertheless,	O
few	O
of	O
the	O
respondents	O
reported	O
working	O
in	O
the	O
field	O
or	O
having	O
PTLDS	B-KP
themselves.	O
	
There	O
are	O
many	O
schools	O
of	O
public	O
health	O
located	O
in	O
the	O
northeastern	O
US,	O
however	O
schools	O
in	O
Lyme	B-KP
endemic	I-KP
states	I-KP
represent	O
only	O
30%	O
of	O
all	O
schools	O
surveyed	O
and	O
40%	O
of	O
all	O
emails	O
sent	O
were	O
to	O
schools	O
in	O
endemic	B-KP
states.	I-KP
	
An	O
equal	O
number	O
of	O
respondents	O
from	O
both	O
endemic	B-KP
states	I-KP
and	O
non-endemic	B-KP
states	I-KP
show	O
that	O
a	O
greater	O
percentage	O
of	O
respondents	O
from	O
endemic	O
state	O
schools	O
responded	O
to	O
the	O
survey.	O
	
However,	O
this	O
would	O
cause	O
us	O
to	O
hypothesize	O
that	O
there	O
would	O
be	O
an	O
overestimation	O
of	O
understanding	O
about	O
the	O
diseases	O
in	O
question,	O
an	O
overestimate	O
of	O
teaching	O
rates,	O
and	O
more	O
personal	O
and	O
professional	O
experience.	O
	
Despite	O
the	O
higher	O
response	O
rates	O
from	O
those	O
in	O
the	O
endemic	B-KP
states,	I-KP
the	O
data	O
still	O
show	O
much	O
uncertainty.	O
	
Limitations	O
of	O
this	O
study	O
are	O
primarily	O
related	O
to	O
the	O
response	O
rate	O
of	O
the	O
survey	O
(15%).	O
	
Due	O
to	O
the	O
low	O
number	O
of	O
published	O
studies	O
of	O
public	O
health	O
faculties	O
using	O
internet	O
based	O
surveys,	O
it	O
is	O
unclear	O
if	O
this	O
is	O
an	O
acceptable	O
response	O
rate	O
or	O
how	O
it	O
compares	O
to	O
other	O
unpublished	O
studies	O
of	O
this	O
population.	O
	
It	O
is	O
hypothesized	O
that	O
respondents	O
may	O
have	O
been	O
more	O
likely	O
to	O
have	O
an	O
interest	O
or	O
personal	O
experience	O
with	O
Lyme	B-KP
disease,	I-KP
meaning	O
that	O
their	O
answers	O
may	O
not	O
be	O
representative	O
of	O
others	O
in	O
the	O
field.	O
	
Nevertheless,	O
few	O
of	O
the	O
respondents	O
reported	O
working	O
in	O
the	O
field	O
or	O
having	O
PTLDS	B-KP
themselves.	O
	
There	O
are	O
many	O
schools	O
of	O
public	O
health	O
located	O
in	O
the	O
northeastern	O
US,	O
however	O
schools	O
in	O
Lyme	B-KP
endemic	I-KP
states	I-KP
represent	O
only	O
30%	O
of	O
all	O
schools	O
surveyed	O
and	O
40%	O
of	O
all	O
emails	O
sent	O
were	O
to	O
schools	O
in	O
endemic	B-KP
states.	I-KP
	
An	O
equal	O
number	O
of	O
respondents	O
from	O
both	O
endemic	B-KP
states	I-KP
and	O
non-endemic	B-KP
states	I-KP
show	O
that	O
a	O
greater	O
percentage	O
of	O
respondents	O
from	O
endemic	O
state	O
schools	O
responded	O
to	O
the	O
survey.	O
	
However,	O
this	O
would	O
cause	O
us	O
to	O
hypothesize	O
that	O
there	O
would	O
be	O
an	O
overestimation	O
of	O
understanding	O
about	O
the	O
diseases	O
in	O
question,	O
an	O
overestimate	O
of	O
teaching	O
rates,	O
and	O
more	O
personal	O
and	O
professional	O
experience.	O
	
Despite	O
the	O
higher	O
response	O
rates	O
from	O
those	O
in	O
the	O
endemic	B-KP
states,	I-KP
the	O
data	O
still	O
show	O
much	O
uncertainty.	O
	
More	O
than	O
90%	O
of	O
faculty	O
respondents	O
from	O
both	O
Lyme	B-KP
endemic	I-KP
and	O
non-endemic	B-KP
regions	I-KP
agree	O
that	O
Lyme	B-KP
disease	I-KP
is	O
common	O
in	O
certain	O
regions	O
of	O
the	O
US.	O
	
Most	O
faculty	O
members	O
(88%)	O
agree	O
that	O
the	O
geographical	O
range	O
of	O
Lyme	B-KP
disease	I-KP
will	O
increase	O
in	O
the	O
future.	O
	
The	O
majority	O
do	O
not	O
have	O
professional	O
experience,	O
defined	O
as	O
having	O
been	O
taught	O
about,	O
cared	O
for	O
patients	O
with,	O
or	O
done	O
research	O
on,	O
Lyme	B-KP
disease	I-KP
(66%)	O
or	O
PTLDS	B-KP
(83%).	O
	
While	O
many	O
are	O
unsure	O
of	O
the	O
research	O
funding	O
environment	O
for	O
Lyme	B-KP
disease	I-KP
and	O
PTLDS	B-KP
(82%),	O
17%	O
believe	O
that	O
these	O
diseases	O
are	O
underfunded.	O
	
Likewise,	O
85%	O
of	O
surveyed	O
faculty	O
members	O
believe	O
that	O
more	O
public	O
health	O
education	O
is	O
needed	O
surrounding	O
Lyme	B-KP
disease	I-KP
and	O
PTLDS.	B-KP
	
Pvalues	O
indicating	O
statistically	O
significant	O
differences	O
between	O
the	O
Lyme	B-KP
endemic	I-KP
and	O
non-Lyme	B-KP
endemic	I-KP
groups	I-KP
for	O
these	O
analyses	O
are	O
shown	O
at	O
the	O
bottom	O
of	O
Table	O
2.	O
	
More	O
than	O
90%	O
of	O
faculty	O
respondents	O
from	O
both	O
Lyme	B-KP
endemic	I-KP
and	O
non-endemic	B-KP
regions	I-KP
agree	O
that	O
Lyme	B-KP
disease	I-KP
is	O
common	O
in	O
certain	O
regions	O
of	O
the	O
US.	O
	
Most	O
faculty	O
members	O
(88%)	O
agree	O
that	O
the	O
geographical	O
range	O
of	O
Lyme	B-KP
disease	I-KP
will	O
increase	O
in	O
the	O
future.	O
	
The	O
majority	O
do	O
not	O
have	O
professional	O
experience,	O
defined	O
as	O
having	O
been	O
taught	O
about,	O
cared	O
for	O
patients	O
with,	O
or	O
done	O
research	O
on,	O
Lyme	B-KP
disease	I-KP
(66%)	O
or	O
PTLDS	B-KP
(83%).	O
	
While	O
many	O
are	O
unsure	O
of	O
the	O
research	O
funding	O
environment	O
for	O
Lyme	B-KP
disease	I-KP
and	O
PTLDS	B-KP
(82%),	O
17%	O
believe	O
that	O
these	O
diseases	O
are	O
underfunded.	O
	
Likewise,	O
85%	O
of	O
surveyed	O
faculty	O
members	O
believe	O
that	O
more	O
public	O
health	O
education	O
is	O
needed	O
surrounding	O
Lyme	B-KP
disease	I-KP
and	O
PTLDS.	B-KP
	
Pvalues	O
indicating	O
statistically	O
significant	O
differences	O
between	O
the	O
Lyme	B-KP
endemic	I-KP
and	O
non-Lyme	B-KP
endemic	I-KP
groups	I-KP
for	O
these	O
analyses	O
are	O
shown	O
at	O
the	O
bottom	O
of	O
Table	O
2.	O
	
North	O
American	O
Lyme	B-KP
disease	I-KP
or	O
borreliosis	B-KP
results	I-KP
from	O
infection	O
by	O
the	O
tick-borne	O
spirochete	B-KP
Borrelia	I-KP
burgdorferi.	I-KP
	
The	O
organism	O
is	O
uncommon	O
in	O
temperate	O
climates.	O
	
The	O
geographic	O
distribution	O
reported	O
by	O
the	O
Centers	O
for	O
Disease	O
Control	O
in	O
Morbidity	O
and	O
Mortality	O
Weekly	O
Report	O
reveals	O
only	O
12	O
cases	O
of	O
Lyme	B-KP
disease	I-KP
reported	O
in	O
Florida	O
as	O
compared	O
with	O
6,418	O
in	O
New	O
York	O
and	O
1,478	O
in	O
Connecticut	O
by	O
1990	O
[1].	O
	
In	O
the	O
endemic	B-KP
regions,	I-KP
Lyme	B-KP
disease	I-KP
is	O
often	O
included	O
in	O
a	O
differential	O
diagnosis	O
because	O
of	O
the	O
protean	B-KP
clinical	I-KP
manifestations	I-KP
involving	I-KP
skin,	I-KP
heart,	B-KP
musculoskeletal,	B-KP
and	O
nervous	B-KP
systems.	I-KP
	
The	O
clinical	O
features	O
of	O
Lyme	B-KP
neuroborreliosis	I-KP
(LN)	B-KP
have	O
been	O
described	O
in	O
previous	O
publications	O
[2-7].	O
	
Encephalopathy	I-KP
may	O
be	O
manifested	O
by	O
behavioral	I-KP
changes;	O
signs	O
and	O
symptoms	O
of	O
increased	O
intracranial	I-KP
pressure,	O
including	O
a	B-KP
sixth	I-KP
nerve	I-KP
palsy;	O
and	B-KP
unilateral	I-KP
or	I-KP
bilateral	I-KP
facial	I-KP
paralysis,	O
There	O
has	O
not	O
been	O
a	O
description	O
of	I-KP
intranuclear	I-KP
ophthalmoplegia.	O
	
The	O
case	O
we	O
report	O
is	O
unique	O
because	O
of	O
the	O
abrupt	O
signs	O
of	I-KP
brainstem	I-KP
dysfunction	O
suggesting	O
a	O
single	O
lesion	O
that	O
might	O
have	O
resulted	O
from	B-KP
neoplasia.	O
	
North	O
American	O
Lyme	B-KP
disease	I-KP
or	O
borreliosis	B-KP
results	I-KP
from	O
infection	O
by	O
the	O
tick-borne	O
spirochete	B-KP
Borrelia	I-KP
burgdorferi.	I-KP
	
The	O
organism	O
is	O
uncommon	O
in	O
temperate	O
climates.	O
	
The	O
geographic	O
distribution	O
reported	O
by	O
the	O
Centers	O
for	O
Disease	O
Control	O
in	O
Morbidity	O
and	O
Mortality	O
Weekly	O
Report	O
reveals	O
only	O
12	O
cases	O
of	O
Lyme	B-KP
disease	I-KP
reported	O
in	O
Florida	O
as	O
compared	O
with	O
6,418	O
in	O
New	O
York	O
and	O
1,478	O
in	O
Connecticut	O
by	O
1990	O
[1].	O
	
In	O
the	O
endemic	B-KP
regions,	I-KP
Lyme	B-KP
disease	I-KP
is	O
often	O
included	O
in	O
a	O
differential	O
diagnosis	O
because	O
of	O
the	O
protean	B-KP
clinical	I-KP
manifestations	I-KP
involving	I-KP
skin,	I-KP
heart,	B-KP
musculoskeletal,	B-KP
and	O
nervous	B-KP
systems.	I-KP
	
The	O
clinical	O
features	O
of	O
Lyme	B-KP
neuroborreliosis	I-KP
(LN)	B-KP
have	O
been	O
described	O
in	O
previous	O
publications	O
[2-7].	O
	
Encephalopathy	I-KP
may	O
be	O
manifested	O
by	O
behavioral	I-KP
changes;	O
signs	O
and	O
symptoms	O
of	O
increased	O
intracranial	I-KP
pressure,	O
including	O
a	B-KP
sixth	I-KP
nerve	I-KP
palsy;	O
and	B-KP
unilateral	I-KP
or	I-KP
bilateral	I-KP
facial	I-KP
paralysis,	O
There	O
has	O
not	O
been	O
a	O
description	O
of	I-KP
intranuclear	I-KP
ophthalmoplegia.	O
	
The	O
case	O
we	O
report	O
is	O
unique	O
because	O
of	O
the	O
abrupt	O
signs	O
of	I-KP
brainstem	I-KP
dysfunction	O
suggesting	O
a	O
single	O
lesion	O
that	O
might	O
have	O
resulted	O
from	B-KP
neoplasia.	O
	
Neurologic	B-KP
manifestations	I-KP
of	I-KP
borreliosis	I-KP
are	O
less	O
common	O
in	O
children	O
than	O
in	O
adults.	O
	
In	O
reports	O
of	O
139	O
LN	B-KP
patients,	O
only	O
five	O
were	O
less	O
than	O
18	O
years	O
of	O
age	O
[2,3,6,11].	O
	
All	O
five	O
had	O
Lyme	B-KP
meningitis.	I-KP
	
Three	O
of	O
the	O
five	O
also	O
had	O
a	O
unilateral	B-KP
facial	I-KP
palsy.	I-KP
	
Excellent	O
recovery	O
followed	O
antibiotic	B-KP
therapy	I-KP
in	O
each	O
case.	O
	
In	O
46	O
children	O
with	O
Lyme	B-KP
arthritis,	I-KP
a	O
10	O
year	O
follow-up	O
revealed	O
neurologic	O
symptoms	O
in	O
only	O
four	O
[12].	O
	
The	O
symptoms	O
included	O
headache	B-KP
and	O
memory	O
impairment	O
in	O
two,	O
seizures	O
in	O
one,	O
and	O
optic	B-KP
neuropathy	I-KP
with	O
myelopathy	B-KP
in	O
one.	O
	
The	O
neurologic	O
complaints	O
in	O
these	O
patients	O
began	O
4	O
to	O
12	O
years	O
after	O
the	O
onset	O
of	O
arthritis.	O
	
Neurologic	B-KP
manifestations	I-KP
of	I-KP
borreliosis	I-KP
are	O
less	O
common	O
in	O
children	O
than	O
in	O
adults.	O
	
In	O
reports	O
of	O
139	O
LN	B-KP
patients,	O
only	O
five	O
were	O
less	O
than	O
18	O
years	O
of	O
age	O
[2,3,6,11].	O
	
All	O
five	O
had	O
Lyme	B-KP
meningitis.	I-KP
	
Three	O
of	O
the	O
five	O
also	O
had	O
a	O
unilateral	B-KP
facial	I-KP
palsy.	I-KP
	
Excellent	O
recovery	O
followed	O
antibiotic	B-KP
therapy	I-KP
in	O
each	O
case.	O
	
In	O
46	O
children	O
with	O
Lyme	B-KP
arthritis,	I-KP
a	O
10	O
year	O
follow-up	O
revealed	O
neurologic	O
symptoms	O
in	O
only	O
four	O
[12].	O
	
The	O
symptoms	O
included	O
headache	B-KP
and	O
memory	O
impairment	O
in	O
two,	O
seizures	O
in	O
one,	O
and	O
optic	B-KP
neuropathy	I-KP
with	O
myelopathy	B-KP
in	O
one.	O
	
The	O
neurologic	O
complaints	O
in	O
these	O
patients	O
began	O
4	O
to	O
12	O
years	O
after	O
the	O
onset	O
of	O
arthritis.	O
	
Treatment	O
for	O
patients	O
with	O
erythema	B-KP
migrans	I-KP
typically	O
involves	O
oral	B-KP
doxycycline	I-KP
or	O
amoxicillin,	B-KP
[5-7]	O
and	O
most	O
patients	O
treated	O
with	O
either	O
of	O
these	O
agents	O
for	O
local	O
infection	O
have	O
an	O
excellent	O
response.	O
	
However,	O
not	O
all	O
patients	O
given	O
oral	B-KP
antibiotics	I-KP
for	O
early	O
disease	O
have	O
a	O
favorable	O
outcome,	O
[8,9]	O
perhaps	O
because	O
the	O
drugs	O
have	O
insufficient	O
activity	O
against	O
borrelia	B-KP
in	O
the	O
central	B-KP
nervous	I-KP
system.	I-KP
	
[10]	O
Ceftriaxone	B-KP
is	O
highly	O
active	O
against	O
B.	B-KP
	
burgdorferi	I-KP
and	O
reaches	O
high	O
levels	O
in	O
the	O
cerebrospinal	B-KP
fluid	I-KP
and	O
synovial	B-KP
fluid.	I-KP
	
[10,11]	O
Treatment	O
with	O
ceftriaxone	B-KP
is	O
effective	O
in	O
acute	O
disseminated	O
Lyme	B-KP
disease,	I-KP
including	O
that	O
manifested	O
by	O
neuroborreliosis,	B-KP
carditis,	B-KP
and	O
meningitis.	B-KP
	
[11-13]	O
We	O
conducted	O
a	O
study	O
to	O
compare	O
the	O
effectiveness	O
and	O
tolerability	O
of	O
parenteral	B-KP
ceftriaxone	I-KP
and	O
standard	B-KP
oral	I-KP
therapy	I-KP
in	O
patients	O
with	O
acute	O
disseminated	O
B.	B-KP
	
burgdorferi	I-KP
infection	I-KP
but	O
without	O
meningitis.	B-KP
	
Treatment	O
for	O
patients	O
with	O
erythema	B-KP
migrans	I-KP
typically	O
involves	O
oral	B-KP
doxycycline	I-KP
or	O
amoxicillin,	B-KP
[5-7]	O
and	O
most	O
patients	O
treated	O
with	O
either	O
of	O
these	O
agents	O
for	O
local	O
infection	O
have	O
an	O
excellent	O
response.	O
	
However,	O
not	O
all	O
patients	O
given	O
oral	B-KP
antibiotics	I-KP
for	O
early	O
disease	O
have	O
a	O
favorable	O
outcome,	O
[8,9]	O
perhaps	O
because	O
the	O
drugs	O
have	O
insufficient	O
activity	O
against	O
borrelia	B-KP
in	O
the	O
central	B-KP
nervous	I-KP
system.	I-KP
	
[10]	O
Ceftriaxone	B-KP
is	O
highly	O
active	O
against	O
B.	B-KP
	
burgdorferi	I-KP
and	O
reaches	O
high	O
levels	O
in	O
the	O
cerebrospinal	B-KP
fluid	I-KP
and	O
synovial	B-KP
fluid.	I-KP
	
[10,11]	O
Treatment	O
with	O
ceftriaxone	B-KP
is	O
effective	O
in	O
acute	O
disseminated	O
Lyme	B-KP
disease,	I-KP
including	O
that	O
manifested	O
by	O
neuroborreliosis,	B-KP
carditis,	B-KP
and	O
meningitis.	B-KP
	
[11-13]	O
We	O
conducted	O
a	O
study	O
to	O
compare	O
the	O
effectiveness	O
and	O
tolerability	O
of	O
parenteral	B-KP
ceftriaxone	I-KP
and	O
standard	B-KP
oral	I-KP
therapy	I-KP
in	O
patients	O
with	O
acute	O
disseminated	O
B.	B-KP
	
burgdorferi	I-KP
infection	I-KP
but	O
without	O
meningitis.	B-KP
	
Patients	O
who	O
had	O
been	O
in	O
areas	O
where	O
Lyme	B-KP
disease	I-KP
is	O
endemic,	O
who	O
were	O
eight	O
years	O
of	O
age	O
or	O
older,	O
and	O
who	O
had	O
acute	O
disseminated	O
Lyme	B-KP
borreliosis	I-KP
were	O
eligible	O
for	O
enrollment	O
in	O
this	O
openlabel,	O
controlled,	O
randomized,	O
multicenter	O
study.	O
	
The	O
study	O
was	O
conducted	O
between	O
May	O
1990	O
and	O
June	O
1994.	O
	
Erythema	B-KP
migrans,	I-KP
defined	O
as	O
an	O
expanding,	O
annular,	O
erythematous	B-KP
skin	I-KP
lesion	I-KP
at	O
least	O
5	O
cm	O
in	O
diameter,	O
was	O
required	O
for	O
study	O
entry.	O
	
Disseminated	B-KP
disease	I-KP
was	O
considered	O
present	O
if	O
the	O
patient	O
had	O
one	O
or	O
more	O
of	O
the	O
following:	O
more	O
than	O
one	O
erythema	B-KP
migrans	I-KP
lesion;	I-KP
carditis	B-KP
manifested	I-KP
by	I-KP
heart	I-KP
block;	I-KP
neurologic	O
abnormalities	O
(seventh-cranial-nerve	B-KP
palsy	I-KP
or	O
radiculitis	O
of	O
less	O
than	O
three	O
months’	O
duration);	O
and	O
acute	I-KP
large-joint	I-KP
arthritis.\nWe	O
excluded	O
pregnant	O
or	O
nursing	O
women	O
and	O
patients	O
with	O
evidence	O
of	O
syphilis,	O
meningitis,	O
or	O
collagen	I-KP
vascular	I-KP
disease;	O
current	O
symptoms	O
of	O
Lyme	I-KP
disease	I-KP
for	O
which	O
they	O
had	O
previously	O
received	O
treatment;	O
a	O
serious	O
underlying	O
disease	O
that	O
precluded	O
the	O
evaluation	O
of	O
the	O
response	O
to	O
treatment;	O
gallbladder	I-KP
disease;	O
or	O
hypersensitivity	O
to	O
ceftriaxone	I-KP
or	O
doxycycline.	O
	
Patients	O
treated	O
with	O
antimicrobial	O
agents	O
effective	O
in	O
Lyme	I-KP
disease	I-KP
within	O
48	O
hours	O
before	O
study	O
entry	O
or	O
treated	O
with	O
an	O
investigational	O
compound	O
within	O
two	O
weeks	O
before	O
study	O
entry	O
were	O
also	O
excluded,	O
as	O
were	O
patients	O
with	O
meningitis	I-KP
or	O
encephalitis.	O
	
Patients	O
who	O
had	O
been	O
in	O
areas	O
where	O
Lyme	B-KP
disease	I-KP
is	O
endemic,	O
who	O
were	O
eight	O
years	O
of	O
age	O
or	O
older,	O
and	O
who	O
had	O
acute	O
disseminated	O
Lyme	B-KP
borreliosis	I-KP
were	O
eligible	O
for	O
enrollment	O
in	O
this	O
openlabel,	O
controlled,	O
randomized,	O
multicenter	O
study.	O
	
The	O
study	O
was	O
conducted	O
between	O
May	O
1990	O
and	O
June	O
1994.	O
	
Erythema	B-KP
migrans,	I-KP
defined	O
as	O
an	O
expanding,	O
annular,	O
erythematous	B-KP
skin	I-KP
lesion	I-KP
at	O
least	O
5	O
cm	O
in	O
diameter,	O
was	O
required	O
for	O
study	O
entry.	O
	
Disseminated	B-KP
disease	I-KP
was	O
considered	O
present	O
if	O
the	O
patient	O
had	O
one	O
or	O
more	O
of	O
the	O
following:	O
more	O
than	O
one	O
erythema	B-KP
migrans	I-KP
lesion;	I-KP
carditis	B-KP
manifested	I-KP
by	I-KP
heart	I-KP
block;	I-KP
neurologic	O
abnormalities	O
(seventh-cranial-nerve	B-KP
palsy	I-KP
or	O
radiculitis	O
of	O
less	O
than	O
three	O
months’	O
duration);	O
and	O
acute	I-KP
large-joint	I-KP
arthritis.\nWe	O
excluded	O
pregnant	O
or	O
nursing	O
women	O
and	O
patients	O
with	O
evidence	O
of	O
syphilis,	O
meningitis,	O
or	O
collagen	I-KP
vascular	I-KP
disease;	O
current	O
symptoms	O
of	O
Lyme	I-KP
disease	I-KP
for	O
which	O
they	O
had	O
previously	O
received	O
treatment;	O
a	O
serious	O
underlying	O
disease	O
that	O
precluded	O
the	O
evaluation	O
of	O
the	O
response	O
to	O
treatment;	O
gallbladder	I-KP
disease;	O
or	O
hypersensitivity	O
to	O
ceftriaxone	I-KP
or	O
doxycycline.	O
	
Patients	O
treated	O
with	O
antimicrobial	O
agents	O
effective	O
in	O
Lyme	I-KP
disease	I-KP
within	O
48	O
hours	O
before	O
study	O
entry	O
or	O
treated	O
with	O
an	O
investigational	O
compound	O
within	O
two	O
weeks	O
before	O
study	O
entry	O
were	O
also	O
excluded,	O
as	O
were	O
patients	O
with	O
meningitis	I-KP
or	O
encephalitis.	O
	
One	O
patient	O
in	O
each	O
treatment	O
group	O
had	O
objective	O
evidence	O
of	O
Lyme	B-KP
disease	I-KP
at	O
the	O
last	O
evaluation	O
(i.e.,	O
treatment	O
failed).	O
	
A	O
patient	O
in	O
the	O
ceftriaxone	B-KP
group	I-KP
who	O
presented	O
with	O
seventh-cranial-nerve	B-KP
palsy	I-KP
and	O
normal	O
results	O
on	O
lumbar	B-KP
puncture	I-KP
continued	O
to	O
have	O
palsy	B-KP
at	O
the	O
three-month	O
follow-up	O
and	O
was	O
given	O
ceftriaxone	B-KP
for	O
an	O
additional	O
five	O
weeks.	O
	
Despite	O
treatment,	O
the	O
palsy	B-KP
persisted.	O
	
In	O
a	O
second	O
patient,	O
large-joint	B-KP
arthritis	I-KP
developed	O
during	O
treatment	O
with	O
doxycycline;	B-KP
this	O
patient	O
also	O
had	O
fatigue,	O
joint	B-KP
swelling,	I-KP
limitation	O
of	O
joint	O
movement,	O
arthralgia,	B-KP
and	O
myalgia;	B-KP
he	O
subsequently	O
received	O
intravenous	B-KP
ceftriaxone	I-KP
for	O
three	O
weeks	O
and	O
had	O
a	O
complete	O
resolution	O
of	O
all	O
signs	O
and	O
symptoms.	O
	
One	O
patient	O
in	O
each	O
treatment	O
group	O
had	O
objective	O
evidence	O
of	O
Lyme	B-KP
disease	I-KP
at	O
the	O
last	O
evaluation	O
(i.e.,	O
treatment	O
failed).	O
	
A	O
patient	O
in	O
the	O
ceftriaxone	B-KP
group	I-KP
who	O
presented	O
with	O
seventh-cranial-nerve	B-KP
palsy	I-KP
and	O
normal	O
results	O
on	O
lumbar	B-KP
puncture	I-KP
continued	O
to	O
have	O
palsy	B-KP
at	O
the	O
three-month	O
follow-up	O
and	O
was	O
given	O
ceftriaxone	B-KP
for	O
an	O
additional	O
five	O
weeks.	O
	
Despite	O
treatment,	O
the	O
palsy	B-KP
persisted.	O
	
In	O
a	O
second	O
patient,	O
large-joint	B-KP
arthritis	I-KP
developed	O
during	O
treatment	O
with	O
doxycycline;	B-KP
this	O
patient	O
also	O
had	O
fatigue,	O
joint	B-KP
swelling,	I-KP
limitation	O
of	O
joint	O
movement,	O
arthralgia,	B-KP
and	O
myalgia;	B-KP
he	O
subsequently	O
received	O
intravenous	B-KP
ceftriaxone	I-KP
for	O
three	O
weeks	O
and	O
had	O
a	O
complete	O
resolution	O
of	O
all	O
signs	O
and	O
symptoms.	O
	
Signs	O
and	O
symptoms	O
attributable	O
to	O
the	O
nervous	O
or	O
musculoskeletal	B-KP
system	I-KP
have	O
been	O
noted	O
by	O
other	O
investigators.	O
	
Two	O
separate,	O
large,	O
retrospective	O
studies	O
of	O
patients	O
treated	O
for	O
early	B-KP
Lyme	I-KP
disease	I-KP
found	O
a	O
surprisingly	O
high	O
incidence	O
of	O
continued	O
signs	O
and	O
symptoms,	O
especially	O
if	O
treatment	O
was	O
delayed.	O
	
[8,9]	O
Shadick	O
et	O
al.8	O
found	O
that	O
34	O
percent	O
of	O
patients	O
in	O
a	O
suburban	O
area	O
of	O
highly	B-KP
endemic	I-KP
disease	I-KP
just	O
north	O
of	O
Boston	O
who	O
had	O
been	O
treated	O
for	O
early	B-KP
Lyme	I-KP
disease	I-KP
had	O
long-term	O
sequelae,	O
including	O
arthritis,	B-KP
arthralgia,	B-KP
cognitive	B-KP
impairment,	I-KP
and	O
neuropathy.	B-KP
	
A	O
similar	O
investigation	O
carried	O
out	O
in	O
Westchester	O
County,	O
New	O
York,	O
[9]	O
found	O
that	O
114	O
of	O
the	O
215	O
patients	O
studied	O
(53	O
percent)	O
had	O
persistent	O
signs	O
and	O
symptoms,	O
including	O
neurologic,	B-KP
cardiac,	B-KP
and	O
musculoskeletal	B-KP
disorders.	I-KP
	
Of	O
the	O
114	O
patients	O
with	O
ongoing	O
problems,	O
35	O
(31	O
percent)	O
had	O
clinically	O
important	O
fatigue	O
and	O
arthralgia	O
as	O
their	O
chief	O
symptoms.	O
	
These	O
retrospective	O
studies	O
suggest	O
that	O
perhaps	O
more	O
attention	O
should	O
be	O
paid	O
to	O
minor	O
post-treatment	O
symptoms.	O
	
Although	O
arthralgia	B-KP
and	O
fatigue	B-KP
have	O
been	O
reported	O
after	O
the	O
administration	O
of	O
both	O
oral	B-KP
and	I-KP
parenteral	I-KP
antibiotics	I-KP
for	O
early	B-KP
Lyme	I-KP
disease,	I-KP
[6,16-18]	O
the	O
incidence	O
is	O
generally	O
low.	O
	
Mild	B-KP
arthralgia,	I-KP
fatigue,	B-KP
and	O
headache	B-KP
were	O
noted	O
after	O
therapy	O
with	O
intravenous	B-KP
ceftriaxone	I-KP
and	O
oral	B-KP
penicillin,	I-KP
[17]	O
and	O
arthralgia	B-KP
was	O
noted	O
after	O
oral	B-KP
treatment	I-KP
with	I-KP
amoxicillin	I-KP
plus	O
probenecid	B-KP
or	O
with	O
doxycycline.	B-KP
	
[6]	O
One	O
year	O
after	O
treatment	O
with	O
cefuroxime	B-KP
axetil	I-KP
or	O
doxycycline,	B-KP
approximately	O
10	O
percent	O
of	O
patients	O
reported	O
the	O
persistence	O
of	O
mild-to-severe	B-KP
fatigue,	I-KP
arthralgia,	B-KP
and	O
myalgia.	B-KP
	
[16]	O
Signs	O
and	O
symptoms	O
attributable	O
to	O
the	O
nervous	O
or	O
musculoskeletal	B-KP
system	I-KP
have	O
been	O
noted	O
by	O
other	O
investigators.	O
	
Two	O
separate,	O
large,	O
retrospective	O
studies	O
of	O
patients	O
treated	O
for	O
early	B-KP
Lyme	I-KP
disease	I-KP
found	O
a	O
surprisingly	O
high	O
incidence	O
of	O
continued	O
signs	O
and	O
symptoms,	O
especially	O
if	O
treatment	O
was	O
delayed.	O
	
[8,9]	O
Shadick	O
et	O
al.8	O
found	O
that	O
34	O
percent	O
of	O
patients	O
in	O
a	O
suburban	O
area	O
of	O
highly	B-KP
endemic	I-KP
disease	I-KP
just	O
north	O
of	O
Boston	O
who	O
had	O
been	O
treated	O
for	O
early	B-KP
Lyme	I-KP
disease	I-KP
had	O
long-term	O
sequelae,	O
including	O
arthritis,	B-KP
arthralgia,	B-KP
cognitive	B-KP
impairment,	I-KP
and	O
neuropathy.	B-KP
	
A	O
similar	O
investigation	O
carried	O
out	O
in	O
Westchester	O
County,	O
New	O
York,	O
[9]	O
found	O
that	O
114	O
of	O
the	O
215	O
patients	O
studied	O
(53	O
percent)	O
had	O
persistent	O
signs	O
and	O
symptoms,	O
including	O
neurologic,	B-KP
cardiac,	B-KP
and	O
musculoskeletal	B-KP
disorders.	I-KP
	
Of	O
the	O
114	O
patients	O
with	O
ongoing	O
problems,	O
35	O
(31	O
percent)	O
had	O
clinically	O
important	O
fatigue	O
and	O
arthralgia	O
as	O
their	O
chief	O
symptoms.	O
	
These	O
retrospective	O
studies	O
suggest	O
that	O
perhaps	O
more	O
attention	O
should	O
be	O
paid	O
to	O
minor	O
post-treatment	O
symptoms.	O
	
Although	O
arthralgia	B-KP
and	O
fatigue	B-KP
have	O
been	O
reported	O
after	O
the	O
administration	O
of	O
both	O
oral	B-KP
and	I-KP
parenteral	I-KP
antibiotics	I-KP
for	O
early	B-KP
Lyme	I-KP
disease,	I-KP
[6,16-18]	O
the	O
incidence	O
is	O
generally	O
low.	O
	
Mild	B-KP
arthralgia,	I-KP
fatigue,	B-KP
and	O
headache	B-KP
were	O
noted	O
after	O
therapy	O
with	O
intravenous	B-KP
ceftriaxone	I-KP
and	O
oral	B-KP
penicillin,	I-KP
[17]	O
and	O
arthralgia	B-KP
was	O
noted	O
after	O
oral	B-KP
treatment	I-KP
with	I-KP
amoxicillin	I-KP
plus	O
probenecid	B-KP
or	O
with	O
doxycycline.	B-KP
	
[6]	O
One	O
year	O
after	O
treatment	O
with	O
cefuroxime	B-KP
axetil	I-KP
or	O
doxycycline,	B-KP
approximately	O
10	O
percent	O
of	O
patients	O
reported	O
the	O
persistence	O
of	O
mild-to-severe	B-KP
fatigue,	I-KP
arthralgia,	B-KP
and	O
myalgia.	B-KP
	
[16]	O
LNB	B-KP
is,	O
inmany	O
cases,	O
responsive	O
to	O
appropriate	O
antimicrobial	O
therapy	O
and	O
the	O
clinical	O
improvement	O
sustained	O
by	O
the	O
antibiotic	O
treatment	O
provide	O
further	O
evidence	O
for	O
the	O
direct	O
contribution	O
of	O
B.	B-KP
	
burgdorferi	I-KP
in	O
disease	B-KP
pathogenesis.	I-KP
	
However,	O
the	O
chronic	B-KP
persistence,	I-KP
the	O
frequent	O
reoccurrence	O
of	O
LNB	B-KP
and	O
the	O
ability	O
of	O
B.	B-KP
	
burgdorferi	I-KP
to	O
tolerate	O
multiple	B-KP
cycles	I-KP
of	I-KP
antibiotic	I-KP
treatment	I-KP
is	O
strongly	O
suggestive	O
for	O
the	O
formation	O
of	O
biofilm	B-KP
or	O
biofilmlike	B-KP
protective	I-KP
structure	I-KP
(20–23).	O
	
Indeed,	O
different	O
studies	O
have	O
shown	O
that	O
B.	B-KP
	
burgdorferi	I-KP
can	O
switch	O
fromamotile	B-KP
to	O
a	O
stationary	O
status,	O
in	O
which	O
the	O
cells	O
are	O
embedded	O
within	O
a	O
biofilm	B-KP
matrix	I-KP
(22).	O
	
B.	B-KP
	
burgdorferi	I-KP
biofilms	I-KP
have	O
been	O
observed	O
both	O
in	O
vitro	O
and	O
in	O
human	B-KP
infected	I-KP
skin	I-KP
tissues	I-KP
(22,	O
23).	O
	
These	O
structures	O
express	O
different	O
mucopolysaccharides,	B-KP
particularly	O
alginate,	B-KP
extracellular	B-KP
DNA	I-KP
and	O
calcium,	O
which	O
are	O
all	O
typical	O
markers	O
of	O
biofilm	B-KP
(22).	O
	
The	O
presence	O
of	O
biofilm	B-KP
may	O
explain	O
the	O
low	O
rate	O
of	O
Borrelia	B-KP
detection	I-KP
in	O
the	O
blood	B-KP
of	O
infected	O
patients	O
as	O
well	O
as	O
the	O
ability	O
of	O
the	O
spirochetes	B-KP
to	O
evade	O
the	O
host	B-KP
immune	I-KP
systemand	O
resist	O
the	O
antibiotic	B-KP
therapy	I-KP
(21,	O
24–27).	O
	
LNB	B-KP
is,	O
inmany	O
cases,	O
responsive	O
to	O
appropriate	O
antimicrobial	O
therapy	O
and	O
the	O
clinical	O
improvement	O
sustained	O
by	O
the	O
antibiotic	O
treatment	O
provide	O
further	O
evidence	O
for	O
the	O
direct	O
contribution	O
of	O
B.	B-KP
	
burgdorferi	I-KP
in	O
disease	B-KP
pathogenesis.	I-KP
	
However,	O
the	O
chronic	B-KP
persistence,	I-KP
the	O
frequent	O
reoccurrence	O
of	O
LNB	B-KP
and	O
the	O
ability	O
of	O
B.	B-KP
	
burgdorferi	I-KP
to	O
tolerate	O
multiple	B-KP
cycles	I-KP
of	I-KP
antibiotic	I-KP
treatment	I-KP
is	O
strongly	O
suggestive	O
for	O
the	O
formation	O
of	O
biofilm	B-KP
or	O
biofilmlike	B-KP
protective	I-KP
structure	I-KP
(20–23).	O
	
Indeed,	O
different	O
studies	O
have	O
shown	O
that	O
B.	B-KP
	
burgdorferi	I-KP
can	O
switch	O
fromamotile	B-KP
to	O
a	O
stationary	O
status,	O
in	O
which	O
the	O
cells	O
are	O
embedded	O
within	O
a	O
biofilm	B-KP
matrix	I-KP
(22).	O
	
B.	B-KP
	
burgdorferi	I-KP
biofilms	I-KP
have	O
been	O
observed	O
both	O
in	O
vitro	O
and	O
in	O
human	B-KP
infected	I-KP
skin	I-KP
tissues	I-KP
(22,	O
23).	O
	
These	O
structures	O
express	O
different	O
mucopolysaccharides,	B-KP
particularly	O
alginate,	B-KP
extracellular	B-KP
DNA	I-KP
and	O
calcium,	O
which	O
are	O
all	O
typical	O
markers	O
of	O
biofilm	B-KP
(22).	O
	
The	O
presence	O
of	O
biofilm	B-KP
may	O
explain	O
the	O
low	O
rate	O
of	O
Borrelia	B-KP
detection	I-KP
in	O
the	O
blood	B-KP
of	O
infected	O
patients	O
as	O
well	O
as	O
the	O
ability	O
of	O
the	O
spirochetes	B-KP
to	O
evade	O
the	O
host	B-KP
immune	I-KP
systemand	O
resist	O
the	O
antibiotic	B-KP
therapy	I-KP
(21,	O
24–27).	O
	
The	O
distribution	O
and	O
relative	O
frequency	O
of	O
infection	O
by	O
the	O
different	O
genospecies	O
of	O
Borrelia	B-KP
sensu	I-KP
latu	I-KP
vary	O
across	O
European	O
regions.	O
	
B.	B-KP
	
burgdorferi	I-KP
sensu	I-KP
lato	I-KP
comprises	O
20	O
different	O
genospecies	O
and	O
this	O
diversity	O
correlates	O
with	O
the	O
large	O
variability	O
in	O
the	O
clinical	O
manifestations	O
observed	O
in	O
LB	B-KP
(4,	O
13,	O
63).	O
	
In	O
the	O
northern	O
and	O
eastern	O
Europe	O
B.	B-KP
	
afzelii	I-KP
is	O
the	O
most	O
prevalent	O
species,	O
whereas	O
in	O
Western	O
European	O
countries	O
B.	B-KP
	
garinii	I-KP
is	O
the	O
most	O
common	B-KP
pathogen	I-KP
(4,	O
29).	O
	
B.	B-KP
	
afzelii,	I-KP
B.	B-KP
	
garini,	I-KP
and	O
the	O
recently	O
identified	O
species	O
B.	B-KP
	
bavariensis	I-KP
are	O
major	O
cause	O
of	O
LB	B-KP
and	O
LNB	B-KP
in	O
Europe	O
(52,	O
64–68).	O
	
The	O
heterogeneity	O
among	O
B.	B-KP
	
burgdorferi	I-KP
sensu	I-KP
lato	I-KP
genospecies	I-KP
is	O
linked	O
to	O
different	O
geographical	O
areas,	O
which,	O
in	O
turn,	O
correlates	O
with	O
the	O
different	O
clinical	O
expression	O
of	O
human	O
LB	B-KP
(69).	O
	
For	O
instance,	O
B.	B-KP
	
afzelii	I-KP
induces	O
prevalently	O
skin	B-KP
infections,	I-KP
whereas	O
B.	B-KP
	
garinii	I-KP
is	O
in	O
most	O
cases	O
neurotropic	B-KP
(5,	O
69).	O
	
Other	O
species,	O
such	O
as	O
B.	B-KP
	
lusitaniae	I-KP
or	O
B.	B-KP
	
valaisiana,	I-KP
have	O
only	O
occasionally	O
been	O
associated	O
with	O
human	O
disease	O
(70–72).	O
	
In	O
endemic	B-KP
areas	I-KP
of	O
Europe	O
was	O
proposed	O
that	O
the	O
variety	O
of	O
symptoms	O
observed	O
in	O
children	O
and	O
adults	O
with	O
LNB	B-KP
correlated	O
with	O
the	O
B.	B-KP
	
burgdorferi	I-KP
sensu	I-KP
lato	I-KP
genotype	I-KP
(73–75).	O
	
Individuals	O
with	O
erythema	B-KP
migrans	I-KP
caused	O
by	O
B.	B-KP
	
afzelii	I-KP
and	O
B.	B-KP
	
garinii	I-KP
showed	O
distinct	O
epidemiological	B-KP
and	I-KP
clinical	I-KP
characteristics.	I-KP
	
Indeed,	O
erythema	B-KP
migrans	I-KP
caused	O
by	O
B.	B-KP
	
garinii	I-KP
were	O
located	O
prevalently	O
on	O
the	O
trunk	O
and	O
less	O
often	O
on	O
extremities,	O
had	O
shorter	O
incubation	O
and	O
faster	O
evolution,	O
leading	O
to	O
frequent	O
systemic	O
symptoms,	O
abnormal	O
liver	O
function	O
test	O
results	O
than	O
individuals	O
with	O
erythema	B-KP
migrans	I-KP
caused	O
by	O
B.	B-KP
	
afzelii	I-KP
(76,	O
77).	O
	
The	O
distribution	O
and	O
relative	O
frequency	O
of	O
infection	O
by	O
the	O
different	O
genospecies	O
of	O
Borrelia	B-KP
sensu	I-KP
latu	I-KP
vary	O
across	O
European	O
regions.	O
	
B.	B-KP
	
burgdorferi	I-KP
sensu	I-KP
lato	I-KP
comprises	O
20	O
different	O
genospecies	O
and	O
this	O
diversity	O
correlates	O
with	O
the	O
large	O
variability	O
in	O
the	O
clinical	O
manifestations	O
observed	O
in	O
LB	B-KP
(4,	O
13,	O
63).	O
	
In	O
the	O
northern	O
and	O
eastern	O
Europe	O
B.	B-KP
	
afzelii	I-KP
is	O
the	O
most	O
prevalent	O
species,	O
whereas	O
in	O
Western	O
European	O
countries	O
B.	B-KP
	
garinii	I-KP
is	O
the	O
most	O
common	B-KP
pathogen	I-KP
(4,	O
29).	O
	
B.	B-KP
	
afzelii,	I-KP
B.	B-KP
	
garini,	I-KP
and	O
the	O
recently	O
identified	O
species	O
B.	B-KP
	
bavariensis	I-KP
are	O
major	O
cause	O
of	O
LB	B-KP
and	O
LNB	B-KP
in	O
Europe	O
(52,	O
64–68).	O
	
The	O
heterogeneity	O
among	O
B.	B-KP
	
burgdorferi	I-KP
sensu	I-KP
lato	I-KP
genospecies	I-KP
is	O
linked	O
to	O
different	O
geographical	O
areas,	O
which,	O
in	O
turn,	O
correlates	O
with	O
the	O
different	O
clinical	O
expression	O
of	O
human	O
LB	B-KP
(69).	O
	
For	O
instance,	O
B.	B-KP
	
afzelii	I-KP
induces	O
prevalently	O
skin	B-KP
infections,	I-KP
whereas	O
B.	B-KP
	
garinii	I-KP
is	O
in	O
most	O
cases	O
neurotropic	B-KP
(5,	O
69).	O
	
Other	O
species,	O
such	O
as	O
B.	B-KP
	
lusitaniae	I-KP
or	O
B.	B-KP
	
valaisiana,	I-KP
have	O
only	O
occasionally	O
been	O
associated	O
with	O
human	O
disease	O
(70–72).	O
	
In	O
endemic	B-KP
areas	I-KP
of	O
Europe	O
was	O
proposed	O
that	O
the	O
variety	O
of	O
symptoms	O
observed	O
in	O
children	O
and	O
adults	O
with	O
LNB	B-KP
correlated	O
with	O
the	O
B.	B-KP
	
burgdorferi	I-KP
sensu	I-KP
lato	I-KP
genotype	I-KP
(73–75).	O
	
Individuals	O
with	O
erythema	B-KP
migrans	I-KP
caused	O
by	O
B.	B-KP
	
afzelii	I-KP
and	O
B.	B-KP
	
garinii	I-KP
showed	O
distinct	O
epidemiological	B-KP
and	I-KP
clinical	I-KP
characteristics.	I-KP
	
Indeed,	O
erythema	B-KP
migrans	I-KP
caused	O
by	O
B.	B-KP
	
garinii	I-KP
were	O
located	O
prevalently	O
on	O
the	O
trunk	O
and	O
less	O
often	O
on	O
extremities,	O
had	O
shorter	O
incubation	O
and	O
faster	O
evolution,	O
leading	O
to	O
frequent	O
systemic	O
symptoms,	O
abnormal	O
liver	O
function	O
test	O
results	O
than	O
individuals	O
with	O
erythema	B-KP
migrans	I-KP
caused	O
by	O
B.	B-KP
	
afzelii	I-KP
(76,	O
77).	O
	
The	O
expression	O
of	O
different	O
proteins,	O
including	O
OspC,	B-KP
ErpP,	B-KP
ErpA,	B-KP
ErpC,	B-KP
and	O
enolase	B-KP
is	O
required	O
to	O
readily	O
immobilize	O
host	B-KP
plasminogen	I-KP
on	O
spirochetal	B-KP
surface,	I-KP
facilitating	O
efficient	O
dissemination	O
(116–118).	O
	
Plasminogen	B-KP
is	O
a	O
glycoprotein	B-KP
produced	O
by	O
the	O
liver	O
and	O
abundant	O
in	O
the	O
plasma	O
and	O
in	O
certain	O
tissues	O
(119).	O
	
Conversion	O
of	O
plasminogen	B-KP
to	I-KP
active	I-KP
plasmin	I-KP
is	O
promoted	O
by	O
proteolytic	B-KP
activation	I-KP
induced	O
by	O
either	O
tissue-type	B-KP
plasminogen	I-KP
activator	I-KP
(tPA)	B-KP
and/or	O
urokinase-type	I-KP
plasminogen	I-KP
activator	I-KP
urokinase	I-KP
(uPA).	B-KP
	
Plasmin	I-KP
is	O
responsible	O
for	O
intravascular	I-KP
fibrinolysis	I-KP
and	O
contributes	O
to	O
numerous	O
physiological	O
and	O
pathological	O
processes,	O
including	O
tissue	I-KP
remodeling,	O
cell	I-KP
migration,	O
thrombolysis,	O
wound	O
healing,	O
and	O
cancer	O
progression	O
(120,	O
121).	O
	
Invasive	I-KP
forms	I-KP
of	I-KP
B.	I-KP
	
burgdorferi	I-KP
are	O
known	O
to	O
expresses	O
multiple	O
plasminogen-binding	I-KP
surface	I-KP
proteins	I-KP
that	O
likely	O
assist	O
pathogen	I-KP
dissemination	I-KP
through	O
host	I-KP
tissues	I-KP
(120,	O
122).	O
	
Enolase	I-KP
is	O
an	O
integral	I-KP
enzyme	I-KP
of	I-KP
the	I-KP
glycolysis	I-KP
and	I-KP
gluconeogenesis	I-KP
pathways,	O
and	O
a	O
multifunctional	O
protein	O
found	O
in	O
both	O
prokaryote	O
and	O
eukaryotes	O
(123).	O
	
In	O
eukaryotic	I-KP
cells,	O
surface	I-KP
enolase	I-KP
acts	O
as	O
a	B-KP
plasminogen	I-KP
receptor	I-KP
in	I-KP
certain	I-KP
tumor	I-KP
cells	O
(123,	O
124).	O
	
Similarly,	O
this	O
enzyme	O
is	O
also	O
localized	O
on	O
the	O
cell	O
surface	O
of	O
different	O
microorganisms	O
including	O
B.	I-KP
	
burgdorferi	O
(118,	O
125–127).	O
	
The	B-KP
surface-localized	I-KP
enolase	I-KP
acts	I-KP
as	I-KP
a	I-KP
plasminogen	I-KP
receptor	O
contributing	O
to	O
spirochetal	O
survival	O
in	O
feeding	O
ticks	O
(118).	O
	
Although	O
dispensable	O
for	O
infection,	O
plasminogen	O
is	O
required	O
for	O
dissemination	O
in	O
ticks,	O
and	O
its	O
absence	O
is	O
associated	O
with	O
a	O
decreased	O
spirochetemia	O
in	O
plasminogen-deficient	O
mice	O
(128).	O
	
Surface-associated	I-KP
plasmin	I-KP
on	I-KP
B.	I-KP
	
burgdorferi	I-KP
degrade	I-KP
fibronectin,	O
which	O
is	O
an	O
important	O
component	O
of	O
the	B-KP
ECM,	B-KP
laminin	O
and	I-KP
vitronectin	O
(129,	O
130).	B-KP
	
B.	I-KP
	
burgdorferi	O
also	O
induces	O
the	O
release	O
of	I-KP
host	I-KP
matrix	I-KP
metalloproteases	O
9	I-KP
(MMP-9)	O
and	I-KP
MMP-1,	O
and	I-KP
plasmin-coated	I-KP
B.	I-KP
	
burgdorferi	I-KP
activates	I-KP
pro-MMP-9,	O
leading	O
to	O
degradation	O
of	O
basement	O
membranes	O
(131).	O
	
The	O
expression	O
of	O
different	O
proteins,	O
including	O
OspC,	B-KP
ErpP,	B-KP
ErpA,	B-KP
ErpC,	B-KP
and	O
enolase	B-KP
is	O
required	O
to	O
readily	O
immobilize	O
host	B-KP
plasminogen	I-KP
on	O
spirochetal	B-KP
surface,	I-KP
facilitating	O
efficient	O
dissemination	O
(116–118).	O
	
Plasminogen	B-KP
is	O
a	O
glycoprotein	B-KP
produced	O
by	O
the	O
liver	O
and	O
abundant	O
in	O
the	O
plasma	O
and	O
in	O
certain	O
tissues	O
(119).	O
	
Conversion	O
of	O
plasminogen	B-KP
to	I-KP
active	I-KP
plasmin	I-KP
is	O
promoted	O
by	O
proteolytic	B-KP
activation	I-KP
induced	O
by	O
either	O
tissue-type	B-KP
plasminogen	I-KP
activator	I-KP
(tPA)	B-KP
and/or	O
urokinase-type	I-KP
plasminogen	I-KP
activator	I-KP
urokinase	I-KP
(uPA).	B-KP
	
Plasmin	I-KP
is	O
responsible	O
for	O
intravascular	I-KP
fibrinolysis	I-KP
and	O
contributes	O
to	O
numerous	O
physiological	O
and	O
pathological	O
processes,	O
including	O
tissue	I-KP
remodeling,	O
cell	I-KP
migration,	O
thrombolysis,	O
wound	O
healing,	O
and	O
cancer	O
progression	O
(120,	O
121).	O
	
Invasive	I-KP
forms	I-KP
of	I-KP
B.	I-KP
	
burgdorferi	I-KP
are	O
known	O
to	O
expresses	O
multiple	O
plasminogen-binding	I-KP
surface	I-KP
proteins	I-KP
that	O
likely	O
assist	O
pathogen	I-KP
dissemination	I-KP
through	O
host	I-KP
tissues	I-KP
(120,	O
122).	O
	
Enolase	I-KP
is	O
an	O
integral	I-KP
enzyme	I-KP
of	I-KP
the	I-KP
glycolysis	I-KP
and	I-KP
gluconeogenesis	I-KP
pathways,	O
and	O
a	O
multifunctional	O
protein	O
found	O
in	O
both	O
prokaryote	O
and	O
eukaryotes	O
(123).	O
	
In	O
eukaryotic	I-KP
cells,	O
surface	I-KP
enolase	I-KP
acts	O
as	O
a	B-KP
plasminogen	I-KP
receptor	I-KP
in	I-KP
certain	I-KP
tumor	I-KP
cells	O
(123,	O
124).	O
	
Similarly,	O
this	O
enzyme	O
is	O
also	O
localized	O
on	O
the	O
cell	O
surface	O
of	O
different	O
microorganisms	O
including	O
B.	I-KP
	
burgdorferi	O
(118,	O
125–127).	O
	
The	B-KP
surface-localized	I-KP
enolase	I-KP
acts	I-KP
as	I-KP
a	I-KP
plasminogen	I-KP
receptor	O
contributing	O
to	O
spirochetal	O
survival	O
in	O
feeding	O
ticks	O
(118).	O
	
Although	O
dispensable	O
for	O
infection,	O
plasminogen	O
is	O
required	O
for	O
dissemination	O
in	O
ticks,	O
and	O
its	O
absence	O
is	O
associated	O
with	O
a	O
decreased	O
spirochetemia	O
in	O
plasminogen-deficient	O
mice	O
(128).	O
	
Surface-associated	I-KP
plasmin	I-KP
on	I-KP
B.	I-KP
	
burgdorferi	I-KP
degrade	I-KP
fibronectin,	O
which	O
is	O
an	O
important	O
component	O
of	O
the	B-KP
ECM,	B-KP
laminin	O
and	I-KP
vitronectin	O
(129,	O
130).	B-KP
	
B.	I-KP
	
burgdorferi	O
also	O
induces	O
the	O
release	O
of	I-KP
host	I-KP
matrix	I-KP
metalloproteases	O
9	I-KP
(MMP-9)	O
and	I-KP
MMP-1,	O
and	I-KP
plasmin-coated	I-KP
B.	I-KP
	
burgdorferi	I-KP
activates	I-KP
pro-MMP-9,	O
leading	O
to	O
degradation	O
of	O
basement	O
membranes	O
(131).	O
	
Biofilm	B-KP
production	I-KP
in	I-KP
Borrelia	I-KP
requires	O
the	O
modulation	O
of	O
a	O
complex	B-KP
array	I-KP
of	I-KP
signaling	I-KP
processes	I-KP
which	O
allows	O
spirochetes	B-KP
to	O
communicate	O
with	O
the	O
surrounding	O
environment.	O
	
The	O
RpoN–RpoS	B-KP
alternative	I-KP
sigma	I-KP
factor	I-KP
and	O
the	O
LuxS	B-KP
quorumsensing	I-KP
pathways,	I-KP
which	O
are	O
involved	O
in	O
several	B-KP
cellular	I-KP
functions	I-KP
in	O
response	O
to	O
environmental	O
stresses	O
(pH	B-KP
and	I-KP
temperature	I-KP
variations,	O
high	I-KP
osmolarity,	O
oxidative	I-KP
stress,	O
high	I-KP
cell	I-KP
density,	O
nutrient	I-KP
starvation,	O
host	I-KP
infection),	O
participate	O
in	O
biofilm	I-KP
production	I-KP
in	I-KP
B.	I-KP
	
burgdorferi	I-KP
(22,	O
192).	O
	
The	O
RpoN–RpoS	I-KP
pathway,	O
also	O
known	O
as	O
the	O
σ^{54}-σ^{S}	O
cascade,	O
regulates	O
adaptive	I-KP
changes	I-KP
in	I-KP
B.	I-KP
	
burgdorferi	I-KP
during	O
the	O
transition	O
between	O
the	O
tick	I-KP
vector	I-KP
and	O
mammalian	I-KP
host	I-KP
(91,	O
95).	O
	
The	O
RpoN–RpoS	I-KP
pathway	I-KP
relies	O
on	O
the	O
activity	I-KP
of	I-KP
RpoN	I-KP
(σ^{54}),	O
which	O
controls	O
the	O
transcription	I-KP
of	I-KP
RpoS	I-KP
(σ^{S})	O
through	O
the	O
binding	O
to	O
a	O
canonical	O
−24/−12	O
RpoN-type	I-KP
promoter	I-KP
sequence	I-KP
(95,	O
193).	O
	
The	O
activation	O
of	O
the	O
σ^{54}-σ^{S}	I-KP
cascade,	O
in	O
turn,	O
is	O
modulated	O
by	O
a	B-KP
bacterial	I-KP
enhancer-binding	I-KP
protein	O
(bEBP)/σ^{54}-dependent	O
activator	O
(Rrp2)	O
in	O
concert	O
with	O
BosR	O
(91,	O
95,	O
193–198).	O
	
After	O
the	O
activation,	O
RpoS	O
acts	O
as	O
a	B-KP
global	I-KP
gene	I-KP
regulator	O
controlling	O
the	O
expression	O
of	O
over	O
100	O
different	O
genes	O
involved	O
in	B-KP
stress	I-KP
responses,	O
host	I-KP
infection	I-KP
and	I-KP
survival,	O
including	O
biofilm	I-KP
formation	O
(87,	O
95,	O
182).	O
	
Biofilm	B-KP
production	I-KP
in	I-KP
Borrelia	I-KP
requires	O
the	O
modulation	O
of	O
a	O
complex	B-KP
array	I-KP
of	I-KP
signaling	I-KP
processes	I-KP
which	O
allows	O
spirochetes	B-KP
to	O
communicate	O
with	O
the	O
surrounding	O
environment.	O
	
The	O
RpoN–RpoS	B-KP
alternative	I-KP
sigma	I-KP
factor	I-KP
and	O
the	O
LuxS	B-KP
quorumsensing	I-KP
pathways,	I-KP
which	O
are	O
involved	O
in	O
several	B-KP
cellular	I-KP
functions	I-KP
in	O
response	O
to	O
environmental	O
stresses	O
(pH	B-KP
and	I-KP
temperature	I-KP
variations,	O
high	I-KP
osmolarity,	O
oxidative	I-KP
stress,	O
high	I-KP
cell	I-KP
density,	O
nutrient	I-KP
starvation,	O
host	I-KP
infection),	O
participate	O
in	O
biofilm	I-KP
production	I-KP
in	I-KP
B.	I-KP
	
burgdorferi	I-KP
(22,	O
192).	O
	
The	O
RpoN–RpoS	I-KP
pathway,	O
also	O
known	O
as	O
the	O
σ^{54}-σ^{S}	O
cascade,	O
regulates	O
adaptive	I-KP
changes	I-KP
in	I-KP
B.	I-KP
	
burgdorferi	I-KP
during	O
the	O
transition	O
between	O
the	O
tick	I-KP
vector	I-KP
and	O
mammalian	I-KP
host	I-KP
(91,	O
95).	O
	
The	O
RpoN–RpoS	I-KP
pathway	I-KP
relies	O
on	O
the	O
activity	I-KP
of	I-KP
RpoN	I-KP
(σ^{54}),	O
which	O
controls	O
the	O
transcription	I-KP
of	I-KP
RpoS	I-KP
(σ^{S})	O
through	O
the	O
binding	O
to	O
a	O
canonical	O
−24/−12	O
RpoN-type	I-KP
promoter	I-KP
sequence	I-KP
(95,	O
193).	O
	
The	O
activation	O
of	O
the	O
σ^{54}-σ^{S}	I-KP
cascade,	O
in	O
turn,	O
is	O
modulated	O
by	O
a	B-KP
bacterial	I-KP
enhancer-binding	I-KP
protein	O
(bEBP)/σ^{54}-dependent	O
activator	O
(Rrp2)	O
in	O
concert	O
with	O
BosR	O
(91,	O
95,	O
193–198).	O
	
After	O
the	O
activation,	O
RpoS	O
acts	O
as	O
a	B-KP
global	I-KP
gene	I-KP
regulator	O
controlling	O
the	O
expression	O
of	O
over	O
100	O
different	O
genes	O
involved	O
in	B-KP
stress	I-KP
responses,	O
host	I-KP
infection	I-KP
and	I-KP
survival,	O
including	O
biofilm	I-KP
formation	O
(87,	O
95,	O
182).	O
	
In	O
addition	O
to	O
biofilm	B-KP
formation,	I-KP
the	O
ability	O
of	O
Borrelia	B-KP
to	I-KP
localize	I-KP
intracellularly	I-KP
in	I-KP
the	I-KP
host	I-KP
has	O
been	O
proposed	O
as	O
a	O
echanismwhichmight	O
favor	O
chronic	B-KP
or	I-KP
persistent	I-KP
infection	I-KP
and	O
may	O
contribute	O
in	O
reducing	O
the	O
efficacy	B-KP
of	I-KP
antibiotics.	I-KP
	
However,	O
Borrelia	O
predominantly	O
occupies	O
the	O
extracellularmatrix,	B-KP
and	O
the	O
antibiotics	B-KP
recommended	O
for	O
the	O
treatment	O
of	O
LB	B-KP
are	O
first-line	O
drugs	O
in	O
several	O
intracellular	B-KP
infections	I-KP
(216,	O
217).	O
	
Doxycycline	B-KP
and	O
azithromycin	B-KP
are	O
commonly	O
used	O
for	O
the	O
treatment	O
of	O
Mycoplasma,	B-KP
Chlamydia,	B-KP
and	O
Legionella,	B-KP
while	O
ceftriaxone	B-KP
is	O
effective	O
against	O
Salmonella	B-KP
and	O
Neisseria,	B-KP
and	O
amoxicillin	B-KP
is	O
used	O
to	O
treat	O
Listeria	B-KP
infections	I-KP
(217,	O
218).	O
	
Nevertheless,	O
biofilm	O
production	O
by	O
extracellular	O
bacteria	O
and	O
intracellular	B-KP
localization	I-KP
of	I-KP
Borrelia	I-KP
are	O
not	O
mutually	O
exclusive	O
and	O
may	O
both	O
participate	O
in	O
supporting	O
chronic	B-KP
bacterial	I-KP
persistence	I-KP
in	I-KP
the	I-KP
host.	I-KP
	
In	O
addition	O
to	O
biofilm	B-KP
formation,	I-KP
the	O
ability	O
of	O
Borrelia	B-KP
to	I-KP
localize	I-KP
intracellularly	I-KP
in	I-KP
the	I-KP
host	I-KP
has	O
been	O
proposed	O
as	O
a	O
echanismwhichmight	O
favor	O
chronic	B-KP
or	I-KP
persistent	I-KP
infection	I-KP
and	O
may	O
contribute	O
in	O
reducing	O
the	O
efficacy	B-KP
of	I-KP
antibiotics.	I-KP
	
However,	O
Borrelia	O
predominantly	O
occupies	O
the	O
extracellularmatrix,	B-KP
and	O
the	O
antibiotics	B-KP
recommended	O
for	O
the	O
treatment	O
of	O
LB	B-KP
are	O
first-line	O
drugs	O
in	O
several	O
intracellular	B-KP
infections	I-KP
(216,	O
217).	O
	
Doxycycline	B-KP
and	O
azithromycin	B-KP
are	O
commonly	O
used	O
for	O
the	O
treatment	O
of	O
Mycoplasma,	B-KP
Chlamydia,	B-KP
and	O
Legionella,	B-KP
while	O
ceftriaxone	B-KP
is	O
effective	O
against	O
Salmonella	B-KP
and	O
Neisseria,	B-KP
and	O
amoxicillin	B-KP
is	O
used	O
to	O
treat	O
Listeria	B-KP
infections	I-KP
(217,	O
218).	O
	
Nevertheless,	O
biofilm	O
production	O
by	O
extracellular	O
bacteria	O
and	O
intracellular	B-KP
localization	I-KP
of	I-KP
Borrelia	I-KP
are	O
not	O
mutually	O
exclusive	O
and	O
may	O
both	O
participate	O
in	O
supporting	O
chronic	B-KP
bacterial	I-KP
persistence	I-KP
in	I-KP
the	I-KP
host.	I-KP
	
LNB	B-KP
is	O
the	O
most	O
dangerous	O
manifestation	O
of	O
Lyme	B-KP
disease.	I-KP
	
Although	O
the	O
early	O
antimicrobial	B-KP
treatment	I-KP
is	O
effective	O
in	O
the	O
majority	O
of	O
patients,	O
persistent	O
forms	O
are	O
relatively	O
common.	O
	
The	O
mechanisms	O
underlying	O
chronic	B-KP
LNB	I-KP
and	O
other	O
persistent	B-KP
forms	I-KP
of	I-KP
Lyme	I-KP
are	O
unknown.	O
	
Patients	O
who	O
have	O
late	O
manifestations	O
of	O
LB	B-KP
generally	O
show	O
a	O
slower	O
response	O
to	O
therapy	O
with	O
incomplete	O
resolution.	O
	
Persistent	B-KP
Borrelia	I-KP
infection	I-KP
requires	O
prolonged	O
antimicrobial	B-KP
treatment,	I-KP
with	O
limited	O
and	O
controversial	O
clinical	O
efficacy.	O
	
Recent	O
evidences	O
suggest	O
that	O
the	O
antibiotic	B-KP
resistance	I-KP
and	O
the	O
reoccurrence	O
of	O
LB	B-KP
are	O
associated	O
with	O
biofilm-like	B-KP
aggregates,	I-KP
which	O
allow	O
Borrelia	B-KP
spp.	I-KP
	
to	O
resist	O
to	O
adverse	O
environmental	O
conditions.	O
	
Several	O
promising	O
FDA-approved	O
drugs	O
have	O
been	O
shown	O
to	O
have	O
excellent	O
antipersister	O
activity	O
when	O
used	O
in	O
combination	O
while	O
their	O
use	O
in	O
monotherapy	B-KP
regimens	I-KP
showed	O
a	O
poor	O
effectiveness.	O
	
This	O
notion	O
should	O
be	O
taken	O
into	O
careful	O
consideration	O
for	O
the	O
clinical	O
management	O
of	O
Lyme	B-KP
Disease	I-KP
in	O
order	O
to	O
prevent	O
long-term	O
complications.	O
	
LNB	B-KP
is	O
the	O
most	O
dangerous	O
manifestation	O
of	O
Lyme	B-KP
disease.	I-KP
	
Although	O
the	O
early	O
antimicrobial	B-KP
treatment	I-KP
is	O
effective	O
in	O
the	O
majority	O
of	O
patients,	O
persistent	O
forms	O
are	O
relatively	O
common.	O
	
The	O
mechanisms	O
underlying	O
chronic	B-KP
LNB	I-KP
and	O
other	O
persistent	B-KP
forms	I-KP
of	I-KP
Lyme	I-KP
are	O
unknown.	O
	
Patients	O
who	O
have	O
late	O
manifestations	O
of	O
LB	B-KP
generally	O
show	O
a	O
slower	O
response	O
to	O
therapy	O
with	O
incomplete	O
resolution.	O
	
Persistent	B-KP
Borrelia	I-KP
infection	I-KP
requires	O
prolonged	O
antimicrobial	B-KP
treatment,	I-KP
with	O
limited	O
and	O
controversial	O
clinical	O
efficacy.	O
	
Recent	O
evidences	O
suggest	O
that	O
the	O
antibiotic	B-KP
resistance	I-KP
and	O
the	O
reoccurrence	O
of	O
LB	B-KP
are	O
associated	O
with	O
biofilm-like	B-KP
aggregates,	I-KP
which	O
allow	O
Borrelia	B-KP
spp.	I-KP
	
to	O
resist	O
to	O
adverse	O
environmental	O
conditions.	O
	
Several	O
promising	O
FDA-approved	O
drugs	O
have	O
been	O
shown	O
to	O
have	O
excellent	O
antipersister	O
activity	O
when	O
used	O
in	O
combination	O
while	O
their	O
use	O
in	O
monotherapy	B-KP
regimens	I-KP
showed	O
a	O
poor	O
effectiveness.	O
	
This	O
notion	O
should	O
be	O
taken	O
into	O
careful	O
consideration	O
for	O
the	O
clinical	O
management	O
of	O
Lyme	B-KP
Disease	I-KP
in	O
order	O
to	O
prevent	O
long-term	O
complications.	O
	
PCR	O
products	O
were	O
analyzed	O
by	O
ethidium	B-KP
bromide	I-KP
staining	I-KP
of	O
agarose	O
gels	O
and	O
confirmed	O
by	O
Southern	B-KP
blot	I-KP
hybridization,	I-KP
performed	O
as	O
described	O
previously	O
with	O
nested	O
probes.	O
	
[11]	O
Briefly,	O
30	O
to	O
50	O
pl	O
from	O
each	O
PCR-amplified	B-KP
fraction	I-KP
was	O
applied	O
to	O
1.5%	O
agarose	O
gel	O
and	O
electrophoresis	B-KP
performed	O
at	O
100	O
V	O
for	O
3	O
to	O
4	O
hours.	O
	
Gels	O
were	O
then	O
rinsed	O
in	O
deionized	O
water,	O
denatured	O
in	O
1.0	O
mmol/L	O
NaCl,	O
0.5	O
mol/L	O
NaOH	O
twice	O
for	O
15	O
minutes,	O
and	O
then	O
neutralized	O
by	O
soaking	O
in	O
0.5	O
mol/L	O
TRIS	O
(pH	O
7.4)/1.5	O
mol/L	O
NaCl	O
twice	O
for	O
15	O
minutes.	O
	
Gels	O
were	O
then	O
transferred	O
into	O
a	O
nylon	B-KP
membrane	I-KP
by	I-KP
capillary	I-KP
blotting	I-KP
and	O
baked	O
for	O
2	O
hours	O
at	O
80”	O
C	O
in	O
a	O
vacuum	O
oven.	O
	
Filters	O
were	O
then	O
prehybridized	O
at	O
42”	O
C	O
for	O
3	O
to	O
6	O
hours	O
in	O
a	O
solution	O
of	O
5x	B-KP
saline-sodium	I-KP
citrate	I-KP
(SSC)	B-KP
(1	O
x	O
SSC	O
=	O
0.15	O
mol/L	O
NaCl	O
and	O
0.015	O
mol/L	O
sodium	O
citrate	O
pH	O
7.4),	O
50	O
mmolIL	O
sodium	O
phosphate	O
pH	O
7.0,	O
0.1%	O
sodium	O
pyrophosphate,	O
10X	O
Denhardt’s	O
solution	O
(0.2%	O
bovine	O
serum	O
albumin,	O
Ficoll,	O
and	O
polyvinyl	O
pyrrolidone),	O
and	O
100	O
ug/rnl	O
denatured	O
herring	O
sperm	O
DNA,	O
and	O
then	O
hybridized	O
at	O
37”	O
C	O
in	O
a	O
fresh	O
solution	O
containing	O
a	O
phosphorus	O
32	O
end-labeled	O
oligonucleotide	O
probe	O
for	O
20	O
to	O
25	O
hours9,	O
l2	O
Blots	O
were	O
washed	O
in	O
2X	I-KP
SSC,	O
0.5%	O
SDS	O
twice	O
for	O
15	O
minutes	O
at	O
room	O
temperature,	O
then	O
in	O
0.1%	O
SSC,	O
0.5%	O
SDS	O
four	O
times	O
for	O
15	O
minutes	O
at	O
40”	O
C,	O
and	O
finally	O
in	O
0.1%	O
SSC	O
twice	O
for	O
15	O
minutes	O
at	O
40”	O
C.	O
	
Filters	O
were	O
then	O
exposed	O
to	O
Kodax	O
X-AR	O
fiti	O
(Eastman	O
Kodak,	O
Rochester,	O
N.Y.)	O
with	O
a	O
Comex	O
Lighting	O
Plus	O
intensifying	O
screen	O
@u	O
Pont,	O
Boston,	O
Mass.)	O
at	O
-70”	O
C	O
for	O
1	O
to	O
3	O
days.	O
	
PCR	O
products	O
were	O
analyzed	O
by	O
ethidium	B-KP
bromide	I-KP
staining	I-KP
of	O
agarose	O
gels	O
and	O
confirmed	O
by	O
Southern	B-KP
blot	I-KP
hybridization,	I-KP
performed	O
as	O
described	O
previously	O
with	O
nested	O
probes.	O
	
[11]	O
Briefly,	O
30	O
to	O
50	O
pl	O
from	O
each	O
PCR-amplified	B-KP
fraction	I-KP
was	O
applied	O
to	O
1.5%	O
agarose	O
gel	O
and	O
electrophoresis	B-KP
performed	O
at	O
100	O
V	O
for	O
3	O
to	O
4	O
hours.	O
	
Gels	O
were	O
then	O
rinsed	O
in	O
deionized	O
water,	O
denatured	O
in	O
1.0	O
mmol/L	O
NaCl,	O
0.5	O
mol/L	O
NaOH	O
twice	O
for	O
15	O
minutes,	O
and	O
then	O
neutralized	O
by	O
soaking	O
in	O
0.5	O
mol/L	O
TRIS	O
(pH	O
7.4)/1.5	O
mol/L	O
NaCl	O
twice	O
for	O
15	O
minutes.	O
	
Gels	O
were	O
then	O
transferred	O
into	O
a	O
nylon	B-KP
membrane	I-KP
by	I-KP
capillary	I-KP
blotting	I-KP
and	O
baked	O
for	O
2	O
hours	O
at	O
80”	O
C	O
in	O
a	O
vacuum	O
oven.	O
	
Filters	O
were	O
then	O
prehybridized	O
at	O
42”	O
C	O
for	O
3	O
to	O
6	O
hours	O
in	O
a	O
solution	O
of	O
5x	B-KP
saline-sodium	I-KP
citrate	I-KP
(SSC)	B-KP
(1	O
x	O
SSC	O
=	O
0.15	O
mol/L	O
NaCl	O
and	O
0.015	O
mol/L	O
sodium	O
citrate	O
pH	O
7.4),	O
50	O
mmolIL	O
sodium	O
phosphate	O
pH	O
7.0,	O
0.1%	O
sodium	O
pyrophosphate,	O
10X	O
Denhardt’s	O
solution	O
(0.2%	O
bovine	O
serum	O
albumin,	O
Ficoll,	O
and	O
polyvinyl	O
pyrrolidone),	O
and	O
100	O
ug/rnl	O
denatured	O
herring	O
sperm	O
DNA,	O
and	O
then	O
hybridized	O
at	O
37”	O
C	O
in	O
a	O
fresh	O
solution	O
containing	O
a	O
phosphorus	O
32	O
end-labeled	O
oligonucleotide	O
probe	O
for	O
20	O
to	O
25	O
hours9,	O
l2	O
Blots	O
were	O
washed	O
in	O
2X	I-KP
SSC,	O
0.5%	O
SDS	O
twice	O
for	O
15	O
minutes	O
at	O
room	O
temperature,	O
then	O
in	O
0.1%	O
SSC,	O
0.5%	O
SDS	O
four	O
times	O
for	O
15	O
minutes	O
at	O
40”	O
C,	O
and	O
finally	O
in	O
0.1%	O
SSC	O
twice	O
for	O
15	O
minutes	O
at	O
40”	O
C.	O
	
Filters	O
were	O
then	O
exposed	O
to	O
Kodax	O
X-AR	O
fiti	O
(Eastman	O
Kodak,	O
Rochester,	O
N.Y.)	O
with	O
a	O
Comex	O
Lighting	O
Plus	O
intensifying	O
screen	O
@u	O
Pont,	O
Boston,	O
Mass.)	O
at	O
-70”	O
C	O
for	O
1	O
to	O
3	O
days.	O
	
Cranial	B-KP
neuropathy	I-KP
is	O
the	O
most	O
frequent	O
objective	O
neurological	O
sign	O
in	O
Lyme	B-KP
neuroborreliosis	I-KP
and	O
has	O
been	O
found	O
in	O
47%-82%	O
of	O
patients	O
with	O
early	B-KP
neurological	I-KP
involvement	I-KP
[1].	O
	
Although	O
Borrelia	B-KP
burgdorferi	I-KP
sensu	I-KP
lato	I-KP
may	O
affect	O
most	O
cranial	B-KP
nerves,	I-KP
facial	B-KP
nerve	I-KP
paresis	I-KP
is	O
the	O
most	O
common	O
manifestation	O
of	O
infection.	O
	
Unilateral	B-KP
or	I-KP
bilateral	I-KP
facial	I-KP
palsy	I-KP
has	O
been	O
described	O
in	O
72%-92%	O
of	O
patients	O
with	O
cranial	B-KP
nerve	I-KP
affection	I-KP
[1,2].	O
	
In	O
previous	O
Scandinavian	O
studies	O
of	O
patients	O
with	O
Lyme	B-KP
neuroborreliosis,	I-KP
facial	B-KP
palsy	I-KP
was	O
seen	O
in	O
35%-51%	O
of	O
the	O
cases	O
[3,4].	O
	
Lyme	B-KP
disease-associated	I-KP
facial	I-KP
weakness	I-KP
is	O
often	O
rapid	O
in	O
onset	O
and	O
is	O
frequently	O
accompanied	O
by	O
painful	O
meningoradiculoneuritis,	B-KP
earlier	O
described	O
as	O
Garin-Bujadoux-Bannwarth's	B-KP
syndrome	I-KP
[1].	O
	
Facial	B-KP
palsy	I-KP
in	O
Lyme	B-KP
disease	I-KP
has	O
often	O
been	O
viewed	O
as	O
a	O
peripheral	B-KP
neuropathy,	I-KP
although	O
most	O
patients	O
have	O
CSF	B-KP
abnormalities	I-KP
with	O
lymphocytic	B-KP
pleocytosis	I-KP
and	O
an	O
increased	O
number	O
of	O
plasma	B-KP
cells,	I-KP
increased	O
CSF	B-KP
protein	I-KP
concentrations	I-KP
indicating	O
blood-CSF	B-KP
barrier	I-KP
damage,	I-KP
intrathecal	B-KP
Ig	I-KP
production,	I-KP
and	O
increased	O
levels	O
of	O
a	O
CSF	B-KP
glial	I-KP
protein	I-KP
marker	I-KP
(glial	B-KP
fibrillary	I-KP
acidic	I-KP
protein)	O
[5].	O
	
These	O
findings	O
imply	O
that	O
the	O
brain	B-KP
parenchyma	I-KP
is	O
likely	O
to	O
be	O
involved	O
even	O
in	O
early	B-KP
Lyme	I-KP
neuroborreliosis.	I-KP
	
Cranial	B-KP
neuropathy	I-KP
is	O
the	O
most	O
frequent	O
objective	O
neurological	O
sign	O
in	O
Lyme	B-KP
neuroborreliosis	I-KP
and	O
has	O
been	O
found	O
in	O
47%-82%	O
of	O
patients	O
with	O
early	B-KP
neurological	I-KP
involvement	I-KP
[1].	O
	
Although	O
Borrelia	B-KP
burgdorferi	I-KP
sensu	I-KP
lato	I-KP
may	O
affect	O
most	O
cranial	B-KP
nerves,	I-KP
facial	B-KP
nerve	I-KP
paresis	I-KP
is	O
the	O
most	O
common	O
manifestation	O
of	O
infection.	O
	
Unilateral	B-KP
or	I-KP
bilateral	I-KP
facial	I-KP
palsy	I-KP
has	O
been	O
described	O
in	O
72%-92%	O
of	O
patients	O
with	O
cranial	B-KP
nerve	I-KP
affection	I-KP
[1,2].	O
	
In	O
previous	O
Scandinavian	O
studies	O
of	O
patients	O
with	O
Lyme	B-KP
neuroborreliosis,	I-KP
facial	B-KP
palsy	I-KP
was	O
seen	O
in	O
35%-51%	O
of	O
the	O
cases	O
[3,4].	O
	
Lyme	B-KP
disease-associated	I-KP
facial	I-KP
weakness	I-KP
is	O
often	O
rapid	O
in	O
onset	O
and	O
is	O
frequently	O
accompanied	O
by	O
painful	O
meningoradiculoneuritis,	B-KP
earlier	O
described	O
as	O
Garin-Bujadoux-Bannwarth's	B-KP
syndrome	I-KP
[1].	O
	
Facial	B-KP
palsy	I-KP
in	O
Lyme	B-KP
disease	I-KP
has	O
often	O
been	O
viewed	O
as	O
a	O
peripheral	B-KP
neuropathy,	I-KP
although	O
most	O
patients	O
have	O
CSF	B-KP
abnormalities	I-KP
with	O
lymphocytic	B-KP
pleocytosis	I-KP
and	O
an	O
increased	O
number	O
of	O
plasma	B-KP
cells,	I-KP
increased	O
CSF	B-KP
protein	I-KP
concentrations	I-KP
indicating	O
blood-CSF	B-KP
barrier	I-KP
damage,	I-KP
intrathecal	B-KP
Ig	I-KP
production,	I-KP
and	O
increased	O
levels	O
of	O
a	O
CSF	B-KP
glial	I-KP
protein	I-KP
marker	I-KP
(glial	B-KP
fibrillary	I-KP
acidic	I-KP
protein)	O
[5].	O
	
These	O
findings	O
imply	O
that	O
the	O
brain	B-KP
parenchyma	I-KP
is	O
likely	O
to	O
be	O
involved	O
even	O
in	O
early	B-KP
Lyme	I-KP
neuroborreliosis.	I-KP
	
The	O
tick	O
life	O
cycle	O
for	O
the	O
majority	O
of	O
tick	O
species	O
found	O
in	O
the	O
UK	O
takes	O
on	O
average	O
three	O
years	O
and	O
is	O
made	O
up	O
of	O
three	O
active	O
life	B-KP
stages	I-KP
–	O
the	O
larvae,	O
nymphs	O
and	O
adults.	O
	
Unlike	O
biting	O
insects,	O
each	O
tick	O
feeds	O
only	O
once	O
per	O
life	O
stage,	O
but	O
each	O
feed	O
takes	O
a	O
number	O
of	O
days.	O
	
The	O
six-legged	O
larvae	O
feed	O
on	O
average	O
two	O
to	O
six	O
days	O
on	O
small	O
mammals	O
or	O
birds.	O
	
Once	O
fully	O
engorged,	O
they	O
drop	O
off	O
the	O
host	B-KP
and	O
rest	O
in	O
the	O
vegetation	O
layer	O
on	O
the	O
ground,	O
before	O
moulting	O
to	O
the	O
nymph	O
stage.	O
	
The	O
nymphs	O
are	O
slightly	O
larger,	O
have	O
eight	O
legs	O
and	O
feed	O
for	O
three	O
to	O
eight	O
days	O
on	O
slightly	O
larger	O
mammalian	B-KP
or	I-KP
avian	I-KP
hosts.	I-KP
	
Again,	O
once	O
fully	O
engorged,	O
they	O
drop	O
off	O
the	O
host	B-KP
and	O
undergo	O
the	O
moult	O
to	O
the	O
adult	O
stage.	O
	
The	O
emergent	O
male	O
adults	O
of	O
some	O
species	O
only	O
feed	O
intermittently	O
and	O
do	O
not	O
engorge.	O
	
The	O
female	O
adults	O
of	O
I.	B-KP
	
ricinus	I-KP
feed	O
for	O
five	O
to	O
12	O
days	O
on	O
larger	O
mammals	O
such	O
as	O
deer	O
and	O
livestock.	O
	
Following	O
engorgement	O
and	O
mating,	O
the	O
females	O
drop	O
off	O
the	O
host	O
to	O
lay	O
several	O
thousand	O
eggs	O
before	O
dying.	O
	
In	O
a	O
three-year	O
life	O
cycle,	O
a	O
tick	O
will	O
only	O
spend	O
about	O
three	O
weeks	O
on	O
animals.	O
	
The	O
processes	O
of	O
blood	O
meal	O
digestion,	O
moulting	O
and	O
egg	O
laying	O
occur	O
over	O
a	O
period	O
of	O
months,	O
during	O
which	O
time,	O
the	O
ticks	O
rest	O
in	O
the	O
vegetation	O
layer.	O
	
They	O
are	O
sensitive	O
to	O
climatic	O
conditions,	O
particularly	O
temperature	O
and	O
humidity,	O
but	O
dense	O
ground	O
cover	O
vegetation	O
or	O
leaf	O
litter,	O
where	O
the	O
humidity	O
is	O
higher,	O
will	O
prevent	O
the	O
ticks	O
from	O
drying	O
out.	O
	
The	O
tick	O
life	O
cycle	O
for	O
the	O
majority	O
of	O
tick	O
species	O
found	O
in	O
the	O
UK	O
takes	O
on	O
average	O
three	O
years	O
and	O
is	O
made	O
up	O
of	O
three	O
active	O
life	B-KP
stages	I-KP
–	O
the	O
larvae,	O
nymphs	O
and	O
adults.	O
	
Unlike	O
biting	O
insects,	O
each	O
tick	O
feeds	O
only	O
once	O
per	O
life	O
stage,	O
but	O
each	O
feed	O
takes	O
a	O
number	O
of	O
days.	O
	
The	O
six-legged	O
larvae	O
feed	O
on	O
average	O
two	O
to	O
six	O
days	O
on	O
small	O
mammals	O
or	O
birds.	O
	
Once	O
fully	O
engorged,	O
they	O
drop	O
off	O
the	O
host	B-KP
and	O
rest	O
in	O
the	O
vegetation	O
layer	O
on	O
the	O
ground,	O
before	O
moulting	O
to	O
the	O
nymph	O
stage.	O
	
The	O
nymphs	O
are	O
slightly	O
larger,	O
have	O
eight	O
legs	O
and	O
feed	O
for	O
three	O
to	O
eight	O
days	O
on	O
slightly	O
larger	O
mammalian	B-KP
or	I-KP
avian	I-KP
hosts.	I-KP
	
Again,	O
once	O
fully	O
engorged,	O
they	O
drop	O
off	O
the	O
host	B-KP
and	O
undergo	O
the	O
moult	O
to	O
the	O
adult	O
stage.	O
	
The	O
emergent	O
male	O
adults	O
of	O
some	O
species	O
only	O
feed	O
intermittently	O
and	O
do	O
not	O
engorge.	O
	
The	O
female	O
adults	O
of	O
I.	B-KP
	
ricinus	I-KP
feed	O
for	O
five	O
to	O
12	O
days	O
on	O
larger	O
mammals	O
such	O
as	O
deer	O
and	O
livestock.	O
	
Following	O
engorgement	O
and	O
mating,	O
the	O
females	O
drop	O
off	O
the	O
host	O
to	O
lay	O
several	O
thousand	O
eggs	O
before	O
dying.	O
	
In	O
a	O
three-year	O
life	O
cycle,	O
a	O
tick	O
will	O
only	O
spend	O
about	O
three	O
weeks	O
on	O
animals.	O
	
The	O
processes	O
of	O
blood	O
meal	O
digestion,	O
moulting	O
and	O
egg	O
laying	O
occur	O
over	O
a	O
period	O
of	O
months,	O
during	O
which	O
time,	O
the	O
ticks	O
rest	O
in	O
the	O
vegetation	O
layer.	O
	
They	O
are	O
sensitive	O
to	O
climatic	O
conditions,	O
particularly	O
temperature	O
and	O
humidity,	O
but	O
dense	O
ground	O
cover	O
vegetation	O
or	O
leaf	O
litter,	O
where	O
the	O
humidity	O
is	O
higher,	O
will	O
prevent	O
the	O
ticks	O
from	O
drying	O
out.	O
	
Among	O
the	O
approximately	O
50	O
000	O
locally	O
acquired	O
vector-borne	B-KP
disease	I-KP
cases	O
reported	O
annually	O
from	O
the	O
contiguous	O
United	O
States,	O
roughly	O
95%	O
are	O
caused	O
by	O
tick-borne	B-KP
pathogens	I-KP
and	O
>70%	O
are	O
Lyme	B-KP
disease	I-KP
[1].	O
	
Lyme	B-KP
disease	I-KP
is	O
caused	O
by	O
the	O
spirochetes	B-KP
Borrelia	I-KP
burgdorferi	I-KP
sensu	I-KP
stricto	I-KP
(herein	O
referred	O
to	O
as	O
B.	B-KP
	
burgdorferi)	I-KP
[2],	O
or	O
much	O
less	O
commonly	O
by	O
Borrelia	B-KP
mayonii	I-KP
[3];	O
both	O
are	O
transmitted	O
by	O
the	O
blacklegged	O
tick,	O
Ixodes	B-KP
scapularis	I-KP
(including	O
the	O
junior	O
synonym,	O
Ixodes	B-KP
dammini)	I-KP
in	O
the	O
eastern	O
United	O
States	O
where	O
the	O
vast	O
majority	O
of	O
cases	O
occur	O
[4,5].	O
	
Over	O
the	O
past	O
two	O
decades,	O
we	O
have	O
seen	O
expansions	O
in	O
both	O
the	O
geographic	O
range	O
of	O
I.	B-KP
	
scapularis	I-KP
[6]	O
(Figure	O
1A,B)	O
and	O
the	O
incidence	O
and	O
geographic	O
range	O
of	O
Lyme	B-KP
disease	I-KP
and	O
other	O
I.	B-KP
	
scapularis-borne	I-KP
diseases	I-KP
[7,8]	O
(Figure	O
1C,D).	O
	
In	O
addition,	O
new	O
I.	B-KP
	
scapularis-borne	I-KP
human	I-KP
pathogens	I-KP
continue	O
to	O
be	O
discovered.	O
	
As	O
of	O
2017,	O
seven	O
microorganisms	O
transmitted	O
by	O
I.	B-KP
	
scapularis	I-KP
–	O
including	O
five	O
bacteria	O
(Anaplasma	B-KP
phagocytophilum,	O
Bo.	I-KP
	
burgdorferi,	O
Bo.	I-KP
	
mayonii,	O
Bo.	I-KP
	
miyamotoi,	O
and	O
E.	I-KP
	
muris	I-KP
eauclarensis),	O
one	O
protozoan	O
parasite	O
(Babesia	B-KP
microti),	O
and	O
one	O
virus	O
(Powassan	B-KP
virus)	O
–	O
are	O
known	O
to	O
cause	O
illness	O
in	O
humans	O
[7,9].	O
	
The	O
recognition	O
of	O
this	O
diverse	O
guild	O
of	O
I.	I-KP
	
scapularis-borne	I-KP
pathogens	I-KP
over	O
the	O
last	O
five	O
decades	O
marks	O
a	O
significant	O
shift	O
in	O
the	O
perceived	O
medical	O
importance	O
of	O
the	O
tick;	O
prior	O
to	O
1970,	O
I.	I-KP
	
scapularis	I-KP
was	O
not	O
considered	O
an	O
important	I-KP
vector	I-KP
of	I-KP
human	I-KP
pathogens	I-KP
(Figure	O
2).	O
	
Among	O
the	O
approximately	O
50	O
000	O
locally	O
acquired	O
vector-borne	B-KP
disease	I-KP
cases	O
reported	O
annually	O
from	O
the	O
contiguous	O
United	O
States,	O
roughly	O
95%	O
are	O
caused	O
by	O
tick-borne	B-KP
pathogens	I-KP
and	O
>70%	O
are	O
Lyme	B-KP
disease	I-KP
[1].	O
	
Lyme	B-KP
disease	I-KP
is	O
caused	O
by	O
the	O
spirochetes	B-KP
Borrelia	I-KP
burgdorferi	I-KP
sensu	I-KP
stricto	I-KP
(herein	O
referred	O
to	O
as	O
B.	B-KP
	
burgdorferi)	I-KP
[2],	O
or	O
much	O
less	O
commonly	O
by	O
Borrelia	B-KP
mayonii	I-KP
[3];	O
both	O
are	O
transmitted	O
by	O
the	O
blacklegged	O
tick,	O
Ixodes	B-KP
scapularis	I-KP
(including	O
the	O
junior	O
synonym,	O
Ixodes	B-KP
dammini)	I-KP
in	O
the	O
eastern	O
United	O
States	O
where	O
the	O
vast	O
majority	O
of	O
cases	O
occur	O
[4,5].	O
	
Over	O
the	O
past	O
two	O
decades,	O
we	O
have	O
seen	O
expansions	O
in	O
both	O
the	O
geographic	O
range	O
of	O
I.	B-KP
	
scapularis	I-KP
[6]	O
(Figure	O
1A,B)	O
and	O
the	O
incidence	O
and	O
geographic	O
range	O
of	O
Lyme	B-KP
disease	I-KP
and	O
other	O
I.	B-KP
	
scapularis-borne	I-KP
diseases	I-KP
[7,8]	O
(Figure	O
1C,D).	O
	
In	O
addition,	O
new	O
I.	B-KP
	
scapularis-borne	I-KP
human	I-KP
pathogens	I-KP
continue	O
to	O
be	O
discovered.	O
	
As	O
of	O
2017,	O
seven	O
microorganisms	O
transmitted	O
by	O
I.	B-KP
	
scapularis	I-KP
–	O
including	O
five	O
bacteria	O
(Anaplasma	B-KP
phagocytophilum,	O
Bo.	I-KP
	
burgdorferi,	O
Bo.	I-KP
	
mayonii,	O
Bo.	I-KP
	
miyamotoi,	O
and	O
E.	I-KP
	
muris	I-KP
eauclarensis),	O
one	O
protozoan	O
parasite	O
(Babesia	B-KP
microti),	O
and	O
one	O
virus	O
(Powassan	B-KP
virus)	O
–	O
are	O
known	O
to	O
cause	O
illness	O
in	O
humans	O
[7,9].	O
	
The	O
recognition	O
of	O
this	O
diverse	O
guild	O
of	O
I.	I-KP
	
scapularis-borne	I-KP
pathogens	I-KP
over	O
the	O
last	O
five	O
decades	O
marks	O
a	O
significant	O
shift	O
in	O
the	O
perceived	O
medical	O
importance	O
of	O
the	O
tick;	O
prior	O
to	O
1970,	O
I.	I-KP
	
scapularis	I-KP
was	O
not	O
considered	O
an	O
important	I-KP
vector	I-KP
of	I-KP
human	I-KP
pathogens	I-KP
(Figure	O
2).	O
	
Tick	O
surveillance	O
is	O
not	O
standardized	O
or	O
routine,	O
thus	O
hampering	O
our	O
ability	O
to	O
monitor	O
changes	O
in	O
the	O
distribution	O
and	O
abundance	O
of	O
I.	B-KP
	
scapularis	I-KP
[6,30].	O
	
Retrospective	O
review	O
of	O
I.	B-KP
	
scapularis	I-KP
records	O
reveals	O
remarkable	O
range	O
expansion	O
over	O
the	O
past	O
century,	O
particularly	O
in	O
the	O
northern	O
portion	O
of	O
the	O
eastern	O
United	O
States.	O
	
The	O
earliest	O
record	O
of	O
the	O
tick	O
in	O
the	O
northeast	O
dates	O
back	O
to	O
the	O
1920s	O
near	O
Cape	O
Cod,	O
Massachusetts	O
[31].	O
	
By	O
1945,	O
I.	B-KP
	
scapularis	I-KP
was	O
recorded	O
sporadically	O
from	O
states	O
along	O
the	O
northern	O
Atlantic	O
coast,	O
but	O
its	O
core	B-KP
distribution	I-KP
was	O
primarily	O
in	O
the	O
Gulf	O
Coast	O
states	O
and	O
the	O
southeast	O
[10].	O
	
In	O
the	O
early	O
1960s,	O
focal	O
populations	O
were	O
reported	O
along	O
the	O
New	O
England	O
coast	O
and	O
in	O
Rhode	O
Island,	O
and	O
later	O
in	O
that	O
decade	O
records	O
emerged	O
from	O
Long	O
Island,	O
New	O
York,	O
and	O
northwestern	O
Wisconsin.	O
	
During	O
the	O
1970s,	O
the	O
reported	O
distribution	O
of	O
the	O
tick	O
expanded,	O
and	O
its	O
abundance	O
increased	O
along	O
the	O
Atlantic	O
coast	O
from	O
New	O
England	O
to	O
the	O
mid-Atlantic	O
states;	O
expansion	O
inland	O
continued	O
through	O
the	O
1980s	O
and	O
1990s	O
[30,31].	O
	
Tick	O
surveillance	O
is	O
not	O
standardized	O
or	O
routine,	O
thus	O
hampering	O
our	O
ability	O
to	O
monitor	O
changes	O
in	O
the	O
distribution	O
and	O
abundance	O
of	O
I.	B-KP
	
scapularis	I-KP
[6,30].	O
	
Retrospective	O
review	O
of	O
I.	B-KP
	
scapularis	I-KP
records	O
reveals	O
remarkable	O
range	O
expansion	O
over	O
the	O
past	O
century,	O
particularly	O
in	O
the	O
northern	O
portion	O
of	O
the	O
eastern	O
United	O
States.	O
	
The	O
earliest	O
record	O
of	O
the	O
tick	O
in	O
the	O
northeast	O
dates	O
back	O
to	O
the	O
1920s	O
near	O
Cape	O
Cod,	O
Massachusetts	O
[31].	O
	
By	O
1945,	O
I.	B-KP
	
scapularis	I-KP
was	O
recorded	O
sporadically	O
from	O
states	O
along	O
the	O
northern	O
Atlantic	O
coast,	O
but	O
its	O
core	B-KP
distribution	I-KP
was	O
primarily	O
in	O
the	O
Gulf	O
Coast	O
states	O
and	O
the	O
southeast	O
[10].	O
	
In	O
the	O
early	O
1960s,	O
focal	O
populations	O
were	O
reported	O
along	O
the	O
New	O
England	O
coast	O
and	O
in	O
Rhode	O
Island,	O
and	O
later	O
in	O
that	O
decade	O
records	O
emerged	O
from	O
Long	O
Island,	O
New	O
York,	O
and	O
northwestern	O
Wisconsin.	O
	
During	O
the	O
1970s,	O
the	O
reported	O
distribution	O
of	O
the	O
tick	O
expanded,	O
and	O
its	O
abundance	O
increased	O
along	O
the	O
Atlantic	O
coast	O
from	O
New	O
England	O
to	O
the	O
mid-Atlantic	O
states;	O
expansion	O
inland	O
continued	O
through	O
the	O
1980s	O
and	O
1990s	O
[30,31].	O
	
Lyme	B-KP
disease	I-KP
was	O
first	O
recognized	O
in	O
the	O
United	O
States	O
as	O
a	O
new	O
form	O
of	O
inflammatory	B-KP
arthritis	I-KP
in	O
1975	O
[52].	O
	
In	O
1982,	O
a	O
spirochete,	O
later	O
namedBo.	O
	
burgdorferi	I-KP
[53],	O
was	O
identified	O
as	O
the	O
etiological	B-KP
agent	I-KP
and	O
shown	O
to	O
be	O
transmissible	O
by	O
I.	B-KP
	
scapularis	I-KP
[2,5].	O
	
Although	O
numerous	O
small	O
mammals	O
and	O
birds	O
have	O
been	O
implicated	O
as	O
reservoirs	B-KP
of	I-KP
Bo.	I-KP
	
burgdorferi,	I-KP
the	O
white-footed	O
mouse	O
is	O
among	O
the	O
most	O
important	O
reservoirs	O
in	O
the	O
eastern	O
United	O
States	O
[15,36,54,55].\nHuman	O
granulocytic	I-KP
anaplasmosis,	I-KP
originally	O
described	O
as	O
human	B-KP
granulocytic	I-KP
ehrlichiosis	I-KP
(Ehrlichia	B-KP
phagocytophila),	O
was	O
first	O
identified	O
in	O
six	O
patients	O
from	O
northern	O
Minnesota	O
and	O
Wisconsin	O
presenting	O
with	O
acute	I-KP
febrile	I-KP
illnesses	I-KP
between	O
1990	O
and	O
1993.	O
	
The	O
timing	O
of	O
onset	O
of	O
cases	O
was	O
consistent	O
with	O
host-seeking	I-KP
activity	I-KP
of	I-KP
I.	I-KP
	
scapularis	I-KP
and	I-KP
Dermacentor	I-KP
variabilis	I-KP
and	O
the	O
former	O
was	O
implicated	O
as	O
a	O
vector	O
based	O
on	O
evidence	O
that	O
the	O
closely	O
related	O
Ixodes	I-KP
ricinus	I-KP
transmits	O
E.	I-KP
	
phagocytophila	I-KP
in	O
Europe	O
[56].	O
	
In	O
1996,	O
I.	I-KP
	
scapularis	I-KP
was	O
experimentally	O
confirmed	O
as	O
a	B-KP
vector	I-KP
of	I-KP
E.	I-KP
	
phagocytophila,	O
and	B-KP
P.	I-KP
	
leucopus	O
was	O
shown	O
to	O
be	O
a	O
competent	O
reservoir	O
[57].	O
	
In	O
2001,	O
this	B-KP
intraleukocytic	I-KP
bacterium	O
was	O
renamed	O
A.	I-KP
	
phagocytophilum	O
[58].	O
	
Lyme	B-KP
disease	I-KP
was	O
first	O
recognized	O
in	O
the	O
United	O
States	O
as	O
a	O
new	O
form	O
of	O
inflammatory	B-KP
arthritis	I-KP
in	O
1975	O
[52].	O
	
In	O
1982,	O
a	O
spirochete,	O
later	O
namedBo.	O
	
burgdorferi	I-KP
[53],	O
was	O
identified	O
as	O
the	O
etiological	B-KP
agent	I-KP
and	O
shown	O
to	O
be	O
transmissible	O
by	O
I.	B-KP
	
scapularis	I-KP
[2,5].	O
	
Although	O
numerous	O
small	O
mammals	O
and	O
birds	O
have	O
been	O
implicated	O
as	O
reservoirs	B-KP
of	I-KP
Bo.	I-KP
	
burgdorferi,	I-KP
the	O
white-footed	O
mouse	O
is	O
among	O
the	O
most	O
important	O
reservoirs	O
in	O
the	O
eastern	O
United	O
States	O
[15,36,54,55].\nHuman	O
granulocytic	I-KP
anaplasmosis,	I-KP
originally	O
described	O
as	O
human	B-KP
granulocytic	I-KP
ehrlichiosis	I-KP
(Ehrlichia	B-KP
phagocytophila),	O
was	O
first	O
identified	O
in	O
six	O
patients	O
from	O
northern	O
Minnesota	O
and	O
Wisconsin	O
presenting	O
with	O
acute	I-KP
febrile	I-KP
illnesses	I-KP
between	O
1990	O
and	O
1993.	O
	
The	O
timing	O
of	O
onset	O
of	O
cases	O
was	O
consistent	O
with	O
host-seeking	I-KP
activity	I-KP
of	I-KP
I.	I-KP
	
scapularis	I-KP
and	I-KP
Dermacentor	I-KP
variabilis	I-KP
and	O
the	O
former	O
was	O
implicated	O
as	O
a	O
vector	O
based	O
on	O
evidence	O
that	O
the	O
closely	O
related	O
Ixodes	I-KP
ricinus	I-KP
transmits	O
E.	I-KP
	
phagocytophila	I-KP
in	O
Europe	O
[56].	O
	
In	O
1996,	O
I.	I-KP
	
scapularis	I-KP
was	O
experimentally	O
confirmed	O
as	O
a	B-KP
vector	I-KP
of	I-KP
E.	I-KP
	
phagocytophila,	O
and	B-KP
P.	I-KP
	
leucopus	O
was	O
shown	O
to	O
be	O
a	O
competent	O
reservoir	O
[57].	O
	
In	O
2001,	O
this	B-KP
intraleukocytic	I-KP
bacterium	O
was	O
renamed	O
A.	I-KP
	
phagocytophilum	O
[58].	O
	
Bo.	B-KP
	
burgdorferi	I-KP
and	O
Ba.	B-KP
	
microti	I-KP
share	O
a	O
common	B-KP
reservoir,	I-KP
the	O
white-footed	O
mouse,	O
explaining	O
the	O
increased	O
likelihood	O
of	O
finding	O
coinfections	O
more	O
often	O
than	O
expected	O
by	O
chance	O
[85,86,91].	O
	
Recent	O
evidence	O
suggests	O
that	O
Bo.	B-KP
	
burgdorferi	I-KP
promotes	O
transmission	O
of	O
Ba.	B-KP
	
microti,	I-KP
and	O
the	O
former	O
typically	O
becomes	O
established	O
in	O
new	O
foci	O
before	O
the	O
latter	O
[85,86,91,92].	O
	
By	O
contrast,	O
coinfection	O
with	O
Bo.	B-KP
	
burgdorferi	I-KP
and	O
A.	B-KP
	
phagocytophilum	I-KP
are	O
typically	O
observed	O
at	O
rates	O
expected	O
based	O
on	O
prevalence	O
of	O
each	O
infection	O
individually,	O
suggesting	O
independent	B-KP
enzootic	I-KP
transmission	I-KP
maintenance	I-KP
cycles	I-KP
[83,84,87,93].	O
	
Although,	O
the	O
efficiency	O
of	O
I.	B-KP
	
scapularis	I-KP
to	O
transmit	O
Bo.	B-KP
	
burgdorferi	I-KP
or	O
A.	B-KP
	
phagocytophilum	I-KP
is	O
not	O
affected	O
by	O
coinfection	O
[84],	O
coinfection	O
in	O
mice	O
has	O
been	O
shown	O
to	O
increase	O
pathogen	B-KP
acquisition	I-KP
by	O
feeding	O
larvae,	O
compared	O
with	O
rates	O
observed	O
when	O
feeding	O
on	O
singly	O
infected	O
mice	O
[94].	O
	
The	O
relative	O
abundance	O
of	O
various	O
hosts	O
in	O
a	O
community	O
likely	O
influences	O
the	O
probability	O
of	O
coinfections	B-KP
occurring.	O
	
Although	O
reported	O
less	O
commonly	O
as	O
a	O
coinfection	B-KP
with	O
Bo.	B-KP
	
burgdorferi	I-KP
compared	O
with	O
A.	B-KP
	
phagocytophilum	I-KP
or	O
Ba.	B-KP
	
microti,	I-KP
coinfection	O
with	O
Bo.	B-KP
	
miyamotoi	I-KP
appears	O
to	O
occur	O
at	O
rates	O
expected	O
by	O
chance,	O
or	O
lower,	O
again	O
suggesting	O
independent	O
mechanisms	O
of	O
persistence	O
[76,82].	O
	
Bo.	B-KP
	
burgdorferi	I-KP
and	O
Ba.	B-KP
	
microti	I-KP
share	O
a	O
common	B-KP
reservoir,	I-KP
the	O
white-footed	O
mouse,	O
explaining	O
the	O
increased	O
likelihood	O
of	O
finding	O
coinfections	O
more	O
often	O
than	O
expected	O
by	O
chance	O
[85,86,91].	O
	
Recent	O
evidence	O
suggests	O
that	O
Bo.	B-KP
	
burgdorferi	I-KP
promotes	O
transmission	O
of	O
Ba.	B-KP
	
microti,	I-KP
and	O
the	O
former	O
typically	O
becomes	O
established	O
in	O
new	O
foci	O
before	O
the	O
latter	O
[85,86,91,92].	O
	
By	O
contrast,	O
coinfection	O
with	O
Bo.	B-KP
	
burgdorferi	I-KP
and	O
A.	B-KP
	
phagocytophilum	I-KP
are	O
typically	O
observed	O
at	O
rates	O
expected	O
based	O
on	O
prevalence	O
of	O
each	O
infection	O
individually,	O
suggesting	O
independent	B-KP
enzootic	I-KP
transmission	I-KP
maintenance	I-KP
cycles	I-KP
[83,84,87,93].	O
	
Although,	O
the	O
efficiency	O
of	O
I.	B-KP
	
scapularis	I-KP
to	O
transmit	O
Bo.	B-KP
	
burgdorferi	I-KP
or	O
A.	B-KP
	
phagocytophilum	I-KP
is	O
not	O
affected	O
by	O
coinfection	O
[84],	O
coinfection	O
in	O
mice	O
has	O
been	O
shown	O
to	O
increase	O
pathogen	B-KP
acquisition	I-KP
by	O
feeding	O
larvae,	O
compared	O
with	O
rates	O
observed	O
when	O
feeding	O
on	O
singly	O
infected	O
mice	O
[94].	O
	
The	O
relative	O
abundance	O
of	O
various	O
hosts	O
in	O
a	O
community	O
likely	O
influences	O
the	O
probability	O
of	O
coinfections	B-KP
occurring.	O
	
Although	O
reported	O
less	O
commonly	O
as	O
a	O
coinfection	B-KP
with	O
Bo.	B-KP
	
burgdorferi	I-KP
compared	O
with	O
A.	B-KP
	
phagocytophilum	I-KP
or	O
Ba.	B-KP
	
microti,	I-KP
coinfection	O
with	O
Bo.	B-KP
	
miyamotoi	I-KP
appears	O
to	O
occur	O
at	O
rates	O
expected	O
by	O
chance,	O
or	O
lower,	O
again	O
suggesting	O
independent	O
mechanisms	O
of	O
persistence	O
[76,82].	O
	
Compared	O
with	O
Lyme	B-KP
disease,	I-KP
the	O
incidence	O
of	O
reported	O
anaplasmosis,	B-KP
Powassan	B-KP
virus	I-KP
disease,	I-KP
and	O
babesiosis	B-KP
is	O
several	O
orders	O
of	O
magnitude	O
lower,	O
and	O
their	O
geographic	O
distribution	O
appears	O
to	O
be	O
similar	O
but	O
more	O
restricted;	O
like	O
the	O
distribution	O
of	O
Lyme	B-KP
disease	I-KP
cases,	I-KP
the	O
geographic	O
range	O
of	O
anaplasmosis	B-KP
and	O
babesiosis	B-KP
has	O
similarly	O
spread	O
over	O
time	O
(Figure	O
4)	O
[7,19,95,98,99].	O
	
Over	O
96%	O
of	O
Lyme	B-KP
disease	I-KP
cases	I-KP
are	O
reported	O
from	O
just	O
14	O
states	O
in	O
the	O
northeast,	O
mid-Atlantic	O
and	O
the	O
upper	O
Midwest	O
[95].	O
	
Since	O
the	O
mid-1990s,	O
the	O
number	O
of	O
counties	O
with	O
a	O
high	O
incidence	O
of	O
Lyme	B-KP
disease	I-KP
has	O
increased	O
by	O
approximately	O
300%	O
[48].	O
	
As	O
it	O
is	O
not	O
a	O
notifiable	O
condition,	O
trends	O
in	O
incidence	O
and	O
geographic	O
range	O
of	O
Bo.	B-KP
	
miyamotoi	I-KP
disease	I-KP
cases	I-KP
are	O
not	O
well	O
characterized,	O
but	O
the	O
geographic	O
range	O
is	O
likely	O
similer	O
to	O
that	O
of	O
Lyme	B-KP
disease	I-KP
[100].	O
	
By	O
contrast,	O
ehrlichiosis,	B-KP
caused	O
by	O
E.	B-KP
	
muris	I-KP
eauclarensis,	I-KP
thus	O
far	O
has	O
been	O
reported	O
only	O
from	O
the	O
upper	O
Midwest	O
[65].	O
	
Compared	O
with	O
Lyme	B-KP
disease,	I-KP
the	O
incidence	O
of	O
reported	O
anaplasmosis,	B-KP
Powassan	B-KP
virus	I-KP
disease,	I-KP
and	O
babesiosis	B-KP
is	O
several	O
orders	O
of	O
magnitude	O
lower,	O
and	O
their	O
geographic	O
distribution	O
appears	O
to	O
be	O
similar	O
but	O
more	O
restricted;	O
like	O
the	O
distribution	O
of	O
Lyme	B-KP
disease	I-KP
cases,	I-KP
the	O
geographic	O
range	O
of	O
anaplasmosis	B-KP
and	O
babesiosis	B-KP
has	O
similarly	O
spread	O
over	O
time	O
(Figure	O
4)	O
[7,19,95,98,99].	O
	
Over	O
96%	O
of	O
Lyme	B-KP
disease	I-KP
cases	I-KP
are	O
reported	O
from	O
just	O
14	O
states	O
in	O
the	O
northeast,	O
mid-Atlantic	O
and	O
the	O
upper	O
Midwest	O
[95].	O
	
Since	O
the	O
mid-1990s,	O
the	O
number	O
of	O
counties	O
with	O
a	O
high	O
incidence	O
of	O
Lyme	B-KP
disease	I-KP
has	O
increased	O
by	O
approximately	O
300%	O
[48].	O
	
As	O
it	O
is	O
not	O
a	O
notifiable	O
condition,	O
trends	O
in	O
incidence	O
and	O
geographic	O
range	O
of	O
Bo.	B-KP
	
miyamotoi	I-KP
disease	I-KP
cases	I-KP
are	O
not	O
well	O
characterized,	O
but	O
the	O
geographic	O
range	O
is	O
likely	O
similer	O
to	O
that	O
of	O
Lyme	B-KP
disease	I-KP
[100].	O
	
By	O
contrast,	O
ehrlichiosis,	B-KP
caused	O
by	O
E.	B-KP
	
muris	I-KP
eauclarensis,	I-KP
thus	O
far	O
has	O
been	O
reported	O
only	O
from	O
the	O
upper	O
Midwest	O
[65].	O
	
Potential	O
future	O
magic	O
bullet	O
solutions,	O
capable	O
of	O
both	O
ensuring	O
that	O
the	O
bite	O
of	O
an	O
infected	O
tick	O
does	O
not	O
result	O
in	O
illness	O
and	O
having	O
the	O
potential	O
to	O
rapidly	O
and	O
dramatically	O
reduce	O
I.	B-KP
	
scapularis-borne	I-KP
human	I-KP
infections	I-KP
at	O
the	O
population	O
level,	O
include	O
(i)	O
human	B-KP
vaccines	I-KP
or	I-KP
prophylactic	I-KP
antibody	I-KP
treatments	I-KP
against	O
Lyme	B-KP
disease	I-KP
spirochetes	I-KP
or	O
other	O
I.	B-KP
	
scapularis-borne	I-KP
pathogens	I-KP
[104,105,109,110],	O
and	O
(ii)	O
transmission-blocking	B-KP
anti-tick	I-KP
vaccines	I-KP
for	O
human	O
use	O
with	O
potential	O
for	O
simultaneous	O
protection	O
against	O
multiple	O
I.	B-KP
	
scapularis-borne	I-KP
pathogens	I-KP
[111–115].	O
	
These	O
approaches	O
would	O
not	O
require	O
daily	O
action	O
and	O
vigilance,	O
and	O
they	O
would	O
be	O
effective	O
regardless	O
of	O
whether	O
or	O
not	O
bites	O
by	O
infected	O
ticks	O
are	O
noticed.	O
	
If	O
proven	O
to	O
be	O
safe,	O
effective,	O
and	O
acceptable	O
for	O
widespread	O
use,	O
there	O
is	O
no	O
question	O
that	O
the	O
re-emergence	O
of	O
a	O
human	O
vaccine	B-KP
against	I-KP
Bo.	I-KP
	
burgdorferi,	I-KP
or	O
the	O
emergence	O
of	O
a	O
prophylactic	B-KP
antibody	I-KP
treatment,	I-KP
would	O
be	O
the	O
most	O
effective	O
ways	O
to	O
rapidly	O
reduce	O
Lyme	B-KP
disease	I-KP
cases.	O
	
However,	O
neither	O
approach	O
would	O
address	O
the	O
remaining	O
I.	B-KP
	
scapularis-borne	I-KP
pathogens,	I-KP
several	O
of	O
which	O
are	O
on	O
the	O
rise	O
(Figure	O
4).	O
	
A	O
transmission-blocking	B-KP
anti-tick	I-KP
vaccine	I-KP
could	O
potentially	O
address	O
that	O
shortcoming,	O
but	O
only	O
if	O
it	O
proves	O
to	O
act	O
quickly	O
and	O
effectively	O
enough	O
on	O
an	O
infected	O
tick	O
to	O
prevent	O
or	O
substantially	O
reduce	O
the	O
likelihood	O
of	O
pathogen	B-KP
transmission	I-KP
occurring	O
before	O
the	O
tick	O
is	O
incapacitated.	O
	
These	O
urgently	O
needed	O
approaches	O
merit	O
greater	O
resources	O
to	O
expeditiously	O
move	O
them	O
forward	O
in	O
a	O
pipeline	O
from	O
prevention	O
concept	O
to	O
proven	O
solution	O
and	O
become,	O
should	O
they	O
be	O
successful,	O
cornerstones	O
in	O
public	O
health	O
programs	O
to	O
reduce	O
I.	B-KP
	
scapularis-borne	I-KP
infections.	I-KP
	
Potential	O
future	O
magic	O
bullet	O
solutions,	O
capable	O
of	O
both	O
ensuring	O
that	O
the	O
bite	O
of	O
an	O
infected	O
tick	O
does	O
not	O
result	O
in	O
illness	O
and	O
having	O
the	O
potential	O
to	O
rapidly	O
and	O
dramatically	O
reduce	O
I.	B-KP
	
scapularis-borne	I-KP
human	I-KP
infections	I-KP
at	O
the	O
population	O
level,	O
include	O
(i)	O
human	B-KP
vaccines	I-KP
or	I-KP
prophylactic	I-KP
antibody	I-KP
treatments	I-KP
against	O
Lyme	B-KP
disease	I-KP
spirochetes	I-KP
or	O
other	O
I.	B-KP
	
scapularis-borne	I-KP
pathogens	I-KP
[104,105,109,110],	O
and	O
(ii)	O
transmission-blocking	B-KP
anti-tick	I-KP
vaccines	I-KP
for	O
human	O
use	O
with	O
potential	O
for	O
simultaneous	O
protection	O
against	O
multiple	O
I.	B-KP
	
scapularis-borne	I-KP
pathogens	I-KP
[111–115].	O
	
These	O
approaches	O
would	O
not	O
require	O
daily	O
action	O
and	O
vigilance,	O
and	O
they	O
would	O
be	O
effective	O
regardless	O
of	O
whether	O
or	O
not	O
bites	O
by	O
infected	O
ticks	O
are	O
noticed.	O
	
If	O
proven	O
to	O
be	O
safe,	O
effective,	O
and	O
acceptable	O
for	O
widespread	O
use,	O
there	O
is	O
no	O
question	O
that	O
the	O
re-emergence	O
of	O
a	O
human	O
vaccine	B-KP
against	I-KP
Bo.	I-KP
	
burgdorferi,	I-KP
or	O
the	O
emergence	O
of	O
a	O
prophylactic	B-KP
antibody	I-KP
treatment,	I-KP
would	O
be	O
the	O
most	O
effective	O
ways	O
to	O
rapidly	O
reduce	O
Lyme	B-KP
disease	I-KP
cases.	O
	
However,	O
neither	O
approach	O
would	O
address	O
the	O
remaining	O
I.	B-KP
	
scapularis-borne	I-KP
pathogens,	I-KP
several	O
of	O
which	O
are	O
on	O
the	O
rise	O
(Figure	O
4).	O
	
A	O
transmission-blocking	B-KP
anti-tick	I-KP
vaccine	I-KP
could	O
potentially	O
address	O
that	O
shortcoming,	O
but	O
only	O
if	O
it	O
proves	O
to	O
act	O
quickly	O
and	O
effectively	O
enough	O
on	O
an	O
infected	O
tick	O
to	O
prevent	O
or	O
substantially	O
reduce	O
the	O
likelihood	O
of	O
pathogen	B-KP
transmission	I-KP
occurring	O
before	O
the	O
tick	O
is	O
incapacitated.	O
	
These	O
urgently	O
needed	O
approaches	O
merit	O
greater	O
resources	O
to	O
expeditiously	O
move	O
them	O
forward	O
in	O
a	O
pipeline	O
from	O
prevention	O
concept	O
to	O
proven	O
solution	O
and	O
become,	O
should	O
they	O
be	O
successful,	O
cornerstones	O
in	O
public	O
health	O
programs	O
to	O
reduce	O
I.	B-KP
	
scapularis-borne	I-KP
infections.	I-KP
	
An	O
additional	O
problem	O
is	O
that	O
the	O
clinical	O
spectrum	O
of	O
these	O
patients	O
now	O
encompasses	O
a	O
more	O
diverse	O
number	O
of	O
causes	O
other	O
than	O
nonpolio	B-KP
enteroviruses,	I-KP
including:	O
(1)	O
meningitis	B-KP
due	O
to	O
culturable	O
pathogens	O
in	O
which	O
the	O
pathogen	B-KP
concentration	I-KP
in	I-KP
CSF	I-KP
is	O
below	O
the	O
diagnostic	O
sensitivity	O
of	O
standard	B-KP
microbiologic	I-KP
stains	I-KP
(eg,	O
Mycobacterium	B-KP
tuberculosis,	I-KP
Listeria	B-KP
monocytogenes,	I-KP
Cryptococcus	B-KP
neoformans)	I-KP
[6];	O
(2)	O
meningitis	B-KP
due	O
to	O
treatable	O
causes	O
not	O
culturable	O
from	O
CSF	B-KP
under	O
routine	O
conditions	O
(eg,	O
human	B-KP
immuno-deficiency	I-KP
virus	I-KP
[HIV],	B-KP
Lyme	I-KP
disease,	O
syphilis);	O
and	O
(3)	O
systemic	O
illnesses	O
(eg,	O
bacteremia,	O
endocarditis,	O
vasculitis)	O
or	O
parameningeal	B-KP
focal	I-KP
processes	I-KP
(eg,	O
brain	B-KP
tumor,	I-KP
brain	B-KP
or	I-KP
paraspinal	I-KP
abscess,	I-KP
transverse	B-KP
myelitis,	I-KP
herpes	B-KP
simplex	I-KP
encephalitis),	O
many	O
of	O
which	O
are	O
inherently	O
treatable.	O
	
An	O
increasingly	O
complex	O
host	O
population	O
with	O
an	O
expanding	O
array	O
of	O
treatable	O
possibilities	O
fosters	O
confusion	O
in	O
management,	O
unnecessary	O
diagnostic	O
testing,	O
and	O
misdirected	O
expenditures.	O
	
An	O
additional	O
problem	O
is	O
that	O
the	O
clinical	O
spectrum	O
of	O
these	O
patients	O
now	O
encompasses	O
a	O
more	O
diverse	O
number	O
of	O
causes	O
other	O
than	O
nonpolio	B-KP
enteroviruses,	I-KP
including:	O
(1)	O
meningitis	B-KP
due	O
to	O
culturable	O
pathogens	O
in	O
which	O
the	O
pathogen	B-KP
concentration	I-KP
in	I-KP
CSF	I-KP
is	O
below	O
the	O
diagnostic	O
sensitivity	O
of	O
standard	B-KP
microbiologic	I-KP
stains	I-KP
(eg,	O
Mycobacterium	B-KP
tuberculosis,	I-KP
Listeria	B-KP
monocytogenes,	I-KP
Cryptococcus	B-KP
neoformans)	I-KP
[6];	O
(2)	O
meningitis	B-KP
due	O
to	O
treatable	O
causes	O
not	O
culturable	O
from	O
CSF	B-KP
under	O
routine	O
conditions	O
(eg,	O
human	B-KP
immuno-deficiency	I-KP
virus	I-KP
[HIV],	B-KP
Lyme	I-KP
disease,	O
syphilis);	O
and	O
(3)	O
systemic	O
illnesses	O
(eg,	O
bacteremia,	O
endocarditis,	O
vasculitis)	O
or	O
parameningeal	B-KP
focal	I-KP
processes	I-KP
(eg,	O
brain	B-KP
tumor,	I-KP
brain	B-KP
or	I-KP
paraspinal	I-KP
abscess,	I-KP
transverse	B-KP
myelitis,	I-KP
herpes	B-KP
simplex	I-KP
encephalitis),	O
many	O
of	O
which	O
are	O
inherently	O
treatable.	O
	
An	O
increasingly	O
complex	O
host	O
population	O
with	O
an	O
expanding	O
array	O
of	O
treatable	O
possibilities	O
fosters	O
confusion	O
in	O
management,	O
unnecessary	O
diagnostic	O
testing,	O
and	O
misdirected	O
expenditures.	O
	
We	O
believe	O
the	O
observations	O
in	O
this	O
study	O
highlight	O
the	O
need	O
for	O
an	O
improved	O
taxonomy	O
of	O
this	O
clinical	B-KP
syndrome.	I-KP
	
Aseptic	B-KP
meningitis	I-KP
is	O
by	O
definition	O
a	O
diagnosis	O
in	O
retrospect,	O
is	O
often	O
inappropriately	O
used	O
in-terchangeably	O
with	O
viral	B-KP
meningitis,	I-KP
[13,15]	O
and	O
does	O
not	O
accurately	O
reflect	O
the	O
prospective	O
management	O
dilemmas	O
faced	O
by	O
the	O
clinician.	O
	
Recent	O
technical	O
advances	O
using	O
polymerase	B-KP
chain	I-KP
reaction	I-KP
assays	I-KP
for	O
enteroviral	B-KP
ribonucleic	I-KP
acid	I-KP
[16,17]	O
and	O
cytokine	B-KP
levels	I-KP
(interleukin-1,	B-KP
tumor	I-KP
necrosis	I-KP
factor)	O
[18,19]	O
in	O
CSF	I-KP
to	O
distinguish	I-KP
viral	I-KP
from	I-KP
bacterial	I-KP
meningitis	I-KP
are	I-KP
important,	O
but	O
are	O
not	O
widely	O
available	O
and	O
oversimplify	O
the	O
complexity	O
of	O
differential	O
diagnoses	O
and	O
management	O
dilemmas.	O
	
The	O
terms	O
\"enigmatic	B-KP
meningitis\"	O
or	O
\"meningitis	O
of	O
unknown	O
origin\"	O
(ie,	O
acute	I-KP
meningitis	I-KP
with	I-KP
a	I-KP
negative	I-KP
CSF	I-KP
Gram's	I-KP
stain)	O
would	O
be	O
more	O
precise,	O
inclusive,	O
and	O
realistic	O
for	O
practitioners,	O
and	O
would	O
provide	O
an	O
improved	O
taxonomy	O
for	O
future	O
prospective	O
studies.\nThis	O
study	O
shows	O
that	O
the	O
clinical	O
presentation	O
of	O
patients	O
with	O
acute	I-KP
meningitis	I-KP
with	I-KP
a	I-KP
Gram's	I-KP
stain	I-KP
negative	I-KP
for	I-KP
bacteria	O
(or	B-KP
enigmatic	I-KP
meningitis)	O
is	O
a	O
common	O
presenting	O
emergency	O
department	O
problem:	O
approximately	O
86	O
cases	O
per	O
year	O
in	O
an	O
emergency	O
department	O
with	O
71,000	O
visits	O
per	O
year.	O
	
A	O
conservative	O
estimate,	O
therefore,	O
is	O
about	O
1	O
case	O
per	O
1,000	O
visits	O
per	O
year.	O
	
Extrapolating	O
this	O
estimate	O
to	O
short-term,	O
general,	O
nonfederal	O
hospitals	O
in	O
the	O
United	O
States	O
(n	O
=	O
5,202)	O
in	O
which	O
there	O
were	O
an	O
estimated	O
85,143,562	O
total	O
emergency	O
department	O
visits	O
in	O
1990,	O
[20]	O
one	O
would	O
anticipate	O
about	O
85,000	O
cases	O
of	I-KP
enigmatic	I-KP
meningitis	O
per	O
year	O
in	O
the	O
United	O
States.	O
	
Given	O
recent	O
data	O
documenting	O
the	O
high	O
expenditures	O
for	O
inpatient	O
care	O
in	O
the	O
United	O
States	O
($4,814	O
per	O
admission),	O
[21]	O
it	O
can	O
be	O
estimated	O
that	O
over	O
300	O
million	O
dollars	O
is	O
being	O
spent	O
annually	O
on	O
these	O
patients.	O
	
Although	O
this	O
is	O
only	O
an	O
estimate,	O
the	O
high	O
cost	O
of	O
potentially	O
inappropriate	O
evaluation	O
and	O
hospitalization	O
supports	O
the	O
concept	O
that	O
this	O
is	O
a	O
formidable	O
but	O
neglected	O
problem.	O
	
Efforts	O
to	O
identify	O
and	O
reduce	O
unnecessary	O
hospitalization,	O
use	O
of	O
antibiotics,	O
and	O
imaging	O
are	O
urgently	O
needed.	O
	
We	O
believe	O
the	O
observations	O
in	O
this	O
study	O
highlight	O
the	O
need	O
for	O
an	O
improved	O
taxonomy	O
of	O
this	O
clinical	B-KP
syndrome.	I-KP
	
Aseptic	B-KP
meningitis	I-KP
is	O
by	O
definition	O
a	O
diagnosis	O
in	O
retrospect,	O
is	O
often	O
inappropriately	O
used	O
in-terchangeably	O
with	O
viral	B-KP
meningitis,	I-KP
[13,15]	O
and	O
does	O
not	O
accurately	O
reflect	O
the	O
prospective	O
management	O
dilemmas	O
faced	O
by	O
the	O
clinician.	O
	
Recent	O
technical	O
advances	O
using	O
polymerase	B-KP
chain	I-KP
reaction	I-KP
assays	I-KP
for	O
enteroviral	B-KP
ribonucleic	I-KP
acid	I-KP
[16,17]	O
and	O
cytokine	B-KP
levels	I-KP
(interleukin-1,	B-KP
tumor	I-KP
necrosis	I-KP
factor)	O
[18,19]	O
in	O
CSF	I-KP
to	O
distinguish	I-KP
viral	I-KP
from	I-KP
bacterial	I-KP
meningitis	I-KP
are	I-KP
important,	O
but	O
are	O
not	O
widely	O
available	O
and	O
oversimplify	O
the	O
complexity	O
of	O
differential	O
diagnoses	O
and	O
management	O
dilemmas.	O
	
The	O
terms	O
\"enigmatic	B-KP
meningitis\"	O
or	O
\"meningitis	O
of	O
unknown	O
origin\"	O
(ie,	O
acute	I-KP
meningitis	I-KP
with	I-KP
a	I-KP
negative	I-KP
CSF	I-KP
Gram's	I-KP
stain)	O
would	O
be	O
more	O
precise,	O
inclusive,	O
and	O
realistic	O
for	O
practitioners,	O
and	O
would	O
provide	O
an	O
improved	O
taxonomy	O
for	O
future	O
prospective	O
studies.\nThis	O
study	O
shows	O
that	O
the	O
clinical	O
presentation	O
of	O
patients	O
with	O
acute	I-KP
meningitis	I-KP
with	I-KP
a	I-KP
Gram's	I-KP
stain	I-KP
negative	I-KP
for	I-KP
bacteria	O
(or	B-KP
enigmatic	I-KP
meningitis)	O
is	O
a	O
common	O
presenting	O
emergency	O
department	O
problem:	O
approximately	O
86	O
cases	O
per	O
year	O
in	O
an	O
emergency	O
department	O
with	O
71,000	O
visits	O
per	O
year.	O
	
A	O
conservative	O
estimate,	O
therefore,	O
is	O
about	O
1	O
case	O
per	O
1,000	O
visits	O
per	O
year.	O
	
Extrapolating	O
this	O
estimate	O
to	O
short-term,	O
general,	O
nonfederal	O
hospitals	O
in	O
the	O
United	O
States	O
(n	O
=	O
5,202)	O
in	O
which	O
there	O
were	O
an	O
estimated	O
85,143,562	O
total	O
emergency	O
department	O
visits	O
in	O
1990,	O
[20]	O
one	O
would	O
anticipate	O
about	O
85,000	O
cases	O
of	I-KP
enigmatic	I-KP
meningitis	O
per	O
year	O
in	O
the	O
United	O
States.	O
	
Given	O
recent	O
data	O
documenting	O
the	O
high	O
expenditures	O
for	O
inpatient	O
care	O
in	O
the	O
United	O
States	O
($4,814	O
per	O
admission),	O
[21]	O
it	O
can	O
be	O
estimated	O
that	O
over	O
300	O
million	O
dollars	O
is	O
being	O
spent	O
annually	O
on	O
these	O
patients.	O
	
Although	O
this	O
is	O
only	O
an	O
estimate,	O
the	O
high	O
cost	O
of	O
potentially	O
inappropriate	O
evaluation	O
and	O
hospitalization	O
supports	O
the	O
concept	O
that	O
this	O
is	O
a	O
formidable	O
but	O
neglected	O
problem.	O
	
Efforts	O
to	O
identify	O
and	O
reduce	O
unnecessary	O
hospitalization,	O
use	O
of	O
antibiotics,	O
and	O
imaging	O
are	O
urgently	O
needed.	O
	
The	O
patient	O
had	O
a	O
history	O
of	O
diffuse	O
large	O
non-Hodgkin’s	B-KP
B	I-KP
cell	I-KP
CNS	I-KP
lymphoma.	I-KP
	
This	O
had	O
been	O
diagnosed	O
10	O
years	O
before	O
admission	O
and	O
treated	O
with	O
chemotherapeutic	B-KP
doses	I-KP
of	I-KP
methotrexate	I-KP
(MTX),	B-KP
and	O
was	O
followed	O
by	O
maintenance	O
MTX	I-KP
infusions.	O
	
She	O
had	O
achieved	O
a	O
complete	O
remission	O
for	O
4	O
years	O
on	O
this	O
regimen.	O
	
Six	O
years	O
before	O
admission,	O
the	O
patient	O
had	O
experienced	O
a	O
recurrence	O
of	O
her	O
CNS	I-KP
lymphoma,	O
manifested	O
by	O
cognitive	O
changes	O
and	O
accompanied	O
by	O
radiologic	O
evidence	O
of	O
new	O
lesions	I-KP
on	O
a	B-KP
brain	I-KP
MRI	I-KP
scan.	O
	
She	O
resumed	O
therapy	O
with	O
MTX,	O
which	O
continued	O
through	O
2004.	O
	
In	O
2005,	O
she	O
developed	O
new	O
brain	I-KP
lesions	I-KP
that	O
were	O
treated	O
with	O
the	O
combination	O
of	O
high-dose	I-KP
MTX,	O
rituximab,	O
and	O
temozolomide.	O
	
This	O
regimen	O
induced	O
another	O
complete	O
remission,	O
but	O
she	O
experienced	O
a	O
third	O
recurrence	O
in	O
2006,	O
at	O
which	O
time	O
she	O
was	O
treated	O
with	O
myeloablative	I-KP
chemotherapy	I-KP
consisting	I-KP
of	I-KP
cytarabine	I-KP
(Ara-C)/etoposide	O
(VP-16),	O
followed	O
by	O
autologous	O
bone	O
marrow	O
rescue.	O
	
Following	O
her	O
bone	O
marrow	O
transplant,	O
she	O
had	O
remained	O
in	O
remission	O
until	O
the	O
time	O
of	O
the	O
current	O
presentation.	O
	
Aside	O
from	O
her	O
oncologic	O
history,	O
the	O
only	O
other	O
past	O
medical	O
history	O
of	O
note	O
was	O
a	O
caesarean	O
section	O
delivery	O
performed	O
in	O
early	O
2002,	O
followed	O
by	O
a	O
hysterectomy	O
for	O
placenta	O
previa.	O
	
The	O
patient	O
had	O
a	O
history	O
of	O
diffuse	O
large	O
non-Hodgkin’s	B-KP
B	I-KP
cell	I-KP
CNS	I-KP
lymphoma.	I-KP
	
This	O
had	O
been	O
diagnosed	O
10	O
years	O
before	O
admission	O
and	O
treated	O
with	O
chemotherapeutic	B-KP
doses	I-KP
of	I-KP
methotrexate	I-KP
(MTX),	B-KP
and	O
was	O
followed	O
by	O
maintenance	O
MTX	I-KP
infusions.	O
	
She	O
had	O
achieved	O
a	O
complete	O
remission	O
for	O
4	O
years	O
on	O
this	O
regimen.	O
	
Six	O
years	O
before	O
admission,	O
the	O
patient	O
had	O
experienced	O
a	O
recurrence	O
of	O
her	O
CNS	I-KP
lymphoma,	O
manifested	O
by	O
cognitive	O
changes	O
and	O
accompanied	O
by	O
radiologic	O
evidence	O
of	O
new	O
lesions	I-KP
on	O
a	B-KP
brain	I-KP
MRI	I-KP
scan.	O
	
She	O
resumed	O
therapy	O
with	O
MTX,	O
which	O
continued	O
through	O
2004.	O
	
In	O
2005,	O
she	O
developed	O
new	O
brain	I-KP
lesions	I-KP
that	O
were	O
treated	O
with	O
the	O
combination	O
of	O
high-dose	I-KP
MTX,	O
rituximab,	O
and	O
temozolomide.	O
	
This	O
regimen	O
induced	O
another	O
complete	O
remission,	O
but	O
she	O
experienced	O
a	O
third	O
recurrence	O
in	O
2006,	O
at	O
which	O
time	O
she	O
was	O
treated	O
with	O
myeloablative	I-KP
chemotherapy	I-KP
consisting	I-KP
of	I-KP
cytarabine	I-KP
(Ara-C)/etoposide	O
(VP-16),	O
followed	O
by	O
autologous	O
bone	O
marrow	O
rescue.	O
	
Following	O
her	O
bone	O
marrow	O
transplant,	O
she	O
had	O
remained	O
in	O
remission	O
until	O
the	O
time	O
of	O
the	O
current	O
presentation.	O
	
Aside	O
from	O
her	O
oncologic	O
history,	O
the	O
only	O
other	O
past	O
medical	O
history	O
of	O
note	O
was	O
a	O
caesarean	O
section	O
delivery	O
performed	O
in	O
early	O
2002,	O
followed	O
by	O
a	O
hysterectomy	O
for	O
placenta	O
previa.	O
	
Upon	O
arrival	O
in	O
the	O
Cardiac	O
Unit,	O
her	O
temperature	O
was	O
98.2°F,	O
her	O
pulse	O
was	O
60	O
beats/minute,	O
her	O
blood	B-KP
pressure	I-KP
was	O
112/60	O
mm	O
Hg,	O
and	O
her	O
respiratory	B-KP
rate	I-KP
and	O
room	B-KP
air	I-KP
oxygen	I-KP
saturation	I-KP
were	O
16	O
breaths/minute	O
and	O
98%,	O
respectively.	O
	
She	O
appeared	O
comfortable	O
lying	O
in	O
bed.	O
	
Her	O
mucous	B-KP
membranes	I-KP
were	O
moist	O
and	O
the	O
conjunctivae	O
were	O
not	O
injected.	O
	
She	O
had	O
no	O
oral	B-KP
lesions.	I-KP
	
She	O
had	O
easily	O
palpable,	O
nontender	B-KP
temporal	I-KP
arteries.	I-KP
	
No	O
lymphadenopathy	B-KP
was	O
appreciated	O
at	O
the	O
cervical,	B-KP
supraclavicular,	B-KP
axillary,	B-KP
abdominal,	B-KP
or	O
inguinal	B-KP
sites.	I-KP
	
Her	O
neck	O
was	O
supple,	O
and	O
inspection	O
revealed	O
a	O
right-sided	B-KP
internal	I-KP
jugular	I-KP
venous-access	I-KP
catheter.	I-KP
	
The	O
lung	O
fields	O
were	O
clear	O
to	O
auscultation.	O
	
Her	O
cardiac	O
examination	O
was	O
notable	O
for	O
a	O
paced	O
rhythm	O
of	O
60	O
beats/minute	O
without	O
murmurs,	O
rubs,	O
or	O
gallops.	O
	
There	O
were	O
no	O
subclavian	B-KP
or	I-KP
carotid	I-KP
bruits.	I-KP
	
The	O
abdominal	O
examination	O
showed	O
no	O
organomegaly	O
and	O
a	O
soft,	O
nontender	O
abdomen.	O
	
She	O
had	O
no	O
clubbing,	O
cyanosis,	O
or	O
edema	O
on	O
any	O
extremity.	O
	
The	O
fingers	O
were	O
without	O
tapering	O
or	O
dilatation	O
of	O
her	O
nailbed	B-KP
capillaries,	I-KP
and	O
her	O
peripheral	O
pulses	O
were	O
full	O
and	O
symmetric	O
throughout.	O
	
There	O
was	O
no	O
rash.	B-KP
	
The	O
neurologic	O
examination	O
revealed	O
a	O
patient	O
who	O
was	O
awake,	O
alert,	O
and	O
oriented.	O
	
The	O
extraocular	O
movements	O
were	O
full	O
and	O
the	O
visual	O
fields	O
were	O
intact.	O
	
Cranial	B-KP
nerve	I-KP
V	I-KP
was	O
intact	O
in	O
all	O
3	O
distributions,	O
as	O
were	O
cranial	B-KP
nerves	I-KP
VII–XII.	I-KP
	
There	O
was	O
normal	O
bulk,	O
tone,	O
and	O
power	O
of	O
the	O
muscles,	O
and	O
the	O
sensory	O
examination	O
was	O
intact	O
to	O
light	O
touch,	O
pinprick,	O
and	O
vibration.	O
	
The	O
deep	B-KP
tendon	I-KP
reflexes	I-KP
were	O
2	O
and	O
symmetric,	O
and	O
the	O
plantar	B-KP
responses	I-KP
were	I-KP
flexor.	I-KP
	
The	O
patient’s	O
speech	O
was	O
normal.	O
	
Upon	O
arrival	O
in	O
the	O
Cardiac	O
Unit,	O
her	O
temperature	O
was	O
98.2°F,	O
her	O
pulse	O
was	O
60	O
beats/minute,	O
her	O
blood	B-KP
pressure	I-KP
was	O
112/60	O
mm	O
Hg,	O
and	O
her	O
respiratory	B-KP
rate	I-KP
and	O
room	B-KP
air	I-KP
oxygen	I-KP
saturation	I-KP
were	O
16	O
breaths/minute	O
and	O
98%,	O
respectively.	O
	
She	O
appeared	O
comfortable	O
lying	O
in	O
bed.	O
	
Her	O
mucous	B-KP
membranes	I-KP
were	O
moist	O
and	O
the	O
conjunctivae	O
were	O
not	O
injected.	O
	
She	O
had	O
no	O
oral	B-KP
lesions.	I-KP
	
She	O
had	O
easily	O
palpable,	O
nontender	B-KP
temporal	I-KP
arteries.	I-KP
	
No	O
lymphadenopathy	B-KP
was	O
appreciated	O
at	O
the	O
cervical,	B-KP
supraclavicular,	B-KP
axillary,	B-KP
abdominal,	B-KP
or	O
inguinal	B-KP
sites.	I-KP
	
Her	O
neck	O
was	O
supple,	O
and	O
inspection	O
revealed	O
a	O
right-sided	B-KP
internal	I-KP
jugular	I-KP
venous-access	I-KP
catheter.	I-KP
	
The	O
lung	O
fields	O
were	O
clear	O
to	O
auscultation.	O
	
Her	O
cardiac	O
examination	O
was	O
notable	O
for	O
a	O
paced	O
rhythm	O
of	O
60	O
beats/minute	O
without	O
murmurs,	O
rubs,	O
or	O
gallops.	O
	
There	O
were	O
no	O
subclavian	B-KP
or	I-KP
carotid	I-KP
bruits.	I-KP
	
The	O
abdominal	O
examination	O
showed	O
no	O
organomegaly	O
and	O
a	O
soft,	O
nontender	O
abdomen.	O
	
She	O
had	O
no	O
clubbing,	O
cyanosis,	O
or	O
edema	O
on	O
any	O
extremity.	O
	
The	O
fingers	O
were	O
without	O
tapering	O
or	O
dilatation	O
of	O
her	O
nailbed	B-KP
capillaries,	I-KP
and	O
her	O
peripheral	O
pulses	O
were	O
full	O
and	O
symmetric	O
throughout.	O
	
There	O
was	O
no	O
rash.	B-KP
	
The	O
neurologic	O
examination	O
revealed	O
a	O
patient	O
who	O
was	O
awake,	O
alert,	O
and	O
oriented.	O
	
The	O
extraocular	O
movements	O
were	O
full	O
and	O
the	O
visual	O
fields	O
were	O
intact.	O
	
Cranial	B-KP
nerve	I-KP
V	I-KP
was	O
intact	O
in	O
all	O
3	O
distributions,	O
as	O
were	O
cranial	B-KP
nerves	I-KP
VII–XII.	I-KP
	
There	O
was	O
normal	O
bulk,	O
tone,	O
and	O
power	O
of	O
the	O
muscles,	O
and	O
the	O
sensory	O
examination	O
was	O
intact	O
to	O
light	O
touch,	O
pinprick,	O
and	O
vibration.	O
	
The	O
deep	B-KP
tendon	I-KP
reflexes	I-KP
were	O
2	O
and	O
symmetric,	O
and	O
the	O
plantar	B-KP
responses	I-KP
were	I-KP
flexor.	I-KP
	
The	O
patient’s	O
speech	O
was	O
normal.	O
	
Lyme	B-KP
carditis	I-KP
is	O
estimated	O
to	O
occur	O
in	O
4	O
–10%	O
of	O
untreated	O
patients	O
with	O
Lyme	B-KP
disease	I-KP
in	O
the	O
US	O
(17,18).	O
	
It	O
occurs	O
most	O
often	O
during	O
stage	B-KP
2	I-KP
of	I-KP
the	I-KP
B	I-KP
burgdorferi	I-KP
infection,	I-KP
the	O
early	O
disseminated	O
stage,	O
accompanied	O
by	O
neurologic	B-KP
symptoms	I-KP
and	O
musculoskeletal	B-KP
symptoms.	I-KP
	
The	O
early	O
disseminated	O
stage	O
usually	O
develops	O
weeks	O
to	O
months	O
after	O
the	O
appearance	O
of	O
an	O
erythema	B-KP
migrans	I-KP
lesion	I-KP
(14).	O
	
Our	O
patient	O
indicated	O
that	O
she	O
had	O
an	O
erythematous	B-KP
rash	I-KP
on	O
her	O
thigh	O
several	O
months	O
before	O
these	O
symptoms,	O
and	O
this	O
most	O
likely	O
represented	O
an	O
erythema	B-KP
migrans	I-KP
lesion.	I-KP
	
The	O
principal	O
manifestation	O
of	O
Lyme	B-KP
carditis	I-KP
is	O
a	O
self-limited	O
conduction	O
defect,	O
usually	O
consisting	O
of	O
variable	O
degrees	O
of	O
AV	O
conduction	O
delay.	O
	
Carditis	O
can	O
lead	O
to	O
lightheadedness,	O
syncope,	B-KP
dyspnea,	B-KP
palpitations,	B-KP
and	O
chest	B-KP
pain,	I-KP
but	O
it	O
can	O
also	O
be	O
asymptomatic,	O
a	O
fact	O
that	O
probably	O
contributes	O
to	O
an	O
underestimation	O
of	O
this	O
complication’s	O
true	O
prevalence.	O
	
B	B-KP
burgdorferi	I-KP
infections	I-KP
have	O
also	O
been	O
reported	O
to	O
cause	O
pericarditis,	B-KP
endocarditis,	B-KP
myocarditis,	B-KP
pericardial	B-KP
effusion,	I-KP
myocardial	B-KP
infarction,	I-KP
coronary	B-KP
artery	I-KP
aneurysm,	I-KP
prolonged	B-KP
QT	I-KP
interval,	I-KP
and	O
congestive	B-KP
heart	I-KP
failure.	I-KP
	
The	O
conduction	O
abnormalities	O
are	O
generally	O
limited,	O
with	O
CHB	O
resolving	O
by	O
an	O
average	O
of	O
one	O
week	O
and	O
lesser	O
degrees	O
of	O
block	O
by	O
one	O
month.	O
	
Temporary	O
pacemakers	O
are	O
required	O
in	O
a	O
minority	O
of	O
cases.	O
	
The	O
need	O
for	O
permanent	O
pacing	O
despite	O
antibiotics	B-KP
is	O
quite	O
rare.	O
	
Lyme	B-KP
carditis	I-KP
is	O
estimated	O
to	O
occur	O
in	O
4	O
–10%	O
of	O
untreated	O
patients	O
with	O
Lyme	B-KP
disease	I-KP
in	O
the	O
US	O
(17,18).	O
	
It	O
occurs	O
most	O
often	O
during	O
stage	B-KP
2	I-KP
of	I-KP
the	I-KP
B	I-KP
burgdorferi	I-KP
infection,	I-KP
the	O
early	O
disseminated	O
stage,	O
accompanied	O
by	O
neurologic	B-KP
symptoms	I-KP
and	O
musculoskeletal	B-KP
symptoms.	I-KP
	
The	O
early	O
disseminated	O
stage	O
usually	O
develops	O
weeks	O
to	O
months	O
after	O
the	O
appearance	O
of	O
an	O
erythema	B-KP
migrans	I-KP
lesion	I-KP
(14).	O
	
Our	O
patient	O
indicated	O
that	O
she	O
had	O
an	O
erythematous	B-KP
rash	I-KP
on	O
her	O
thigh	O
several	O
months	O
before	O
these	O
symptoms,	O
and	O
this	O
most	O
likely	O
represented	O
an	O
erythema	B-KP
migrans	I-KP
lesion.	I-KP
	
The	O
principal	O
manifestation	O
of	O
Lyme	B-KP
carditis	I-KP
is	O
a	O
self-limited	O
conduction	O
defect,	O
usually	O
consisting	O
of	O
variable	O
degrees	O
of	O
AV	O
conduction	O
delay.	O
	
Carditis	O
can	O
lead	O
to	O
lightheadedness,	O
syncope,	B-KP
dyspnea,	B-KP
palpitations,	B-KP
and	O
chest	B-KP
pain,	I-KP
but	O
it	O
can	O
also	O
be	O
asymptomatic,	O
a	O
fact	O
that	O
probably	O
contributes	O
to	O
an	O
underestimation	O
of	O
this	O
complication’s	O
true	O
prevalence.	O
	
B	B-KP
burgdorferi	I-KP
infections	I-KP
have	O
also	O
been	O
reported	O
to	O
cause	O
pericarditis,	B-KP
endocarditis,	B-KP
myocarditis,	B-KP
pericardial	B-KP
effusion,	I-KP
myocardial	B-KP
infarction,	I-KP
coronary	B-KP
artery	I-KP
aneurysm,	I-KP
prolonged	B-KP
QT	I-KP
interval,	I-KP
and	O
congestive	B-KP
heart	I-KP
failure.	I-KP
	
The	O
conduction	O
abnormalities	O
are	O
generally	O
limited,	O
with	O
CHB	O
resolving	O
by	O
an	O
average	O
of	O
one	O
week	O
and	O
lesser	O
degrees	O
of	O
block	O
by	O
one	O
month.	O
	
Temporary	O
pacemakers	O
are	O
required	O
in	O
a	O
minority	O
of	O
cases.	O
	
The	O
need	O
for	O
permanent	O
pacing	O
despite	O
antibiotics	B-KP
is	O
quite	O
rare.	O
	
Patients	O
were	O
considered	O
to	O
have	O
LM	B-KP
if	O
the	O
cerebrospinal	B-KP
fluid	I-KP
(CSF)	B-KP
examination	O
showed	O
.8	I-KP
white	I-KP
blood	I-KP
cells	I-KP
per	O
cubic	O
millimeter	O
(nontraumatic	O
tap)	O
and	O
they	O
had	O
erythema	I-KP
migrans	I-KP
(EM)	B-KP
and/or	O
positive	O
Lyme	I-KP
serology.	O
	
Serologic	I-KP
tests	I-KP
for	O
Borrelia	I-KP
burgdorferi	I-KP
were	O
performed	O
in	O
our	O
laboratory	O
by	O
previously	O
described	O
techniques,	O
[5]	O
although	O
some	O
patients	O
had	O
tests	O
performed	O
by	O
offsite	O
commercial	O
laboratories.	O
	
A	B-KP
positive	I-KP
western	I-KP
blot	I-KP
test	O
(by	O
laboratory-determined	O
criteria,5	O
because	O
most	O
cases	O
occurred	O
before	O
standardized	O
western	O
blot	O
interpretive	O
criteria	O
[6])	O
was	O
considered	O
to	O
be	O
evidence	O
of	B-KP
Lyme	I-KP
disease.	O
	
In	O
cases	O
where	O
western	I-KP
blotting	O
was	O
not	O
performed,	O
the	B-KP
enzyme	I-KP
immunoassays	O
were	O
considered	O
true	O
positives	O
if	O
the	O
results	O
were	O
greater	O
than	O
twice	O
the	O
lower	O
limit	O
of	O
a	O
reactive	O
result.	O
	
VM	O
was	O
identified	O
by	O
using	O
the	O
same	B-KP
CSF	O
criteria,	O
in	O
addition	O
to	O
laboratory	O
confirmation	O
of	I-KP
viral	I-KP
infection	O
(ie,	B-KP
positive	I-KP
CSF,	B-KP
nasopharyngeal,	O
or	I-KP
rectal	I-KP
cultures	O
[poliovirus	I-KP
in	I-KP
rectal	I-KP
cultures	O
was	O
considered	O
to	O
be	O
vaccine	O
related	O
and	O
not	O
causal	O
for	I-KP
meningitis]).	O
	
Patients	O
were	O
considered	O
to	O
have	O
LM	B-KP
if	O
the	O
cerebrospinal	B-KP
fluid	I-KP
(CSF)	B-KP
examination	O
showed	O
.8	I-KP
white	I-KP
blood	I-KP
cells	I-KP
per	O
cubic	O
millimeter	O
(nontraumatic	O
tap)	O
and	O
they	O
had	O
erythema	I-KP
migrans	I-KP
(EM)	B-KP
and/or	O
positive	O
Lyme	I-KP
serology.	O
	
Serologic	I-KP
tests	I-KP
for	O
Borrelia	I-KP
burgdorferi	I-KP
were	O
performed	O
in	O
our	O
laboratory	O
by	O
previously	O
described	O
techniques,	O
[5]	O
although	O
some	O
patients	O
had	O
tests	O
performed	O
by	O
offsite	O
commercial	O
laboratories.	O
	
A	B-KP
positive	I-KP
western	I-KP
blot	I-KP
test	O
(by	O
laboratory-determined	O
criteria,5	O
because	O
most	O
cases	O
occurred	O
before	O
standardized	O
western	O
blot	O
interpretive	O
criteria	O
[6])	O
was	O
considered	O
to	O
be	O
evidence	O
of	B-KP
Lyme	I-KP
disease.	O
	
In	O
cases	O
where	O
western	I-KP
blotting	O
was	O
not	O
performed,	O
the	B-KP
enzyme	I-KP
immunoassays	O
were	O
considered	O
true	O
positives	O
if	O
the	O
results	O
were	O
greater	O
than	O
twice	O
the	O
lower	O
limit	O
of	O
a	O
reactive	O
result.	O
	
VM	O
was	O
identified	O
by	O
using	O
the	O
same	B-KP
CSF	O
criteria,	O
in	O
addition	O
to	O
laboratory	O
confirmation	O
of	I-KP
viral	I-KP
infection	O
(ie,	B-KP
positive	I-KP
CSF,	B-KP
nasopharyngeal,	O
or	I-KP
rectal	I-KP
cultures	O
[poliovirus	I-KP
in	I-KP
rectal	I-KP
cultures	O
was	O
considered	O
to	O
be	O
vaccine	O
related	O
and	O
not	O
causal	O
for	I-KP
meningitis]).	O
	
Aseptic	B-KP
meningitis,	I-KP
a	O
clinical	O
syndrome	O
of	O
meningeal	B-KP
inflammation	I-KP
in	O
which	O
common	O
bacterial	O
agents	O
cannot	O
be	O
identified	O
in	O
CSF,	B-KP
is	O
associated	O
with	O
a	O
variety	O
of	O
infectious	O
and	O
noninfectious	O
causes.	O
	
A	O
recent	O
review	O
of	O
168	O
adult	O
and	O
pediatric	O
patients	O
with	O
meningitis	B-KP
and	O
a	O
negative	O
Gram	O
stain	O
reported	O
that	O
a	O
definitive	O
cause	O
was	O
established	O
in	O
23%	O
of	O
patients.	O
	
[7]	O
Transverse	B-KP
myelitis,	I-KP
malignancy,	B-KP
syphilis,	B-KP
bacteremia,	B-KP
Lyme	B-KP
disease,	I-KP
and	O
viral	B-KP
meningoencephalitis	I-KP
were	O
the	O
most	O
common	O
diagnoses.	O
	
In	O
children,	O
viral	B-KP
agents,	I-KP
especially	O
Coxsackie	B-KP
and	I-KP
echoviruses,	I-KP
are	O
the	O
most	O
common	O
causes	O
of	O
aseptic	B-KP
meningitis.	I-KP
	
[8]	O
Lyme	B-KP
disease	I-KP
is	O
the	O
most	O
common	O
vector-borne	B-KP
infection	I-KP
in	O
the	O
United	O
States	O
and	O
children	O
comprise	O
a	O
large	O
proportion	O
of	O
cases.9	O
Reported	O
cases	O
of	O
Lyme	B-KP
disease	I-KP
in	O
children	O
exceeded	O
7	O
per	O
100	O
000	O
in	O
1996,	O
[9]	O
but	O
frequencies	O
manyfold	O
higher	O
are	O
reported	O
in	O
endemic	B-KP
areas	I-KP
in	O
the	O
northeastern	O
and	O
north	O
central	O
United	O
States.	O
	
[10]	O
Because	O
of	O
underreporting	O
of	O
cases,	O
it	O
is	O
likely	O
that	O
the	O
true	O
rates	O
are	O
even	O
higher.	O
	
[11]	O
The	O
importance	O
and	O
spectrum	O
of	O
Lyme	B-KP
neuroborreliosis	I-KP
in	O
children	O
has	O
been	O
reported	O
in	O
both	O
the	O
United	O
States	O
and	O
Europe,	O
and	O
differences	O
from	O
adult	O
disease	O
have	O
been	O
noted.	O
	
[12,13]	O
Aseptic	B-KP
meningitis,	I-KP
a	O
clinical	O
syndrome	O
of	O
meningeal	B-KP
inflammation	I-KP
in	O
which	O
common	O
bacterial	O
agents	O
cannot	O
be	O
identified	O
in	O
CSF,	B-KP
is	O
associated	O
with	O
a	O
variety	O
of	O
infectious	O
and	O
noninfectious	O
causes.	O
	
A	O
recent	O
review	O
of	O
168	O
adult	O
and	O
pediatric	O
patients	O
with	O
meningitis	B-KP
and	O
a	O
negative	O
Gram	O
stain	O
reported	O
that	O
a	O
definitive	O
cause	O
was	O
established	O
in	O
23%	O
of	O
patients.	O
	
[7]	O
Transverse	B-KP
myelitis,	I-KP
malignancy,	B-KP
syphilis,	B-KP
bacteremia,	B-KP
Lyme	B-KP
disease,	I-KP
and	O
viral	B-KP
meningoencephalitis	I-KP
were	O
the	O
most	O
common	O
diagnoses.	O
	
In	O
children,	O
viral	B-KP
agents,	I-KP
especially	O
Coxsackie	B-KP
and	I-KP
echoviruses,	I-KP
are	O
the	O
most	O
common	O
causes	O
of	O
aseptic	B-KP
meningitis.	I-KP
	
[8]	O
Lyme	B-KP
disease	I-KP
is	O
the	O
most	O
common	O
vector-borne	B-KP
infection	I-KP
in	O
the	O
United	O
States	O
and	O
children	O
comprise	O
a	O
large	O
proportion	O
of	O
cases.9	O
Reported	O
cases	O
of	O
Lyme	B-KP
disease	I-KP
in	O
children	O
exceeded	O
7	O
per	O
100	O
000	O
in	O
1996,	O
[9]	O
but	O
frequencies	O
manyfold	O
higher	O
are	O
reported	O
in	O
endemic	B-KP
areas	I-KP
in	O
the	O
northeastern	O
and	O
north	O
central	O
United	O
States.	O
	
[10]	O
Because	O
of	O
underreporting	O
of	O
cases,	O
it	O
is	O
likely	O
that	O
the	O
true	O
rates	O
are	O
even	O
higher.	O
	
[11]	O
The	O
importance	O
and	O
spectrum	O
of	O
Lyme	B-KP
neuroborreliosis	I-KP
in	O
children	O
has	O
been	O
reported	O
in	O
both	O
the	O
United	O
States	O
and	O
Europe,	O
and	O
differences	O
from	O
adult	O
disease	O
have	O
been	O
noted.	O
	
[12,13]	O
The	O
fact	O
that	O
LM	B-KP
and	O
VM	B-KP
are	O
both	O
most	O
frequent	O
during	O
the	O
warmer	O
months	O
may	O
lead	O
to	O
confusion	O
in	O
diagnosis	O
and	O
errors	O
in	O
management	O
(ie,	O
failure	O
to	O
provide	B-KP
effective	I-KP
therapy	I-KP
for	O
LM	B-KP
and	O
unnecessary	O
antibiotic	B-KP
treatment	I-KP
for	O
VM).	B-KP
	
Rapid	O
techniques	O
for	O
diagnosis	O
of	O
VM	B-KP
will	O
facilitate	O
appropriate	O
management,	O
[8]	O
but	O
such	O
technology	O
is	O
not	O
widely	O
available.	O
	
The	O
diagnosis	O
of	O
LM	B-KP
is	O
most	O
often	O
based	O
on	O
the	O
finding	O
of	O
CSF	B-KP
pleocytosis	I-KP
associated	O
with	O
the	O
occurrence	O
of	O
EM	B-KP
and/or	O
positive	B-KP
serologic	I-KP
tests.	I-KP
	
However,	O
both	O
enzyme	B-KP
immunoassay	I-KP
and	O
western	B-KP
blot	I-KP
tests	I-KP
for	O
antibody	O
may	O
be	O
negative	O
or	O
indeterminate	O
early	O
in	O
infection	O
when	O
dissemination	O
to	O
the	O
nervous	B-KP
system	I-KP
occurs.	O
	
[3]	O
Also,	O
delays	O
in	O
performing	O
or	O
reporting	O
these	O
tests	O
may	O
lead	O
to	O
delays	O
that	O
can	O
hinder	O
diagnosis	O
and	O
treatment.	O
	
More	O
specific	O
techniques	O
for	O
confirming	O
LM	B-KP
include	O
tests	O
for	O
intrathecal	O
production	O
of	O
specific	O
antibody16,17	B-KP
and	O
demonstration	O
of	O
Borrelia	B-KP
burgdorferi	I-KP
DNA	I-KP
by	O
polymerase	B-KP
chain	I-KP
reaction.	I-KP
	
[2,18]	O
However,	O
the	O
polymerase	B-KP
chain	I-KP
reaction	I-KP
test	I-KP
usually	O
is	O
not	O
rapid	O
and	O
is	O
not	O
very	O
sensitive.	O
	
[2,18]	O
The	O
fact	O
that	O
LM	B-KP
and	O
VM	B-KP
are	O
both	O
most	O
frequent	O
during	O
the	O
warmer	O
months	O
may	O
lead	O
to	O
confusion	O
in	O
diagnosis	O
and	O
errors	O
in	O
management	O
(ie,	O
failure	O
to	O
provide	B-KP
effective	I-KP
therapy	I-KP
for	O
LM	B-KP
and	O
unnecessary	O
antibiotic	B-KP
treatment	I-KP
for	O
VM).	B-KP
	
Rapid	O
techniques	O
for	O
diagnosis	O
of	O
VM	B-KP
will	O
facilitate	O
appropriate	O
management,	O
[8]	O
but	O
such	O
technology	O
is	O
not	O
widely	O
available.	O
	
The	O
diagnosis	O
of	O
LM	B-KP
is	O
most	O
often	O
based	O
on	O
the	O
finding	O
of	O
CSF	B-KP
pleocytosis	I-KP
associated	O
with	O
the	O
occurrence	O
of	O
EM	B-KP
and/or	O
positive	B-KP
serologic	I-KP
tests.	I-KP
	
However,	O
both	O
enzyme	B-KP
immunoassay	I-KP
and	O
western	B-KP
blot	I-KP
tests	I-KP
for	O
antibody	O
may	O
be	O
negative	O
or	O
indeterminate	O
early	O
in	O
infection	O
when	O
dissemination	O
to	O
the	O
nervous	B-KP
system	I-KP
occurs.	O
	
[3]	O
Also,	O
delays	O
in	O
performing	O
or	O
reporting	O
these	O
tests	O
may	O
lead	O
to	O
delays	O
that	O
can	O
hinder	O
diagnosis	O
and	O
treatment.	O
	
More	O
specific	O
techniques	O
for	O
confirming	O
LM	B-KP
include	O
tests	O
for	O
intrathecal	O
production	O
of	O
specific	O
antibody16,17	B-KP
and	O
demonstration	O
of	O
Borrelia	B-KP
burgdorferi	I-KP
DNA	I-KP
by	O
polymerase	B-KP
chain	I-KP
reaction.	I-KP
	
[2,18]	O
However,	O
the	O
polymerase	B-KP
chain	I-KP
reaction	I-KP
test	I-KP
usually	O
is	O
not	O
rapid	O
and	O
is	O
not	O
very	O
sensitive.	O
	
[2,18]	O
A	O
5-year-old	O
girl	O
with	O
no	O
significant	O
medical	O
history	O
presented	O
with	O
unsteady	O
gait	O
that	O
first	O
appeared	O
4	O
days	O
prior	O
to	O
examination.	O
	
In	O
the	O
intervening	O
period,	O
her	O
gait	O
progressively	O
worsened	O
until	O
she	O
was	O
unable	O
to	O
walk.	O
	
There	O
was	O
no	O
history	O
of	O
fever,	B-KP
rash,	B-KP
recent	O
immunizations,	O
tick	O
bite,	O
or	O
exposures	O
to	O
infectious	B-KP
disease.	I-KP
	
Medical	O
history	O
was	O
unremarkable.	O
	
The	O
family	O
lives	O
in	O
Silifke/Mersin,	O
which	O
is	O
a	O
semiurban	O
area	O
in	O
southern	O
coast	O
of	O
Anatolia	O
(Mediterranean	O
region).	O
	
Vital	O
signs	O
and	O
physical	O
examination	O
were	O
normal.	O
	
On	O
neurological	B-KP
examination,	I-KP
her	O
higher	O
mental	O
functions	O
and	O
cranial	B-KP
nerve	I-KP
functions	I-KP
were	O
normal	O
and	O
there	O
were	O
no	O
signs	O
of	O
meningitis.	B-KP
	
She	O
had	O
bilateral	B-KP
cerebellar	I-KP
signs	I-KP
in	O
the	O
form	O
of	O
hypotonia	O
of	O
all	O
limbs,	O
dysarthria,	B-KP
nystagmus,	B-KP
bilateral	B-KP
dysmetria,	I-KP
and	O
intention	B-KP
tremor.	I-KP
	
She	O
also	O
exhibited	O
marked	B-KP
ataxia.	I-KP
	
Superficial	B-KP
and	I-KP
deep	I-KP
tendon	I-KP
reflexes	I-KP
were	O
normal	O
and	O
plantar	O
responses	O
were	O
flexor.	O
	
Laboratory	O
analyses	O
revealed	O
normal	O
blood	B-KP
leukocyte	I-KP
count	I-KP
(5670/mm3),	O
serum	B-KP
C-reactive	I-KP
protein	I-KP
(3	O
mg/L),	O
and	O
erythrocyte	B-KP
sedimentation	I-KP
rate	I-KP
(30	O
mm/h).	O
	
Neither	O
computed	B-KP
tomography	I-KP
(CT)	B-KP
nor	O
magnetic	I-KP
resonance	I-KP
imaging	I-KP
(MRI)	B-KP
revealed	O
any	O
abnormalities	O
in	O
the	O
brain.	O
	
Cerebrospinal	I-KP
fluid	I-KP
(CSF)	B-KP
showed	O
a	B-KP
mild	I-KP
pleocytosis	O
(30	O
cells/mm3,	O
all	O
mononuclear)	O
but	O
normal	O
protein	O
and	O
glucose	O
concentrations.	O
	
Acyclovir,	O
cefotaxime,	O
and	B-KP
clarithromycin	O
were	O
administered	O
empirically.	O
	
Serum	O
markers	O
for	B-KP
herpes	I-KP
simplex	I-KP
virus,	O
cytomegalovirus,	O
varicella	I-KP
zoster,	O
mumps,	O
rubella,	O
rubeola,	O
Epstein-Barr	I-KP
virus,	O
and	B-KP
mycoplasma	O
were	O
all	O
negative.	O
	
Intravenous	I-KP
immunoglobulin	O
(IVIG)	O
infusion	O
was	O
started	O
on	O
day	O
7	O
to	O
suppress	O
the	B-KP
postviral	I-KP
immune	I-KP
response	O
that	O
may	O
be	O
responsible	O
for	B-KP
acute	I-KP
cerebellar	I-KP
ataxia.	O
	
On	O
the	O
fifth	O
day	O
after	O
admission,	O
serologic	O
evaluation	O
for	B-KP
Borrelia	I-KP
burgdorferi	O
was	O
positive	O
for	B-KP
pathogen-specific	I-KP
IgM	O
but	O
negative	O
for	B-KP
IgG.	O
	
After	O
we	O
obtained	O
these	O
results,	O
the	O
history	O
of	O
the	O
patient	O
was	O
reevaluated	O
for	O
tick	O
bite.	O
	
She	O
did	O
not	O
recall	O
any	O
injury,	O
rash,	O
or	O
tick	O
bite.	B-KP
	
Acyclovir	O
and	I-KP
clarithromycin	O
were	O
discontinued	O
on	O
day	O
10	O
and	O
she	O
was	O
administered	O
intravenous	I-KP
cefotaxime	O
200	O
mg/kg	O
per	O
day	O
for	O
the	O
next	O
28	O
days.	O
	
Because	O
the	O
patient	O
did	O
not	O
give	O
permission	O
for	O
a	O
new	O
lumbar	O
puncture,	O
CSF	I-KP
Lyme	I-KP
serology	O
could	O
not	O
be	O
performed.	O
	
Her	O
gait	O
improved	O
gradually	O
during	O
cefotaxime	O
treatment.	O
	
At	O
the	O
time	O
of	O
discharge	O
on	O
day	O
28,	B-KP
her	I-KP
neurologic	I-KP
examination	O
was	O
normal.	O
	
Serum	O
was	O
positive	O
for	B-KP
both	I-KP
B.	I-KP
	
burgdorferi	I-KP
IgM	I-KP
and	I-KP
IgG	I-KP
antibodies	O
on	O
day	O
28	O
but	O
only	B-KP
for	O
IgG	O
on	O
day	O
120.	O
	
A	O
5-year-old	O
girl	O
with	O
no	O
significant	O
medical	O
history	O
presented	O
with	O
unsteady	O
gait	O
that	O
first	O
appeared	O
4	O
days	O
prior	O
to	O
examination.	O
	
In	O
the	O
intervening	O
period,	O
her	O
gait	O
progressively	O
worsened	O
until	O
she	O
was	O
unable	O
to	O
walk.	O
	
There	O
was	O
no	O
history	O
of	O
fever,	B-KP
rash,	B-KP
recent	O
immunizations,	O
tick	O
bite,	O
or	O
exposures	O
to	O
infectious	B-KP
disease.	I-KP
	
Medical	O
history	O
was	O
unremarkable.	O
	
The	O
family	O
lives	O
in	O
Silifke/Mersin,	O
which	O
is	O
a	O
semiurban	O
area	O
in	O
southern	O
coast	O
of	O
Anatolia	O
(Mediterranean	O
region).	O
	
Vital	O
signs	O
and	O
physical	O
examination	O
were	O
normal.	O
	
On	O
neurological	B-KP
examination,	I-KP
her	O
higher	O
mental	O
functions	O
and	O
cranial	B-KP
nerve	I-KP
functions	I-KP
were	O
normal	O
and	O
there	O
were	O
no	O
signs	O
of	O
meningitis.	B-KP
	
She	O
had	O
bilateral	B-KP
cerebellar	I-KP
signs	I-KP
in	O
the	O
form	O
of	O
hypotonia	O
of	O
all	O
limbs,	O
dysarthria,	B-KP
nystagmus,	B-KP
bilateral	B-KP
dysmetria,	I-KP
and	O
intention	B-KP
tremor.	I-KP
	
She	O
also	O
exhibited	O
marked	B-KP
ataxia.	I-KP
	
Superficial	B-KP
and	I-KP
deep	I-KP
tendon	I-KP
reflexes	I-KP
were	O
normal	O
and	O
plantar	O
responses	O
were	O
flexor.	O
	
Laboratory	O
analyses	O
revealed	O
normal	O
blood	B-KP
leukocyte	I-KP
count	I-KP
(5670/mm3),	O
serum	B-KP
C-reactive	I-KP
protein	I-KP
(3	O
mg/L),	O
and	O
erythrocyte	B-KP
sedimentation	I-KP
rate	I-KP
(30	O
mm/h).	O
	
Neither	O
computed	B-KP
tomography	I-KP
(CT)	B-KP
nor	O
magnetic	I-KP
resonance	I-KP
imaging	I-KP
(MRI)	B-KP
revealed	O
any	O
abnormalities	O
in	O
the	O
brain.	O
	
Cerebrospinal	I-KP
fluid	I-KP
(CSF)	B-KP
showed	O
a	B-KP
mild	I-KP
pleocytosis	O
(30	O
cells/mm3,	O
all	O
mononuclear)	O
but	O
normal	O
protein	O
and	O
glucose	O
concentrations.	O
	
Acyclovir,	O
cefotaxime,	O
and	B-KP
clarithromycin	O
were	O
administered	O
empirically.	O
	
Serum	O
markers	O
for	B-KP
herpes	I-KP
simplex	I-KP
virus,	O
cytomegalovirus,	O
varicella	I-KP
zoster,	O
mumps,	O
rubella,	O
rubeola,	O
Epstein-Barr	I-KP
virus,	O
and	B-KP
mycoplasma	O
were	O
all	O
negative.	O
	
Intravenous	I-KP
immunoglobulin	O
(IVIG)	O
infusion	O
was	O
started	O
on	O
day	O
7	O
to	O
suppress	O
the	B-KP
postviral	I-KP
immune	I-KP
response	O
that	O
may	O
be	O
responsible	O
for	B-KP
acute	I-KP
cerebellar	I-KP
ataxia.	O
	
On	O
the	O
fifth	O
day	O
after	O
admission,	O
serologic	O
evaluation	O
for	B-KP
Borrelia	I-KP
burgdorferi	O
was	O
positive	O
for	B-KP
pathogen-specific	I-KP
IgM	O
but	O
negative	O
for	B-KP
IgG.	O
	
After	O
we	O
obtained	O
these	O
results,	O
the	O
history	O
of	O
the	O
patient	O
was	O
reevaluated	O
for	O
tick	O
bite.	O
	
She	O
did	O
not	O
recall	O
any	O
injury,	O
rash,	O
or	O
tick	O
bite.	B-KP
	
Acyclovir	O
and	I-KP
clarithromycin	O
were	O
discontinued	O
on	O
day	O
10	O
and	O
she	O
was	O
administered	O
intravenous	I-KP
cefotaxime	O
200	O
mg/kg	O
per	O
day	O
for	O
the	O
next	O
28	O
days.	O
	
Because	O
the	O
patient	O
did	O
not	O
give	O
permission	O
for	O
a	O
new	O
lumbar	O
puncture,	O
CSF	I-KP
Lyme	I-KP
serology	O
could	O
not	O
be	O
performed.	O
	
Her	O
gait	O
improved	O
gradually	O
during	O
cefotaxime	O
treatment.	O
	
At	O
the	O
time	O
of	O
discharge	O
on	O
day	O
28,	B-KP
her	I-KP
neurologic	I-KP
examination	O
was	O
normal.	O
	
Serum	O
was	O
positive	O
for	B-KP
both	I-KP
B.	I-KP
	
burgdorferi	I-KP
IgM	I-KP
and	I-KP
IgG	I-KP
antibodies	O
on	O
day	O
28	O
but	O
only	B-KP
for	O
IgG	O
on	O
day	O
120.	O
	
The	O
onset	O
of	O
acute	O
cerebellar	O
ataxia	O
varies	O
from	O
a	O
few	O
days	O
to	O
several	O
weeks	O
after	O
an	O
acute	B-KP
febrile	I-KP
illness.	I-KP
	
Cerebellar	O
signs	O
are	O
observed	O
following	O
many	O
infectious	B-KP
diseases,	I-KP
including	O
varicella-zoster,	B-KP
Epstein-Barr,	B-KP
entero-virus,	B-KP
rubeola,	B-KP
parvovirus,	B-KP
and	O
mycoplasma	B-KP
infections.	I-KP
	
Varicella	B-KP
is	O
among	O
the	O
most	O
common	O
of	O
these	O
infectious	B-KP
agents	I-KP
in	O
young	O
children.	O
	
The	O
pathogenesis	B-KP
of	I-KP
ataxia	I-KP
remains	O
unclear,	O
but	O
emerging	O
evidence	O
suggests	O
that	O
an	O
autoimmune	B-KP
mechanism	I-KP
may	O
be	O
involved.	O
	
Antiviral	B-KP
antibodies	I-KP
and	I-KP
autoreactive	I-KP
antibodies	I-KP
targeting	I-KP
cerebellar	I-KP
neurons,	I-KP
possibly	O
autoantibodies	B-KP
specific	O
for	O
the	O
centrosome	B-KP
protein	I-KP
pericentrin,	I-KP
have	O
been	O
detected	O
in	O
the	O
CSF	B-KP
of	O
varicella	O
patients.	O
	
In	O
other	O
cases,	O
viral	B-KP
nucleic	I-KP
acids	I-KP
have	O
been	O
identified	O
in	O
the	O
CSF,	B-KP
suggesting	O
that	O
the	O
pathogen	B-KP
may	O
directly	O
invade	O
the	O
central	B-KP
nervous	I-KP
system	I-KP
[12,13].	O
	
As	O
can	O
be	O
seen	O
in	O
Table	O
1,	O
cerebellar	O
involvement	O
in	O
the	O
form	O
of	O
cerebritis	B-KP
or	O
acute	B-KP
demyelinating	I-KP
encephalomyelitis	I-KP
are	O
described	O
in	O
patients	O
with	O
Lyme	B-KP
disease;	I-KP
however,	O
this	O
case	O
is	O
the	O
first	O
report	O
of	O
acute	B-KP
cerebellar	I-KP
ataxia	I-KP
associated	O
with	O
Lyme	B-KP
disease	I-KP
in	O
the	O
literature.	O
	
The	O
onset	O
of	O
acute	O
cerebellar	O
ataxia	O
varies	O
from	O
a	O
few	O
days	O
to	O
several	O
weeks	O
after	O
an	O
acute	B-KP
febrile	I-KP
illness.	I-KP
	
Cerebellar	O
signs	O
are	O
observed	O
following	O
many	O
infectious	B-KP
diseases,	I-KP
including	O
varicella-zoster,	B-KP
Epstein-Barr,	B-KP
entero-virus,	B-KP
rubeola,	B-KP
parvovirus,	B-KP
and	O
mycoplasma	B-KP
infections.	I-KP
	
Varicella	B-KP
is	O
among	O
the	O
most	O
common	O
of	O
these	O
infectious	B-KP
agents	I-KP
in	O
young	O
children.	O
	
The	O
pathogenesis	B-KP
of	I-KP
ataxia	I-KP
remains	O
unclear,	O
but	O
emerging	O
evidence	O
suggests	O
that	O
an	O
autoimmune	B-KP
mechanism	I-KP
may	O
be	O
involved.	O
	
Antiviral	B-KP
antibodies	I-KP
and	I-KP
autoreactive	I-KP
antibodies	I-KP
targeting	I-KP
cerebellar	I-KP
neurons,	I-KP
possibly	O
autoantibodies	B-KP
specific	O
for	O
the	O
centrosome	B-KP
protein	I-KP
pericentrin,	I-KP
have	O
been	O
detected	O
in	O
the	O
CSF	B-KP
of	O
varicella	O
patients.	O
	
In	O
other	O
cases,	O
viral	B-KP
nucleic	I-KP
acids	I-KP
have	O
been	O
identified	O
in	O
the	O
CSF,	B-KP
suggesting	O
that	O
the	O
pathogen	B-KP
may	O
directly	O
invade	O
the	O
central	B-KP
nervous	I-KP
system	I-KP
[12,13].	O
	
As	O
can	O
be	O
seen	O
in	O
Table	O
1,	O
cerebellar	O
involvement	O
in	O
the	O
form	O
of	O
cerebritis	B-KP
or	O
acute	B-KP
demyelinating	I-KP
encephalomyelitis	I-KP
are	O
described	O
in	O
patients	O
with	O
Lyme	B-KP
disease;	I-KP
however,	O
this	O
case	O
is	O
the	O
first	O
report	O
of	O
acute	B-KP
cerebellar	I-KP
ataxia	I-KP
associated	O
with	O
Lyme	B-KP
disease	I-KP
in	O
the	O
literature.	O
	
While	O
on	O
a	O
2-week	O
summer	O
camping	O
trip	O
in	O
southern	O
Pennsylvania,	O
a	O
previously	O
healthy	O
15	O
year-old	O
boy	O
presented	O
to	O
a	O
nearby	O
emergency	O
department	O
after	O
several	O
days	O
of	O
subjective	O
fever,	B-KP
malaise,	B-KP
and	O
severe	B-KP
left	I-KP
arm	I-KP
radicular	I-KP
pain.	I-KP
	
He	O
was	O
diagnosed	O
with	O
dehydration,	O
administered	O
intravenous	B-KP
fluids,	I-KP
and	O
discharged.	O
	
Several	O
days	O
later	O
after	O
returning	O
home	O
his	O
arm	O
pain	O
resolved,	O
but	O
then	O
he	O
developed	O
right-sided	B-KP
neck	I-KP
pain,	I-KP
headache,	B-KP
and	O
difficulty	O
concentrating.	O
	
One	O
week	O
later,	O
he	O
complained	O
of	O
tinnitus,	B-KP
taste	O
disturbance,	O
otalgia,	B-KP
and	O
subjective	B-KP
hearing	I-KP
loss	I-KP
in	O
his	O
right	O
ear.	O
	
Three	O
weeks	O
into	O
his	O
illness,	O
the	O
patient	O
presented	O
to	O
a	O
local	O
emergency	O
department	O
for	O
right-sided,	O
upper,	O
and	O
lower	B-KP
facial	I-KP
muscle	I-KP
weakness.	I-KP
	
He	O
had	O
no	O
previous	O
complaints	O
of	O
erythema	B-KP
chronicum	I-KP
migrans,	I-KP
arthralgias,	B-KP
or	O
arthritis.	B-KP
	
He	O
was	O
diagnosed	O
with	O
Bell’s	B-KP
Palsy,	I-KP
and	O
serologies	O
for	O
Lyme	B-KP
disease,	I-KP
herpes	B-KP
simplex	I-KP
virus	I-KP
1	I-KP
and	I-KP
2,	I-KP
and	O
Epstein-Barr	B-KP
virus	I-KP
were	O
obtained.	O
	
His	O
primary	O
care	O
physician	O
prescribed	O
doxy-cycline	B-KP
for	O
a	O
positive	B-KP
Lyme	I-KP
antibody	I-KP
test	I-KP
and	O
referred	O
to	O
the	O
pediatric	O
infectious	O
disease	O
clinic.	O
	
While	O
on	O
a	O
2-week	O
summer	O
camping	O
trip	O
in	O
southern	O
Pennsylvania,	O
a	O
previously	O
healthy	O
15	O
year-old	O
boy	O
presented	O
to	O
a	O
nearby	O
emergency	O
department	O
after	O
several	O
days	O
of	O
subjective	O
fever,	B-KP
malaise,	B-KP
and	O
severe	B-KP
left	I-KP
arm	I-KP
radicular	I-KP
pain.	I-KP
	
He	O
was	O
diagnosed	O
with	O
dehydration,	O
administered	O
intravenous	B-KP
fluids,	I-KP
and	O
discharged.	O
	
Several	O
days	O
later	O
after	O
returning	O
home	O
his	O
arm	O
pain	O
resolved,	O
but	O
then	O
he	O
developed	O
right-sided	B-KP
neck	I-KP
pain,	I-KP
headache,	B-KP
and	O
difficulty	O
concentrating.	O
	
One	O
week	O
later,	O
he	O
complained	O
of	O
tinnitus,	B-KP
taste	O
disturbance,	O
otalgia,	B-KP
and	O
subjective	B-KP
hearing	I-KP
loss	I-KP
in	O
his	O
right	O
ear.	O
	
Three	O
weeks	O
into	O
his	O
illness,	O
the	O
patient	O
presented	O
to	O
a	O
local	O
emergency	O
department	O
for	O
right-sided,	O
upper,	O
and	O
lower	B-KP
facial	I-KP
muscle	I-KP
weakness.	I-KP
	
He	O
had	O
no	O
previous	O
complaints	O
of	O
erythema	B-KP
chronicum	I-KP
migrans,	I-KP
arthralgias,	B-KP
or	O
arthritis.	B-KP
	
He	O
was	O
diagnosed	O
with	O
Bell’s	B-KP
Palsy,	I-KP
and	O
serologies	O
for	O
Lyme	B-KP
disease,	I-KP
herpes	B-KP
simplex	I-KP
virus	I-KP
1	I-KP
and	I-KP
2,	I-KP
and	O
Epstein-Barr	B-KP
virus	I-KP
were	O
obtained.	O
	
His	O
primary	O
care	O
physician	O
prescribed	O
doxy-cycline	B-KP
for	O
a	O
positive	B-KP
Lyme	I-KP
antibody	I-KP
test	I-KP
and	O
referred	O
to	O
the	O
pediatric	O
infectious	O
disease	O
clinic.	O
	
The	O
most	O
common	O
manifestations	O
of	O
pediatric	B-KP
neuroborreliosis	I-KP
is	O
CN	B-KP
VII	I-KP
palsy	I-KP
(unilateral	O
or	O
bilateral)	O
and	O
lymphocytic	B-KP
meningitis.	I-KP
	
Among	O
pediatric	O
patients	O
with	O
neuroborreliosis,	B-KP
approximately	O
15%	O
will	O
have	O
CN	B-KP
VII	I-KP
palsy,	I-KP
and	O
of	O
those,	O
between	O
30%-40%	O
present	O
with	O
bilateral	O
deficits.	O
	
[2]	O
CNs	B-KP
III,	I-KP
VI,	O
and	O
VIII	O
are	O
the	O
next	O
most	O
commonly	O
affected.	O
	
Although	O
involvement	O
of	O
these	O
CNs	B-KP
is	O
often	O
diagnosed	O
clinically,	O
MRI	B-KP
has	O
been	O
used	O
as	O
a	O
noninvasive	O
imaging	O
modality	O
to	O
confirm	O
clinical	O
findings.	O
	
Our	O
patient	O
only	O
presented	O
with	O
signs	O
of	O
right-sided	B-KP
CNs	I-KP
VII	I-KP
and	I-KP
VIII	I-KP
involvement	O
on	O
examination	O
but	O
was	O
found	O
to	O
have	O
inflammation	O
of	O
right	B-KP
CN	I-KP
III,	I-KP
X,	O
and	O
CN	B-KP
V	I-KP
bilaterally	O
on	O
post-gadolinium	O
MRI	O
without	O
concomitant	O
clinical	O
manifestations.	O
	
Clinically	O
“silent”	O
enhancement	O
of	O
CNs	B-KP
on	O
MRI	B-KP
has	O
previously	O
been	O
reported	O
in	O
pediatric	B-KP
cases	I-KP
of	I-KP
neuroborreliosis.	I-KP
	
Baumann	O
et	O
al.3	O
presented	O
a	O
case	O
of	O
pediatric	B-KP
neuroborreliosis	I-KP
with	O
only	O
a	O
clinically	O
apparent,	O
right-sided	B-KP
CN	I-KP
VI	I-KP
palsy	I-KP
despite	O
an	O
MRI	B-KP
demonstrating	O
abnormal	O
enhancement	O
of	O
CN	B-KP
VI	I-KP
bilaterally	I-KP
as	O
well	O
as	O
CN	B-KP
III	I-KP
ipsilaterally.	I-KP
	
Silent	O
thalamic	B-KP
lesions	I-KP
have	O
also	O
been	O
reported	O
in	O
pediatric	O
patients	O
with	O
neuroborreliosis.4	O
In	O
this	O
case,	O
the	O
extent	O
of	O
CN	B-KP
inflammation	I-KP
even	O
without	O
concomitant	O
clinical	O
manifestations	O
is	O
unique	O
within	O
cases	O
of	O
NorthAmerican	B-KP
neuroborreliosis,	I-KP
particularly	O
for	O
our	O
patient’s	O
age	O
group.	O
	
The	O
most	O
common	O
manifestations	O
of	O
pediatric	B-KP
neuroborreliosis	I-KP
is	O
CN	B-KP
VII	I-KP
palsy	I-KP
(unilateral	O
or	O
bilateral)	O
and	O
lymphocytic	B-KP
meningitis.	I-KP
	
Among	O
pediatric	O
patients	O
with	O
neuroborreliosis,	B-KP
approximately	O
15%	O
will	O
have	O
CN	B-KP
VII	I-KP
palsy,	I-KP
and	O
of	O
those,	O
between	O
30%-40%	O
present	O
with	O
bilateral	O
deficits.	O
	
[2]	O
CNs	B-KP
III,	I-KP
VI,	O
and	O
VIII	O
are	O
the	O
next	O
most	O
commonly	O
affected.	O
	
Although	O
involvement	O
of	O
these	O
CNs	B-KP
is	O
often	O
diagnosed	O
clinically,	O
MRI	B-KP
has	O
been	O
used	O
as	O
a	O
noninvasive	O
imaging	O
modality	O
to	O
confirm	O
clinical	O
findings.	O
	
Our	O
patient	O
only	O
presented	O
with	O
signs	O
of	O
right-sided	B-KP
CNs	I-KP
VII	I-KP
and	I-KP
VIII	I-KP
involvement	O
on	O
examination	O
but	O
was	O
found	O
to	O
have	O
inflammation	O
of	O
right	B-KP
CN	I-KP
III,	I-KP
X,	O
and	O
CN	B-KP
V	I-KP
bilaterally	O
on	O
post-gadolinium	O
MRI	O
without	O
concomitant	O
clinical	O
manifestations.	O
	
Clinically	O
“silent”	O
enhancement	O
of	O
CNs	B-KP
on	O
MRI	B-KP
has	O
previously	O
been	O
reported	O
in	O
pediatric	B-KP
cases	I-KP
of	I-KP
neuroborreliosis.	I-KP
	
Baumann	O
et	O
al.3	O
presented	O
a	O
case	O
of	O
pediatric	B-KP
neuroborreliosis	I-KP
with	O
only	O
a	O
clinically	O
apparent,	O
right-sided	B-KP
CN	I-KP
VI	I-KP
palsy	I-KP
despite	O
an	O
MRI	B-KP
demonstrating	O
abnormal	O
enhancement	O
of	O
CN	B-KP
VI	I-KP
bilaterally	I-KP
as	O
well	O
as	O
CN	B-KP
III	I-KP
ipsilaterally.	I-KP
	
Silent	O
thalamic	B-KP
lesions	I-KP
have	O
also	O
been	O
reported	O
in	O
pediatric	O
patients	O
with	O
neuroborreliosis.4	O
In	O
this	O
case,	O
the	O
extent	O
of	O
CN	B-KP
inflammation	I-KP
even	O
without	O
concomitant	O
clinical	O
manifestations	O
is	O
unique	O
within	O
cases	O
of	O
NorthAmerican	B-KP
neuroborreliosis,	I-KP
particularly	O
for	O
our	O
patient’s	O
age	O
group.	O
	
Bell’s	B-KP
palsy	I-KP
represents	O
an	O
idiopathic,	O
unilateral	B-KP
facial	I-KP
paralysis	I-KP
with	O
an	O
annual	O
incidence	O
of	O
approximately	O
15	O
per	O
100,000.	O
	
[1]	O
It	O
remains	O
the	O
most	O
common	O
cause	O
of	O
unilateral	B-KP
facial	I-KP
paralysis,	I-KP
affecting	O
men	O
and	O
women	O
equally,	O
and	O
although	O
the	O
median	O
age	O
at	O
onset	O
is	O
40	O
years,	O
it	O
can	O
occur	O
at	O
any	O
age.	O
	
[2]	O
Patients	O
with	O
Bell’s	B-KP
palsy	I-KP
commonly	O
present	O
with	O
partial	B-KP
or	I-KP
complete	I-KP
weakness	I-KP
of	I-KP
the	I-KP
muscles	I-KP
of	I-KP
half	I-KP
of	I-KP
the	I-KP
face,	I-KP
resulting	O
in	O
an	O
inability	O
to	O
raise	O
eyebrows,	O
wrinkle	O
the	O
forehead,	O
or	O
close	O
the	O
eyelid;	O
loss	O
of	O
the	O
nasolabial	O
fold;	O
and	O
drooping	O
of	O
the	O
angle	O
of	O
the	O
mouth.	O
	
Other	O
associated	O
symptoms	O
include	O
alterations	O
in	O
taste,	O
hyperacusis,	B-KP
inability	O
to	O
produce	O
tears,	O
and	O
a	O
subjective	O
feeling	O
of	O
facial	O
numbness,	O
though	O
objective	O
sensation	O
is	O
preserved.\nThe	O
pathophysiology	O
of	O
Bell’s	B-KP
palsy	I-KP
involves	O
inflammation	O
of	O
the	O
facial	B-KP
nerve	I-KP
at	O
the	O
geniculate	B-KP
ganglion,	I-KP
causing	O
compression	O
and	O
associated	O
ischemia	B-KP
or	O
demyelination.	B-KP
	
[3]	O
Symptoms	O
are	O
often	O
acute	O
and	O
progressive,	O
evolving	O
during	O
1	O
day	O
to	O
1	O
week.	O
	
It	O
has	O
been	O
postulated	O
that	O
the	O
herpes	B-KP
simplex	I-KP
virus	I-KP
type	I-KP
1	I-KP
may	O
play	O
a	O
causative	O
role,	O
though	O
this	O
theory	O
is	O
still	O
in	O
question.	O
	
[4]	O
If	O
left	O
untreated,	O
approximately	O
85%	O
of	O
patients	O
with	O
Bell’s	B-KP
palsy	I-KP
will	O
experience	O
some	O
recovery,	O
[5]	O
and	O
treatment	O
with	O
corticosteroids,	B-KP
with	O
or	O
without	O
antiviral	B-KP
medications,	I-KP
has	O
been	O
shown	O
to	O
improve	O
outcomes.	O
	
[6,7]	O
Bell’s	B-KP
palsy	I-KP
represents	O
an	O
idiopathic,	O
unilateral	B-KP
facial	I-KP
paralysis	I-KP
with	O
an	O
annual	O
incidence	O
of	O
approximately	O
15	O
per	O
100,000.	O
	
[1]	O
It	O
remains	O
the	O
most	O
common	O
cause	O
of	O
unilateral	B-KP
facial	I-KP
paralysis,	I-KP
affecting	O
men	O
and	O
women	O
equally,	O
and	O
although	O
the	O
median	O
age	O
at	O
onset	O
is	O
40	O
years,	O
it	O
can	O
occur	O
at	O
any	O
age.	O
	
[2]	O
Patients	O
with	O
Bell’s	B-KP
palsy	I-KP
commonly	O
present	O
with	O
partial	B-KP
or	I-KP
complete	I-KP
weakness	I-KP
of	I-KP
the	I-KP
muscles	I-KP
of	I-KP
half	I-KP
of	I-KP
the	I-KP
face,	I-KP
resulting	O
in	O
an	O
inability	O
to	O
raise	O
eyebrows,	O
wrinkle	O
the	O
forehead,	O
or	O
close	O
the	O
eyelid;	O
loss	O
of	O
the	O
nasolabial	O
fold;	O
and	O
drooping	O
of	O
the	O
angle	O
of	O
the	O
mouth.	O
	
Other	O
associated	O
symptoms	O
include	O
alterations	O
in	O
taste,	O
hyperacusis,	B-KP
inability	O
to	O
produce	O
tears,	O
and	O
a	O
subjective	O
feeling	O
of	O
facial	O
numbness,	O
though	O
objective	O
sensation	O
is	O
preserved.\nThe	O
pathophysiology	O
of	O
Bell’s	B-KP
palsy	I-KP
involves	O
inflammation	O
of	O
the	O
facial	B-KP
nerve	I-KP
at	O
the	O
geniculate	B-KP
ganglion,	I-KP
causing	O
compression	O
and	O
associated	O
ischemia	B-KP
or	O
demyelination.	B-KP
	
[3]	O
Symptoms	O
are	O
often	O
acute	O
and	O
progressive,	O
evolving	O
during	O
1	O
day	O
to	O
1	O
week.	O
	
It	O
has	O
been	O
postulated	O
that	O
the	O
herpes	B-KP
simplex	I-KP
virus	I-KP
type	I-KP
1	I-KP
may	O
play	O
a	O
causative	O
role,	O
though	O
this	O
theory	O
is	O
still	O
in	O
question.	O
	
[4]	O
If	O
left	O
untreated,	O
approximately	O
85%	O
of	O
patients	O
with	O
Bell’s	B-KP
palsy	I-KP
will	O
experience	O
some	O
recovery,	O
[5]	O
and	O
treatment	O
with	O
corticosteroids,	B-KP
with	O
or	O
without	O
antiviral	B-KP
medications,	I-KP
has	O
been	O
shown	O
to	O
improve	O
outcomes.	O
	
[6,7]	O
The	O
unique	O
linkage	O
number	O
was	O
used	O
to	O
link	O
subjects	O
from	O
the	O
index	B-KP
ED	I-KP
visit	O
to	O
subsequent	O
ED	I-KP
encounters	I-KP
or	O
hospitalizations	O
within	O
90	O
days.	O
	
Our	O
primary	O
outcome	O
was	O
a	O
composite	O
of	O
the	O
following	O
serious	O
ED	I-KP
or	O
inpatient	O
discharge	O
diagnoses	O
(by	O
ICD-9	O
code)	O
within	O
90	O
days	O
of	O
the	O
index	B-KP
ED	I-KP
Bell’s	I-KP
palsy	I-KP
diagnosis:	I-KP
ischemic	B-KP
stroke	I-KP
(433.01,	O
433.11,	O
433.21,	O
433.31,	O
433.81,	O
433.91,	O
434.01,	O
434.11,	O
434.91,	O
and	O
436),	O
combined	O
with	O
an	O
algorithm	O
previously	O
validated	O
for	O
identifying	O
acute	O
ischemic	O
stroke11),	O
intracranial	B-KP
hemorrhage	I-KP
(431),	O
or	O
subarachnoid	B-KP
hemorrhage	I-KP
(430);	O
brain	B-KP
tumor	I-KP
(191);	O
central	B-KP
nervous	I-KP
system	I-KP
infection,	I-KP
including	O
meningitis,	B-KP
encephalitis,	B-KP
and	O
brain	B-KP
abscess	I-KP
(320-326);	O
HIV	O
(042);	O
Guillain-Barré	B-KP
syndrome	I-KP
(357.0);	O
Lyme	B-KP
disease	I-KP
(088.81);	O
otitis	B-KP
media	I-KP
or	O
mastoiditis	B-KP
(381-383);	O
or	O
herpes	B-KP
zoster	I-KP
(053).	O
	
These	O
diagnoses	O
were	O
chosen	O
a	O
priori	O
to	O
represent	O
distinct	O
and	O
clinically	O
important	O
disease	O
entities	O
that	O
may	O
present	O
in	O
a	O
similar	O
fashion	O
to	O
Bell’s	B-KP
palsy.	I-KP
	
We	O
excluded	O
some	O
common	O
mimics	O
from	O
our	O
outcomes	O
(eg,	O
diabetic	B-KP
neuropathy,	I-KP
sarcoidosis)	B-KP
because,	O
although	O
they	O
may	O
initially	O
be	O
confused	O
with	O
Bell’s	B-KP
palsy,	I-KP
the	O
clinical	O
significance	O
of	O
misdiagnosis	O
is	O
unclear	O
and	O
patient	O
outcomes	O
would	O
generally	O
not	O
be	O
expected	O
to	O
worsen	O
from	O
delayed	O
diagnosis.	O
	
Additionally,	O
we	O
excluded	O
mortality	O
as	O
a	O
separate	O
outcome	O
because	O
any	O
death	O
related	O
to	O
one	O
of	O
the	O
outcome	O
diagnoses	O
would	O
already	O
be	O
captured.	O
	
The	O
unique	O
linkage	O
number	O
was	O
used	O
to	O
link	O
subjects	O
from	O
the	O
index	B-KP
ED	I-KP
visit	O
to	O
subsequent	O
ED	I-KP
encounters	I-KP
or	O
hospitalizations	O
within	O
90	O
days.	O
	
Our	O
primary	O
outcome	O
was	O
a	O
composite	O
of	O
the	O
following	O
serious	O
ED	I-KP
or	O
inpatient	O
discharge	O
diagnoses	O
(by	O
ICD-9	O
code)	O
within	O
90	O
days	O
of	O
the	O
index	B-KP
ED	I-KP
Bell’s	I-KP
palsy	I-KP
diagnosis:	I-KP
ischemic	B-KP
stroke	I-KP
(433.01,	O
433.11,	O
433.21,	O
433.31,	O
433.81,	O
433.91,	O
434.01,	O
434.11,	O
434.91,	O
and	O
436),	O
combined	O
with	O
an	O
algorithm	O
previously	O
validated	O
for	O
identifying	O
acute	O
ischemic	O
stroke11),	O
intracranial	B-KP
hemorrhage	I-KP
(431),	O
or	O
subarachnoid	B-KP
hemorrhage	I-KP
(430);	O
brain	B-KP
tumor	I-KP
(191);	O
central	B-KP
nervous	I-KP
system	I-KP
infection,	I-KP
including	O
meningitis,	B-KP
encephalitis,	B-KP
and	O
brain	B-KP
abscess	I-KP
(320-326);	O
HIV	O
(042);	O
Guillain-Barré	B-KP
syndrome	I-KP
(357.0);	O
Lyme	B-KP
disease	I-KP
(088.81);	O
otitis	B-KP
media	I-KP
or	O
mastoiditis	B-KP
(381-383);	O
or	O
herpes	B-KP
zoster	I-KP
(053).	O
	
These	O
diagnoses	O
were	O
chosen	O
a	O
priori	O
to	O
represent	O
distinct	O
and	O
clinically	O
important	O
disease	O
entities	O
that	O
may	O
present	O
in	O
a	O
similar	O
fashion	O
to	O
Bell’s	B-KP
palsy.	I-KP
	
We	O
excluded	O
some	O
common	O
mimics	O
from	O
our	O
outcomes	O
(eg,	O
diabetic	B-KP
neuropathy,	I-KP
sarcoidosis)	B-KP
because,	O
although	O
they	O
may	O
initially	O
be	O
confused	O
with	O
Bell’s	B-KP
palsy,	I-KP
the	O
clinical	O
significance	O
of	O
misdiagnosis	O
is	O
unclear	O
and	O
patient	O
outcomes	O
would	O
generally	O
not	O
be	O
expected	O
to	O
worsen	O
from	O
delayed	O
diagnosis.	O
	
Additionally,	O
we	O
excluded	O
mortality	O
as	O
a	O
separate	O
outcome	O
because	O
any	O
death	O
related	O
to	O
one	O
of	O
the	O
outcome	O
diagnoses	O
would	O
already	O
be	O
captured.	O
	
Table	O
2	O
shows	O
the	O
results	O
of	O
our	O
multivariate	O
model,	O
which	O
identified	O
multiple	O
factors	O
associated	O
with	O
the	O
likelihood	O
of	O
receiving	O
an	O
alternative	O
diagnosis.	O
	
Demographic	O
factors	O
or	O
comorbid	O
conditions	O
positively	O
associated	O
included	O
increasing	O
age	O
(HR	O
1.11,	O
95%	O
CI	O
1.01	O
to	O
1.21,	O
for	O
every	O
10	O
years),	O
black	O
compared	O
with	O
white	O
race	O
(HR	O
1.68;	O
95%	O
CI	O
1.13	O
to	O
2.48),	O
and	O
diabetes	B-KP
mellitus	I-KP
(HR	O
1.46;	O
95%	O
CI	O
1.10	O
to	O
1.95).	O
	
The	O
use	O
of	O
CT	B-KP
or	O
MRI	B-KP
imaging	I-KP
on	O
the	O
index	O
visit	O
was	O
also	O
associated	O
with	O
an	O
increase	O
in	O
the	O
misdiagnosis	O
of	O
Bell’s	B-KP
palsy	I-KP
(HR	O
1.43;	O
95%	O
CI	O
1.10	O
to	O
1.85).	O
	
Private	O
insurance	O
compared	O
with	O
Medicare	O
was	O
negatively	O
associated	O
with	O
an	O
alternative	O
diagnosis	O
(HR	O
0.65;	O
95%	O
CI	O
0.46	O
to	O
0.93).\nThe	O
alternative	O
diagnoses	O
made	O
on	O
follow-up	O
are	O
listed	O
in	O
Table	O
3,	O
stratified	O
by	O
7-,	O
14-,	O
30-,	O
and	O
90-day	O
follow-up.	O
	
Of	O
the	O
356	O
individuals	O
with	O
an	O
alternative	O
diagnosis	O
within	O
90	O
days,	O
142	O
(39.9%)	O
were	O
within	O
7	O
days.	O
	
Most	O
common	O
at	O
all	O
4	O
intervals	O
were	O
ischemic	B-KP
stroke,	I-KP
herpes	B-KP
zoster,	I-KP
Guillain-Barré	B-KP
syndrome,	I-KP
and	O
otitis	B-KP
media,	I-KP
accounting	O
for	O
85.4%	O
of	O
all	O
alternative	O
diagnoses.	O
	
Table	O
2	O
shows	O
the	O
results	O
of	O
our	O
multivariate	O
model,	O
which	O
identified	O
multiple	O
factors	O
associated	O
with	O
the	O
likelihood	O
of	O
receiving	O
an	O
alternative	O
diagnosis.	O
	
Demographic	O
factors	O
or	O
comorbid	O
conditions	O
positively	O
associated	O
included	O
increasing	O
age	O
(HR	O
1.11,	O
95%	O
CI	O
1.01	O
to	O
1.21,	O
for	O
every	O
10	O
years),	O
black	O
compared	O
with	O
white	O
race	O
(HR	O
1.68;	O
95%	O
CI	O
1.13	O
to	O
2.48),	O
and	O
diabetes	B-KP
mellitus	I-KP
(HR	O
1.46;	O
95%	O
CI	O
1.10	O
to	O
1.95).	O
	
The	O
use	O
of	O
CT	B-KP
or	O
MRI	B-KP
imaging	I-KP
on	O
the	O
index	O
visit	O
was	O
also	O
associated	O
with	O
an	O
increase	O
in	O
the	O
misdiagnosis	O
of	O
Bell’s	B-KP
palsy	I-KP
(HR	O
1.43;	O
95%	O
CI	O
1.10	O
to	O
1.85).	O
	
Private	O
insurance	O
compared	O
with	O
Medicare	O
was	O
negatively	O
associated	O
with	O
an	O
alternative	O
diagnosis	O
(HR	O
0.65;	O
95%	O
CI	O
0.46	O
to	O
0.93).\nThe	O
alternative	O
diagnoses	O
made	O
on	O
follow-up	O
are	O
listed	O
in	O
Table	O
3,	O
stratified	O
by	O
7-,	O
14-,	O
30-,	O
and	O
90-day	O
follow-up.	O
	
Of	O
the	O
356	O
individuals	O
with	O
an	O
alternative	O
diagnosis	O
within	O
90	O
days,	O
142	O
(39.9%)	O
were	O
within	O
7	O
days.	O
	
Most	O
common	O
at	O
all	O
4	O
intervals	O
were	O
ischemic	B-KP
stroke,	I-KP
herpes	B-KP
zoster,	I-KP
Guillain-Barré	B-KP
syndrome,	I-KP
and	O
otitis	B-KP
media,	I-KP
accounting	O
for	O
85.4%	O
of	O
all	O
alternative	O
diagnoses.	O
	
We	O
found	O
that	O
10.9%	O
of	O
patients	O
who	O
received	O
a	O
misdiagnosis	O
of	O
Bell’s	B-KP
palsy	I-KP
went	O
on	O
to	O
receive	O
a	O
diagnosis	O
of	O
Guillain-Barré	B-KP
syndrome	I-KP
on	O
90-day	O
follow-up.	O
	
Guillain-Barré	B-KP
syndrome	I-KP
encompasses	O
multiple	O
heterogeneous	B-KP
immune-mediated	I-KP
neuropathies,	I-KP
generally	O
presenting	O
with	O
progressive	B-KP
and	I-KP
symmetric	I-KP
motor	I-KP
weakness	I-KP
and	O
loss	O
of	O
deep	B-KP
tendon	I-KP
reflexes.Multiple	O
variants	O
of	O
Guillain-Barré	B-KP
syndrome	I-KP
exist,	O
with	O
acute	B-KP
inflammatory	I-KP
demyelinating	I-KP
polyneuropathy,	I-KP
the	O
classic	O
form	O
with	O
ascending	B-KP
paralysis,	I-KP
accounting	O
for	O
the	O
majority	O
of	O
cases.	O
	
[27]	O
Variants	O
of	O
Guillain-Barré	B-KP
syndrome	I-KP
may	O
involve	O
the	O
cranial	B-KP
nerves,	I-KP
including	O
Miller	B-KP
Fisher	I-KP
syndrome,	I-KP
typically	O
presenting	O
with	O
ophthalmoplegia,	B-KP
ataxia,	B-KP
and	O
areflexia	B-KP
with	O
subsequent	O
descending	O
paralysis.	O
	
Miller	B-KP
Fisher	I-KP
syndrome	I-KP
accounts	O
for	O
approximately	O
5%	O
of	O
all	O
cases	O
of	O
Guillain-Barré	B-KP
syndrome	I-KP
and	O
may	O
progress	O
in	O
half	O
of	O
cases	O
to	O
cause	O
various	O
other	O
cranial	B-KP
nerve	I-KP
abnormalities.28,29	O
Additional	O
variants	O
of	O
Guillain-Barré	B-KP
syndrome	I-KP
that	O
may	O
overlap	O
with	O
Miller	B-KP
Fisher	I-KP
syndrome	I-KP
and	O
initially	O
present	O
with	O
facial	O
symptoms	O
include	O
Bickerstaff	B-KP
encephalitis	I-KP
and	O
pharyngeal-cervical-brachial	B-KP
weakness,	I-KP
though	O
both	O
of	O
these	O
entities	O
may	O
have	O
multiple	O
associated	O
symptoms	O
that	O
would	O
generally	O
preclude	O
a	O
diagnosis	O
of	O
Bell’s	B-KP
palsy.	I-KP
	
[30,31]	O
More	O
detailed	O
research	O
may	O
be	O
warranted	O
to	O
investigate	O
the	O
association	O
between	O
ED	B-KP
misdiagnosis	I-KP
of	I-KP
Bell’s	I-KP
palsy	I-KP
and	O
subsequent	O
diagnosis	O
of	O
Guillain-Barré	B-KP
syndrome.	I-KP
	
We	O
found	O
that	O
10.9%	O
of	O
patients	O
who	O
received	O
a	O
misdiagnosis	O
of	O
Bell’s	B-KP
palsy	I-KP
went	O
on	O
to	O
receive	O
a	O
diagnosis	O
of	O
Guillain-Barré	B-KP
syndrome	I-KP
on	O
90-day	O
follow-up.	O
	
Guillain-Barré	B-KP
syndrome	I-KP
encompasses	O
multiple	O
heterogeneous	B-KP
immune-mediated	I-KP
neuropathies,	I-KP
generally	O
presenting	O
with	O
progressive	B-KP
and	I-KP
symmetric	I-KP
motor	I-KP
weakness	I-KP
and	O
loss	O
of	O
deep	B-KP
tendon	I-KP
reflexes.Multiple	O
variants	O
of	O
Guillain-Barré	B-KP
syndrome	I-KP
exist,	O
with	O
acute	B-KP
inflammatory	I-KP
demyelinating	I-KP
polyneuropathy,	I-KP
the	O
classic	O
form	O
with	O
ascending	B-KP
paralysis,	I-KP
accounting	O
for	O
the	O
majority	O
of	O
cases.	O
	
[27]	O
Variants	O
of	O
Guillain-Barré	B-KP
syndrome	I-KP
may	O
involve	O
the	O
cranial	B-KP
nerves,	I-KP
including	O
Miller	B-KP
Fisher	I-KP
syndrome,	I-KP
typically	O
presenting	O
with	O
ophthalmoplegia,	B-KP
ataxia,	B-KP
and	O
areflexia	B-KP
with	O
subsequent	O
descending	O
paralysis.	O
	
Miller	B-KP
Fisher	I-KP
syndrome	I-KP
accounts	O
for	O
approximately	O
5%	O
of	O
all	O
cases	O
of	O
Guillain-Barré	B-KP
syndrome	I-KP
and	O
may	O
progress	O
in	O
half	O
of	O
cases	O
to	O
cause	O
various	O
other	O
cranial	B-KP
nerve	I-KP
abnormalities.28,29	O
Additional	O
variants	O
of	O
Guillain-Barré	B-KP
syndrome	I-KP
that	O
may	O
overlap	O
with	O
Miller	B-KP
Fisher	I-KP
syndrome	I-KP
and	O
initially	O
present	O
with	O
facial	O
symptoms	O
include	O
Bickerstaff	B-KP
encephalitis	I-KP
and	O
pharyngeal-cervical-brachial	B-KP
weakness,	I-KP
though	O
both	O
of	O
these	O
entities	O
may	O
have	O
multiple	O
associated	O
symptoms	O
that	O
would	O
generally	O
preclude	O
a	O
diagnosis	O
of	O
Bell’s	B-KP
palsy.	I-KP
	
[30,31]	O
More	O
detailed	O
research	O
may	O
be	O
warranted	O
to	O
investigate	O
the	O
association	O
between	O
ED	B-KP
misdiagnosis	I-KP
of	I-KP
Bell’s	I-KP
palsy	I-KP
and	O
subsequent	O
diagnosis	O
of	O
Guillain-Barré	B-KP
syndrome.	I-KP
	
Between	O
January	O
2000	O
and	O
April	O
2004,	O
healthy	O
volunteers	O
(controls)	O
and	O
individuals	O
with	O
a	O
history	O
of	O
Lyme	B-KP
disease	I-KP
(patients)	O
between	O
the	O
ages	O
of	O
18	O
and	O
65	O
years	O
were	O
recruited;	O
follow-up	O
evaluations	O
were	O
completed	O
by	O
April	O
2005.	O
	
The	O
institutional	O
review	O
boards	O
at	O
Columbia	O
University	O
and	O
the	O
New	O
York	O
State	O
Psychiatric	O
Institute	O
approved	O
the	O
study,	O
and	O
all	O
participants	O
provided	O
written	O
informed	O
consent.	O
	
Evaluations	O
were	O
conducted	O
at	O
the	O
New	O
York	O
State	O
Psychiatric	O
Institute	O
and	O
Columbia	O
University	O
Medical	O
Center.	O
	
Treatments	O
were	O
conducted	O
at	O
each	O
patient’s	O
home.	O
	
Patients	O
met	O
the	O
following	O
criteria:	O
(1)	O
history	O
of	O
physician-documented	O
erythema	B-KP
migrans	I-KP
or	O
U.S.	O
	
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(CDC)-defined	O
manifestation	O
of	O
Lyme	B-KP
disease,	I-KP
and	O
a	O
positive	O
or	O
equivocal	O
ELISA	B-KP
confirmed	O
by	O
positive	B-KP
Western	I-KP
blot	I-KP
serology6,7;	O
(2)	O
current	O
positive	B-KP
IgG	I-KP
Western	I-KP
blot	I-KP
using	O
CDC	O
surveillance	O
criteria,	O
assessed	O
using	O
a	O
single	O
reference	O
laboratory	O
(University	O
Hospital	O
of	O
Stony	O
Brook);	O
(3)	O
treatment	O
for	O
Lyme	B-KP
disease	I-KP
with	O
at	O
least	O
3	O
weeks	O
of	O
IV	B-KP
ceftriaxone,	I-KP
completed	O
at	O
least	O
4	O
months	O
before	O
study	O
entry;	O
(4)	O
subjective	O
memory	O
impairment	O
that,	O
by	O
participant	O
report,	O
started	O
after	O
the	O
onset	O
of	O
Lyme	B-KP
disease;	I-KP
and	O
(5)	O
objective	O
evidence	O
of	O
memory	O
impairment	O
as	O
documented	O
by	O
the	O
Wechsler	B-KP
Memory	I-KP
Scale–III8	O
compared	O
with	O
age-,	O
sex-,	O
and	O
education-adjusted	O
population	O
norms.	O
	
These	O
study	O
criteria	O
were	O
conservative	O
and	O
narrow	O
to	O
enhance	O
diagnostic	O
confidence.	O
	
Prior	O
IV	B-KP
antibiotic	I-KP
therapy	I-KP
was	O
required	O
to	O
ensure	O
that	O
all	O
patients	O
had	O
received	O
treatment	O
considered	O
adequate	O
for	O
neurologic	B-KP
Lyme	I-KP
disease	I-KP
by	O
published	O
guidelines.	O
	
[9,10]	O
Between	O
January	O
2000	O
and	O
April	O
2004,	O
healthy	O
volunteers	O
(controls)	O
and	O
individuals	O
with	O
a	O
history	O
of	O
Lyme	B-KP
disease	I-KP
(patients)	O
between	O
the	O
ages	O
of	O
18	O
and	O
65	O
years	O
were	O
recruited;	O
follow-up	O
evaluations	O
were	O
completed	O
by	O
April	O
2005.	O
	
The	O
institutional	O
review	O
boards	O
at	O
Columbia	O
University	O
and	O
the	O
New	O
York	O
State	O
Psychiatric	O
Institute	O
approved	O
the	O
study,	O
and	O
all	O
participants	O
provided	O
written	O
informed	O
consent.	O
	
Evaluations	O
were	O
conducted	O
at	O
the	O
New	O
York	O
State	O
Psychiatric	O
Institute	O
and	O
Columbia	O
University	O
Medical	O
Center.	O
	
Treatments	O
were	O
conducted	O
at	O
each	O
patient’s	O
home.	O
	
Patients	O
met	O
the	O
following	O
criteria:	O
(1)	O
history	O
of	O
physician-documented	O
erythema	B-KP
migrans	I-KP
or	O
U.S.	O
	
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(CDC)-defined	O
manifestation	O
of	O
Lyme	B-KP
disease,	I-KP
and	O
a	O
positive	O
or	O
equivocal	O
ELISA	B-KP
confirmed	O
by	O
positive	B-KP
Western	I-KP
blot	I-KP
serology6,7;	O
(2)	O
current	O
positive	B-KP
IgG	I-KP
Western	I-KP
blot	I-KP
using	O
CDC	O
surveillance	O
criteria,	O
assessed	O
using	O
a	O
single	O
reference	O
laboratory	O
(University	O
Hospital	O
of	O
Stony	O
Brook);	O
(3)	O
treatment	O
for	O
Lyme	B-KP
disease	I-KP
with	O
at	O
least	O
3	O
weeks	O
of	O
IV	B-KP
ceftriaxone,	I-KP
completed	O
at	O
least	O
4	O
months	O
before	O
study	O
entry;	O
(4)	O
subjective	O
memory	O
impairment	O
that,	O
by	O
participant	O
report,	O
started	O
after	O
the	O
onset	O
of	O
Lyme	B-KP
disease;	I-KP
and	O
(5)	O
objective	O
evidence	O
of	O
memory	O
impairment	O
as	O
documented	O
by	O
the	O
Wechsler	B-KP
Memory	I-KP
Scale–III8	O
compared	O
with	O
age-,	O
sex-,	O
and	O
education-adjusted	O
population	O
norms.	O
	
These	O
study	O
criteria	O
were	O
conservative	O
and	O
narrow	O
to	O
enhance	O
diagnostic	O
confidence.	O
	
Prior	O
IV	B-KP
antibiotic	I-KP
therapy	I-KP
was	O
required	O
to	O
ensure	O
that	O
all	O
patients	O
had	O
received	O
treatment	O
considered	O
adequate	O
for	O
neurologic	B-KP
Lyme	I-KP
disease	I-KP
by	O
published	O
guidelines.	O
	
[9,10]	O
Efficacy	O
analyses	O
were	O
performed	O
using	O
all	O
randomized	O
participants,	O
the	O
intent-to-treat	B-KP
(ITT)	B-KP
sample.	O
	
Lyme	I-KP
patient	I-KP
and	O
healthy	O
controls	O
were	O
compared	O
with	O
respect	O
to	O
demographic	O
and	O
baseline	O
clinical	O
characteristics,	O
using	O
t	O
tests	O
for	O
continuous	O
measures	O
and	O
χ^2	O
tests	O
for	O
categorical	O
measures.\nTests	O
and	O
estimates	O
of	O
differences	O
between	O
groups	O
(IV	B-KP
antibiotic,	O
IV	I-KP
placebo,	O
and	O
healthy	O
controls)	O
with	O
respect	O
to	O
the	O
multivariate	O
measure	O
of	O
cognition	O
(six	O
domains:	O
motor,	O
psychomotor,	O
working	O
memory,	O
attention,	O
verbal	O
fluency,	O
and	O
memory)	O
over	O
time	O
(baseline,	O
week	O
12,	O
and	O
week	O
24)	O
were	O
based	O
on	O
longitudinal	B-KP
mixed-effects	I-KP
models	I-KP
(LMM),	B-KP
[23]	O
which	O
account	O
for	O
the	O
correlation	O
between	O
the	O
domains	O
and	O
between	O
the	O
re-	O
peated	O
observations	O
over	O
time.	O
	
[24]	O
The	O
LMM	I-KP
included	O
main	O
effects	O
and	O
all	O
interaction	O
terms.	O
	
Time	O
was	O
modeled	O
as	O
a	O
nominal	O
factor	O
rather	O
than	O
a	O
continuous	O
variable.\nIncluding	O
all	O
two-	O
and	O
three-way	O
interactions,	O
the	O
model	O
for	O
the	O
covariance	O
structure	O
was	O
selected	O
based	O
on	O
maximizing	O
Bayesian	I-KP
information	I-KP
criteria.	O
	
[25,26]	O
Keeping	O
the	O
model	O
for	O
the	O
covariance	O
as	O
selected,	O
stepwise	O
backward	O
elimination	O
was	O
used	O
to	O
select	O
the	O
“best”	O
model	O
for	O
the	O
mean	O
structure.	O
	
Inference	O
regarding	O
the	O
comparison	O
between	O
the	O
groups	O
was	O
based	O
on	O
the	O
best	O
model.	O
	
Significant	O
omnibus	O
tests	O
for	O
ITT	I-KP
differences	I-KP
among	O
the	O
three	O
groups	O
over	O
time	O
(two-sided	O
α=0.05)	O
were	O
followed	O
by	O
pairwise	O
comparisons;	O
the	O
p	O
values	O
for	O
these	O
post	O
hoc	O
tests	O
are	O
reported	O
unadjusted.	O
	
Efficacy	O
analyses	O
were	O
performed	O
using	O
all	O
randomized	O
participants,	O
the	O
intent-to-treat	B-KP
(ITT)	B-KP
sample.	O
	
Lyme	I-KP
patient	I-KP
and	O
healthy	O
controls	O
were	O
compared	O
with	O
respect	O
to	O
demographic	O
and	O
baseline	O
clinical	O
characteristics,	O
using	O
t	O
tests	O
for	O
continuous	O
measures	O
and	O
χ^2	O
tests	O
for	O
categorical	O
measures.\nTests	O
and	O
estimates	O
of	O
differences	O
between	O
groups	O
(IV	B-KP
antibiotic,	O
IV	I-KP
placebo,	O
and	O
healthy	O
controls)	O
with	O
respect	O
to	O
the	O
multivariate	O
measure	O
of	O
cognition	O
(six	O
domains:	O
motor,	O
psychomotor,	O
working	O
memory,	O
attention,	O
verbal	O
fluency,	O
and	O
memory)	O
over	O
time	O
(baseline,	O
week	O
12,	O
and	O
week	O
24)	O
were	O
based	O
on	O
longitudinal	B-KP
mixed-effects	I-KP
models	I-KP
(LMM),	B-KP
[23]	O
which	O
account	O
for	O
the	O
correlation	O
between	O
the	O
domains	O
and	O
between	O
the	O
re-	O
peated	O
observations	O
over	O
time.	O
	
[24]	O
The	O
LMM	I-KP
included	O
main	O
effects	O
and	O
all	O
interaction	O
terms.	O
	
Time	O
was	O
modeled	O
as	O
a	O
nominal	O
factor	O
rather	O
than	O
a	O
continuous	O
variable.\nIncluding	O
all	O
two-	O
and	O
three-way	O
interactions,	O
the	O
model	O
for	O
the	O
covariance	O
structure	O
was	O
selected	O
based	O
on	O
maximizing	O
Bayesian	I-KP
information	I-KP
criteria.	O
	
[25,26]	O
Keeping	O
the	O
model	O
for	O
the	O
covariance	O
as	O
selected,	O
stepwise	O
backward	O
elimination	O
was	O
used	O
to	O
select	O
the	O
“best”	O
model	O
for	O
the	O
mean	O
structure.	O
	
Inference	O
regarding	O
the	O
comparison	O
between	O
the	O
groups	O
was	O
based	O
on	O
the	O
best	O
model.	O
	
Significant	O
omnibus	O
tests	O
for	O
ITT	I-KP
differences	I-KP
among	O
the	O
three	O
groups	O
over	O
time	O
(two-sided	O
α=0.05)	O
were	O
followed	O
by	O
pairwise	O
comparisons;	O
the	O
p	O
values	O
for	O
these	O
post	O
hoc	O
tests	O
are	O
reported	O
unadjusted.	O
	
Baseline	O
lumbar	B-KP
puncture,	I-KP
conducted	O
in	O
33	O
of	O
the	O
37	O
patients,	O
revealed	O
few	O
abnormalities:	O
mildly	O
elevated	O
WBC	B-KP
(two	O
samples),	O
mildly	O
elevated	O
protein	O
(four	O
samples),	O
and	O
elevated	O
gammaglobulin	B-KP
(one	O
sample).	O
	
Positive	O
results	O
werenoted	O
for	O
22	O
on	O
Lyme	B-KP
ELISA,	I-KP
28	O
on	O
IgG	B-KP
WB,	I-KP
and	O
none	O
on	O
IgM	B-KP
WB.	I-KP
	
For	O
intrathecal	B-KP
Ab	I-KP
production,	I-KP
samples	O
tested	O
positive	O
for	O
4	O
of	O
31	O
(12.9%)	O
patients;	O
each	O
positive	B-KP
intrathecal	I-KP
sample	I-KP
was	O
also	O
seropositive.	B-KP
	
No	O
patient	O
had	O
a	O
positive	O
CSF	B-KP
PCR.	I-KP
	
When	O
cultured,	O
one	O
sample	O
was	O
positive	O
for	O
growth	O
and	O
revealed	O
spirochetes	B-KP
by	O
both	O
phase	O
contrast	O
and	O
dark-field	O
microscopy.	O
	
To	O
exclude	O
contamination	O
as	O
an	O
explanation,	O
the	O
cells’s	B-KP
DNA	I-KP
was	O
extracted	O
and	O
was	O
used	O
as	O
a	O
template	O
for	O
PCR	B-KP
amplification	I-KP
of	O
the	O
spoT	B-KP
gene.	I-KP
	
Examination	O
of	O
the	O
PCR	B-KP
amplicon	I-KP
by	O
agarose	B-KP
gel	I-KP
electrophoresis	I-KP
revealed	O
an	O
approximately	O
3-kbp	O
band,	O
whereas	O
a	O
PCR	B-KP
amplicon	I-KP
from	I-KP
wild-type	I-KP
strains	I-KP
was	O
approximately	O
2	O
kbp.	O
	
Additionally,	O
the	O
B	B-KP
burgdorferi	I-KP
isolated	O
from	O
the	O
CSF	B-KP
culture	I-KP
was	O
able	O
to	O
grow	O
when	O
transferred	O
into	O
BSKII	B-KP
containing	O
kanamycin	B-KP
(5	O
g/mL)	O
plus	O
streptomycin	B-KP
(100	O
g/mL).	O
	
These	O
results	O
strongly	O
suggest	O
that	O
the	O
B	B-KP
burgdorferi	I-KP
strain	I-KP
found	O
in	O
the	O
CSF	B-KP
culture	I-KP
was	O
the	O
result	O
of	O
contamination	O
by	O
a	O
spoT	B-KP
mutant	I-KP
strain	I-KP
(WC07)	B-KP
of	O
B	I-KP
burgdorferi	I-KP
containing	O
a	O
deletion	O
of	O
part	O
of	O
the	O
spoT	I-KP
gene	I-KP
plus	O
the	O
insertion	O
of	O
a	B-KP
streptomycin	I-KP
resistance	I-KP
gene;	O
spoT	I-KP
mutant	I-KP
strains	O
were	O
under	O
investigation	O
in	O
the	O
lab	O
at	O
the	O
time	O
of	O
the	O
culture.	O
	
Baseline	O
lumbar	B-KP
puncture,	I-KP
conducted	O
in	O
33	O
of	O
the	O
37	O
patients,	O
revealed	O
few	O
abnormalities:	O
mildly	O
elevated	O
WBC	B-KP
(two	O
samples),	O
mildly	O
elevated	O
protein	O
(four	O
samples),	O
and	O
elevated	O
gammaglobulin	B-KP
(one	O
sample).	O
	
Positive	O
results	O
werenoted	O
for	O
22	O
on	O
Lyme	B-KP
ELISA,	I-KP
28	O
on	O
IgG	B-KP
WB,	I-KP
and	O
none	O
on	O
IgM	B-KP
WB.	I-KP
	
For	O
intrathecal	B-KP
Ab	I-KP
production,	I-KP
samples	O
tested	O
positive	O
for	O
4	O
of	O
31	O
(12.9%)	O
patients;	O
each	O
positive	B-KP
intrathecal	I-KP
sample	I-KP
was	O
also	O
seropositive.	B-KP
	
No	O
patient	O
had	O
a	O
positive	O
CSF	B-KP
PCR.	I-KP
	
When	O
cultured,	O
one	O
sample	O
was	O
positive	O
for	O
growth	O
and	O
revealed	O
spirochetes	B-KP
by	O
both	O
phase	O
contrast	O
and	O
dark-field	O
microscopy.	O
	
To	O
exclude	O
contamination	O
as	O
an	O
explanation,	O
the	O
cells’s	B-KP
DNA	I-KP
was	O
extracted	O
and	O
was	O
used	O
as	O
a	O
template	O
for	O
PCR	B-KP
amplification	I-KP
of	O
the	O
spoT	B-KP
gene.	I-KP
	
Examination	O
of	O
the	O
PCR	B-KP
amplicon	I-KP
by	O
agarose	B-KP
gel	I-KP
electrophoresis	I-KP
revealed	O
an	O
approximately	O
3-kbp	O
band,	O
whereas	O
a	O
PCR	B-KP
amplicon	I-KP
from	I-KP
wild-type	I-KP
strains	I-KP
was	O
approximately	O
2	O
kbp.	O
	
Additionally,	O
the	O
B	B-KP
burgdorferi	I-KP
isolated	O
from	O
the	O
CSF	B-KP
culture	I-KP
was	O
able	O
to	O
grow	O
when	O
transferred	O
into	O
BSKII	B-KP
containing	O
kanamycin	B-KP
(5	O
g/mL)	O
plus	O
streptomycin	B-KP
(100	O
g/mL).	O
	
These	O
results	O
strongly	O
suggest	O
that	O
the	O
B	B-KP
burgdorferi	I-KP
strain	I-KP
found	O
in	O
the	O
CSF	B-KP
culture	I-KP
was	O
the	O
result	O
of	O
contamination	O
by	O
a	O
spoT	B-KP
mutant	I-KP
strain	I-KP
(WC07)	B-KP
of	O
B	I-KP
burgdorferi	I-KP
containing	O
a	O
deletion	O
of	O
part	O
of	O
the	O
spoT	I-KP
gene	I-KP
plus	O
the	O
insertion	O
of	O
a	B-KP
streptomycin	I-KP
resistance	I-KP
gene;	O
spoT	I-KP
mutant	I-KP
strains	O
were	O
under	O
investigation	O
in	O
the	O
lab	O
at	O
the	O
time	O
of	O
the	O
culture.	O
	
Five	O
patients	O
withdrew	O
from	O
the	O
study	O
because	O
of	O
adverse	O
events:	O
two	O
because	O
of	O
thrombus	B-KP
(both	O
on	O
drug),	O
one	O
because	O
of	O
staphylococcal	B-KP
infection	I-KP
(on	O
placebo),	O
one	O
because	O
of	O
an	O
allergic	O
reaction	O
(on	O
drug),	O
and	O
one	O
because	O
of	O
worsening	O
joint	O
pain	O
(on	O
placebo)	O
that	O
required	O
narcotic	B-KP
pain	I-KP
medication.	I-KP
	
Four	O
patients	O
remained	O
in	O
the	O
study	O
despite	O
adverse	O
events	O
that	O
required	O
either	O
early	O
termination	O
of	O
study	O
medication	O
(three	O
on	O
drug;	O
two	O
with	O
allergic	O
reactions,	O
and	O
one	O
with	O
abdominal	O
pain)	O
or	O
hospitalization	O
(one	O
on	O
drug;	O
cholecystectomy	B-KP
at	O
week	O
16);	O
for	O
these	O
patients,	O
ratings	O
at	O
weeks	O
12	O
and	O
24	O
continued	O
to	O
be	O
conducted	O
without	O
revealing	O
treatment	O
randomization.	O
	
The	O
adverse	O
reactions	O
of	O
seven	O
of	O
these	O
nine	O
patients	O
were	O
thought	O
likely	O
to	O
have	O
been	O
directly	O
related	O
to	O
the	O
study	O
treatment	O
(presence	O
of	O
a	O
PICC	B-KP
line	I-KP
or	I-KP
medication),	O
for	O
a	O
rate	O
of	O
treatment-related	O
adverse	O
events	O
of	O
6	O
of	O
23	O
(26.1%)	O
among	O
patients	O
given	O
IV	B-KP
ceftriaxone	I-KP
and	O
1	O
of	O
14	O
(7.1%)	O
among	O
patients	O
given	O
IV	B-KP
placebo;	I-KP
all	O
patients	O
recovered	O
fully.	O
	
Five	O
patients	O
withdrew	O
from	O
the	O
study	O
because	O
of	O
adverse	O
events:	O
two	O
because	O
of	O
thrombus	B-KP
(both	O
on	O
drug),	O
one	O
because	O
of	O
staphylococcal	B-KP
infection	I-KP
(on	O
placebo),	O
one	O
because	O
of	O
an	O
allergic	O
reaction	O
(on	O
drug),	O
and	O
one	O
because	O
of	O
worsening	O
joint	O
pain	O
(on	O
placebo)	O
that	O
required	O
narcotic	B-KP
pain	I-KP
medication.	I-KP
	
Four	O
patients	O
remained	O
in	O
the	O
study	O
despite	O
adverse	O
events	O
that	O
required	O
either	O
early	O
termination	O
of	O
study	O
medication	O
(three	O
on	O
drug;	O
two	O
with	O
allergic	O
reactions,	O
and	O
one	O
with	O
abdominal	O
pain)	O
or	O
hospitalization	O
(one	O
on	O
drug;	O
cholecystectomy	B-KP
at	O
week	O
16);	O
for	O
these	O
patients,	O
ratings	O
at	O
weeks	O
12	O
and	O
24	O
continued	O
to	O
be	O
conducted	O
without	O
revealing	O
treatment	O
randomization.	O
	
The	O
adverse	O
reactions	O
of	O
seven	O
of	O
these	O
nine	O
patients	O
were	O
thought	O
likely	O
to	O
have	O
been	O
directly	O
related	O
to	O
the	O
study	O
treatment	O
(presence	O
of	O
a	O
PICC	B-KP
line	I-KP
or	I-KP
medication),	O
for	O
a	O
rate	O
of	O
treatment-related	O
adverse	O
events	O
of	O
6	O
of	O
23	O
(26.1%)	O
among	O
patients	O
given	O
IV	B-KP
ceftriaxone	I-KP
and	O
1	O
of	O
14	O
(7.1%)	O
among	O
patients	O
given	O
IV	B-KP
placebo;	I-KP
all	O
patients	O
recovered	O
fully.	O
	
Conclusions	O
from	O
this	O
study	O
are	O
mixed.	O
	
At	O
the	O
primary	O
efficacy	O
end	O
point	O
of	O
week	O
12,	O
IV	B-KP
ceftriaxone	I-KP
treatment	O
resulted	O
in	O
greater	O
improvement	O
in	O
cognition	O
and,	O
among	O
the	O
more	O
impaired,	O
in	O
physical	O
functioning,	O
pain,	O
and	O
fatigue.	O
	
Clinical	O
significance,	O
however,	O
depends	O
on	O
long-term	O
effects.	O
	
Notable	O
were	O
the	O
long-term	O
benefits	O
for	O
the	O
ceftriaxone	B-KP
group	I-KP
on	O
physical	O
functioning	O
and	O
pain	O
among	O
the	O
more	O
severely	O
affected	O
patients	O
at	O
baseline,	O
because	O
these	O
are	O
among	O
the	O
most	O
troubling	O
aspects	O
of	O
posttreatment	B-KP
Lyme	I-KP
disease.	I-KP
	
[28]	O
However,	O
our	O
primary	O
interest	O
in	O
this	O
study	O
was	O
on	O
cognition,	O
for	O
which	O
the	O
improvement	O
was	O
not	O
sustained	O
to	O
week	O
24.	O
	
Further,	O
adverse	O
effects	O
attributed	O
to	O
IV	B-KP
ceftriaxone	I-KP
occurred	O
in	O
26%	O
of	O
patients.	O
	
Therefore,	O
considering	O
both	O
the	O
limited	O
duration	O
of	O
cognitive	O
improvement	O
and	O
the	O
risks,	O
10	O
weeks	O
of	O
IV	B-KP
ceftriaxone	I-KP
and	O
then	O
14	O
weeks	O
of	O
no	O
antibiotic	B-KP
is	O
not	O
an	O
effective	O
strategy	O
for	O
sustained	O
cognitive	O
improvement.	O
	
Although	O
certain	O
subgroups	O
(patients	O
with	O
more	O
joint	O
or	O
neurologic	B-KP
abnormalities)	I-KP
may	O
experience	O
long-term	O
benefit	O
from	O
ceftriaxone,	B-KP
the	O
predictor	O
analyses	O
were	O
exploratory	O
rather	O
than	O
hypothesis	O
driven,	O
and	O
they	O
require	O
independent	O
confirmation.	O
	
Pending	O
such	O
confirmation,	O
treatment	O
strategies	O
that	O
are	O
safer	O
and	O
more	O
durable	O
are	O
needed.	O
	
Conclusions	O
from	O
this	O
study	O
are	O
mixed.	O
	
At	O
the	O
primary	O
efficacy	O
end	O
point	O
of	O
week	O
12,	O
IV	B-KP
ceftriaxone	I-KP
treatment	O
resulted	O
in	O
greater	O
improvement	O
in	O
cognition	O
and,	O
among	O
the	O
more	O
impaired,	O
in	O
physical	O
functioning,	O
pain,	O
and	O
fatigue.	O
	
Clinical	O
significance,	O
however,	O
depends	O
on	O
long-term	O
effects.	O
	
Notable	O
were	O
the	O
long-term	O
benefits	O
for	O
the	O
ceftriaxone	B-KP
group	I-KP
on	O
physical	O
functioning	O
and	O
pain	O
among	O
the	O
more	O
severely	O
affected	O
patients	O
at	O
baseline,	O
because	O
these	O
are	O
among	O
the	O
most	O
troubling	O
aspects	O
of	O
posttreatment	B-KP
Lyme	I-KP
disease.	I-KP
	
[28]	O
However,	O
our	O
primary	O
interest	O
in	O
this	O
study	O
was	O
on	O
cognition,	O
for	O
which	O
the	O
improvement	O
was	O
not	O
sustained	O
to	O
week	O
24.	O
	
Further,	O
adverse	O
effects	O
attributed	O
to	O
IV	B-KP
ceftriaxone	I-KP
occurred	O
in	O
26%	O
of	O
patients.	O
	
Therefore,	O
considering	O
both	O
the	O
limited	O
duration	O
of	O
cognitive	O
improvement	O
and	O
the	O
risks,	O
10	O
weeks	O
of	O
IV	B-KP
ceftriaxone	I-KP
and	O
then	O
14	O
weeks	O
of	O
no	O
antibiotic	B-KP
is	O
not	O
an	O
effective	O
strategy	O
for	O
sustained	O
cognitive	O
improvement.	O
	
Although	O
certain	O
subgroups	O
(patients	O
with	O
more	O
joint	O
or	O
neurologic	B-KP
abnormalities)	I-KP
may	O
experience	O
long-term	O
benefit	O
from	O
ceftriaxone,	B-KP
the	O
predictor	O
analyses	O
were	O
exploratory	O
rather	O
than	O
hypothesis	O
driven,	O
and	O
they	O
require	O
independent	O
confirmation.	O
	
Pending	O
such	O
confirmation,	O
treatment	O
strategies	O
that	O
are	O
safer	O
and	O
more	O
durable	O
are	O
needed.	O
	
B.	B-KP
	
burgdorferi	I-KP
(ATCC	O
B31),	O
grown	O
to	O
late	O
log	O
phase	O
at	O
338C	O
in	O
BSK-H	O
medium	O
(Sigma,	O
St.	O
	
Louis,	O
Mo.),	O
was	O
used	O
as	O
a	O
Lyme	B-KP
antigen	I-KP
source.	I-KP
	
Spirochetes	B-KP
were	O
electrophoresed	O
on	O
10%	O
polyacrylamide	B-KP
gels	I-KP
by	O
using	O
the	O
discontinuous	O
buffer	O
system	O
of	O
Laemmli	O
and	O
Fayre	O
(12).	O
	
Separated	O
proteins	B-KP
were	O
transferred	O
to	O
nitrocellulose	O
by	O
means	O
of	O
a	O
Nova	B-KP
blot	I-KP
semidry	I-KP
transfer	I-KP
system	I-KP
(Pharmacia,	O
Piscataway,	O
N.J.).	O
	
Following	O
transfer,	O
the	O
nitrocellulose	B-KP
membranes	I-KP
were	O
blocked	O
by	O
overnight	O
incubation	O
at	O
48C	O
with	O
0.5%	O
bovine	B-KP
serum	I-KP
albumin	I-KP
in	I-KP
PBS.	I-KP
	
Membranes	O
were	O
next	O
cut	O
into	O
strips,	O
dried,	O
and	O
stored	O
desiccated	O
until	O
needed.\nSera	O
were	O
tested	O
for	O
IgG	B-KP
and	I-KP
IgM	I-KP
antibodies	I-KP
to	I-KP
B.	I-KP
	
burgdorferi	I-KP
antigens	I-KP
by	O
incubating	O
rehydrated	O
strips	O
with	O
a	O
1:100	O
dilution	O
of	O
test	O
serum	O
in	O
1%	O
nonfat	O
milk	O
containing	O
PBS	O
for	O
1	O
h	O
at	O
room	O
temperature.	O
	
The	O
strips	O
were	O
then	O
washed	O
three	O
times	O
and	O
a	O
1:1,000	O
dilution	O
of	O
biotinylated	B-KP
antiserum	I-KP
(goat	B-KP
anti-human	I-KP
IgG	I-KP
γ	I-KP
chain	I-KP
specific	I-KP
or	O
IgM	I-KP
m	I-KP
chain	I-KP
specific)	O
was	O
added	O
for	O
a	O
1-h	O
incubation;	O
incubation	O
was	O
followed	O
by	O
three	O
washes.	O
	
Peroxidase-conjugated	I-KP
streptavidin	I-KP
(diluted	O
1:1,000)	O
was	O
then	O
added,	O
and	O
the	O
mixture	O
was	O
allowed	O
to	O
incubate	O
for	O
1	O
h	O
at	O
room	O
temperature.	O
	
The	O
strips	O
were	O
then	O
washed	O
as	O
before	O
and	O
2	O
ml	O
of	O
substrate	O
solution	O
(4-chloro-1-naphthol)	O
was	O
added.	O
	
After	O
a	O
final	O
wash	O
in	O
distilled	O
water,	O
the	O
strips	O
were	O
dried	O
and	O
evaluated	O
for	O
reactivity	O
by	O
comparison	O
with	O
controls.	O
	
B.	B-KP
	
burgdorferi	I-KP
(ATCC	O
B31),	O
grown	O
to	O
late	O
log	O
phase	O
at	O
338C	O
in	O
BSK-H	O
medium	O
(Sigma,	O
St.	O
	
Louis,	O
Mo.),	O
was	O
used	O
as	O
a	O
Lyme	B-KP
antigen	I-KP
source.	I-KP
	
Spirochetes	B-KP
were	O
electrophoresed	O
on	O
10%	O
polyacrylamide	B-KP
gels	I-KP
by	O
using	O
the	O
discontinuous	O
buffer	O
system	O
of	O
Laemmli	O
and	O
Fayre	O
(12).	O
	
Separated	O
proteins	B-KP
were	O
transferred	O
to	O
nitrocellulose	O
by	O
means	O
of	O
a	O
Nova	B-KP
blot	I-KP
semidry	I-KP
transfer	I-KP
system	I-KP
(Pharmacia,	O
Piscataway,	O
N.J.).	O
	
Following	O
transfer,	O
the	O
nitrocellulose	B-KP
membranes	I-KP
were	O
blocked	O
by	O
overnight	O
incubation	O
at	O
48C	O
with	O
0.5%	O
bovine	B-KP
serum	I-KP
albumin	I-KP
in	I-KP
PBS.	I-KP
	
Membranes	O
were	O
next	O
cut	O
into	O
strips,	O
dried,	O
and	O
stored	O
desiccated	O
until	O
needed.\nSera	O
were	O
tested	O
for	O
IgG	B-KP
and	I-KP
IgM	I-KP
antibodies	I-KP
to	I-KP
B.	I-KP
	
burgdorferi	I-KP
antigens	I-KP
by	O
incubating	O
rehydrated	O
strips	O
with	O
a	O
1:100	O
dilution	O
of	O
test	O
serum	O
in	O
1%	O
nonfat	O
milk	O
containing	O
PBS	O
for	O
1	O
h	O
at	O
room	O
temperature.	O
	
The	O
strips	O
were	O
then	O
washed	O
three	O
times	O
and	O
a	O
1:1,000	O
dilution	O
of	O
biotinylated	B-KP
antiserum	I-KP
(goat	B-KP
anti-human	I-KP
IgG	I-KP
γ	I-KP
chain	I-KP
specific	I-KP
or	O
IgM	I-KP
m	I-KP
chain	I-KP
specific)	O
was	O
added	O
for	O
a	O
1-h	O
incubation;	O
incubation	O
was	O
followed	O
by	O
three	O
washes.	O
	
Peroxidase-conjugated	I-KP
streptavidin	I-KP
(diluted	O
1:1,000)	O
was	O
then	O
added,	O
and	O
the	O
mixture	O
was	O
allowed	O
to	O
incubate	O
for	O
1	O
h	O
at	O
room	O
temperature.	O
	
The	O
strips	O
were	O
then	O
washed	O
as	O
before	O
and	O
2	O
ml	O
of	O
substrate	O
solution	O
(4-chloro-1-naphthol)	O
was	O
added.	O
	
After	O
a	O
final	O
wash	O
in	O
distilled	O
water,	O
the	O
strips	O
were	O
dried	O
and	O
evaluated	O
for	O
reactivity	O
by	O
comparison	O
with	O
controls.	O
	
Lyme	B-KP
disease	I-KP
can	O
be	O
difficult	O
to	O
diagnose,	O
but	O
because	O
of	O
the	O
rising	O
incidence	O
in	O
Canada	O
it	O
is	O
important	O
to	O
maintain	O
a	O
high	O
index	O
of	O
suspicion.	O
	
Laboratory	O
diagnosis	O
is	O
a	O
2-step	O
process.5	O
In	O
this	O
case,	O
the	O
emergency	O
physician	O
ordered	O
the	O
screening	O
ELISA	B-KP
(enzyme-linked	B-KP
immunosorbent	I-KP
assay)	O
for	O
your	O
patient.	O
	
If	O
the	O
ELISA	I-KP
result	O
is	O
equivocal	O
or	O
positive,	O
order	O
a	O
Western	O
blot.	O
	
A	O
positive	O
Western	I-KP
blot	I-KP
result	O
confirms	O
the	O
diagnosis.5	O
Lyme	I-KP
disease	I-KP
should	O
be	O
considered	O
in	O
any	O
patient	O
with	O
a	O
new	O
onset	O
of	O
Bell	I-KP
palsy.	O
	
Current	O
treatment	O
recommendations	O
for	O
early	O
disseminated	O
Lyme	I-KP
disease	I-KP
with	O
central	I-KP
nervous	I-KP
system	I-KP
involvement	O
include	O
ceftriaxone	I-KP
and	O
oxycycline.	O
	
[6]	O
For	O
this	O
patient,	O
you	O
order	O
a	B-KP
Western	I-KP
blot,	O
extend	O
his	O
prescription	O
of	B-KP
doxycycline	O
to	O
complete	O
a	O
full	O
21-day	O
course,	O
arrange	O
follow-up,	O
and	O
reassure	O
him	O
that	O
most	B-KP
Lyme	I-KP
disease	O
facial	I-KP
palsies	O
resolve.	O
	
Lyme	B-KP
disease	I-KP
can	O
be	O
difficult	O
to	O
diagnose,	O
but	O
because	O
of	O
the	O
rising	O
incidence	O
in	O
Canada	O
it	O
is	O
important	O
to	O
maintain	O
a	O
high	O
index	O
of	O
suspicion.	O
	
Laboratory	O
diagnosis	O
is	O
a	O
2-step	O
process.5	O
In	O
this	O
case,	O
the	O
emergency	O
physician	O
ordered	O
the	O
screening	O
ELISA	B-KP
(enzyme-linked	B-KP
immunosorbent	I-KP
assay)	O
for	O
your	O
patient.	O
	
If	O
the	O
ELISA	I-KP
result	O
is	O
equivocal	O
or	O
positive,	O
order	O
a	O
Western	O
blot.	O
	
A	O
positive	O
Western	I-KP
blot	I-KP
result	O
confirms	O
the	O
diagnosis.5	O
Lyme	I-KP
disease	I-KP
should	O
be	O
considered	O
in	O
any	O
patient	O
with	O
a	O
new	O
onset	O
of	O
Bell	I-KP
palsy.	O
	
Current	O
treatment	O
recommendations	O
for	O
early	O
disseminated	O
Lyme	I-KP
disease	I-KP
with	O
central	I-KP
nervous	I-KP
system	I-KP
involvement	O
include	O
ceftriaxone	I-KP
and	O
oxycycline.	O
	
[6]	O
For	O
this	O
patient,	O
you	O
order	O
a	B-KP
Western	I-KP
blot,	O
extend	O
his	O
prescription	O
of	B-KP
doxycycline	O
to	O
complete	O
a	O
full	O
21-day	O
course,	O
arrange	O
follow-up,	O
and	O
reassure	O
him	O
that	O
most	B-KP
Lyme	I-KP
disease	O
facial	I-KP
palsies	O
resolve.	O
	
The	O
risk	O
of	O
human	O
infection	O
with	O
B	B-KP
burgdorferi	I-KP
is	O
determined	O
by	O
the	O
geographic	O
distribution	O
of	O
vector	O
tick	O
species,	O
local	O
factors	O
that	O
increase	O
or	O
decrease	O
tick	O
abundance	O
and	O
rates	O
of	O
infection,	O
and	O
human	O
behaviors	O
that	O
affect	O
the	O
likelihood	O
of	O
being	O
bitten.	O
	
In	O
the	O
Northeast	O
where	O
homes	O
are	O
often	O
situated	O
in	O
heavily	O
tick-infested	O
areas,	O
exposure	O
is	O
thought	O
to	O
occur	O
primarily	O
in	O
the	O
peridomestic	O
environment	O
immediately	O
around	O
the	O
home.	O
	
[44–47]	O
In	O
the	O
North	O
Central	O
states,	O
areas	O
of	O
highest	O
risk	O
are	O
often	O
lightly	O
populated	O
[48];	O
infection	O
in	O
these	O
areas	O
is	O
more	O
often	O
related	O
to	O
weekend	O
travel	O
and	O
recreation.	O
	
Specific	O
peridomestic	B-KP
risk	I-KP
factors	I-KP
include	O
the	O
presence	O
of	O
a	O
suitable	O
tick	O
habitat,	O
landscaping	O
practices	O
that	O
enhance	O
tick	O
survival	O
(eg,	O
failure	O
to	O
clear	O
leaf	O
litter),	O
deer	O
density,	O
and	O
outdoor	O
activities,	O
such	O
as	O
gardening.	O
	
[49–53]	O
Certain	O
occupations	O
and	O
hobbies	O
also	O
increase	O
the	O
risk	O
of	O
infection.	O
	
Forestry	O
workers,	O
farmers,	O
soldiers,	O
hunters,	O
hikers,	O
and	O
orienteers	O
have	O
higher	O
rates	O
of	O
infection	O
in	O
studies	O
from	O
the	O
United	O
States,	O
[54]	O
Asia,	O
[55,56]	O
and	O
throughout	O
Europe.57–61	O
Animal	O
studies	O
and	O
clinical	O
observations	O
indicate	O
that	O
I	B-KP
scapularis	I-KP
ticks	I-KP
require	O
at	O
least	O
36	O
hours	O
of	O
attachment	O
in	O
order	O
to	O
transmit	O
B	B-KP
burgdorferi,	I-KP
62	O
supporting	O
a	O
possible	O
preventive	O
role	O
for	O
daily	O
tick	O
checks	O
and	O
showering	O
after	O
potential	O
exposure.	O
	
[53,63]	O
Unfortunately,	O
similar	O
studies	O
have	O
demonstrated	O
that	O
I	B-KP
ricinus	I-KP
ticks,	I-KP
especially	O
when	O
infected	O
with	O
B	B-KP
afzelii,	I-KP
can	O
transmit	O
infection	O
efficiently	O
after	O
much	O
shorter	O
periods	O
of	O
attachment.	O
	
[2]	O
The	O
risk	O
of	O
human	O
infection	O
with	O
B	B-KP
burgdorferi	I-KP
is	O
determined	O
by	O
the	O
geographic	O
distribution	O
of	O
vector	O
tick	O
species,	O
local	O
factors	O
that	O
increase	O
or	O
decrease	O
tick	O
abundance	O
and	O
rates	O
of	O
infection,	O
and	O
human	O
behaviors	O
that	O
affect	O
the	O
likelihood	O
of	O
being	O
bitten.	O
	
In	O
the	O
Northeast	O
where	O
homes	O
are	O
often	O
situated	O
in	O
heavily	O
tick-infested	O
areas,	O
exposure	O
is	O
thought	O
to	O
occur	O
primarily	O
in	O
the	O
peridomestic	O
environment	O
immediately	O
around	O
the	O
home.	O
	
[44–47]	O
In	O
the	O
North	O
Central	O
states,	O
areas	O
of	O
highest	O
risk	O
are	O
often	O
lightly	O
populated	O
[48];	O
infection	O
in	O
these	O
areas	O
is	O
more	O
often	O
related	O
to	O
weekend	O
travel	O
and	O
recreation.	O
	
Specific	O
peridomestic	B-KP
risk	I-KP
factors	I-KP
include	O
the	O
presence	O
of	O
a	O
suitable	O
tick	O
habitat,	O
landscaping	O
practices	O
that	O
enhance	O
tick	O
survival	O
(eg,	O
failure	O
to	O
clear	O
leaf	O
litter),	O
deer	O
density,	O
and	O
outdoor	O
activities,	O
such	O
as	O
gardening.	O
	
[49–53]	O
Certain	O
occupations	O
and	O
hobbies	O
also	O
increase	O
the	O
risk	O
of	O
infection.	O
	
Forestry	O
workers,	O
farmers,	O
soldiers,	O
hunters,	O
hikers,	O
and	O
orienteers	O
have	O
higher	O
rates	O
of	O
infection	O
in	O
studies	O
from	O
the	O
United	O
States,	O
[54]	O
Asia,	O
[55,56]	O
and	O
throughout	O
Europe.57–61	O
Animal	O
studies	O
and	O
clinical	O
observations	O
indicate	O
that	O
I	B-KP
scapularis	I-KP
ticks	I-KP
require	O
at	O
least	O
36	O
hours	O
of	O
attachment	O
in	O
order	O
to	O
transmit	O
B	B-KP
burgdorferi,	I-KP
62	O
supporting	O
a	O
possible	O
preventive	O
role	O
for	O
daily	O
tick	O
checks	O
and	O
showering	O
after	O
potential	O
exposure.	O
	
[53,63]	O
Unfortunately,	O
similar	O
studies	O
have	O
demonstrated	O
that	O
I	B-KP
ricinus	I-KP
ticks,	I-KP
especially	O
when	O
infected	O
with	O
B	B-KP
afzelii,	I-KP
can	O
transmit	O
infection	O
efficiently	O
after	O
much	O
shorter	O
periods	O
of	O
attachment.	O
	
[2]	O
As	O
shown	O
for	O
the	O
years	O
2010	O
to	O
2013,	O
Lyme	B-KP
disease	I-KP
incidence	O
is	O
bimodal	O
with	O
respect	O
to	O
age,	O
with	O
highest	O
rates	O
among	O
children	O
aged	O
5	O
to	O
15	O
years	O
and	O
adults	O
older	O
than	O
50	O
years	O
(Fig.	O
	
5).	O
	
In	O
the	O
United	O
States,	O
the	O
incidence	O
is	O
higher	O
among	O
males	O
in	O
all	O
age	O
groups.	O
	
In	O
contrast,	O
females	O
account	O
for	O
51%	O
to	O
60%	O
of	O
identified	O
cases	O
in	O
many	O
European	O
series,	O
yielding	O
an	O
incidence	O
higher	O
than	O
males	O
in	O
at	O
least	O
some	O
series.	O
	
[28,61,86,87]	O
Although	O
these	O
patterns	O
likely	O
reflect	O
behavior-related	O
differences	O
in	O
exposure	O
across	O
populations,	O
age	O
and	O
sex-specific	O
differences	O
in	O
susceptibility	O
and	O
care-seeking	O
behavior	O
may	O
also	O
contribute.	O
	
Over	O
time,	O
the	O
US	O
incidence	O
has	O
increased	O
disproportionately	O
among	O
males,	O
shifting	O
the	O
overall	O
sex	O
ratio	O
from	O
51%	O
male	O
in	O
1992	O
to	O
53%	O
male	O
in	O
2006.	O
	
[28]	O
This	O
sex-specific	O
increase	O
has	O
been	O
most	O
pronounced	O
among	O
children.	O
	
In	O
a	O
separate	O
analysis	O
of	O
US	O
data	O
for	O
2001	O
to	O
2002,	O
age	O
and	O
sex	O
distribution	O
were	O
found	O
to	O
vary	O
among	O
cases	O
reported	O
in	O
endemic	B-KP
and	I-KP
nonendemic	I-KP
areas.	I-KP
	
[88]	O
In	O
12	O
high-incidence	O
states,	O
the	O
modal	O
age	O
for	O
cases	O
was	O
6	O
years,	O
and	O
54%	O
were	O
among	O
males.	O
	
In	O
contrast,	O
in	O
nonendemic	B-KP
states,	I-KP
the	O
modal	O
age	O
was	O
44	O
years,	O
and	O
47%	O
were	O
among	O
males.	O
	
Barring	O
fundamental	O
differences	O
in	O
risk	O
factors	O
for	O
infection,	O
this	O
discrepancy	O
suggests	O
misclassification	O
(ie,	O
that	O
a	O
substantial	O
proportion	O
of	O
illnesses	O
reported	O
in	O
nonendemic	B-KP
areas	I-KP
are	O
actually	O
caused	O
by	O
other	O
conditions).	O
	
This	O
finding	O
is	O
consistent	O
with	O
a	O
higher	O
risk	O
of	O
misdiagnosis	O
in	O
nonendemic	B-KP
areas,	I-KP
a	O
consequence	O
of	O
the	O
effect	O
of	O
prior	O
probability	O
on	O
the	O
predictive	O
value	O
of	O
clinical	O
and	O
laboratory	O
findings.	O
	
[89]	O
As	O
shown	O
for	O
the	O
years	O
2010	O
to	O
2013,	O
Lyme	B-KP
disease	I-KP
incidence	O
is	O
bimodal	O
with	O
respect	O
to	O
age,	O
with	O
highest	O
rates	O
among	O
children	O
aged	O
5	O
to	O
15	O
years	O
and	O
adults	O
older	O
than	O
50	O
years	O
(Fig.	O
	
5).	O
	
In	O
the	O
United	O
States,	O
the	O
incidence	O
is	O
higher	O
among	O
males	O
in	O
all	O
age	O
groups.	O
	
In	O
contrast,	O
females	O
account	O
for	O
51%	O
to	O
60%	O
of	O
identified	O
cases	O
in	O
many	O
European	O
series,	O
yielding	O
an	O
incidence	O
higher	O
than	O
males	O
in	O
at	O
least	O
some	O
series.	O
	
[28,61,86,87]	O
Although	O
these	O
patterns	O
likely	O
reflect	O
behavior-related	O
differences	O
in	O
exposure	O
across	O
populations,	O
age	O
and	O
sex-specific	O
differences	O
in	O
susceptibility	O
and	O
care-seeking	O
behavior	O
may	O
also	O
contribute.	O
	
Over	O
time,	O
the	O
US	O
incidence	O
has	O
increased	O
disproportionately	O
among	O
males,	O
shifting	O
the	O
overall	O
sex	O
ratio	O
from	O
51%	O
male	O
in	O
1992	O
to	O
53%	O
male	O
in	O
2006.	O
	
[28]	O
This	O
sex-specific	O
increase	O
has	O
been	O
most	O
pronounced	O
among	O
children.	O
	
In	O
a	O
separate	O
analysis	O
of	O
US	O
data	O
for	O
2001	O
to	O
2002,	O
age	O
and	O
sex	O
distribution	O
were	O
found	O
to	O
vary	O
among	O
cases	O
reported	O
in	O
endemic	B-KP
and	I-KP
nonendemic	I-KP
areas.	I-KP
	
[88]	O
In	O
12	O
high-incidence	O
states,	O
the	O
modal	O
age	O
for	O
cases	O
was	O
6	O
years,	O
and	O
54%	O
were	O
among	O
males.	O
	
In	O
contrast,	O
in	O
nonendemic	B-KP
states,	I-KP
the	O
modal	O
age	O
was	O
44	O
years,	O
and	O
47%	O
were	O
among	O
males.	O
	
Barring	O
fundamental	O
differences	O
in	O
risk	O
factors	O
for	O
infection,	O
this	O
discrepancy	O
suggests	O
misclassification	O
(ie,	O
that	O
a	O
substantial	O
proportion	O
of	O
illnesses	O
reported	O
in	O
nonendemic	B-KP
areas	I-KP
are	O
actually	O
caused	O
by	O
other	O
conditions).	O
	
This	O
finding	O
is	O
consistent	O
with	O
a	O
higher	O
risk	O
of	O
misdiagnosis	O
in	O
nonendemic	B-KP
areas,	I-KP
a	O
consequence	O
of	O
the	O
effect	O
of	O
prior	O
probability	O
on	O
the	O
predictive	O
value	O
of	O
clinical	O
and	O
laboratory	O
findings.	O
	
[89]	O
